fluorouracil has been researched along with Hepatocellular Carcinoma in 1089 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Excerpt | Relevance | Reference |
---|---|---|
"Interventional hepatic arterial infusion chemotherapy of infusional fluorouracil, leucovorin, and oxaliplatin (HAIC-FO) displayed an encouraging safety profile and antitumor activity in a previous phase II trial and a propensity-score-matching study involving patients with locally advanced hepatocellular carcinoma (HCC)." | 9.51 | Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1). ( Chen, QF; Deng, HJ; He, M; Lai, JF; Li, JB; Li, SL; Lyu, N; Mu, LW; Wang, X; Zhao, M, 2022) |
"A PHY906 and capecitabine combination could be effective as a salvage therapy for patients with hepatocellular carcinoma (HCC) previously treated with multiple systemic therapies." | 9.41 | A Phase II Clinical Trial on the Combination Therapy of PHY906 Plus Capecitabine in Hepatocellular Carcinoma. ( Changou, CA; Chen, LT; Cheng, YC; Liu, S; Liu, SH; Luh, F; Shiah, HS; Yen, Y, 2021) |
"Sorafenib is the first-line treatment for hepatocellular carcinoma with portal vein invasion; however, it has shown unsatisfactory survival benefit." | 9.30 | Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial. ( Chen, M; Fang, W; Guo, R; Guo, Y; He, M; Le, Y; Li, Q; Shen, J; Shi, M; Tan, G; Wei, W; Wu, X; Xu, L; Zhao, M; Zhou, Y; Zhou, Z; Zou, R, 2019) |
"In patients with advanced hepatocellular carcinoma (HCC), evidence is unclear as to whether hepatic arterial infusion chemotherapy (HAIC) or sorafenib is superior." | 9.27 | Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): an open label, non-comparative, phase II trial. ( Aikata, H; Amano, H; Awai, K; Chayama, K; Hatooka, M; Hiramatsu, A; Imamura, M; Inagaki, Y; Katamura, Y; Kawakami, Y; Kawaoka, T; Kohno, H; Masaki, K; Morio, K; Moriya, T; Murakami, E; Nagaoki, Y; Nakahara, T; Tamura, T; Tsuge, M; Waki, K, 2018) |
"The aim of this study was to investigate the dose-limiting toxicities (DLTs) and determine the recommended doses in the Phase I part of the study, and to evaluate the efficacy and toxicity in the Phase II part, of continuous hepatic intra-arterial infusion therapy with 5-fluorouracil, mitoxantrone and cisplatin (FMP therapy) in patients with advanced hepatocellular carcinoma (HCC)." | 9.24 | A Phase I/II trial of continuous hepatic intra-arterial infusion of 5-fluorouracil, mitoxantrone and cisplatin for advanced hepatocellular carcinoma. ( Arai, Y; Furuse, J; Ikeda, M; Inaba, Y; Kobayashi, T; Mitsunaga, S; Morizane, C; Okusaka, T; Sato, Y; Ueno, H, 2017) |
"Raltitrexed has shown efficacy and safety in many tumor types; however, the clinical data on the treatment of hepatocellular carcinoma is rare." | 9.22 | Raltitrexed plus oxaliplatin-based transarterial chemoembolization in patients with unresectable hepatocellular carcinoma. ( Chen, C; Cheng, L; Fan, L; Hu, T; Lu, J; Lu, X; Ma, Y; Ni, B; Ou, S; Qi, F; Yi, X; Yu, L; Zhang, C; Zhao, C; Zheng, Z, 2016) |
"The present pilot study aimed to evaluate the safety and efficacy of hepatic arterial infusion chemotherapy (HAIC) with interferon-beta (IFN-β) and 5-fluorouracil (5-FU) in patients with advanced hepatocellular carcinoma (HCC)." | 9.19 | Pilot Study of Hepatic Arterial Infusion Chemotherapy with Interferon-beta and 5-fluorouracil: A New Chemotherapy for Patients with Advanced Hepatocellular Carcinoma. ( Fukunaga, A; Hirano, G; Irie, M; Iwashita, H; Iwata, K; Kora, S; Kunimoto, H; Kuno, S; Morihara, D; Nishizawa, S; Sakisaka, S; Sakurai, K; Shakado, S; Sohda, T; Takeyama, Y; Tanaka, T; Tsuchiya, N; Yokoyama, K; Yoshimitsu, K; Yotsumoto, K, 2014) |
"The only approved systemic therapy for patients with advanced hepatocellular carcinoma (HCC) till now is sorafenib." | 9.17 | Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma. ( Abdel-Rahman, O; Abdel-Wahab, M; Abdel-Wahab, S; Elbassiony, M; Ellithy, M; Shaker, M, 2013) |
"To determine whether FOLFOX4 (infusional fluorouracil, leucovorin, and oxaliplatin) administered as palliative chemotherapy to patients with advanced hepatocellular carcinoma (HCC) provides a survival benefit and efficacy versus doxorubicin." | 9.17 | Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. ( Bai, Y; Bhudhisawasdi, V; Chao, Y; Fan, J; Kang, WK; Lee, JH; Lim, HY; Qin, S; Sun, Y; Thongprasert, S; Yang, TS; Zhou, Y, 2013) |
"Sorafenib is a multi-kinase inhibitor, which was approved as first-line treatment for patients with advanced hepatocellular carcinoma (HCC)." | 9.16 | Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma. ( Kang, WK; Lee, J; Lee, SJ; Lim, HY; Park, JO; Park, SH; Park, YS; Yim, DS, 2012) |
"To compare the efficacy of transcatheter arterial chemoembolization (TACE) using multiple anticancer drugs (epirubicin, cisplatin, mitomycin C, and 5-furuorouracil: Multi group) with TACE using epirubicin (EP group) for hepatocellular carcinoma (HCC)." | 9.16 | Prospective evaluation of transcatheter arterial chemoembolization (TACE) with multiple anti-cancer drugs (epirubicin, cisplatin, mitomycin c, 5-fluorouracil) compared with TACE with epirubicin for treatment of hepatocellular carcinoma. ( Ikoma, A; Kawai, N; Minamiguchi, H; Nakai, M; Nakata, K; Sahara, S; Sanda, H; Sato, M; Shirai, S; Sonomura, T; Tanaka, T, 2012) |
"Eniluracil (EU) is a potent dihydropyrimidine (DPD) inhibitor, which improves the oral bio-availability of 5-fluorouracil (5-FU) and may overcome fluoropyrimidine (FP) resistance in hepatocellular carcinoma (HCC)." | 9.15 | Final results of a prematurely discontinued Phase 1/2 study of eniluracil with escalating doses of 5-fluorouracil administered orally in patients with advanced hepatocellular carcinoma. ( Chang, AY; de Lima Lopes, G; Dicksey, JS; Palalay, M; Peters, WP, 2011) |
"We investigated whether adjuvant hepatic arterial infusional chemotherapy (HAIC) with 5-fluorouracil (5-FU) and cisplatin reduces the recurrence of hepatocellular carcinoma (HCC) after curative resection." | 9.15 | Adjuvant hepatic arterial infusional chemotherapy with 5-fluorouracil and cisplatin after curative resection of hepatocellular carcinoma. ( Ahn, SH; Choi, SB; Han, KH; Kim, DY; Kim, KS; Kim, SU; Lee, DY; Lee, KH; Park, JY; Park, MS, 2011) |
"This randomized phase II trial compared the response rates to treatment with interferon (IFN) combined with hepatic arterial infusion of fluorouracil (FU) plus cisplatin (CDDP) or FU alone in patients with advanced hepatocellular carcinoma (HCC)." | 9.15 | Randomized, phase II study comparing interferon combined with hepatic arterial infusion of fluorouracil plus cisplatin and fluorouracil alone in patients with advanced hepatocellular carcinoma. ( Arai, K; Honda, M; Kaneko, S; Mizukoshi, E; Nakamoto, Y; Sakai, A; Sunagozaka, H; Terashima, T; Ueda, T; Yamashita, T, 2011) |
"This pilot phase II study was designed to determine the efficacy, toxicities, and biological activity of multiple hepatic arterial injections of recombinant adenovirus p53 (rAd-p53) and 5-fluorouracil (5-FU) after transcatheter arterial chemoembolization (TACE) when compared with TACE alone in patients with unresectable hepatocellular carcinoma (HCC)." | 9.14 | Multiple hepatic arterial injections of recombinant adenovirus p53 and 5-fluorouracil after transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a pilot phase II trial. ( Chen, W; Liu, J; Tian, G; Zhou, JS, 2009) |
"Although hepatic arterial infusion chemotherapy (HAIC) using low-dose 5-fluorouracil (5-FU) and cisplatin (low-dose FP) is commonly used for advanced hepatocellular carcinoma (HCC) with vascular invasion in Japan, few reports have investigated the efficacy and safety of this approach." | 9.14 | Hepatic arterial infusion chemotherapy using low-dose 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma. ( Chung, H; Hagiwara, S; Inoue, T; Ishikawa, E; Kitai, S; Kudo, M; Minami, Y; Nagai, T; Takita, M; Tatsumi, C; Ueda, T; Ueshima, K; Yada, N, 2010) |
"To evaluate the time dependence of intra-arterial 5-fluorouracil (5-FU) therapy for advanced hepatocellular carcinoma (aHCC)." | 9.12 | Twenty-four hour intra-arterial infusion of 5-fluorouracil, cisplatin, and leucovorin is more effective than 6-hour infusion for advanced hepatocellular carcinoma. ( Higami, K; Ikoma, A; Ishii, K; Kanayama, M; Matsumaru, K; Miki, K; Momiyama, K; Nagai, H; Okano, N; Sumino, Y; Watanabe, M, 2007) |
"The authors reported previously the beneficial effects of interferon (IFN)-alpha/5-fluorouracil (5-FU) combination therapy for patients with advanced hepatocellular carcinoma (HCC) who have tumor thrombi in the major portal branches." | 9.12 | Interferon-alpha and 5-fluorouracil combination therapy after palliative hepatic resection in patients with advanced hepatocellular carcinoma, portal venous tumor thrombus in the major trunk, and multiple nodules. ( Dono, K; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Ota, H; Sakon, M; Takeda, Y; Umeshita, K; Wada, H, 2007) |
"The aim of the current study was to evaluate the antitumor activity and toxicity of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin (FMP therapy) in chemotherapy-naive patients with metastatic hepatocellular carcinoma (HCC)." | 9.11 | A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma. ( Ikeda, M; Morizane, C; Okusaka, T; Takezako, Y; Ueno, H, 2005) |
"To evaluate the efficacy of combination chemotherapy with interferon-alpha (IFNalpha) and 5-fluorouracil (5-FU) in patients with advanced hepatocellular carcinoma (HCC)." | 9.11 | Re-evaluation of antitumor effects of combination chemotherapy with interferon-alpha and 5-fluorouracil for advanced hepatocellular carcinoma. ( Enjoji, M; Kohjima, M; Kotoh, K; Miyagi, Y; Morizono, S; Nakamuta, M; Yoshimoto, T, 2005) |
"We tested the efficacy of a systemic chemotherapy regimen combining epirubicin, cisplatinum and infusional 5-fluorouracil (ECF) in a cohort of patients with hepatocellular carcinoma (HCC) who could not be given surgical, intraarterial or percutaneous treatment." | 9.10 | Treatment of hepatocellular carcinoma (HCC) with systemic chemotherapy combining epirubicin, cisplatinum and infusional 5-fluorouracil (ECF regimen). ( Boucher, E; Boudjema, K; Brissot, P; Corbinais, S; Raoul, JL, 2002) |
"Because cirrhosis is extremely common in hepatocellular carcinoma (HCC) in the United States, and it precludes the use of several chemotherapy agents, this phase II trial of fluorouracil (FU) and recombinant interferon alfa-2b (rIFNalpha2b) in HCC was launched with the assumption that it could be tolerated by cirrhotics." | 9.10 | Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma. ( Brown, TD; Curley, SA; Ellis, LM; Hassan, MM; Lozano, RD; Patt, YZ; Vauthey, JN, 2003) |
"In this study the maximum tolerated dose of 5-fluorouracil administered by 5-day (120-h) continuous infusion every 4 weeks was investigated and the pharmacokinetics in patients with hepatocellular carcinoma were evaluated." | 9.10 | Phase I and pharmacokinetic study of 5-fluorouracil administered by 5-day continuous infusion in patients with hepatocellular carcinoma. ( Ikeda, M; Kuriyama, H; Okada, S; Okusaka, T; Ueno, H, 2002) |
"This multicenter, open-label study evaluated a 28-day oral regimen of 5-FU (1 mg/m2 twice daily) plus the dihydropyrimidine dehydrogenase inhibitor, eniluracil (10 mg/m2 twice daily), in patients with chemotherapy-naive or anthracycline-refractory inoperable hepatocellular carcinoma." | 9.10 | Oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma. ( Abramson, N; Benson, AB; Bonny, T; Burnhan, JP; Hohneker, J; Klencke, B; Levin, J; McGuirt, C; Mitchell, E; Ritch, P, 2002) |
"A phase II trial of 5-fluorouracil (5-FU) [250-450 mg/m2/day x 5 days as an intravenous (IV) bolus] combined with calcium leucovorin (500 mg/m2/day x 5 1/2 days by continuous IV infusion) administered on a 28-day schedule was performed in 15 patients with advanced hepatocellular carcinoma." | 9.08 | 5-Fluorouracil and high-dose calcium leucovorin for hepatocellular carcinoma: a phase II trial. ( Akman, S; Coluzzi, P; Doroshow, J; Leong, L; Margolin, K; Morgan, RJ; Raschko, J; Shibata, S; Somlo, G; Tetef, M, 1995) |
"A 52 years old female with hepatocellular carcinoma (HCC) was treated successfully with Tamoxifen." | 8.77 | [Hepatocellular carcinoma (HCC): the long-term response to tamoxifen. A clinical case report and review of the literature]. ( Belli, L; Morgante, A; Passalacqua, G; Rabitti, G; Recchia, F; Rodorigo, C, 1989) |
"Evaluate the efficacy and safety of triple therapeutic method (Hepatic Aarterial Infusion Chemotherapy-HAIC, lenvatinib and sequential ablation) in the treatment for Advanced Hepatocellular carcinoma (Ad-HCC)." | 8.31 | Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and sequential ablation in the treatment of advanced hepatocellular carcinoma. ( An, C; Guo, J; Li, C; Li, W; Lin, Y; Liu, Y; Qiao, Y; Zhou, M, 2023) |
"Hepatic arterial infusion chemotherapy (HAIC) with fluorouracil, leucovorin, and oxaliplatin (FOLFOX), lenvatinib and programmed death receptor-1 signaling inhibitors (PD1s) all alone have been proven effective in treating advanced hepatocellular carcinoma (HCC), yet the efficacy and safety of the tri-combination therapy in treating HCC patients with portal vein tumor thrombosis (PVTT) remains unknown." | 8.31 | Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis. ( Chen, J; Chen, M; Fu, Y; Hu, D; Hu, Z; Pang, Y; Peng, W; Wang, J; Xu, L; Yang, Z; Zhang, W; Zhang, Y; Zhou, Z, 2023) |
"0NHAC-FUA) was fabricated through an amide condensation reaction to improve the therapeutic efficacy of 5-Fluorouracil (5-FU) in hepatocellular carcinoma (HCC)." | 8.12 | Functionalized PAMAM-based Nanoformulation for Targeted Delivery of 5-Fluorouracil in Hepatocellular Carcinoma. ( Chen, H; Chen, S; He, D; Li, Q; Liu, D; Ouyang, H; Pan, W; Wang, X; Xie, W; Yu, C, 2022) |
"Hepatic arterial infusion chemotherapy (HAIC) with oxaliplatin and 5-fluorouracil was effective in unresectable hepatocellular carcinoma (HCC)." | 8.12 | One day versus two days of hepatic arterial infusion with oxaliplatin and fluorouracil for patients with unresectable hepatocellular carcinoma. ( Chen, M; He, M; Huang, Y; Kan, A; Lai, Z; Li, Q; Lin, X; Shi, M; Wei, W; Wen, D; Xu, L, 2022) |
"Objective To investigate the effect of curcumin combined with 5-FU on autophagy and Yes-associated protein (YAP) expression in hepatocellular carcinoma cells." | 8.02 | [Curcumin combined with 5-FU promotes autophagy and down-regulates the expression of Yes-associated protein (YAP) in hepatocellular carcinoma cells]. ( Wang, X; Zhu, J, 2021) |
" The differentiation-inducing capacity of arsenic trioxide (ATO) in hepatocellular carcinoma (HCC) and the underlying mechanism were previously unknown." | 8.02 | Arsenic trioxide induces differentiation of cancer stem cells in hepatocellular carcinoma through inhibition of LIF/JAK1/STAT3 and NF-kB signaling pathways synergistically. ( Cao, Y; Cheng, JW; Fan, J; Hu, B; Huang, A; Huang, XW; Qiu, SJ; Sun, YF; Yang, XR; Zeng, HY; Zhang, X; Zhou, J, 2021) |
" sorafenib as sequential maintenance therapy following liver-directed concurrent chemoradiotherapy (LD-CCRT) for locally advanced-stage hepatocellular carcinoma (HCC)." | 8.02 | Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma. ( Ahn, SH; Beom, SH; Choi, HJ; Han, KH; Han, S; Kim, BK; Kim, DY; Kim, HR; Kim, SU; Lee, H; Lee, HW; Lee, JS; Park, JY; Seong, J; Won, JY, 2021) |
"To compare the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) with a modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX) regimen with that of transarterial chemoembolization as a locoregional treatment for patients with locally advanced hepatocellular carcinoma (HCC)." | 8.02 | Hepatic Artery Infusion Chemotherapy Using Fluorouracil, Leucovorin, and Oxaliplatin versus Transarterial Chemoembolization as Initial Treatment for Locally Advanced Hepatocellular Carcinoma: A Propensity Score-Matching Analysis. ( Deng, H; Han, X; He, M; Lai, J; Li, J; Li, S; Lyu, N; Shi, M; Wang, H; Zhao, M, 2021) |
"The first choice of treatment in Hepatocellular Carcinoma (HCC) is 5-fluorouracil (5-FU)." | 7.96 | Targeted Nanoparticles for Co-delivery of 5-FU and Nitroxoline, a Cathepsin B Inhibitor, in HepG2 Cells of Hepatocellular Carcinoma. ( Fard, MM; Hassanzadeh, F; Mirian, M; Varshosaz, J, 2020) |
"Intestinal mucositis is the most common side effect of 5-fluorouracil (5-Fu) treatment in cancer patients." | 7.96 | Protective effect of Andrographolide on 5-Fu induced intestinal mucositis by regulating p38 MAPK signaling pathway. ( Li, M; Liu, D; Xiang, DC; Xu, YJ; Yang, JY; Zhang, CL; Zhang, S; Zhu, C, 2020) |
"To compare the outcome of hepatic arterial infusion chemotherapy combined with radiotherapy (HAIC + RT) versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma (HCC) and major portal vein tumor thrombosis (PVTT)." | 7.88 | Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor Thrombosis. ( Aikata, H; Aisaka, Y; Chayama, K; Hatooka, M; Hiramatsu, A; Honda, Y; Hyogo, H; Imamura, M; Inagaki, Y; Kawakami, Y; Kawaoka, T; Kimura, T; Kodama, K; Kohno, H; Masaki, K; Mori, N; Morio, K; Moriya, T; Murakami, E; Nagata, Y; Nakahara, T; Nishida, Y; Nonaka, M; Takaki, S; Tsuge, M; Tsuji, K; Uchikawa, S, 2018) |
"To compare the overall survival (OS) and disease progression free survival (PFS) in patients with advanced hepatocellular carcinoma (Ad-HCC) who are undergoing hepatic arterial infusion (HAI) of oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment vs." | 7.88 | Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma. ( Cai, X; Deng, H; Guo, R; Kong, Y; Li, J; Li, S; Lin, Y; Liu, Y; Lyu, N; Mu, L; Shi, M; Wu, P; Xie, Q; Xu, L; Zhang, Z; Zhao, M; Zheng, L, 2018) |
"5-Fluorouracil (5-FU) has been widely applied to treat various types of cancers, including hepatocellular carcinoma (HCC)." | 7.88 | lncRNA KRAL reverses 5-fluorouracil resistance in hepatocellular carcinoma cells by acting as a ceRNA against miR-141. ( Lin, X; Pan, C; Shi, L; Shi, Y; Wei, X; Wu, L; Zheng, J, 2018) |
"We investigated the role of vitamin D (Vit D) alone and in combination with 5-fluorouracil (5-FU) in thioacetamide (TAA)-induced hepatocellular carcinoma (HCC) in rats." | 7.88 | Vitamin D potentiates anti-tumor activity of 5-fluorouracil via modulating caspase-3 and TGF-β1 expression in hepatocellular carcinoma-induced in rats. ( Eissa, LA; El-Karef, A; El-Mesery, M; R Ebrahim, A, 2018) |
"Argininosuccinate synthetase (ASS), a key enzyme to synthesize arginine is down regulated in many tumors including hepatocellular carcinoma (HCC)." | 7.85 | The Combination of Arginine Deprivation and 5-Fluorouracil Improves Therapeutic Efficacy in Argininosuccinate Synthetase Negative Hepatocellular Carcinoma. ( Bhudhisawasdi, V; Li, YY; Navasumrit, P; Parnlob, V; Ruchirawat, M; Savaraj, N; Sricharunrat, T; Thongkum, A; Wangpaichitr, M; Wu, C, 2017) |
"This study aimed to investigate the therapeutic effects of 5-fluorouracil (5-FU)-loaded nanobubbles irradiated with low-intensity, low-frequency ultrasound in nude mice with hepatocellular carcinoma (HCC)." | 7.85 | The use of 5-fluorouracil-loaded nanobubbles combined with low-frequency ultrasound to treat hepatocellular carcinoma in nude mice. ( Deng, H; He, C; Jing, Z; Li, H; Li, Q; Liu, C; Ma, W; Xie, J, 2017) |
" Here, we investigated the synergistic effect of OMT with 5-fluorouracil (5-Fu) on the tumor growth inhibition of hepatocellular carcinoma cells (HCC; Hep-G2 and SMMC-7721) and explored the underlying mechanism." | 7.83 | Oxymatrine synergistically enhances the inhibitory effect of 5-fluorouracil on hepatocellular carcinoma in vitro and in vivo. ( Bi, T; Dai, W; Gao, Q; Liu, Y; Qian, L; Shen, G; Wang, G, 2016) |
"To compare the outcome of 5-fluorouracil (FU)-based hepatic arterial infusion chemotherapy (HAIC) with sorafenib monotherapy in patients with hepatocellular carcinoma (HCC) refractory to transcatheter arterial chemoembolization (TACE)." | 7.83 | Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy and Sorafenib in Patients with Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization. ( Aikata, H; Aisaka, Y; Chayama, K; Hatooka, M; Hiramatsu, A; Honda, Y; Hyogo, H; Imamura, M; Kawakami, Y; Kawaoka, T; Kobayashi, T; Kohno, H; Mori, N; Morio, K; Moriya, T; Murakami, E; Nonaka, M; Takaki, S; Tsuji, K; Waki, K, 2016) |
"This study aimed to investigate the pharmaco-economic implications of FOLFOX4 or sorafenib for advanced hepatocellular carcinoma in China." | 7.83 | FOLFOX4 or sorafenib as the first-line treatments for advanced hepatocellular carcinoma: A cost-effectiveness analysis. ( Li, Q; Wen, F; Zhang, P, 2016) |
"The aim of this study was to compare the efficacy of hepatic arterial infusion chemotherapy (HAIC) and sorafenib in advanced hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT)." | 7.81 | A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. ( Bae, SH; Cho, SB; Chung, WJ; Jang, JY; Kim, YS; Lee, SH; Park, JY; Park, SY; Song, DS; Song, MJ; Yang, JM; Yim, HJ, 2015) |
" Here, we investigated the correlation between microRNA-21 expression and hepatic arterial infusion chemotherapy with 5-fluorouracil and pirarubicin (HAIC) for hepatocellular carcinoma (HCC)." | 7.81 | Targeting the microRNA-21/AP1 axis by 5-fluorouracil and pirarubicin in human hepatocellular carcinoma. ( Chen, S; Dong, L; Guo, W; He, X; Kong, Y; Li, J; Liu, C; Liu, W; Song, W; Wang, F; Yu, J; Yu, S; Zheng, Y, 2015) |
" The present study is designed to explore the influence of CGA on the effects of 5-fluorouracil (5-FU) on human hepatocellular carcinoma cells (HepG2 and Hep3B)." | 7.81 | Chlorogenic acid enhances the effects of 5-fluorouracil in human hepatocellular carcinoma cells through the inhibition of extracellular signal-regulated kinases. ( Dong, L; Han, J; Hou, N; Li, J; Song, Y; Yan, Y, 2015) |
"To investigate transarterial chemoembolization (TACE) with hepatic infusion of oxaliplatin and 5-fluorouracil and Lipiodol chemoembolization in large hepatocellular carcinoma (HCC)." | 7.81 | Oxaliplatin and 5-fluorouracil hepatic infusion with lipiodolized chemoembolization in large hepatocellular carcinoma. ( Chen, RX; Chen, Y; Gan, YH; Ge, NL; Le, F; Li, JH; Li, LX; Ren, ZG; Wang, YH; Xia, JL; Xie, XY; Xue, TC; Ye, SL; Zhang, BH; Zhang, JB; Zhang, L, 2015) |
"Sorafenib is the standard treatment for advanced hepatocellular carcinoma (HCC) with distant metastasis, unresectable HCC, and those refractory to transcatheter arterial chemoembolization (TACE) or with macroscopic vascular invasion (MVI)." | 7.81 | Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma. ( Aikata, H; Chayama, K; Fukuhara, T; Hatooka, M; Hiramatsu, A; Hyogo, H; Imamura, M; Kawakami, Y; Kawaoka, T; Kobayashi, T; Kohno, H; Miyaki, D; Morio, K; Morio, R; Moriya, T; Naeshiro, N; Takahashi, S; Tsuji, K; Waki, K, 2015) |
"5-Fluorouracil (5-FU) is one of the most common chemotherapeutic agents used for the treatment of hepatocellular carcinoma (HCC)." | 7.80 | The monoclonal antibody CH12 augments 5-fluorouracil-induced growth suppression of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III. ( Dong, Q; Gao, H; Jiang, H; Kong, J; Li, Z; Luo, X; Shi, B; Wang, H; Zhang, J, 2014) |
"Sorafenib treatment has shown to improve the survival in patients with advanced hepatocellular carcinoma (HCC) when compared with placebo." | 7.80 | Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability. ( Byun, KS; Kang, K; Kang, SH; Kim, JH; Lee, HJ; Lee, SJ; Suh, SJ; Yeon, JE; Yim, HJ; Yoo, YJ; Yoon, EL, 2014) |
"To evaluate the clinical efficacy and safety of epirubicin, cisplatin, and 5-FU combination chemotherapy for the sorafenib-refractory metastatic hepatocellular carcinoma (HCC)." | 7.80 | Epirubicin, cisplatin, 5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma. ( Bae, SH; Choi, JY; Lee, JE; Lee, MA; Yoon, SK; You, YK, 2014) |
"5-fluorouracil (5-FU)-based chemotherapy is widely used in the treatment of human hepatocellular carcinoma." | 7.80 | Overexpression of microRNA-125b sensitizes human hepatocellular carcinoma cells to 5-fluorouracil through inhibition of glycolysis by targeting hexokinase II. ( Gao, S; Jiang, JX; Pan, YZ; Sun, CY; Yu, C, 2014) |
" The present study investigated the ability of metformin to reverse multidrug resistance (MDR) in human hepatocellular carcinoma Bel‑7402/5‑fluorouracil (5‑Fu; Bel/Fu) cells." | 7.80 | Metformin reverses multidrug resistance in human hepatocellular carcinoma Bel‑7402/5‑fluorouracil cells. ( Feng, T; Gao, Z; Hou, Z; Jia, K; Li, Y; Ling, S; Sun, D; Tian, Y; Wang, L; Xu, F; Zhang, H, 2014) |
"Oral tegafur/uracil therapy has been indicated for patients with hepatocellular carcinoma (HCC) and is often used as a single-agent treatment." | 7.79 | Genetic polymorphisms of enzymes related to oral tegafur/uracil therapeutic efficacy in patients with hepatocellular carcinoma. ( Akizuki, S; Fushiya, N; Nishino, H; Ohnishi, A; Takagi, I, 2013) |
"The purpose of this study was to evaluate the factors associated with response rate, resectability, and survival after cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) combination therapy in patients with initially unresectable hepatocellular carcinoma." | 7.79 | Modified cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma. ( Abbruzzese, JL; Aloia, TA; Curley, SA; Hassabo, HM; Hassan, MM; Kaseb, AO; Lozano, RD; Patt, YZ; Roses, RE; Shindoh, J; Vauthey, JN; Zimmitti, G, 2013) |
"Recently, a phase II clinical trial in hepatocellular carcinoma (HCC) has suggested that the combination of sorafenib and 5-fluorouracil (5-FU) is feasible and side effects are manageable." | 7.79 | Schedule-dependent antitumor effects of 5-fluorouracil combined with sorafenib in hepatocellular carcinoma. ( Deng, L; Jia, Q; Ren, Z; Shen, H; Wang, Y; Wu, W, 2013) |
"To investigate the efficacy and safety of capecitabine and oxaliplatin (CapeOx) for extrahepatic metastasis after local treatment of hepatocellular carcinoma (HCC)." | 7.79 | Efficacy of capecitabine and oxaliplatin regimen for extrahepatic metastasis of hepatocellular carcinoma following local treatments. ( Dong, JC; He, SL; Liu, LM; Shen, J; Sun, XJ; Zhu, XJ, 2013) |
"A 57-year-old Caucasian man with a history of Child's class A hepatitis C, cirrhosis and progressive multifocal hepatocellular carcinoma was treated with sorafenib but progressed after 7 months of stable disease." | 7.79 | Complete radiographic remission with 5-fluorouracil and leucovorin after sorafenib failure in hepatocellular carcinoma: is there a role for chemotherapy after targeted agents? ( Tan-Shalaby, J, 2013) |
" The aim of this study is to investigate the role and mechanism of mir-23a in enhancing the anti-tumor effect of topoisomerase 2A (TOP2A) poison etoposide in human hepatocellular carcinoma (HCC)." | 7.79 | MiR-23a-mediated inhibition of topoisomerase 1 expression potentiates cell response to etoposide in human hepatocellular carcinoma. ( Feng, Y; Man, K; Tsao, SW; Wang, N; Zhang, Z; Zhu, M, 2013) |
"We report a case of long-term survival of a patient with hepatocellular carcinoma( HCC) with portal vein tumor thrombus (PVTT) treated with fluorouracil arterial infusion and interferon therapy (FAIT)." | 7.79 | [Long-term survival of a patient with hepatocellular carcinoma with portal vein tumor thrombus treated with interferon-α and 5-fluorouracil combination therapy]. ( Akita, H; Doki, Y; Eguchi, H; Hama, N; Kawamoto, K; Kobayashi, S; Mori, M; Nagano, H; Tomimaru, Y; Tsuda, Y; Umeshita, K; Wada, H, 2013) |
"Thalidomide has shown modest activity in advanced hepatocellular carcinomas (HCCs)." | 7.78 | Activity of thalidomide and capecitabine in patients with advanced hepatocellular carcinoma. ( Ang, SF; Choo, SP; Foo, KF; Ong, SY; Poon, DY; Tan, SH; Toh, HC, 2012) |
"Tanshinone IIA (Tan-IIA) decreases the viability of human hepatocellular carcinoma (HCC) cells through the induction of apoptosis in vitro." | 7.78 | Tanshinone IIA inhibits human hepatocellular carcinoma J5 cell growth by increasing Bax and caspase 3 and decreasing CD31 expression in vivo. ( Chen, DR; Chen, YL; Cheng, CY; Chien, SY; Kuo, SJ; Su, CC, 2012) |
"We examined the background, survival rates, median survival time and side effects of 15 cases in which systemic chemotherapy using carboplatin and 5-fluorouracil was done (chemotherapy group) and 59 cases in which chemotherapy was not done (non-chemotherapy group) out of a total of 74 cases of patients with extrahepatic metastasis from hepatocellular carcinoma." | 7.78 | Systemic chemotherapy using carboplatin and 5-fluorouracil for extrahepatic metastasis of hepatocellular carcinoma. ( Fukunaga, A; Hirano, G; Irie, M; Iwashita, H; Iwata, K; Kunimoto, H; Morihara, D; Sakamoto, M; Sakisaka, S; Sakurai, K; Shakado, S; Sohda, T; Takeyama, Y; Ueda, S; Yokoyama, K; Yotsumoto, K, 2012) |
"Cancer stem-like cells previusly isolated from a hepatocellular carcinoma biopsy were treated with metformin, PIAF chemotherapy regimen and the combination of these two protocols." | 7.78 | Metformin plus PIAF combination chemotherapy for hepatocellular carcinoma. ( Aldea, M; Berindan, I; Cristea, V; Irimie, A; Kacso, G; Petrushev, B; Pop, T; Soritau, O; Susman, S; Tomuleasa, C, 2012) |
"Hepatic arterial infusion chemotherapy (HAIC) combined with sorafenib is considered to be a promising therapeutic strategy for patients with advanced hepatocellular carcinoma." | 7.78 | Hepatic arterial thrombosis: a critical complication during combination therapy of arterial chemoinfusion and sorafenib. ( Anai, H; Kichikawa, K; Maeda, S; Masada, T; Nishiofuku, H; Sueyoshi, S; Tanaka, T, 2012) |
"There has been no report on sorafenib therapy in patients with metastatic hepatocellular carcinoma (HCC) who had been treated with systemic chemotherapy." | 7.77 | Clinical outcomes of sorafenib treatment in patients with metastatic hepatocellular carcinoma who had been previously treated with fluoropyrimidine plus platinum-based chemotherapy. ( Bang, YJ; Han, SW; Im, SA; Kim, JW; Kim, TY; Lee, JO; Oh, DY, 2011) |
"Although 5-fluorouracil (5-FU) is one of the most commonly used chemotherapeutic agents in various cancer including hepatocellular carcinoma (HCC), chemoresistance has precluded single use of 5-FU in clinical settings." | 7.77 | Vitamin K2 augments 5-fluorouracil-induced growth inhibition of human hepatocellular carcinoma cells by inhibiting NF-κB activation. ( Eguchi, Y; Hamajima, H; Iwane, S; Kawaguchi, Y; Mizuta, T; Ozaki, I; Takahashi, H; Yamamoto, K; Zhang, H, 2011) |
"This study evaluated the efficacy of combined 5-fluorouracil (5-FU) and pegylated interferon (PEG-IFN) α-2b in patients with advanced hepatocellular carcinoma (HCC)." | 7.77 | Combination therapy of intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma. ( Kasai, K; Kasai, Y; Kuroda, H; Miyamoto, Y; Oikawa, K; Sawara, K; Suzuki, K; Takikawa, Y; Ushio, A, 2011) |
"Many clinical reports have proven that the combination therapy of interferon-alpha plus 5-fluorouracil is remarkably effective for advanced hepatocellular carcinoma (HCC)." | 7.77 | Combination of interferon-α and 5-fluorouracil induces apoptosis through mitochondrial pathway in hepatocellular carcinoma in vitro. ( Deng, B; Mao, H; Qu, X; Sun, J; Wang, Q; Xie, F; Yang, Y; Yin, H; Zhang, J, 2011) |
"To evaluate the efficacy of intra-arterial 5-fluorouracil (5-FU) and subcutaneous interferon (IFN) combined with image-guided radiation therapy (IGRT) in advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT)." | 7.77 | Efficacy of therapy for advanced hepatocellular carcinoma: intra-arterial 5-fluorouracil and subcutaneous interferon with image-guided radiation. ( Abo, D; Asaka, M; Chuma, M; Hige, S; Horimoto, H; Kato, M; Kobayashi, T; Nakai, M; Nakanishi, M; Ogawa, K; Sakuhara, Y; Shimizu, S; Shirato, H; Sho, T; Taguchi, H; Terashita, K; Tsukuda, Y; Tsunematsu, S; Yamamoto, Y, 2011) |
"We previously reported the beneficial effects of a combination therapy of interferon (IFN)-α/5-fluorouracil (FU) for advanced hepatocellular carcinoma (HCC) with tumor thrombi in the major portal branches." | 7.77 | Long-term outcome of combined interferon-α and 5-fluorouracil treatment for advanced hepatocellular carcinoma with major portal vein thrombosis. ( Doki, Y; Eguchi, H; Kobayashi, S; Marubashi, S; Mori, M; Nagano, H; Osuga, K; Tanemura, M; Tomimaru, Y; Umeshita, K; Wada, H, 2011) |
"To investigate the apoptotic activities of casticin in hepatocellular carcinoma (HCC) cells and its molecular mechanisms." | 7.77 | Casticin-induced apoptosis involves death receptor 5 upregulation in hepatocellular carcinoma cells. ( Cao, JG; Liu, F; Sheng, XF; Tian, L; Yang, J; Yang, Y, 2011) |
"Sorafenib is the only therapy approved for advanced hepatocellular carcinoma no longer eligible for transcatheter arterial chemoembolization." | 7.77 | Hepatic intra-arterial cetuximab in combination with 5-fluorouracil and cisplatin as salvage treatment for sorafenib-refractory hepatocellular carcinoma. ( Bernardo, G; Cornalba, G; Delmonte, A; Di Cesare, P; Greco, G; Melchiorre, F; Montagna, B; Poggi, G; Quaretti, P; Riccardi, A; Sottotetti, F; Stella, MG; Tagliaferri, B; Villani, L; Zorzetto, M, 2011) |
"We report a case of successful treatment by interferon-α (IFN) and 5-fluorouracil (5-FU) combination therapy and transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT)." | 7.77 | [A case of successful treatment by interferon-α and 5-fluorouracil combination therapy (FAIT) and transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus]. ( Doki, Y; Eguchi, H; Kawamoto, K; Kishimoto, T; Kobayashi, S; Marubashi, S; Mori, M; Nagano, H; Tanemura, M; Umeshita, K; Wada, H, 2011) |
"To investigate the synergistic inhibitory effects of the combination of 5-fluorouracil (5-FU) with the natural flavanoid oroxylin A on human hepatocellular carcinoma cells HepG2 in vitro and on transplanted murine hepatoma 22 (H22) tumors in vivo and the preliminary mechanisms." | 7.76 | Synergistic effect of 5-fluorouracil and the flavanoid oroxylin A on HepG2 human hepatocellular carcinoma and on H22 transplanted mice. ( Chen, Z; Guo, QL; Mu, R; Qi, Q; Wang, J; Yang, L; You, QD; Zhao, L; Zhao, Q, 2010) |
"We investigated the efficacy of intra-arterial 5-fluorouracil (5-FU) and systemic interferon (IFN)-alpha (5-FU-IFN) in the treatment of hepatocellular carcinoma (HCC) with portal vein tumor thrombosis in the first branch or trunk (Vp3/4) and extrahepatic metastases." | 7.76 | Intra-arterial 5-fluorouracil/interferon combination therapy for hepatocellular carcinoma with portal vein tumor thrombosis and extrahepatic metastases. ( Aikata, H; Chayama, K; Hieda, M; Hiramatsu, A; Ishikawa, M; Kakizawa, H; Katamura, Y; Kawakami, Y; Kawaoka, T; Kimura, Y; Takahashi, S; Takaki, S; Waki, K, 2010) |
"The effects and mechanisms of action of beta-aescin and 5-fluorouracil (5-FU), alone and in combination, were studied in human hepatocellular carcinoma SMMC-7721 cells." | 7.76 | Synergistic effects of beta-aescin and 5-fluorouracil in human hepatocellular carcinoma SMMC-7721 cells. ( Cao, L; Hu, Y; Ming, ZJ; Qiu, YH; Zhang, XG, 2010) |
"Five fluorouracil (5-FU) is extensively used in the treatment of hepatocellular carcinoma (HCC)." | 7.76 | Novel biochemical pathways for 5-Fluorouracil in managing experimental hepatocellular carcinoma in rats. ( Abdel-Hamid, NM; Morsy, MA, 2010) |
"We reported recently the clinical efficiency of interferon (IFN)-α/5-fluorouracil (5-FU) combination therapy in advanced hepatocellular carcinoma (HCC)." | 7.76 | MicroRNA-21 induces resistance to the anti-tumour effect of interferon-α/5-fluorouracil in hepatocellular carcinoma cells. ( Doki, Y; Eguchi, H; Kobayashi, S; Marubashi, S; Mori, M; Nagano, H; Takeda, Y; Tanemura, M; Tomimaru, Y; Tomokuni, A; Umeshita, K; Wada, H, 2010) |
"Type I IFN receptor type 2 (IFNAR2) expression correlates significantly with clinical response to interferon (IFN)-alpha/5-fluorouracil (5-FU) combination therapy for hepatocellular carcinoma (HCC)." | 7.75 | Activation of Wnt/beta-catenin signalling pathway induces chemoresistance to interferon-alpha/5-fluorouracil combination therapy for hepatocellular carcinoma. ( Doki, Y; Dono, K; Kobayashi, S; Marubashi, S; Matsubara, K; Matsuura, N; Monden, M; Mori, M; Murakami, M; Nagano, H; Noda, T; Takeda, Y; Takemasa, I; Umeshita, K; Wada, H; Yoshioka, S, 2009) |
"We evaluated the efficacy and toxicity of combination chemotherapy with capecitabine and cisplatin (XP) in patients with metastatic hepatocellular carcinoma (HCC)." | 7.75 | Combination chemotherapy with capecitabine and cisplatin for patients with metastatic hepatocellular carcinoma. ( Bang, YJ; Im, SA; Kim, JH; Kim, TY; Lee, JO; Lee, KW; Oh, DY, 2009) |
"Resistance to 5-fluorouracil (5-FU) is a major cause of chemotherapy failure in advanced hepatocellular carcinoma (HCC)." | 7.75 | Rosiglitazone sensitizes hepatocellular carcinoma cell lines to 5-fluorouracil antitumor activity through activation of the PPARgamma signaling pathway. ( Cao, LQ; Chen, JS; Chen, XL; Fu, XH; Huang, XH; Jiao, XY; Lu, HW; Peng, HP; Wang, Q; Wang, XL; Xue, P; Zheng, Q, 2009) |
"In this retrospective study, we assessed the efficacy of hepatic arterial infusion chemotherapy (HAIC) using high-dose 5-fluorouracil (5-FU) and cisplatin with or without interferon (IFN)-alpha for the treatment of advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis." | 7.75 | Hepatic arterial infusion chemotherapy using high-dose 5-fluorouracil and cisplatin with or without interferon-alpha for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis. ( Chang, JC; Eun, JR; Kim, JW; Kim, TN; Lee, HJ; Moon, HJ, 2009) |
"The aim was to assess the efficacy and safety of capecitabine (X) plus cisplatin (P) in patients with hepatocellular carcinoma (HCC)." | 7.75 | Efficacy of combination chemotherapy with capecitabine plus cisplatin in patients with unresectable hepatocellular carcinoma. ( Kim, CM; Lee, WJ; Nam, BH; Park, JW; Shim, JH, 2009) |
"Epigallocatechin gallate (EGCG) from green tea could reverse multidrug resistance (MDR) in human hepatocellular carcinoma (HCC) in vitro and in vivo." | 7.74 | [Impact of epigallocatechin gallate on gene expression profiles of human hepatocellular carcinoma cell lines BEL7404/ADM and BEL7402/5-FU]. ( Liang, G; Tang, HH; Zhou, M, 2008) |
"We report a case of combined hepatocellular and cholangiocarcinoma showing tumor growth and invasion to the diaphragm during interferon-alpha (IFN-alpha) and 5-fluorouracil (5-FU) combined intra-arterial chemotherapy." | 7.74 | [A case of combined hepatocellular and cholangiocarcinoma showing tumor growth and invasion to the diaphragm during interferon-alpha and 5-fluorouracil combined intra-arterial chemotherapy]. ( Doki, Y; Dono, K; Kobayashi, S; Marubashi, S; Monden, M; Mori, M; Murakami, M; Nagano, H; Nakayama, M; Noda, T; Shima, T; Takeda, Y; Tomimaru, Y; Umeshita, K; Wakasa, K, 2008) |
"Several studies have reported the efficacy of combination therapy of interferon (IFN) alpha and 5-fluorouracil (5-FU) for hepatocellular carcinoma (HCC)." | 7.74 | Role of the Fas/FasL pathway in combination therapy with interferon-alpha and fluorouracil against hepatocellular carcinoma in vitro. ( Damdinsuren, B; Dono, K; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Noda, T; Ota, H; Sakon, M; Takeda, Y; Umeshita, K; Wada, H; Yamamoto, T, 2007) |
" The aim of our current study was to examine the combined effect of ACE-I and 5-fluorouracil (5-FU), which is widely used for hepatogastrointestinal tumors, on hepatocellular carcinoma (HCC) growth and hepatocarcinogenesis." | 7.74 | Synergistic inhibition of hepatocellular carcinoma growth and hepatocarcinogenesis by combination of 5-fluorouracil and angiotensin-converting enzyme inhibitor via anti-angiogenic activities. ( Akahane, T; Asada, K; Fukui, H; Ikenaka, Y; Kaji, K; Kitade, M; Namisaki, T; Noguchi, R; Tsujimoto, T; Uemura, M; Yamazaki, M; Yanase, K; Yoshii, J; Yoshiji, H, 2007) |
"We experienced a patient who received successful treatment for multiple hepatocellular carcinoma (HCC) nodules, with tumor thrombi in the major portal branches, with intraarterial 5-fluorouracil perfusion chemotherapy combined with subcutaneous interferon-alpha administration." | 7.74 | Successful treatment of multiple hepatocellular carcinoma with tumor thrombi in the major portal branches by intraarterial 5-fluorouracil perfusion chemotherapy combined with subcutaneous interferon-alpha and hepatectomy. ( Damdinsuren, B; Dono, K; Fukuda, K; Imai, Y; Kondo, M; Matsumoto, H; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Noda, T; Ota, H; Sakon, M; Umeshita, K; Wada, H; Wakasa, K; Yamamoto, T, 2007) |
"We encountered a case of peritoneal dissemination of hepatocellular carcinoma, successfully treated with a combination therapy of interferon-alpha-2b and oral tegafur/uracil." | 7.74 | Peritoneal dissemination of hepatocellular carcinoma treated with a combination therapy of interferon-alpha-2b and oral tegafur/uracil. ( Iwasaki, Y; Miyake, Y; Sakaguchi, K; Shiraha, H; Shiratori, Y, 2007) |
"We experienced 20 cases of advanced hepatocellular carcinoma with portal vein tumor thrombosis treated with low-dose cisplatin and 5-fluorouracil (5-FU) chemotherapy via implanted fusion port between August 1999 and September 2003." | 7.74 | [Clinical study of low-dose cisplatin and 5-fluorouracil chemotherapy via implanted fusion port in 20 patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis]. ( Abe, T; Arai, H; Hagiwara, S; Hamada, T; Kosone, T; Naganuma, A; Takagi, H; Toyoda, M; Yanagisawa, M, 2007) |
"We report two cases of hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) and lymph node (LN) metastases successfully treated by hepatic arterial infusion of 5-fluorouracil (5-FU) combined with systemic injection of interferon (IFN)-alpha following hepatic resection for the liver tumor." | 7.74 | Complete remission of hepatocellular carcinoma with portal vein tumor thrombus and lymph node metastases by arterial infusion of 5-fluorouracil and interferon-alpha combination therapy following hepatic resection. ( Damdinsuren, B; Dono, K; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Noda, T; Sakon, M; Takeda, Y; Umeshita, K; Wada, H; Wakasa, K, 2007) |
"We recently reported that interferon-alpha (IFN-alpha) and 5-fluorouracil (5-FU) combination therapy in advanced hepatocellular carcinoma (HCC) achieved excellent clinical results." | 7.74 | Combination therapy of interferon-alpha and 5-fluorouracil inhibits tumor angiogenesis in human hepatocellular carcinoma cells by regulating vascular endothelial growth factor and angiopoietins. ( Arai, I; Damdinsuren, B; Doki, Y; Dono, K; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Noda, T; Ota, H; Sakon, M; Takeda, Y; Umeshita, K; Wada, H; Yamamoto, H, 2007) |
"Intra-arterial 5-fluorouracil (5-FU) plus interferon (IFN) combination therapy is effective against advanced hepatocellular carcinoma (HCC) with portal vein tumour thrombosis." | 7.74 | Similar effects of recombinant interferon-alpha-2b and natural interferon-alpha when combined with intra-arterial 5-fluorouracil for the treatment of advanced hepatocellular carcinoma. ( Aikata, H; Chayama, K; Hiramatsu, A; Ito, K; Jeong, SC; Kawakami, Y; Kodama, H; Miki, D; Shirakawa, H; Takahashi, S; Takaki, S; Toyota, N; Uka, K, 2007) |
"Several studies have reported survival benefits of combination therapy with intraarterial 5-fluorouracil (5-FU) and subcutaneous interferon (IFN) alpha for advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT)." | 7.74 | Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma. ( Aikata, H; Chayama, K; Ito, K; Jeong, SC; Kawaoka, T; Miki, D; Takahashi, S; Takaki, S; Toyota, N; Uka, K, 2007) |
"The combination of intra-arterial low-dose cisplatin and 5-fluorouracil (5-FU) is effective against advanced hepatocellular carcinoma (HCC)." | 7.74 | Systemic gemcitabine combined with intra-arterial low-dose cisplatin and 5-fluorouracil for advanced hepatocellular carcinoma: seven cases. ( Aikata, H; Chayama, K; Ito, K; Kawaoka, T; Miki, D; Saneto, H; Takahashi, S; Takaki, S; Toyota, N; Uka, K, 2008) |
"Several studies showed the effectiveness of combination therapy with IFN-alpha and 5-fluorouracil (5-FU) for advanced hepatocellular carcinoma." | 7.73 | Combination of IFN-alpha and 5-fluorouracil induces apoptosis through IFN-alpha/beta receptor in human hepatocellular carcinoma cells. ( Damdinsuren, B; Dono, K; Eguchi, H; Hiraoka, N; Kondo, M; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Ota, H; Sakon, M; Umeshita, K; Wada, H; Yamamoto, H; Yamamoto, T, 2005) |
"We previously reported the beneficial effects of combination therapy of interferon (IFN)-alpha/5-fluorouracil (FU) for advanced hepatocellular carcinoma (HCC) with tumour thrombi in the major portal branches." | 7.73 | Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression. ( Damdinsuren, B; Dono, K; Eguchi, H; Kondo, M; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Ota, H; Sakon, M; Umeshita, K; Wada, H; Wakasa, K; Yamamoto, T, 2005) |
"We report a case of hepatocellular carcinoma (HCC) treated successfully by transarterial chemoembolization (TACE) followed by combination therapy of 5-fluorouracil (5-FU) and pegylated interferon-alpha (PEG-IFN-alpha)." | 7.73 | Successful treatment of advanced hepatocellular carcinoma by combined administration of 5-fluorouracil and pegylated interferon-alpha. ( Kita, K; Kuriyama, S; Kurokohchi, K; Masaki, T; Takaguchi, K, 2005) |
"We report a case of complete disappearance of multiple lung metastases and mediastinal lymphnode metastasis by intravenous administration of 5-fluorouracil/cisplatin (FP) after operation for primary hepatocellular carcinoma (HCC)." | 7.73 | [Complete disappearance of metastatic lung tumors and mediastinal lymphnode in a case of hepatocellular carcinoma treated by low-dose 5-fluorouracil/cisplatin therapy]. ( Anami, Y; Izai, J; Komiya, H; Matsuda, Y; Oguma, S; Ota, T; Sazawa, Y; Yamaki, T, 2005) |
"We investigated the antiproliferative effects of interferon-alpha (IFN-alpha) and 5-fluorouracil (5-FU) in combination on a hepatocellular carcinoma (HCC) cell line." | 7.73 | Antiproliferative effects of 5-fluorouracil and interferon-alpha in combination on a hepatocellular carcinoma cell line in vitro and in vivo. ( Kojiro, M; Kojiro, S; Momosaki, S; Nishida, N; Ogasawara, S; Takemoto, Y; Yano, H, 2006) |
"Combination therapy with interferon (IFN)-alpha and 5-fluorouracil (5-FU) has been reported to show an improved therapeutic efficacy in patients with advanced hepatocellular carcinoma (HCC) but the mechanism behind this has not been completely elucidated." | 7.73 | The up-regulation of type I interferon receptor gene plays a key role in hepatocellular carcinoma cells in the synergistic antiproliferative effect by 5-fluorouracil and interferon-alpha. ( Hirano, K; Kojiro, M; Kuwano, M; Maruyama, Y; Oie, S; Ono, M; Terada, T; Ueno, T; Yamada, Y; Yano, H, 2006) |
"To investigate the antitumor effect of interferon-alpha 2a (IFN-alpha2a) combined with capecitabine on hepatocellular carcinoma (HCC) in nude mice in relation to thymidine phosphorylase (TP) expression." | 7.72 | Interferon-alpha 2a up-regulated thymidine phosphorylase and enhanced antitumor effect of capecitabine on hepatocellular carcinoma in nude mice. ( Fan, J; Liu, YK; Sun, QM; Tang, ZY; Wu, ZQ; Xiao, YS; Xue, Q; Ye, SL; Zhao, Y; Zhou, J, 2004) |
"We evaluated the anti-tumor efficacy and toxicity of 5-fluorouracil (5-FU), mitoxantrone, and cisplatin (FMP) in patients with advanced hepatocellular carcinoma (HCC), and conducted an analysis of the prognostic factors for response to such therapy and patient survival." | 7.72 | Chemotherapy using 5-fluorouracil, mitoxantrone, and cisplatin for patients with advanced hepatocellular carcinoma: an analysis of 63 cases. ( Chang, HK; Chang, WC; Chen, JS; Liau, CT; Lin, YC; Yang, TS, 2004) |
"5-Fluorouracil (5-FU) as chemotherapy in cases of hepatocellular carcinoma (HCC), was found to initiate hepatotoxic injuries, ascites, leucopenia, thrombocytopenia and myelosupression that limit its use." | 7.72 | A combination therapy with copper nicotinate complex reduces the adverse effects of 5-fluorouracil on patients with hepatocellular carcinoma. ( El-Saadani, MA, 2004) |
"The authors performed a retrospective analysis of all patients with hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), or gallbladder carcinoma (GBC) who were ever treated with oral capecitabine." | 7.72 | Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. ( Aguayo, A; Brown, TD; Charnsangavej, C; Curley, SA; Ellis, LM; Hassan, MM; Lozano, RD; Nooka, AK; Patt, YZ; Schnirer, II; Vauthey, JN; Wolff, RA, 2004) |
"Previously we reported combined chemo-immunotherapy, using interferon (IFN)-alpha and 5-fluorouracil (5-FU) for patients with advanced hepatocellular carcinoma (HCC), and this regimen improved the prognosis." | 7.72 | Interstitial pneumonia induced by combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma. ( Aozasa, K; Dono, K; Hoshida, Y; Iizuka, N; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Sakon, M; Tomita, Y; Umeshita, K; Yamamoto, S, 2004) |
"Recently, combined chemotherapy with 5-fluorouracil (5-FU) and interferon (IFN)-alpha has been reported to show marked effects in patients with advanced hepatocellular carcinoma." | 7.72 | Genes associated with human hepatocellular carcinoma cell chemosensitivity to 5-fluorouracil plus interferon-alpha combination chemotherapy. ( Hoshida, Y; Kato, N; Kawabe, T; Moriyama, M; Omata, M; Otsuka, M; Yoshida, H, 2004) |
"To investigate the effect of biochemical modulation on antitumor activity shown by the combination of 5-Fluorouracil (5-FU) and interferon-alpha (IFN-alpha), experimental therapy was performed on human hepatocellular carcinoma cell (HuH7, PLC/PLF/5) xenografts inoculated into nude mice, using 5-FU and IFN-alpha, either alone or in combination." | 7.72 | [Influence on 5-fluorouracil metabolism by combination of interferon-alpha and 5-fluorouracil against human hepatocellular carcinoma xenografts]. ( Arai, I; Dono, K; Jin, CD; Kishin, R; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Sakon, M; Umeshita, K; Xing, X; Yamamoto, T, 2004) |
"We report a case of diffuse type advanced hepatocellular carcinoma (HCC), which was successfully treated by a combination therapy of interferon-alpha (IFN) and 5-fluorouracil (5-FU)." | 7.72 | [Intrahepatic arterial chemotherapy with 5-fluorouracil and intramuscular interferon-alpha for a patient with diffuse type of hepatocellular carcinoma]. ( Fujiwara, H; Hagiwara, A; Ichikawa, D; Kikuchi, S; Ochiai, T; Okamoto, K; Otsuji, E; Sakakura, C; Sonoyama, T; Ueda, Y; Yamagishi, H, 2004) |
"Our purpose was to explore the contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of IFNalpha and 5-fluorouracil (5-FU) combination therapy for hepatocellular carcinoma (HCC)." | 7.72 | Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of interferon-alpha/5-fluorouracil against Hepatocellular Carcinoma. ( Damdinsuren, B; Dono, K; Eguchi, H; Kondo, M; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Ota, H; Sakon, M; Umeshita, K; Wada, H; Yagita, H; Yamamoto, T, 2004) |
"This study was designed to evaluate the efficacy of hepatic arterial infusion of 5-fluorouracil (5-FU) and cisplatin (CDDP) for unresectable or recurrent hepatocellular carcinoma (HCC) with tumor thrombus of the trunk or first branches of the portal vein (PVTT)." | 7.71 | Hepatic arterial infusion of 5-fluorouracil and cisplatin for unresectable or recurrent hepatocellular carcinoma with tumor thrombus of the portal vein. ( Asahara, T; Haruta, N; Itamoto, T; Ito, K; Naito, A; Nakahara, H; Tashiro, H, 2002) |
"We report a case of recurrent hepatocellular carcinoma (HCC) successfully treated with a combination therapy of interferon-alpha (IFN-alpha) and 5-fluorouracil (5-FU), which was administered intravenously." | 7.71 | [A case of recurrent hepatocellular carcinoma successfully treated with a combination therapy of interferon-alpha and intravenous continuous infusion of 5-fluorouracil]. ( Furuhata, T; Hata, F; Hirata, K; Katsuramaki, T; Kimura, Y; Mukaiya, M; Ohmura, T; Yamaguchi, K, 2002) |
"To investigate the resistance mechanism of 5-fluorouracil (5-FU) in Bel(7402)/5-FU cells which was established in our lab by in vitro continuous stepwise exposure of human hepatocellular carcinoma (HCC) cell line Bel(7402) to 5-FU." | 7.71 | Mechanism of 5-fluorouracil required resistance in human hepatocellular carcinoma cell line Bel(7402). ( Huang, M; Jin, J; Liu, GT; Wei, HL, 2002) |
"A 67-year-old male diagnosed as having inoperable advanced hepatocellular carcinoma with portal invasion was able to undergo resection after continuous intra-arterial chemotherapy with 5-fluorouracil (5-FU) and cisplatin (CDDP)." | 7.71 | [A case of advanced hepatocellular carcinoma with portal invasion resected after treatment by continuous intra-arterial chemotherapy with cisplatin and 5-fluorouracil]. ( Furutani, S; Hara, F; Ikeda, E; Kashiyama, Y; Matsumoto, H; Mitunaga, S; Moriyama, S; Naitoh, M; Nawa, S; Ohtuka, K; Tuji, T, 2001) |
"The objective of the current study was to identify patient and disease related factors that influence response and survival for patients with unresectable hepatocellular carcinoma (HCC) who received a systemic combination chemotherapy consisting of cisplatin, alpha-interferon, doxorubicin, and 5-fluorouracil (PIAF)." | 7.71 | Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy. ( Johnson, PJ; Lai, PB; Lau, WY; Leung, TW; Tang, AM; Yu, SC; Zee, B, 2002) |
"A 69-year-old female with unresectable hepatocellular carcinoma was treated with continuous arterial infusion of low-dose cisplatin (10 mg/body/day) and 5-fluorouracil (250 mg/body/day)." | 7.71 | [A case of hepatocellular carcinoma with portal tumor thrombus effectively treated by arterial infusion chemotherapy with low-dose cisplatin and 5-fluorouracil]. ( Hasebe, Y; Hirano, K; Kobayashi, K; Kurihara, A; Nakazaki, H; Saito, N; Seo, A; Shirasaka, K; Takada, M; Takita, W; Tokura, N; Watanabe, M, 2002) |
"The case described here illustrates the antitumor activity of a four-drug systemic combination chemobiotherapy with platinol, recombinant interferon alpha 2b, doxorubicin (Adriamycin), and 5-fluorouracil (5-FU) (PIAF) in a patient with diffuse hepatocellular carcinoma involving the liver and lungs." | 7.70 | Durable clinical and pathologic response of hepatocellular carcinoma to systemic and hepatic arterial administration of platinol, recombinant interferon alpha 2B, doxorubicin, and 5-fluorouracil: a communication. ( Carrasco, CH; Charnsangavej, C; Cleary, K; Ellis, L; Hoque, A; Lozano, R; Patt, YZ; Roh, M, 1999) |
"In order to assess the efficacy of repeated hepatic arterial infusion (HAI) therapy for advanced hepatocellular carcinoma, we administered HAI therapy using 5-fluorouracil, epirubicin and mitomycin C, with an implanted drug delivery system." | 7.70 | Efficacy of an implanted drug delivery system for advanced hepatocellular carcinoma using 5-fluorouracil, epirubicin and mitomycin C. ( Chiba, T; Ito, K; Kojima, K; Nakajima, N; Seno, H, 1999) |
"Seven patients with postoperative recurrence of hepatocellular carcinoma (HCC) and four patients who underwent absolute non curative resection for HCC were treated with continuous arterial infusion of low-dose cisplatin (CDDP) (10 mg/body/day) and 5-fluorouracil (5-FU) (250 mg/body/day)." | 7.70 | [Study of continuous arterial infusion chemotherapy with low-dose cisplatin and 5-fluorouracil for patients with hepatocellular carcinoma]. ( Maeda, Y; Mori, N; Nisida, M; Oka, M; Takao, T; Tamesa, T; Tangoku, A, 1999) |
"Several clinical trials have demonstrated the effectiveness of combination therapy with 5-fluorouracil (5-FU) and IFN-alpha in colon cancer, hepatocellular carcinoma (HCC), and other malignancies." | 7.70 | Augmentation of antitumor activity of 5-fluorouracil by interferon alpha is associated with up-regulation of p27Kip1 in human hepatocellular carcinoma cells. ( Dono, K; Eguchi, H; Kondo, M; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Sakon, M; Umeshita, K; Yamamoto, H, 2000) |
"1-Hexylcarbamoyl-5-fluorouracil (HCFU) was administered orally to 63 patients with hepatocellular carcinoma (HCC) at a daily dose of 200 to 600 mg." | 7.67 | [Clinical evaluation of 1-hexylcarbamoyl-5-fluorouracil (HCFU) in hepatocellular carcinoma]. ( Abe, M; Hirai, K; Kubo, Y; Majima, Y; Ninomiya, F; Sakai, T; Sakemi, T; Sato, K; Shiraishi, K; Tanikawa, K, 1984) |
"1-Hexylcarbamoyl-5-fluorouracil (HCFU) was orally administered at doses of 300-600 mg daily for 7-360 days to 27 inoperable cirrhotics with hepatocellular carcinoma." | 7.67 | [Role of oral administration of 1-hexyl-carbamoyl-5-fluorouracil (HCFU) for multimodal treatment of inoperable cirrhotics with hepatocellular carcinoma]. ( Akiharu, W; Fujiwara, M; Higashi, T; Ito, T; Kobayashi, M; Nagashima, H; Nakatsukasa, H; Shiota, T; Yamamoto, H; Yamauchi, Y, 1984) |
"In a prospective clinical trial, 65 patients were studied in an investigation into the effects of the oral administration of 5-fluorouracil on resectable and non-resectable hepatocellular carcinoma." | 7.67 | Studies on the chemotherapy with 5-fluorouracil in transcatheter arterial chemoembolization (TAE) treated patients with resectable or non-resectable hepatocellular carcinoma. Osaka Study Group on Hepatocellular Carcinoma. ( , 1989) |
"The metabolism of 1-hexylcarbamoyl-5-fluorouracil (HCFU), a drug prescribed for treating patients with hepatocellular carcinoma (HCC), was studied in relation to liver function, with the objective of clarifying the occurrence of any adverse side-effects on the central nervous system." | 7.67 | Low dose 1-hexylcarbamoyl-5-fluorouracil (HCFU) recommended for cirrhotic patients with hepatocellular carcinoma. ( Kanematsu, T; Shimada, M; Sugimachi, K; Takenaka, K, 1989) |
"HCFU was orally administered to 14 patients with hepatocellular-carcinoma, (including 11 patients with liver cirrhosis) and evaluated of HCFU and 5 fluorouracil (5-FU) levels." | 7.67 | [HCFU and 5-fluorouracil levels in the blood and tissue of hepatocellular carcinoma after oral administration of HCFU]. ( Hamazaki, K; Mimura, H; Mori, M; Orita, K, 1989) |
" In 22 resected patients with hepatocellular carcinoma (HCC), the concentrations of 5-fluorouracil (5-FU), tegafur and uracil were estimated in the serum, liver and cancer tissues after oral administration of UFT (tegafur, 300mg) before operation." | 7.67 | [5-Fluorouracil, tegafur, and uracil concentrations in serum and tissue of the patients with hepatocellular carcinoma after UFT administration]. ( Suenaga, M, 1987) |
"An analysis is done of 40 evaluable patients treated with a combination of 5-Fluorouracil, adriamycin and mitomycin-C for primary hepatocellular carcinoma in Saudi Arabia." | 7.67 | Primary hepatocellular carcinoma in the eastern province of Saudi Arabia: treatment with combination chemotherapy using 5-fluorouracil, Adriamycin and mitomycin-C. ( Abdel Satir, A; Al-Idrissi, HY; Al-Kasem, S; Al-Qurain, A; Ibrahim, EM; Satti, MB, 1985) |
"The pharmacokinetics of 1-(tetrahydro-2-furanyl)-5-fluorouracil (FT) and its conversion into 5-fluorouracil (FUra) in liver tissue were studied in ten patients with hepatocellular carcinoma (HCC)." | 7.67 | Hepatic conversion of 1-(tetrahydro-2-furanyl)-5-fluorouracil into 5-fluorouracil in patients with hepatocellular carcinoma. ( Imai, Y; Kawata, S; Minami, Y; Miyoshi, S; Noda, S; Saitoh, R; Tamura, S; Tarui, S, 1987) |
"Twenty elderly patients with hepatocellular carcinoma were treated with 5-fluorouracil (5-FU) at a daily dose of 200-300 mg per os, and with a combination of 0." | 7.66 | [Treatment of elderly patients with hepatocellular carcinomas with mitomycin C and 5-fluorouracil]. ( Asano, K; Ejiri, T; Fujii, M; Matsuka, Y; Murakami, N, 1982) |
"Among patients with hepatocellular carcinoma (HCC), 85% of patients have an advanced disease stage at diagnosis and curative therapies cannot be performed." | 6.90 | All-trans-retinoic acid (ATRA) plus oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX) versus FOLFOX alone as palliative chemotherapy in patients with advanced hepatocellular carcinoma and extrahepatic metastasis: study protocol for a randomized controll ( Chai, Z; Cheng, S; Liu, C; Shi, J; Sun, J; Wang, N; Zhang, H, 2019) |
"Treatment responses of advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) remain unacceptably low and treatment modalities are limited." | 6.87 | Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis. ( Bae, SH; Cho, SB; Choi, JH; Chung, WJ; Jung, YK; Kim, DY; Kim, SU; Kim, YS; Park, JY; Song, DS; Song, MJ; Suh, SJ; Yim, HJ, 2018) |
"This study aimed to evaluate the efficacy of arterial infusion of 5-fluorouracil (5-FU) combined with subcutaneous injection of pegylated interferon alpha-2b (PEG-IFNα-2b) on unresectable HCC with PVTT and to determine the potential survival benefits of patients from this therapy." | 6.80 | Arterial infusion of 5-fluorouracil combined with subcutaneous injection of pegylated interferon alpha-2b in treating unresectable hepatocellular carcinoma with portal vein tumor thrombus. ( Huang, WJ; Peng, BG; Wang, HY; Wang, YF; Wu, J; Zhou, Q, 2015) |
"Capecitabine was administered daily on days 1-14, while peginterferon α-2a was administered on days 1, 8, and 15." | 6.79 | A phase I/II trial of capecitabine combined with peginterferon α-2a in Patients with sorafenib-refractory advanced hepatocellular carcinoma. ( Chiba, T; Kanai, F; Kanogawa, N; Motoyama, T; Ogasawara, S; Ooka, Y; Suzuki, E; Tawada, A; Yokosuka, AO, 2014) |
"The prognosis of advanced hepatocellular carcinoma (HCC) remains poor, particularly among patients with portal vein tumor thrombosis (PVTT)." | 6.77 | Therapeutic efficacy of combination therapy with intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma with portal venous invasion. ( Kasai, K; Kasai, Y; Kuroda, H; Miyamoto, Y; Oikawa, K; Sawara, K; Suzuki, K; Takikawa, Y; Ushio, A, 2012) |
"Postoperative recurrence of hepatocellular carcinoma (HCC) is a major problem after surgical resection." | 6.75 | Adjuvant therapy with capecitabine postpones recurrence of hepatocellular carcinoma after curative resection: a randomized controlled trial. ( Li, J; Qiu, Y; Shen, F; Shi, L; Wang, K; Wu, M; Xi, T; Xia, Y; Yan, Z, 2010) |
"From 2002 to 2007, a total of 10 consecutive patients with Stage IVA HCC accompanied by PVTT were studied prospectively to examine the efficacy of treatment by intra-arterial infusion of a chemotherapeutic agents consisting of etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil." | 6.73 | Improved survival for hepatocellular carcinoma with portal vein tumor thrombosis treated by intra-arterial chemotherapy combining etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil: a p ( Imai, M; Ishikawa, T; Kamimura, H; Kamimura, T; Ohta, H; Seki, K; Togashi, T; Tsuchiya, A; Watanabe, K; Yoshida, T, 2007) |
"Pravastatin was administered at a daily dose of 40 mg." | 6.70 | Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. ( Imai, Y; Inada, M; Inui, Y; Ito, N; Kawata, S; Matsuda, Y; Matsuzawa, Y; Nagase, T; Noda, S; Tamura, S; Yamasaki, E, 2001) |
"Only a minority of patients with hepatocellular carcinoma (HCC) may benefit from curative treatments, whereas there is no standard therapy for the remaining patients." | 6.70 | A phase II trial of oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma. ( Bruix, J; Castells, L; El-Hariry, I; Llovet, JM; Peachey, M; Ruff, P; Tassopoulos, N, 2001) |
" 4' epidoxorubicin combined with 5-fluorouracil given intra-arterially is not superior to the intravenous therapy, but it may diminish systemic toxicity." | 6.67 | Intra-arterial and intravenous use of 4' epidoxorubicin combined with 5-fluorouracil in primary hepatocellular carcinoma. A randomized comparison. ( Kajanti, M; Mäntylä, M; Pyrhönen, S; Rissanen, P, 1992) |
"In advanced hepatocellular carcinoma, FOLFOX can induce clinically relevant responses, but needs prospective validation." | 6.50 | Oxaliplatin/5-fluorouracil in advanced hepatocellular carcinoma: case report and single-center retrospective review. ( Gillmore, R; Goldstein, R; Mayer, A; Meyer, T; O'Donoghue, P; Thirlwell, C; Yu, D, 2014) |
"The prognosis of hepatocellular carcinoma(HCC) invading the major branches of the portal vein(Vp3 or 4) is extremely poor." | 6.41 | [Development and research of the new therapy for hepatocellular carcinoma--combined interferon and 5-fluorouracil therapy]. ( Monden, M; Nagano, H; Sakon, M, 2002) |
"Salvigenin is a Trimethoxylated Flavone enriched in Scutellariae Barbatae Herba and Scutellariae Radix and is demonstrated to have anti-tumor properties in colon cancer." | 5.91 | Salvigenin Suppresses Hepatocellular Carcinoma Glycolysis and Chemoresistance Through Inactivating the PI3K/AKT/GSK-3β Pathway. ( Chen, H; Chen, J; Chen, Y; Li, A; Liu, J; Ma, L; Shao, H; Tang, Y, 2023) |
"Primary liver hepatocellular carcinoma (HCC) is the third most deadly malignancy worldwide,in part, because it is often diagnosed at an advanced stage." | 5.91 | MESP1-knockdown inhibits the proliferation and epithelial mesenchymal transition of hepatocellular carcinoma and enhances the tumor-suppressive effect of 5-fluorouracil. ( Cai, C; He, X; Ji, S; Xu, M, 2023) |
"5-Fluorouracil (5-FU) has been widely applied in treating cancers." | 5.72 | CDK Inhibition Reverses Acquired 5-Fluorouracil Resistance in Hepatocellular Carcinoma Cells. ( Cheng, L; Li, Z; Pu, Y; Tu, L; Wang, X; Yan, D; Yu, J; Zheng, X, 2022) |
"Cinobufagin is a natural product isolated from the traditional chinese medicine Chansu." | 5.72 | Cinobufagin restrains the growth and triggers DNA damage of human hepatocellular carcinoma cells via proteasome-dependent degradation of thymidylate synthase. ( Chen, Q; Li, H; Sun, Y; Tao, Y; Wang, A; Wu, Q; Yang, A; Yang, J; Zhang, J, 2022) |
"To report the efficacy and safety of postoperative adjuvant hepatic arterial infusion chemotherapy (HAIC) with 5-fluorouracil and oxaliplatin (FOLFOX) in hepatocellular carcinoma (HCC) patients with microvascular invasion (MVI)." | 5.69 | Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With FOLFOX in Hepatocellular Carcinoma With Microvascular Invasion: A Multicenter, Phase III, Randomized Study. ( Cao, MR; Chen, HW; Cheng, Y; Deng, JD; Deng, M; Fang, CK; Guan, RG; Guo, RP; Guo, ZX; Huang, HK; Jiang, YC; Lei, QC; Li, JB; Li, Q; Li, SH; Lin, WP; Ling, YH; Lu, LH; Luo, R; Mei, J; Wang, QX; Wei, W; Wen, YH; Zhao, RC; Zheng, L; Zhong, C; Zou, JW, 2023) |
"Not all patients with unresectable hepatocellular carcinoma (uHCC) benefit from treatment with immune checkpoint inhibitors and molecular-targeted agents." | 5.62 | Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study. ( Chen, S; Guo, W; Huang, X; Li, T; Liu, Z; Wang, P; Wu, Y; Wu, Z; Xu, B; Yu, W, 2021) |
"The extensive drug resistance of hepatocellular carcinoma (HCC) has become a major cause of chemotherapy failure." | 5.56 | Proteomic Analysis Reveals that EPHX1 Contributes to 5-Fluorouracil Resistance in a Human Hepatocellular Carcinoma Cell Line. ( Chu, H; Dong, C; Hao, D; Li, R; Liu, J; Sun, R; Wang, L; Zhang, L; Zhang, Y; Zhao, B, 2020) |
"5-Fluorouracil (5-Fu) is a widely used as an anticancer drug." | 5.56 | CCND1 silencing suppresses liver cancer stem cell differentiation and overcomes 5-Fluorouracil resistance in hepatocellular carcinoma. ( Ding, H; Wang, Y; Zhang, H, 2020) |
" The purpose of this study was to evaluate the safety and efficacy of TACE combined with sorafenib (TACE-sorafenib) and TACE alone for the treatment of Barcelona clinical stage C HCC." | 5.56 | Transarterial Chemoembolization Combined with Sorafenib in Patients with BCLC Stage C Hepatocellular Carcinoma. ( Cheng, DL; Gao, ZG; Hao, YH; Ji, CS; Jia, WD; Liu, KC; Lv, WF; Shi, CS; Su, MX; Xu, SB; Zhou, CZ, 2020) |
" Since 5-FU is an irreversible inhibitor of thymidylate synthetase (TS), we investigated the interactions of let-7c with 5-FU at pharmacodynamic level." | 5.56 | Pharmacokinetic and Pharmacodynamic Factors Contribute to Synergism between Let-7c-5p and 5-Fluorouracil in Inhibiting Hepatocellular Carcinoma Cell Viability. ( Jilek, JL; Tu, MJ; Yu, AM; Zhang, C, 2020) |
"Interventional hepatic arterial infusion chemotherapy of infusional fluorouracil, leucovorin, and oxaliplatin (HAIC-FO) displayed an encouraging safety profile and antitumor activity in a previous phase II trial and a propensity-score-matching study involving patients with locally advanced hepatocellular carcinoma (HCC)." | 5.51 | Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1). ( Chen, QF; Deng, HJ; He, M; Lai, JF; Li, JB; Li, SL; Lyu, N; Mu, LW; Wang, X; Zhao, M, 2022) |
"However, its roles in hepatocellular carcinoma (HCC) cell stemness and chemotherapeutic sensitivity are never been revealed." | 5.51 | Six1 is negatively correlated with poor prognosis and reduces 5-fluorouracil sensitivity via attenuating the stemness of hepatocellular carcinoma cells. ( Chen, K; Chen, Z; Gao, T; Huang, J; Huang, M; Ou, M; Pan, D; Pan, J; Wei, H; Zhong, W, 2019) |
"SIGNIFICANCE: It was reported that many hepatocellular carcinoma patients are resistance to 5-Fu." | 5.51 | Quantitative proteomic and phosphoproteomic studies reveal novel 5-fluorouracil resistant targets in hepatocellular carcinoma. ( Fang, Z; Liu, Z; Miao, QR; Wang, Y; Yao, Y; Ye, M, 2019) |
"5-Fluorouracil (5-FU) is a widely used antitumor drug." | 5.51 | Aluminum chloride causes 5-fluorouracil resistance in hepatocellular carcinoma HepG2 cells. ( Cui, ZG; Feng, Q; Feril, LB; Inadera, H; Li, M; Sun, L; Zakki, SA, 2019) |
"Baicalein is a flavonoid extracted from Radix Scutellariae with anti-HCC activity." | 5.48 | Baicalein sensitizes hepatocellular carcinoma cells to 5-FU and Epirubicin by activating apoptosis and ameliorating P-glycoprotein activity. ( Bie, B; Duan, B; Guo, Y; Huang, C; Li, J; Li, Z; Sun, J; Yang, J; Yang, S; Zhou, R, 2018) |
"Cancer stem cells (CSCs) in hepatocellular carcinoma (HCC) possess tumor-initiating, metastatic, and drug resistance properties." | 5.43 | Comparative study of the effects of PEGylated interferon-α2a versus 5-fluorouracil on cancer stem cells in a rat model of hepatocellular carcinoma. ( El-Boghdady, NA; El-Sayed, AM; Helmy, HS; Motawi, TK, 2016) |
"Metformin plays an anti-proliferative role in tumor cells in many types of cancer." | 5.43 | Metformin mediates resensitivity to 5-fluorouracil in hepatocellular carcinoma via the suppression of YAP. ( Gao, Z; Han, Z; Liang, R; Luo, N; Sun, D; Tang, B; Tian, Y; Wang, C; Wang, L; Zhang, R, 2016) |
"Dioscin is a natural steroid saponin that presents in various plants." | 5.43 | Dioscin suppresses hepatocellular carcinoma tumor growth by inducing apoptosis and regulation of TP53, BAX, BCL2 and cleaved CASP3. ( Du, B; Liu, J; Tan, Y; Wu, Y; Wu, Z; Zeng, X; Zhang, G; Zhang, R; Zhang, W; Zhang, X; Zhao, Y, 2016) |
"Chemotherapy is one of the most common treatments used for hepatocellular carcinoma (HCC), which effectively improves outcome and reduces tumor recurrence." | 5.42 | MicroRNA‑133a and microRNA‑326 co‑contribute to hepatocellular carcinoma 5‑fluorouracil and cisplatin sensitivity by directly targeting B‑cell lymphoma‑extra large. ( Guo, R; Lei, X; Ma, J; Pan, X; Peng, C; Tang, H; Wang, T; Xiang, Q; Yang, X; Yin, J; Yu, J; Zu, X, 2015) |
"Hepatic arterial infusion chemotherapy with oxaliplatin, 5-fluorouracil, and leucovorin (FOLFOX-HAIC) has shown a strong anti-tumor effect in hepatocellular carcinoma in China." | 5.41 | Hepatic arterial infusion chemotherapy for patients with hepatocellular carcinoma: Applicability in Western countries. ( Du, Z; He, M; Kan, A; Lai, Z; Li, Q; Liu, S; Shen, J; Shi, M; Xu, L, 2023) |
"A PHY906 and capecitabine combination could be effective as a salvage therapy for patients with hepatocellular carcinoma (HCC) previously treated with multiple systemic therapies." | 5.41 | A Phase II Clinical Trial on the Combination Therapy of PHY906 Plus Capecitabine in Hepatocellular Carcinoma. ( Changou, CA; Chen, LT; Cheng, YC; Liu, S; Liu, SH; Luh, F; Shiah, HS; Yen, Y, 2021) |
"The incidence of advanced hepatocellular carcinoma (HCC) is increasing worldwide, and its prognosis is extremely poor." | 5.39 | Identification of the genes chemosensitizing hepatocellular carcinoma cells to interferon-α/5-fluorouracil and their clinical significance. ( Azumi, J; Gonda, K; Kanki, K; Mizuta, Y; Nagano, H; Sakabe, T; Shiota, G; Shomori, K; Tsuchiya, H; Wada, H; Yamada, D, 2013) |
"The prognosis of patients with hepatocellular carcinoma (HCC) and portal vein tumor thrombus remains poor." | 5.39 | PTK787/ZK222584 combined with interferon alpha and 5-fluorouracil synergistically inhibits VEGF signaling pathway in hepatocellular carcinoma. ( Akita, H; Doki, Y; Eguchi, H; Hama, N; Katsura, Y; Kawamoto, K; Kobayashi, S; Marubashi, S; Mori, M; Murakami, M; Nagano, H; Tanemura, M; Umeshita, K; Wada, H, 2013) |
"Combination therapies may increase the antitumor effects and reduce the adverse effects for the treatment of hepatocellular carcinoma." | 5.39 | Enhanced 5-fluorouracil cytotoxicity in high COX-2 expressing hepatocellular carcinoma cells by wogonin via the PI3K/Akt pathway. ( Guo, QL; Lu, ZJ; Sha, YY; Yao, J; You, QD; Zhao, L; Zhao, Q; Zhu, BB, 2013) |
"The prognosis in advanced hepatocellular carcinoma (HCC) with multiple intrahepatic metastases is extremely poor." | 5.39 | Debulking surgery followed by intraarterial 5-fluorouracil chemotherapy plus subcutaneous interferon alfa for massive hepatocellular carcinoma with multiple intrahepatic metastases: a pilot study. ( Endo, I; Kumamoto, T; Matsuo, K; Nakagawa, K; Taguri, M; Tanaka, K; Yabushita, Y, 2013) |
"Advanced hepatocellular carcinoma (HCC) with portal vein invasion or intrahepatic metastases has an unfavorable prognosis, even after curative hepatic resection." | 5.39 | Adjuvant hepatic arterial infusion chemotherapy with 5-Fluorouracil and interferon after curative resection of hepatocellular carcinoma: a preliminary report. ( Akiyama, H; Endo, I; Ichikawa, Y; Kumamoto, T; Matsuo, K; Matsuyama, R; Mori, R; Nojiri, K; Ota, M; Takeda, K; Tanaka, K; Taniguchi, K; Ueda, M, 2013) |
"The only drug that improves survival in hepatocellular carcinoma is sorafenib." | 5.38 | Feasibility of oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) in cirrhotic or liver transplant patients: experience in a cohort of advanced hepatocellular carcinoma patients. ( Brezault, C; Cacheux, W; Cessot, A; Chaussade, S; Coriat, R; Durand, JP; Goldwasser, F; Mir, O; Ropert, S, 2012) |
"Baicalein treatment significantly inhibited tumor growth of HCC xenografts in mice." | 5.38 | Preferential inhibition of hepatocellular carcinoma by the flavonoid Baicalein through blocking MEK-ERK signaling. ( Huang, C; Le, XF; Li, J; Li, ZF; Liang, RR; Liu, PJ; Qi, JA; Wang, ZD; Yang, J; Zhang, S, 2012) |
"The primary treatment for nasopharyngeal carcinoma (NPC) is external beam radiotherapy." | 5.38 | Radiotherapy for nasopharyngeal carcinoma and combined capecitabine and nimotuzumab treatment for lung metastases in a liver transplantation recipient: a case experience of sustained complete response. ( Jiang, X; Wang, YX; Yan, D; Yan, S; Yang, J, 2012) |
"Flow cytometry and TUNEL assays in hepatic cancer cells showed that GC/5-FU was associated with higher rates of G0-G1 arrest and apoptosis than 5-FU." | 5.38 | 5-Fluorouracil nanoparticles inhibit hepatocellular carcinoma via activation of the p53 pathway in the orthotopic transplant mouse model. ( Chen, H; Cheng, M; Han, J; He, B; Li, Q; Wan, T; Wang, W; Xu, H; Yang, F; Ye, T; Zha, B; Zhu, W, 2012) |
"The chemoresistance of human hepatocellular carcinoma (HCC) to cytotoxic drugs, especially intrinsic or acquired multidrug resistance (MDR), still remains a major challenge in the management of HCC." | 5.38 | Characterization and resistance mechanisms of a 5-fluorouracil- resistant hepatocellular carcinoma cell line. ( Cheng, BB; Fang, FF; Gu, W; Li, B; Ling, CQ, 2012) |
"To evaluate the therapeutic efficacy of sorafenib in combination with microwave coagulation therapy (MCT) and trans-arterial chemoembolization (TACE) in patients with recurrent liver cancer." | 5.38 | [Therapeutic effects of sorafenib combined with transcatheter arterial chemoembolization and microwave ablation on postsurgical recurrent hepatocellular carcinoma]. ( He, ZY; Hua, XD, 2012) |
"There is no standardized treatment for hepatocellular carcinoma (HCC) with portal vein tumor thrombus." | 5.37 | Tyrosine kinase inhibitor PTK/ZK enhances the antitumor effects of interferon-α/5-fluorouracil therapy for hepatocellular carcinoma cells. ( Doki, Y; Eguchi, H; Kobayashi, S; Marubashi, S; Mori, M; Murakami, M; Nagano, H; Noda, T; Takeda, Y; Tanemura, M; Tomimaru, Y; Umeshita, K; Wada, H, 2011) |
"Treatment by quinacrine alone at concentrations of 10-20 mM for 1-2 d cannot kill hepatocellular carcinoma cells, such as HepG2, Hep3B, Huh7, which are also resistant to TRAIL." | 5.37 | Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents. ( Abdulghani, J; Allen, JE; Dicker, DT; Dolloff, NG; El-Deiry, WS; Gallant, JN; Hong, B; Katz, SI; Navaraj, A; Smith, CD; Wang, W, 2011) |
"Arsenic trioxide was added prior to a tyrosine kinase inhibitor or to a slightly modified PIAF regimen with capecitabine replacing 5-fluorouracil." | 5.37 | Arsenic trioxide plus cisplatin/interferon α-2b/doxorubicin/capecitabine combination chemotherapy for unresectable hepatocellular carcinoma. ( Acalovschi, M; Aldea, M; Fischer-Fodor, E; Irimie, A; Kacso, G; Mosteanu, O; Petrushev, B; Pop, T; Soritau, O; Susman, S; Tomuleasa, C, 2011) |
"Rosiglitazone is a peroxisome proliferators-activated receptor gamma (PPARgamma) ligand, which inhibits tumor growth by activating PPARgamma signaling pathways." | 5.36 | Rosiglitazone enhances 5-fluorouracil-induced cell growth inhibition in hepatocellular carcinoma cell line Hep3B. ( Cao, LQ; Peng, HP; Shao, ZL; Xia, T; Xiao, JB, 2010) |
"d-Allose is a novel anti-tumor monosaccharide that causes cell growth inhibition, specifically of the cancer cells, by inducing the tumor suppressor gene thioredoxin interacting protein (TXNIP)." | 5.35 | Rare sugar D-allose enhances anti-tumor effect of 5-fluorouracil on the human hepatocellular carcinoma cell line HuH-7. ( Dong, Y; Horii, M; Kamitori, K; Sanada, K; Sui, L; Tokuda, M; Yamaguchi, F, 2008) |
": Patients with unresectable hepatocellular carcinoma (HCC) have limited treatment options." | 5.35 | Accelerated treatment using intensity-modulated radiation therapy plus concurrent capecitabine for unresectable hepatocellular carcinoma. ( Al-Osaimi, AM; Angle, JF; Argo, C; Berg, C; Caldwell, S; Hagspiel, KD; McIntosh, A; Northup, P; Rich, TA; Weiss, G, 2009) |
" In this study, we evaluated the response to hepatic arterial infusion of 5-fluorouracil (5-FU) in combination with subcutaneous interferon (IFN)-alpha in patients with advanced HCC." | 5.34 | Hepatic arterial infusion of 5-fluorouracil in combination with subcutaneous interferon-alpha for advanced hepatocellular carcinoma. ( Adachi, Y; Araki, J; Furjita, N; Horiike, S; Itani, T; Iwasa, M; Kaito, M; Kobayashi, Y; Konishi, M; Kuroda, M; Mifuji, R; Tanaka, H; Urawa, N; Yamamoto, M, 2007) |
"5-fluorouracil (5-FU) is a basic agent used in chemotherapy." | 5.34 | Gene expression of 5-fluorouracil metabolic enzymes in hepatocellular carcinoma and non-tumor tissue. ( Ebara, M; Nomura, F; Saisho, H; Shimada, H; Sunaga, M; Tomonaga, T; Yoshikawa, M, 2007) |
"Capecitabine was administered twice daily for 14 days at a total daily dose of 2000 mg/m2." | 5.34 | Capecitabine for treatment of advanced hepatocellular carcinoma. ( Eckel, F; Lersch, C; Mayr, M; Schmid, RM; Schulte-Frohlinde, E; Stock, K; von Delius, S, 2007) |
"Prognosis of advanced hepatocellular carcinoma (HCC) treated by conventional therapies has been considered to be poor." | 5.33 | [Efficacy of hepatic arterial infusion therapy for advanced hepatocellular carcinoma using 5-fluorouracil, epirubicin and mitomycin-C]. ( Ahn, SH; Cho, KB; Choi, JS; Chung, WJ; Hwang, JS; Hwang, JY; Jang, BK; Kim, GC; Kim, YH; Kwon, JH; Kwon, KM; Park, KS, 2005) |
"Thirty-nine patients with hepatocellular carcinoma were treated with oral 5'-DFUR for more than 4 d before operation." | 5.33 | 5-Fluorouracil concentration in blood, liver and tumor tissues and apoptosis of tumor cells after preoperative oral 5'-deoxy-5-fluorouridine in patients with hepatocellular carcinoma. ( Wang, HD; Zheng, JF, 2005) |
"For 15 patients with advanced hepatocellular carcinoma using a same protocol, the response rate of this therapy was 33." | 5.33 | [Successful treatment of combined intraarterial (5-fluorouracil and adriamycin and cisplatin) infusion chemotherapy for advanced hepatocellular carcinoma with multiple intrahepatic metastases and/or portal vein thrombosis--two case reports]. ( Bazarragchaa, D; Dono, K; Kato, H; Marubashi, S; Miyamoto, A; Monden, M; Murakami, T; Nagano, H; Nakamura, H; Nakamura, M; Noda, T; Ota, H; Takeda, Y; Umeshita, K; Wada, H; Yoshioka, S, 2005) |
"Advanced hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT) has a poor prognosis." | 5.33 | [Effect of low dose 5-fluorouracil and cisplatin intra-arterial infusion chemotherapy in advanced hepatocellular carcinoma with decompensated cirrhosis]. ( Cheong, JY; Cho, SW; Choi, JW; Choi, SJ; Hahm, KB; Kim, JH; Kim, JK; Kim, JS; Kwon, HC; Lee, KJ; Lee, KM; Lim, TY; Sim, SJ; Won, JH; Yoo, BM, 2006) |
"The prognosis for patients with hepatocellular carcinoma (HCC) with progressive liver cirrhosis or extrahepatic metastases remains dismal." | 5.33 | [A case of advanced hepatocellular carcinoma with lung metastases and cirrhosis that responded to combination chemotherapy with interferon-alpha and 5-fluorouracil]. ( Ishii, E; Kondo, M; Kudo, T; Mitobe, S; Munakata, M; Muto, O; Okada, R; Sakata, Y; Shitara, K; Yabu, K, 2006) |
"A syngeneic rat model of hepatocellular carcinoma was used." | 5.32 | [Influence of combined cyclosporine A and tacrolimus with 5-fluorouracil on hepatocellular carcinoma rats]. ( Jiang, GP; Li, MW; Xie, HY; Yang, FC; Zeng, QL; Zheng, SS, 2003) |
"Five human hepatoma cell lines (Hep3B, HepG2, HuH7, PLC/PRF/5 and Chang) were used." | 5.32 | The efficacy of the combination therapy of 5-fluorouracil, cisplatin and leucovorin for hepatocellular carcinoma and its predictable factors. ( Iwasaki, T; Kogure, T; Shimosegawa, T; Ueno, Y, 2004) |
"The prognosis of hepatocellular carcinoma (HCC) is very poor, particularly in patients with tumors that have invaded the major branches of the portal vein." | 5.32 | Molecular prediction of response to 5-fluorouracil and interferon-alpha combination chemotherapy in advanced hepatocellular carcinoma. ( Dono, K; Ishii, S; Kato, K; Kurokawa, Y; Matoba, R; Monden, M; Nagano, H; Nakamori, S; Sakon, M; Takemasa, I; Ueno, N; Umeshita, K, 2004) |
"The prognosis of hepatocellular carcinoma (HCC) invading into the major branches of the portal vein (Vp3) is extremely poor." | 5.31 | Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. ( Dono, K; Iijima, S; Imai, Y; Kawata, S; Monden, M; Nagano, H; Nakamori, S; Sakon, M; Umeshita, K; Yamada, A, 2002) |
"Sorafenib is the first-line treatment for hepatocellular carcinoma with portal vein invasion; however, it has shown unsatisfactory survival benefit." | 5.30 | Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial. ( Chen, M; Fang, W; Guo, R; Guo, Y; He, M; Le, Y; Li, Q; Shen, J; Shi, M; Tan, G; Wei, W; Wu, X; Xu, L; Zhao, M; Zhou, Y; Zhou, Z; Zou, R, 2019) |
"Fifteen patients with advanced hepatocellular carcinoma were treated by hepatic arterial infusion (HAI)." | 5.28 | [Hepatocellular carcinoma treated by continuous hepatic arterial infusion of etoposide, CDDP and 5-FU]. ( Akimura, R; Fujii, N; Ikami, I; Kanehira, J; Kimura, T; Midorikawa, H; Nakamura, Y; Sasaki, T; Tarusawa, K; Yodono, H, 1990) |
"In patients with advanced hepatocellular carcinoma (HCC), evidence is unclear as to whether hepatic arterial infusion chemotherapy (HAIC) or sorafenib is superior." | 5.27 | Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): an open label, non-comparative, phase II trial. ( Aikata, H; Amano, H; Awai, K; Chayama, K; Hatooka, M; Hiramatsu, A; Imamura, M; Inagaki, Y; Katamura, Y; Kawakami, Y; Kawaoka, T; Kohno, H; Masaki, K; Morio, K; Moriya, T; Murakami, E; Nagaoki, Y; Nakahara, T; Tamura, T; Tsuge, M; Waki, K, 2018) |
"Pretreatment with tocopheryl nicotinate and indomethacin increased the K values in the control subjects, but was without effect on the K values in patients with primary hepatoma." | 5.26 | Decreased disappearance rate of 1-(2-tetrahydrofuryl)-5-fluorouracil (FT-207) from the blood and its unresponsiveness to tocophreyl nicotinate and indomethacin in patients with primary hepatocellular carcinoma. ( Hobara, N; Watanabe, A, 1979) |
"The aim of this study was to investigate the dose-limiting toxicities (DLTs) and determine the recommended doses in the Phase I part of the study, and to evaluate the efficacy and toxicity in the Phase II part, of continuous hepatic intra-arterial infusion therapy with 5-fluorouracil, mitoxantrone and cisplatin (FMP therapy) in patients with advanced hepatocellular carcinoma (HCC)." | 5.24 | A Phase I/II trial of continuous hepatic intra-arterial infusion of 5-fluorouracil, mitoxantrone and cisplatin for advanced hepatocellular carcinoma. ( Arai, Y; Furuse, J; Ikeda, M; Inaba, Y; Kobayashi, T; Mitsunaga, S; Morizane, C; Okusaka, T; Sato, Y; Ueno, H, 2017) |
"Raltitrexed has shown efficacy and safety in many tumor types; however, the clinical data on the treatment of hepatocellular carcinoma is rare." | 5.22 | Raltitrexed plus oxaliplatin-based transarterial chemoembolization in patients with unresectable hepatocellular carcinoma. ( Chen, C; Cheng, L; Fan, L; Hu, T; Lu, J; Lu, X; Ma, Y; Ni, B; Ou, S; Qi, F; Yi, X; Yu, L; Zhang, C; Zhao, C; Zheng, Z, 2016) |
"To compare the efficacy and safety of chemoembolization alone or chemoembolization combined with hepatic arterial infusion chemotherapy (HAIC), including oxaliplatin (OXA), 5-fluorouracil (5-FU) and folinic acid (CF), in inoperable hepatocellular carcinoma (HCC) without distant metastasis." | 5.20 | Chemoembolization alone vs combined chemoembolization and hepatic arterial infusion chemotherapy in inoperable hepatocellular carcinoma patients. ( Chen, H; Gao, S; Guo, JH; Liu, P; Xu, HF; Yang, RJ; Zhang, PJ; Zhu, X, 2015) |
"The EACH study assessed the efficacy of oxaliplatin, 5-fluorouracil, and leucovorin (the FOLFOX4 regimen) compared with doxorubicin alone in terms of overall survival (OS), progression-free survival (PFS), and safety in patients with advanced hepatocellular carcinoma (HCC)." | 5.19 | Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH study. ( Bai, Y; Cheng, Y; Fan, J; Jian, Z; Li, J; Liang, H; Liang, J; Liang, L; Qin, S; Rau, KM; Shen, L; Sun, Y; Wu, G; Yang, TS; Zhang, Y, 2014) |
" Because previous studies showed that long-term telbivudine treatment improved renal function in chronic hepatitis B virus (HBV) infected patients, we conducted a case-control study to evaluate the clinical outcome of telbivudine preemptive therapy in HBV-related advanced HCC patients treated by combination chemotherapy comprising 5-fluorouracil, mitoxantrone and cisplatin (FMP)." | 5.19 | Significant renoprotective effect of telbivudine during preemptive antiviral therapy in advanced liver cancer patients receiving cisplatin-based chemotherapy: a case-control study. ( Chang, ML; Chen, YC; Chien, RN; Hsu, CW; Lin, CL; Yeh, C; Yeh, CT, 2014) |
"The present pilot study aimed to evaluate the safety and efficacy of hepatic arterial infusion chemotherapy (HAIC) with interferon-beta (IFN-β) and 5-fluorouracil (5-FU) in patients with advanced hepatocellular carcinoma (HCC)." | 5.19 | Pilot Study of Hepatic Arterial Infusion Chemotherapy with Interferon-beta and 5-fluorouracil: A New Chemotherapy for Patients with Advanced Hepatocellular Carcinoma. ( Fukunaga, A; Hirano, G; Irie, M; Iwashita, H; Iwata, K; Kora, S; Kunimoto, H; Kuno, S; Morihara, D; Nishizawa, S; Sakisaka, S; Sakurai, K; Shakado, S; Sohda, T; Takeyama, Y; Tanaka, T; Tsuchiya, N; Yokoyama, K; Yoshimitsu, K; Yotsumoto, K, 2014) |
"The only approved systemic therapy for patients with advanced hepatocellular carcinoma (HCC) till now is sorafenib." | 5.17 | Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma. ( Abdel-Rahman, O; Abdel-Wahab, M; Abdel-Wahab, S; Elbassiony, M; Ellithy, M; Shaker, M, 2013) |
"To determine whether FOLFOX4 (infusional fluorouracil, leucovorin, and oxaliplatin) administered as palliative chemotherapy to patients with advanced hepatocellular carcinoma (HCC) provides a survival benefit and efficacy versus doxorubicin." | 5.17 | Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. ( Bai, Y; Bhudhisawasdi, V; Chao, Y; Fan, J; Kang, WK; Lee, JH; Lim, HY; Qin, S; Sun, Y; Thongprasert, S; Yang, TS; Zhou, Y, 2013) |
"Sorafenib is a multi-kinase inhibitor, which was approved as first-line treatment for patients with advanced hepatocellular carcinoma (HCC)." | 5.16 | Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma. ( Kang, WK; Lee, J; Lee, SJ; Lim, HY; Park, JO; Park, SH; Park, YS; Yim, DS, 2012) |
"To compare the efficacy of transcatheter arterial chemoembolization (TACE) using multiple anticancer drugs (epirubicin, cisplatin, mitomycin C, and 5-furuorouracil: Multi group) with TACE using epirubicin (EP group) for hepatocellular carcinoma (HCC)." | 5.16 | Prospective evaluation of transcatheter arterial chemoembolization (TACE) with multiple anti-cancer drugs (epirubicin, cisplatin, mitomycin c, 5-fluorouracil) compared with TACE with epirubicin for treatment of hepatocellular carcinoma. ( Ikoma, A; Kawai, N; Minamiguchi, H; Nakai, M; Nakata, K; Sahara, S; Sanda, H; Sato, M; Shirai, S; Sonomura, T; Tanaka, T, 2012) |
"Eniluracil (EU) is a potent dihydropyrimidine (DPD) inhibitor, which improves the oral bio-availability of 5-fluorouracil (5-FU) and may overcome fluoropyrimidine (FP) resistance in hepatocellular carcinoma (HCC)." | 5.15 | Final results of a prematurely discontinued Phase 1/2 study of eniluracil with escalating doses of 5-fluorouracil administered orally in patients with advanced hepatocellular carcinoma. ( Chang, AY; de Lima Lopes, G; Dicksey, JS; Palalay, M; Peters, WP, 2011) |
"We investigated whether adjuvant hepatic arterial infusional chemotherapy (HAIC) with 5-fluorouracil (5-FU) and cisplatin reduces the recurrence of hepatocellular carcinoma (HCC) after curative resection." | 5.15 | Adjuvant hepatic arterial infusional chemotherapy with 5-fluorouracil and cisplatin after curative resection of hepatocellular carcinoma. ( Ahn, SH; Choi, SB; Han, KH; Kim, DY; Kim, KS; Kim, SU; Lee, DY; Lee, KH; Park, JY; Park, MS, 2011) |
"This randomized phase II trial compared the response rates to treatment with interferon (IFN) combined with hepatic arterial infusion of fluorouracil (FU) plus cisplatin (CDDP) or FU alone in patients with advanced hepatocellular carcinoma (HCC)." | 5.15 | Randomized, phase II study comparing interferon combined with hepatic arterial infusion of fluorouracil plus cisplatin and fluorouracil alone in patients with advanced hepatocellular carcinoma. ( Arai, K; Honda, M; Kaneko, S; Mizukoshi, E; Nakamoto, Y; Sakai, A; Sunagozaka, H; Terashima, T; Ueda, T; Yamashita, T, 2011) |
"This pilot phase II study was designed to determine the efficacy, toxicities, and biological activity of multiple hepatic arterial injections of recombinant adenovirus p53 (rAd-p53) and 5-fluorouracil (5-FU) after transcatheter arterial chemoembolization (TACE) when compared with TACE alone in patients with unresectable hepatocellular carcinoma (HCC)." | 5.14 | Multiple hepatic arterial injections of recombinant adenovirus p53 and 5-fluorouracil after transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a pilot phase II trial. ( Chen, W; Liu, J; Tian, G; Zhou, JS, 2009) |
"Although hepatic arterial infusion chemotherapy (HAIC) using low-dose 5-fluorouracil (5-FU) and cisplatin (low-dose FP) is commonly used for advanced hepatocellular carcinoma (HCC) with vascular invasion in Japan, few reports have investigated the efficacy and safety of this approach." | 5.14 | Hepatic arterial infusion chemotherapy using low-dose 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma. ( Chung, H; Hagiwara, S; Inoue, T; Ishikawa, E; Kitai, S; Kudo, M; Minami, Y; Nagai, T; Takita, M; Tatsumi, C; Ueda, T; Ueshima, K; Yada, N, 2010) |
"To evaluate the time dependence of intra-arterial 5-fluorouracil (5-FU) therapy for advanced hepatocellular carcinoma (aHCC)." | 5.12 | Twenty-four hour intra-arterial infusion of 5-fluorouracil, cisplatin, and leucovorin is more effective than 6-hour infusion for advanced hepatocellular carcinoma. ( Higami, K; Ikoma, A; Ishii, K; Kanayama, M; Matsumaru, K; Miki, K; Momiyama, K; Nagai, H; Okano, N; Sumino, Y; Watanabe, M, 2007) |
"The authors reported previously the beneficial effects of interferon (IFN)-alpha/5-fluorouracil (5-FU) combination therapy for patients with advanced hepatocellular carcinoma (HCC) who have tumor thrombi in the major portal branches." | 5.12 | Interferon-alpha and 5-fluorouracil combination therapy after palliative hepatic resection in patients with advanced hepatocellular carcinoma, portal venous tumor thrombus in the major trunk, and multiple nodules. ( Dono, K; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Ota, H; Sakon, M; Takeda, Y; Umeshita, K; Wada, H, 2007) |
"The aim of the current study was to evaluate the antitumor activity and toxicity of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin (FMP therapy) in chemotherapy-naive patients with metastatic hepatocellular carcinoma (HCC)." | 5.11 | A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma. ( Ikeda, M; Morizane, C; Okusaka, T; Takezako, Y; Ueno, H, 2005) |
"To evaluate the efficacy of combination chemotherapy with interferon-alpha (IFNalpha) and 5-fluorouracil (5-FU) in patients with advanced hepatocellular carcinoma (HCC)." | 5.11 | Re-evaluation of antitumor effects of combination chemotherapy with interferon-alpha and 5-fluorouracil for advanced hepatocellular carcinoma. ( Enjoji, M; Kohjima, M; Kotoh, K; Miyagi, Y; Morizono, S; Nakamuta, M; Yoshimoto, T, 2005) |
"Pegylated liposomal doxorubicin-based combination chemotherapy with capecitabine or gemcitabine was not effective as salvage therapy in advanced hepatocellular carcinoma." | 5.11 | Pegylated liposomal doxorubicin-based combination chemotherapy as salvage treatment in patients with advanced hepatocellular carcinoma. ( Bai, LY; Chen, PM; Poh, SB, 2005) |
"We tested the efficacy of a systemic chemotherapy regimen combining epirubicin, cisplatinum and infusional 5-fluorouracil (ECF) in a cohort of patients with hepatocellular carcinoma (HCC) who could not be given surgical, intraarterial or percutaneous treatment." | 5.10 | Treatment of hepatocellular carcinoma (HCC) with systemic chemotherapy combining epirubicin, cisplatinum and infusional 5-fluorouracil (ECF regimen). ( Boucher, E; Boudjema, K; Brissot, P; Corbinais, S; Raoul, JL, 2002) |
"Because cirrhosis is extremely common in hepatocellular carcinoma (HCC) in the United States, and it precludes the use of several chemotherapy agents, this phase II trial of fluorouracil (FU) and recombinant interferon alfa-2b (rIFNalpha2b) in HCC was launched with the assumption that it could be tolerated by cirrhotics." | 5.10 | Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma. ( Brown, TD; Curley, SA; Ellis, LM; Hassan, MM; Lozano, RD; Patt, YZ; Vauthey, JN, 2003) |
"In this study the maximum tolerated dose of 5-fluorouracil administered by 5-day (120-h) continuous infusion every 4 weeks was investigated and the pharmacokinetics in patients with hepatocellular carcinoma were evaluated." | 5.10 | Phase I and pharmacokinetic study of 5-fluorouracil administered by 5-day continuous infusion in patients with hepatocellular carcinoma. ( Ikeda, M; Kuriyama, H; Okada, S; Okusaka, T; Ueno, H, 2002) |
"This multicenter, open-label study evaluated a 28-day oral regimen of 5-FU (1 mg/m2 twice daily) plus the dihydropyrimidine dehydrogenase inhibitor, eniluracil (10 mg/m2 twice daily), in patients with chemotherapy-naive or anthracycline-refractory inoperable hepatocellular carcinoma." | 5.10 | Oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma. ( Abramson, N; Benson, AB; Bonny, T; Burnhan, JP; Hohneker, J; Klencke, B; Levin, J; McGuirt, C; Mitchell, E; Ritch, P, 2002) |
"To determine surgical resectability, event-free survival (EFS), and toxicity in children with hepatocellular carcinoma (HCC) randomized to treatment with either cisplatin (CDDP), vincristine, and fluorouracil (regimen A) or CDDP and continuous-infusion doxorubicin (regimen B)." | 5.10 | Hepatocellular carcinoma in children and adolescents: results from the Pediatric Oncology Group and the Children's Cancer Group intergroup study. ( Bowman, LC; Castleberry, RP; Douglass, EC; Feusner, JH; Finegold, MJ; Haas, JE; Katzenstein, HM; Krailo, MD; Liu-Mares, W; Malogolowkin, MH; Newman, K; Ortega, JA; Quinn, JJ; Reynolds, M; Sensel, MG, 2002) |
"The purpose of this Phase II study was to determine the response rate, the toxicity, and the effect on survival of the combination of cisplatin, doxorubicin, 5-fluorouracil, and alpha-IFN (PIAF) in advanced unresectable hepatocellular carcinoma." | 5.09 | Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. ( Chan, AT; Ho, SK; Johnson, PJ; Lau, WY; Leung, NW; Leung, TW; Liew, CT; Mok, TS; Patt, YZ; Tang, AM; Yeo, W; Yu, SC, 1999) |
"A phase II trial of 5-fluorouracil (5-FU) [250-450 mg/m2/day x 5 days as an intravenous (IV) bolus] combined with calcium leucovorin (500 mg/m2/day x 5 1/2 days by continuous IV infusion) administered on a 28-day schedule was performed in 15 patients with advanced hepatocellular carcinoma." | 5.08 | 5-Fluorouracil and high-dose calcium leucovorin for hepatocellular carcinoma: a phase II trial. ( Akman, S; Coluzzi, P; Doroshow, J; Leong, L; Margolin, K; Morgan, RJ; Raschko, J; Shibata, S; Somlo, G; Tetef, M, 1995) |
"A Phase II clinical trial was conducted to evaluate the efficacy of intravenous fluorouracil (5-FU) and subcutaneous recombinant interferon-alpha-2b (rIFN-alpha-2b) in the treatment of hepatocellular carcinoma (HCC) and to define factors that might be predictive of a response to treatment." | 5.07 | Low serum alpha-fetoprotein level in patients with hepatocellular carcinoma as a predictor of response to 5-FU and interferon-alpha-2b. ( Charnsangavej, C; Cleary, K; Fischer, H; Levin, B; Noonan, CA; Patt, YZ; Pazdur, R; Roh, M; Smith, R; Yoffe, B, 1993) |
"We conducted a randomized, controlled trial comparing 5-fluorouracil (5-FU) with or without biological response modifiers (BRMs) as a maintenance therapy for hepatocellular carcinoma (HCC) after treatment with percutaneous ethanol injection (PEI), transcatheter arterial embolization (TAE) or arterial infusion of antitumor agents (AI)." | 5.07 | Clinical study of biological response modifiers as maintenance therapy for hepatocellular carcinoma. ( Fukuda, S; Moriya, N; Sakata, Y; Sasaki, D; Suto, T; Watanabe, Y; Yoshida, Y, 1994) |
"Twenty seven patients with hepatocellular carcinoma were treated by sequential methotrexate (75 mg/m2) and 5-fluorouracil (5-FU) (750 mg/m2) on day 1 followed on days 8-36 by external beam radiotherapy (total dose 30 cGy)." | 5.07 | Combination chemotherapy and radiation for palliation of hepatocellular carcinoma. ( Desai, DC; Desouza, LJ; Dhir, V; Dinshaw, KA; Jagannath, P; Mohandas, KM; Nagral, A; Sharma, V; Swaroop, VS, 1992) |
"In a prospective clinical trial, 39 patients with advanced hepatocellular carcinoma were randomized to receive either Adriamycin (20 patients) or a combination of 5-fluorouracil, methotrexate, cyclophosphamide, and vincristine (19 patients)." | 5.05 | Chemotherapy for advanced hepatocellular carcinoma. Adriamycin versus quadruple chemotherapy. ( Choi, TK; Lee, NW; Wong, J, 1984) |
"Twenty-one patients with biopsy-proven hepatocellular carcinoma were treated with oral or intravenous 5-Fluorouracil according to a randomized treatment schedule." | 5.04 | 5-Flourouracil in hepatocellular carcinoma: report of twenty-one cases. ( Bateman, JR; Durkin, WJ; Link, JS; Paroly, WS; Peters, RL, 1977) |
"We report a case of long-term survival of a patient who received low-dose 5-fluorouracil and cisplatin (FP) systemic chemotherapy and underwent partial resection of the lung for a tumor thrombus in the inferior caval vein (IVC) and multiple lung metastases from recurrent hepatocellular carcinoma (HCC)." | 4.90 | [A case of long-term survival after low-dose FP systemic chemotherapy for a tumor thrombus in the inferior caval vein and multiple lung metastases from recurrent hepatocellular carcinoma]. ( Akasu, I; Fukushima, G; Kataoka, H; Kondo, K; Magata, H; Marutsuka, H; Nakamura, K; Otani, K; Sato, Y; Yano, K; Yonei, A, 2014) |
"A 52 years old female with hepatocellular carcinoma (HCC) was treated successfully with Tamoxifen." | 4.77 | [Hepatocellular carcinoma (HCC): the long-term response to tamoxifen. A clinical case report and review of the literature]. ( Belli, L; Morgante, A; Passalacqua, G; Rabitti, G; Recchia, F; Rodorigo, C, 1989) |
"Evaluate the efficacy and safety of triple therapeutic method (Hepatic Aarterial Infusion Chemotherapy-HAIC, lenvatinib and sequential ablation) in the treatment for Advanced Hepatocellular carcinoma (Ad-HCC)." | 4.31 | Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and sequential ablation in the treatment of advanced hepatocellular carcinoma. ( An, C; Guo, J; Li, C; Li, W; Lin, Y; Liu, Y; Qiao, Y; Zhou, M, 2023) |
"Hepatic arterial infusion chemotherapy (HAIC) with fluorouracil, leucovorin, and oxaliplatin (FOLFOX), lenvatinib and programmed death receptor-1 signaling inhibitors (PD1s) all alone have been proven effective in treating advanced hepatocellular carcinoma (HCC), yet the efficacy and safety of the tri-combination therapy in treating HCC patients with portal vein tumor thrombosis (PVTT) remains unknown." | 4.31 | Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis. ( Chen, J; Chen, M; Fu, Y; Hu, D; Hu, Z; Pang, Y; Peng, W; Wang, J; Xu, L; Yang, Z; Zhang, W; Zhang, Y; Zhou, Z, 2023) |
"0NHAC-FUA) was fabricated through an amide condensation reaction to improve the therapeutic efficacy of 5-Fluorouracil (5-FU) in hepatocellular carcinoma (HCC)." | 4.12 | Functionalized PAMAM-based Nanoformulation for Targeted Delivery of 5-Fluorouracil in Hepatocellular Carcinoma. ( Chen, H; Chen, S; He, D; Li, Q; Liu, D; Ouyang, H; Pan, W; Wang, X; Xie, W; Yu, C, 2022) |
"Hepatic arterial infusion chemotherapy (HAIC) with oxaliplatin and 5-fluorouracil was effective in unresectable hepatocellular carcinoma (HCC)." | 4.12 | One day versus two days of hepatic arterial infusion with oxaliplatin and fluorouracil for patients with unresectable hepatocellular carcinoma. ( Chen, M; He, M; Huang, Y; Kan, A; Lai, Z; Li, Q; Lin, X; Shi, M; Wei, W; Wen, D; Xu, L, 2022) |
"Objective To investigate the effect of curcumin combined with 5-FU on autophagy and Yes-associated protein (YAP) expression in hepatocellular carcinoma cells." | 4.02 | [Curcumin combined with 5-FU promotes autophagy and down-regulates the expression of Yes-associated protein (YAP) in hepatocellular carcinoma cells]. ( Wang, X; Zhu, J, 2021) |
"FOLFOX is a combinational regimen of folinic acid (FnA, FOL), fluorouracil (5-Fu, F) and oxaliplatin (OxP, OX), and has been long considered as the standard treatment of colorectal cancer (CRC) and hepatocellular carcinoma (HCC)." | 4.02 | Two nanoformulations induce reactive oxygen species and immunogenetic cell death for synergistic chemo-immunotherapy eradicating colorectal cancer and hepatocellular carcinoma. ( Guo, J; Huang, L; Liu, Y; Sun, D; Yu, Z; Zou, Y, 2021) |
" The differentiation-inducing capacity of arsenic trioxide (ATO) in hepatocellular carcinoma (HCC) and the underlying mechanism were previously unknown." | 4.02 | Arsenic trioxide induces differentiation of cancer stem cells in hepatocellular carcinoma through inhibition of LIF/JAK1/STAT3 and NF-kB signaling pathways synergistically. ( Cao, Y; Cheng, JW; Fan, J; Hu, B; Huang, A; Huang, XW; Qiu, SJ; Sun, YF; Yang, XR; Zeng, HY; Zhang, X; Zhou, J, 2021) |
"This study aimed to assess the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) with modified FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin) as an alternative treatment option in advanced hepatocellular carcinoma (HCC) patients with failed or unsuitability for transarterial chemoembolization (TACE)." | 4.02 | Hepatic Arterial Infusion Chemotherapy with Modified FOLFOX as an Alternative Treatment Option in Advanced Hepatocellular Carcinoma Patients with Failed or Unsuitability for Transarterial Chemoembolization. ( Chen, MP; Chen, RX; Chen, Y; Ge, NL; Hsu, SJ; Luo, JF; Ren, ZG; Wang, Y; Wang, YH; Xu, X; Yin, X; Zhang, L; Zhao, ZY, 2021) |
"This study aimed to utilize cholesterol conjugation of 5-fluorouracil (5-FUC) and liposomal formulas to enhance the partitioning of 5-FU into low density lipoprotein (LDL) to target hepatocellular carcinoma (HCC)." | 4.02 | Crosstalk of low density lipoprotein and liposome as a paradigm for targeting of 5-fluorouracil into hepatic cells: cytotoxicity and liver deposition. ( Al Meanazel, AT; Al Meanazel, OT; Alanazi, FK; Alanazi, SA; Alomrani, AH; Badran, MM; Elzayat, E; Harisa, GI, 2021) |
" sorafenib as sequential maintenance therapy following liver-directed concurrent chemoradiotherapy (LD-CCRT) for locally advanced-stage hepatocellular carcinoma (HCC)." | 4.02 | Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma. ( Ahn, SH; Beom, SH; Choi, HJ; Han, KH; Han, S; Kim, BK; Kim, DY; Kim, HR; Kim, SU; Lee, H; Lee, HW; Lee, JS; Park, JY; Seong, J; Won, JY, 2021) |
"To compare the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) with a modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX) regimen with that of transarterial chemoembolization as a locoregional treatment for patients with locally advanced hepatocellular carcinoma (HCC)." | 4.02 | Hepatic Artery Infusion Chemotherapy Using Fluorouracil, Leucovorin, and Oxaliplatin versus Transarterial Chemoembolization as Initial Treatment for Locally Advanced Hepatocellular Carcinoma: A Propensity Score-Matching Analysis. ( Deng, H; Han, X; He, M; Lai, J; Li, J; Li, S; Lyu, N; Shi, M; Wang, H; Zhao, M, 2021) |
"The first choice of treatment in Hepatocellular Carcinoma (HCC) is 5-fluorouracil (5-FU)." | 3.96 | Targeted Nanoparticles for Co-delivery of 5-FU and Nitroxoline, a Cathepsin B Inhibitor, in HepG2 Cells of Hepatocellular Carcinoma. ( Fard, MM; Hassanzadeh, F; Mirian, M; Varshosaz, J, 2020) |
"Intestinal mucositis is the most common side effect of 5-fluorouracil (5-Fu) treatment in cancer patients." | 3.96 | Protective effect of Andrographolide on 5-Fu induced intestinal mucositis by regulating p38 MAPK signaling pathway. ( Li, M; Liu, D; Xiang, DC; Xu, YJ; Yang, JY; Zhang, CL; Zhang, S; Zhu, C, 2020) |
"Currently, 5-fluorouracil (5-FU) resistance became a major obstacle to its clinical use for patients with hepatocellular carcinoma (HCC)." | 3.91 | H1, a derivative of tetrandrine, enhances the efficacy of 5-FU in Bel7402/5-FU cells via suppressing STAT3/MCL-1 and inducing PUMA. ( Li, F; Li, Z; Wang, J; Wei, N; Wu, N; Zhang, H, 2019) |
" In this study, a biotin-/lactobionic acid-modified poly(ethylene glycol)-poly(lactic-co-glycolic acid)-poly(ethylene glycol) (BLPP) copolymer was synthesized, and curcumin- and 5-fluorouracil-loaded nanoparticles (BLPPNPs/C + F) were prepared to enhance the treatment of hepatocellular carcinoma." | 3.91 | Dual-Targeting Nanoparticles: Codelivery of Curcumin and 5-Fluorouracil for Synergistic Treatment of Hepatocarcinoma. ( Gao, X; Ji, Y; Jian, X; Li, Z; Liu, Z; Ni, W; Sun, S; Wu, L, 2019) |
"Bile salts (GCDA) promoted the proliferation of hepatocellular carcinoma (HCC) cells (HepG2 and QGY-7703), and GCDA treatment reduced the chemosensitivity of 5-fluorouracil (5FU) in HepG2 and QGY-7703 cells." | 3.91 | Bile salt (glycochenodeoxycholate acid) induces cell survival and chemoresistance in hepatocellular carcinoma. ( Jin, X; Li, X; Liao, M; Wang, C; Xiao, X; Yang, M; Zhang, Y; Zhao, J, 2019) |
"To compare the outcome of hepatic arterial infusion chemotherapy combined with radiotherapy (HAIC + RT) versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma (HCC) and major portal vein tumor thrombosis (PVTT)." | 3.88 | Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor Thrombosis. ( Aikata, H; Aisaka, Y; Chayama, K; Hatooka, M; Hiramatsu, A; Honda, Y; Hyogo, H; Imamura, M; Inagaki, Y; Kawakami, Y; Kawaoka, T; Kimura, T; Kodama, K; Kohno, H; Masaki, K; Mori, N; Morio, K; Moriya, T; Murakami, E; Nagata, Y; Nakahara, T; Nishida, Y; Nonaka, M; Takaki, S; Tsuge, M; Tsuji, K; Uchikawa, S, 2018) |
"To compare the overall survival (OS) and disease progression free survival (PFS) in patients with advanced hepatocellular carcinoma (Ad-HCC) who are undergoing hepatic arterial infusion (HAI) of oxaliplatin, fluorouracil/leucovorin (FOLFOX) treatment vs." | 3.88 | Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma. ( Cai, X; Deng, H; Guo, R; Kong, Y; Li, J; Li, S; Lin, Y; Liu, Y; Lyu, N; Mu, L; Shi, M; Wu, P; Xie, Q; Xu, L; Zhang, Z; Zhao, M; Zheng, L, 2018) |
"5-Fluorouracil (5-FU) has been widely applied to treat various types of cancers, including hepatocellular carcinoma (HCC)." | 3.88 | lncRNA KRAL reverses 5-fluorouracil resistance in hepatocellular carcinoma cells by acting as a ceRNA against miR-141. ( Lin, X; Pan, C; Shi, L; Shi, Y; Wei, X; Wu, L; Zheng, J, 2018) |
"We investigated the role of vitamin D (Vit D) alone and in combination with 5-fluorouracil (5-FU) in thioacetamide (TAA)-induced hepatocellular carcinoma (HCC) in rats." | 3.88 | Vitamin D potentiates anti-tumor activity of 5-fluorouracil via modulating caspase-3 and TGF-β1 expression in hepatocellular carcinoma-induced in rats. ( Eissa, LA; El-Karef, A; El-Mesery, M; R Ebrahim, A, 2018) |
" We found that the downregulation or complete depletion of SND1 enhanced the apoptosis levels of HepG2 and SMMC-7721 cells upon stimulation with 5-Fu (5-fluorouracil), a chemotherapeutic drug for HCC (hepatocellular carcinoma)." | 3.88 | SND1 acts as an anti-apoptotic factor via regulating the expression of lncRNA UCA1 in hepatocellular carcinoma. ( Cui, X; Gao, X; Qian, B; Ren, Y; Su, C; Yang, J; Yao, X; Yao, Z; Zhao, C, 2018) |
"Argininosuccinate synthetase (ASS), a key enzyme to synthesize arginine is down regulated in many tumors including hepatocellular carcinoma (HCC)." | 3.85 | The Combination of Arginine Deprivation and 5-Fluorouracil Improves Therapeutic Efficacy in Argininosuccinate Synthetase Negative Hepatocellular Carcinoma. ( Bhudhisawasdi, V; Li, YY; Navasumrit, P; Parnlob, V; Ruchirawat, M; Savaraj, N; Sricharunrat, T; Thongkum, A; Wangpaichitr, M; Wu, C, 2017) |
"This study aimed to investigate the therapeutic effects of 5-fluorouracil (5-FU)-loaded nanobubbles irradiated with low-intensity, low-frequency ultrasound in nude mice with hepatocellular carcinoma (HCC)." | 3.85 | The use of 5-fluorouracil-loaded nanobubbles combined with low-frequency ultrasound to treat hepatocellular carcinoma in nude mice. ( Deng, H; He, C; Jing, Z; Li, H; Li, Q; Liu, C; Ma, W; Xie, J, 2017) |
" Here, we investigated the synergistic effect of OMT with 5-fluorouracil (5-Fu) on the tumor growth inhibition of hepatocellular carcinoma cells (HCC; Hep-G2 and SMMC-7721) and explored the underlying mechanism." | 3.83 | Oxymatrine synergistically enhances the inhibitory effect of 5-fluorouracil on hepatocellular carcinoma in vitro and in vivo. ( Bi, T; Dai, W; Gao, Q; Liu, Y; Qian, L; Shen, G; Wang, G, 2016) |
"Three human hepatocellular carcinoma cell lines--HepG2, Hep3B and HuH-7--were pre- and post-treated with doxorubicin, 5-fluorouracil (5-FU) and cisplatin." | 3.83 | Epithelial cell adhesion molecule in human hepatocellular carcinoma cell lines: a target of chemoresistence. ( Farmer, RW; Li, Y; Martin, RC; Yang, Y, 2016) |
"To compare the outcome of 5-fluorouracil (FU)-based hepatic arterial infusion chemotherapy (HAIC) with sorafenib monotherapy in patients with hepatocellular carcinoma (HCC) refractory to transcatheter arterial chemoembolization (TACE)." | 3.83 | Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy and Sorafenib in Patients with Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization. ( Aikata, H; Aisaka, Y; Chayama, K; Hatooka, M; Hiramatsu, A; Honda, Y; Hyogo, H; Imamura, M; Kawakami, Y; Kawaoka, T; Kobayashi, T; Kohno, H; Mori, N; Morio, K; Moriya, T; Murakami, E; Nonaka, M; Takaki, S; Tsuji, K; Waki, K, 2016) |
"This study aimed to investigate the pharmaco-economic implications of FOLFOX4 or sorafenib for advanced hepatocellular carcinoma in China." | 3.83 | FOLFOX4 or sorafenib as the first-line treatments for advanced hepatocellular carcinoma: A cost-effectiveness analysis. ( Li, Q; Wen, F; Zhang, P, 2016) |
"The aim of this study was to compare the efficacy of hepatic arterial infusion chemotherapy (HAIC) and sorafenib in advanced hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT)." | 3.81 | A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. ( Bae, SH; Cho, SB; Chung, WJ; Jang, JY; Kim, YS; Lee, SH; Park, JY; Park, SY; Song, DS; Song, MJ; Yang, JM; Yim, HJ, 2015) |
" Here, we investigated the correlation between microRNA-21 expression and hepatic arterial infusion chemotherapy with 5-fluorouracil and pirarubicin (HAIC) for hepatocellular carcinoma (HCC)." | 3.81 | Targeting the microRNA-21/AP1 axis by 5-fluorouracil and pirarubicin in human hepatocellular carcinoma. ( Chen, S; Dong, L; Guo, W; He, X; Kong, Y; Li, J; Liu, C; Liu, W; Song, W; Wang, F; Yu, J; Yu, S; Zheng, Y, 2015) |
" Herein, we report that NPs conjugated with antibody against GRP78 (mAb GRP78-NPs) inhibit the adhesion, invasion, and metastasis of hepatocellular carcinoma (HCC) and promote drug delivery of 5-fluorouracil into GRP78 high-expressed human hepatocellular carcinoma cells." | 3.81 | Nanoparticles inhibit cancer cell invasion and enhance antitumor efficiency by targeted drug delivery via cell surface-related GRP78. ( Li, H; Liu, L; Shi, Y; Su, C; Su, R; Wang, G; Zhao, L, 2015) |
" The present study is designed to explore the influence of CGA on the effects of 5-fluorouracil (5-FU) on human hepatocellular carcinoma cells (HepG2 and Hep3B)." | 3.81 | Chlorogenic acid enhances the effects of 5-fluorouracil in human hepatocellular carcinoma cells through the inhibition of extracellular signal-regulated kinases. ( Dong, L; Han, J; Hou, N; Li, J; Song, Y; Yan, Y, 2015) |
"To investigate transarterial chemoembolization (TACE) with hepatic infusion of oxaliplatin and 5-fluorouracil and Lipiodol chemoembolization in large hepatocellular carcinoma (HCC)." | 3.81 | Oxaliplatin and 5-fluorouracil hepatic infusion with lipiodolized chemoembolization in large hepatocellular carcinoma. ( Chen, RX; Chen, Y; Gan, YH; Ge, NL; Le, F; Li, JH; Li, LX; Ren, ZG; Wang, YH; Xia, JL; Xie, XY; Xue, TC; Ye, SL; Zhang, BH; Zhang, JB; Zhang, L, 2015) |
"Seventy-three patients with liver cirrhosis (LC) and advanced HCC (aHCC) received hepatic arterial infusion chemotherapy (HAIC: leucovorin (LV) at 12 mg/h, cisplatin (CDDP) at 10 mg/h and 5-fluorouracil (5-FU) at 250 mg/22 h) via the proper hepatic artery every 5 days for 4 weeks using a catheter connected to a subcutaneous drug delivery system." | 3.81 | VEGF in patients with advanced hepatocellular carcinoma receiving intra-arterial chemotherapy. ( Matsui, D; Mukozu, T; Nagai, H; Ogino, YU; Sumino, Y, 2015) |
"Sorafenib is the standard treatment for advanced hepatocellular carcinoma (HCC) with distant metastasis, unresectable HCC, and those refractory to transcatheter arterial chemoembolization (TACE) or with macroscopic vascular invasion (MVI)." | 3.81 | Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma. ( Aikata, H; Chayama, K; Fukuhara, T; Hatooka, M; Hiramatsu, A; Hyogo, H; Imamura, M; Kawakami, Y; Kawaoka, T; Kobayashi, T; Kohno, H; Miyaki, D; Morio, K; Morio, R; Moriya, T; Naeshiro, N; Takahashi, S; Tsuji, K; Waki, K, 2015) |
"Sorafenib is a systemic chemotherapeutic agent for advanced hepatocellular carcinoma (HCC)." | 3.81 | Sorafenib inhibits cancer side population cells by targeting c‑Jun N‑terminal kinase signaling. ( Kim, HR; Kim, JB; Kim, YJ; Lee, HS; Lee, M; Lee, S; Park, SY; Yoon, JH, 2015) |
" Here, we report the effect of an APN inhibitor 4cc in enhancing sensitivity of hepatocellular carcinoma (HCC) cell lines and xenograft model in response to 5-fluorouracil (5-FU) in vivo and in vitro." | 3.81 | Aminopeptidase N inhibitor 4cc synergizes antitumor effects of 5-fluorouracil on human liver cancer cells through ROS-dependent CD13 inhibition. ( Dai, G; Duan, Y; Shi, LH; Sun, ZP; Wang, XJ; Xu, WF; Zhang, J; Zhang, XR, 2015) |
"Previously, a pilot genome-wide association study has identified candidate single nucleotide polymorphism predictors for the therapeutic response of 5-fluorouracil, mitoxantrone and cisplatin (FMP) combination chemotherapy in advanced hepatocellular carcinoma (HCC)." | 3.80 | A single nucleotide polymorphism on the GALNT14 gene as an effective predictor of response to chemotherapy in advanced hepatocellular carcinoma. ( Chang, ML; Hsu, CL; Hung, CF; Liang, KH; Lin, CC; Yeh, CT, 2014) |
"5-Fluorouracil (5-FU) is one of the most common chemotherapeutic agents used for the treatment of hepatocellular carcinoma (HCC)." | 3.80 | The monoclonal antibody CH12 augments 5-fluorouracil-induced growth suppression of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III. ( Dong, Q; Gao, H; Jiang, H; Kong, J; Li, Z; Luo, X; Shi, B; Wang, H; Zhang, J, 2014) |
"Sorafenib treatment has shown to improve the survival in patients with advanced hepatocellular carcinoma (HCC) when compared with placebo." | 3.80 | Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability. ( Byun, KS; Kang, K; Kang, SH; Kim, JH; Lee, HJ; Lee, SJ; Suh, SJ; Yeon, JE; Yim, HJ; Yoo, YJ; Yoon, EL, 2014) |
"To evaluate the clinical efficacy and safety of epirubicin, cisplatin, and 5-FU combination chemotherapy for the sorafenib-refractory metastatic hepatocellular carcinoma (HCC)." | 3.80 | Epirubicin, cisplatin, 5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma. ( Bae, SH; Choi, JY; Lee, JE; Lee, MA; Yoon, SK; You, YK, 2014) |
"In present work, lactobionic acid conjugated PLGA nanoparticles (LDNPs) bearing 5-Fluorouracil (5-FU) were developed for targeted delivery to hepatocellular carcinoma." | 3.80 | Targeting liver cancer via ASGP receptor using 5-FU-loaded surface-modified PLGA nanoparticles. ( Dangi, R; Gulbake, A; Hurkat, P; Jain, A; Jain, SK; Shilpi, S, 2014) |
"5-fluorouracil (5-FU)-based chemotherapy is widely used in the treatment of human hepatocellular carcinoma." | 3.80 | Overexpression of microRNA-125b sensitizes human hepatocellular carcinoma cells to 5-fluorouracil through inhibition of glycolysis by targeting hexokinase II. ( Gao, S; Jiang, JX; Pan, YZ; Sun, CY; Yu, C, 2014) |
" The present study investigated the ability of metformin to reverse multidrug resistance (MDR) in human hepatocellular carcinoma Bel‑7402/5‑fluorouracil (5‑Fu; Bel/Fu) cells." | 3.80 | Metformin reverses multidrug resistance in human hepatocellular carcinoma Bel‑7402/5‑fluorouracil cells. ( Feng, T; Gao, Z; Hou, Z; Jia, K; Li, Y; Ling, S; Sun, D; Tian, Y; Wang, L; Xu, F; Zhang, H, 2014) |
"Children with hepatocellular carcinoma (HCC) were treated on a prospective, randomized trial and were then analyzed to determine whether children with the fibrolamellar (FL) histologic variant of HCC have a more favorable presentation, increased surgical resectability, greater response to therapy, and improved outcome compared with children who have typical HCC." | 3.80 | Fibrolamellar hepatocellular carcinoma in children and adolescents. ( Bowman, LC; Castleberry, RP; Douglass, EC; Feusner, JH; Finegold, MJ; Haas, JE; Katzenstein, HM; Krailo, MD; Malogolowkin, MH; Newman, K; Ortega, JA; Qu, W; Quinn, JJ; Reynolds, M; Sensel, MG, 2003) |
"Oral tegafur/uracil therapy has been indicated for patients with hepatocellular carcinoma (HCC) and is often used as a single-agent treatment." | 3.79 | Genetic polymorphisms of enzymes related to oral tegafur/uracil therapeutic efficacy in patients with hepatocellular carcinoma. ( Akizuki, S; Fushiya, N; Nishino, H; Ohnishi, A; Takagi, I, 2013) |
"The purpose of this study was to evaluate the factors associated with response rate, resectability, and survival after cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) combination therapy in patients with initially unresectable hepatocellular carcinoma." | 3.79 | Modified cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma. ( Abbruzzese, JL; Aloia, TA; Curley, SA; Hassabo, HM; Hassan, MM; Kaseb, AO; Lozano, RD; Patt, YZ; Roses, RE; Shindoh, J; Vauthey, JN; Zimmitti, G, 2013) |
"Recently, a phase II clinical trial in hepatocellular carcinoma (HCC) has suggested that the combination of sorafenib and 5-fluorouracil (5-FU) is feasible and side effects are manageable." | 3.79 | Schedule-dependent antitumor effects of 5-fluorouracil combined with sorafenib in hepatocellular carcinoma. ( Deng, L; Jia, Q; Ren, Z; Shen, H; Wang, Y; Wu, W, 2013) |
"To investigate the efficacy and safety of capecitabine and oxaliplatin (CapeOx) for extrahepatic metastasis after local treatment of hepatocellular carcinoma (HCC)." | 3.79 | Efficacy of capecitabine and oxaliplatin regimen for extrahepatic metastasis of hepatocellular carcinoma following local treatments. ( Dong, JC; He, SL; Liu, LM; Shen, J; Sun, XJ; Zhu, XJ, 2013) |
" Our study found that the expression of miR-27a was down-regulated in the multidrug-resistant hepatocellular carcinoma cell line BEL-7402/5-fluorouracil (BEL/5-FU) compared with its parental BEL-7402 cell line, while the MDR1/P-glycoprotein expression was elevated." | 3.79 | MiR-27a modulates the MDR1/P-glycoprotein expression by inhibiting FZD7/β-catenin pathway in hepatocellular carcinoma cells. ( Chen, Z; Hu, T; Huang, C; Li, J; Lv, X; Ma, T; Xu, T; Zhang, L, 2013) |
"To explore the potential of iodized linoleic acid (ILA) and its 5-fluoro-deoxyuridine ester (IFU) to inhibit hepatocellular carcinoma (HCC) cells in vitro and tumors in vivo." | 3.79 | [A preliminary study of the inhibitive efficacy of iodized linoleic acid and its fluorodeoxyuridine ester in hepatocellular cancer]. ( Dai, ZY; Jiang, YB; Kuang, CX; Li, KC; Zeng, XY, 2013) |
"A 57-year-old Caucasian man with a history of Child's class A hepatitis C, cirrhosis and progressive multifocal hepatocellular carcinoma was treated with sorafenib but progressed after 7 months of stable disease." | 3.79 | Complete radiographic remission with 5-fluorouracil and leucovorin after sorafenib failure in hepatocellular carcinoma: is there a role for chemotherapy after targeted agents? ( Tan-Shalaby, J, 2013) |
" The aim of this study is to investigate the role and mechanism of mir-23a in enhancing the anti-tumor effect of topoisomerase 2A (TOP2A) poison etoposide in human hepatocellular carcinoma (HCC)." | 3.79 | MiR-23a-mediated inhibition of topoisomerase 1 expression potentiates cell response to etoposide in human hepatocellular carcinoma. ( Feng, Y; Man, K; Tsao, SW; Wang, N; Zhang, Z; Zhu, M, 2013) |
"Hepatic arterial infusion chemotherapy (HAIC) with 5-fluorouracil and cisplatin for intractable advanced hepatocellular carcinoma (HCC) may have survival benefits." | 3.79 | Efficacy and safety of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma as first-line therapy. ( Lee, HJ; Lee, SH; Oh, MJ, 2013) |
"We report a case of long-term survival of a patient with hepatocellular carcinoma( HCC) with portal vein tumor thrombus (PVTT) treated with fluorouracil arterial infusion and interferon therapy (FAIT)." | 3.79 | [Long-term survival of a patient with hepatocellular carcinoma with portal vein tumor thrombus treated with interferon-α and 5-fluorouracil combination therapy]. ( Akita, H; Doki, Y; Eguchi, H; Hama, N; Kawamoto, K; Kobayashi, S; Mori, M; Nagano, H; Tomimaru, Y; Tsuda, Y; Umeshita, K; Wada, H, 2013) |
"Acquired resistance to 5-fluorouracil (5-FU) is a serious therapeutic obstacle in advanced hepatocellular carcinoma (HCC) patients." | 3.79 | The noncytotoxic dose of sorafenib sensitizes Bel-7402/5-FU cells to 5-FU by down-regulating 5-FU-induced Nrf2 expression. ( Duan, X; Wang, J; Ye, W; Zhang, M; Zhou, S, 2013) |
"Thalidomide has shown modest activity in advanced hepatocellular carcinomas (HCCs)." | 3.78 | Activity of thalidomide and capecitabine in patients with advanced hepatocellular carcinoma. ( Ang, SF; Choo, SP; Foo, KF; Ong, SY; Poon, DY; Tan, SH; Toh, HC, 2012) |
" Swiss mice inoculated with hepatoma HepA(22) or sarcoma 180 (S(180)) cells were treated with ShD or 5-fluorouracil (5Fu)." | 3.78 | Shikonin derivatives protect immune organs from damage and promote immune responses in vivo in tumour-bearing mice. ( BaoJie, G; GuangZhi, Y; LiHua, L; Long, S; Wei, X; Yang, Z; YanYong, H; YingLi, W, 2012) |
"Tanshinone IIA (Tan-IIA) decreases the viability of human hepatocellular carcinoma (HCC) cells through the induction of apoptosis in vitro." | 3.78 | Tanshinone IIA inhibits human hepatocellular carcinoma J5 cell growth by increasing Bax and caspase 3 and decreasing CD31 expression in vivo. ( Chen, DR; Chen, YL; Cheng, CY; Chien, SY; Kuo, SJ; Su, CC, 2012) |
"5-Fluorouracil (5-FU) chemotherapy is the first choice treatment for advanced hepatocellular carcinoma (HCC), and resistance is the major obstacle to successful treatment." | 3.78 | Establishment and characterization of two 5-fluorouracil-resistant hepatocellular carcinoma cell lines. ( Kasamatsu, A; Kobayashi, E; Sakurada, T; Sato, N; Sunaga, M; Tanzawa, H; Uchibori, K; Ueda, S; Uzawa, K; Yokota, S; Yoshikawa, M, 2012) |
"The aim of the present study was to design a targeted delivery system of 5-fluorouracil (5-FU) for hepatocellular carcinoma (HCC)." | 3.78 | Galactosylated nanostructured lipid carriers for delivery of 5-FU to hepatocellular carcinoma. ( Hassanzadeh, F; Khadem, M; Sadeghi, H; Varshosaz, J, 2012) |
"We examined the background, survival rates, median survival time and side effects of 15 cases in which systemic chemotherapy using carboplatin and 5-fluorouracil was done (chemotherapy group) and 59 cases in which chemotherapy was not done (non-chemotherapy group) out of a total of 74 cases of patients with extrahepatic metastasis from hepatocellular carcinoma." | 3.78 | Systemic chemotherapy using carboplatin and 5-fluorouracil for extrahepatic metastasis of hepatocellular carcinoma. ( Fukunaga, A; Hirano, G; Irie, M; Iwashita, H; Iwata, K; Kunimoto, H; Morihara, D; Sakamoto, M; Sakisaka, S; Sakurai, K; Shakado, S; Sohda, T; Takeyama, Y; Ueda, S; Yokoyama, K; Yotsumoto, K, 2012) |
"Cancer stem-like cells previusly isolated from a hepatocellular carcinoma biopsy were treated with metformin, PIAF chemotherapy regimen and the combination of these two protocols." | 3.78 | Metformin plus PIAF combination chemotherapy for hepatocellular carcinoma. ( Aldea, M; Berindan, I; Cristea, V; Irimie, A; Kacso, G; Petrushev, B; Pop, T; Soritau, O; Susman, S; Tomuleasa, C, 2012) |
"Hepatic arterial infusion chemotherapy (HAIC) combined with sorafenib is considered to be a promising therapeutic strategy for patients with advanced hepatocellular carcinoma." | 3.78 | Hepatic arterial thrombosis: a critical complication during combination therapy of arterial chemoinfusion and sorafenib. ( Anai, H; Kichikawa, K; Maeda, S; Masada, T; Nishiofuku, H; Sueyoshi, S; Tanaka, T, 2012) |
"There has been no report on sorafenib therapy in patients with metastatic hepatocellular carcinoma (HCC) who had been treated with systemic chemotherapy." | 3.77 | Clinical outcomes of sorafenib treatment in patients with metastatic hepatocellular carcinoma who had been previously treated with fluoropyrimidine plus platinum-based chemotherapy. ( Bang, YJ; Han, SW; Im, SA; Kim, JW; Kim, TY; Lee, JO; Oh, DY, 2011) |
"Although 5-fluorouracil (5-FU) is one of the most commonly used chemotherapeutic agents in various cancer including hepatocellular carcinoma (HCC), chemoresistance has precluded single use of 5-FU in clinical settings." | 3.77 | Vitamin K2 augments 5-fluorouracil-induced growth inhibition of human hepatocellular carcinoma cells by inhibiting NF-κB activation. ( Eguchi, Y; Hamajima, H; Iwane, S; Kawaguchi, Y; Mizuta, T; Ozaki, I; Takahashi, H; Yamamoto, K; Zhang, H, 2011) |
"This study evaluated the efficacy of combined 5-fluorouracil (5-FU) and pegylated interferon (PEG-IFN) α-2b in patients with advanced hepatocellular carcinoma (HCC)." | 3.77 | Combination therapy of intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma. ( Kasai, K; Kasai, Y; Kuroda, H; Miyamoto, Y; Oikawa, K; Sawara, K; Suzuki, K; Takikawa, Y; Ushio, A, 2011) |
" We investigated the therapeutic efficacies of metronomic S-1, an oral 5-fluorouracil prodrug, and vandetanib, an epidermal growth factor receptor and vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor, in models of hepatocellular carcinoma (HCC)." | 3.77 | Metronomic S-1 chemotherapy and vandetanib: an efficacious and nontoxic treatment for hepatocellular carcinoma. ( Abe, M; Hashimoto, O; Inoue, K; Iwamoto, H; Kerbel, RS; Koga, H; Kurogi, J; Kuwahara, R; Nakamura, T; Niizeki, T; Sata, M; Torimura, T; Ueno, T; Yano, H, 2011) |
"Many clinical reports have proven that the combination therapy of interferon-alpha plus 5-fluorouracil is remarkably effective for advanced hepatocellular carcinoma (HCC)." | 3.77 | Combination of interferon-α and 5-fluorouracil induces apoptosis through mitochondrial pathway in hepatocellular carcinoma in vitro. ( Deng, B; Mao, H; Qu, X; Sun, J; Wang, Q; Xie, F; Yang, Y; Yin, H; Zhang, J, 2011) |
"To evaluate the efficacy of intra-arterial 5-fluorouracil (5-FU) and subcutaneous interferon (IFN) combined with image-guided radiation therapy (IGRT) in advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT)." | 3.77 | Efficacy of therapy for advanced hepatocellular carcinoma: intra-arterial 5-fluorouracil and subcutaneous interferon with image-guided radiation. ( Abo, D; Asaka, M; Chuma, M; Hige, S; Horimoto, H; Kato, M; Kobayashi, T; Nakai, M; Nakanishi, M; Ogawa, K; Sakuhara, Y; Shimizu, S; Shirato, H; Sho, T; Taguchi, H; Terashita, K; Tsukuda, Y; Tsunematsu, S; Yamamoto, Y, 2011) |
"Cytotoxic activity of artemisinin and derivatives in the presence and absence of holo-transferrin and expression of genes involved in resistance of cancer cells were investigated in human cholangiocarcinoma (CL-6) and hepatocarcinoma (Hep-G2) cell lines in vitro." | 3.77 | Cytotoxic activity of artemisinin derivatives against cholangiocarcinoma (CL-6) and hepatocarcinoma (Hep-G2) cell lines. ( Chaijaroenkul, W; Mahavorasirikul, W; Na-Bangchang, K; Viyanant, V, 2011) |
"We previously reported the beneficial effects of a combination therapy of interferon (IFN)-α/5-fluorouracil (FU) for advanced hepatocellular carcinoma (HCC) with tumor thrombi in the major portal branches." | 3.77 | Long-term outcome of combined interferon-α and 5-fluorouracil treatment for advanced hepatocellular carcinoma with major portal vein thrombosis. ( Doki, Y; Eguchi, H; Kobayashi, S; Marubashi, S; Mori, M; Nagano, H; Osuga, K; Tanemura, M; Tomimaru, Y; Umeshita, K; Wada, H, 2011) |
"Combination treatment consisting of hepatic arterial infusion chemotherapy with epirubicin and cisplatin (HAIC-EC) and systemic infusion of low-dose 5-fluorouracil (5-FU) are sometimes effective against advanced hepatocellular carcinoma (HCC)." | 3.77 | Combination treatment with intrahepatic arterial infusion and intratumoral injection chemotherapy in patients with far-advanced hepatocellular carcinoma and arterioportal or arteriovenous shunts: preliminary results. ( Jung, G; Kim, BH; Kim, JS; Kim, NY; Lee, KJ; Park, SJ; Park, YM; Yeon, JW; Yun, HK, 2011) |
"To investigate the apoptotic activities of casticin in hepatocellular carcinoma (HCC) cells and its molecular mechanisms." | 3.77 | Casticin-induced apoptosis involves death receptor 5 upregulation in hepatocellular carcinoma cells. ( Cao, JG; Liu, F; Sheng, XF; Tian, L; Yang, J; Yang, Y, 2011) |
"Sorafenib is the only therapy approved for advanced hepatocellular carcinoma no longer eligible for transcatheter arterial chemoembolization." | 3.77 | Hepatic intra-arterial cetuximab in combination with 5-fluorouracil and cisplatin as salvage treatment for sorafenib-refractory hepatocellular carcinoma. ( Bernardo, G; Cornalba, G; Delmonte, A; Di Cesare, P; Greco, G; Melchiorre, F; Montagna, B; Poggi, G; Quaretti, P; Riccardi, A; Sottotetti, F; Stella, MG; Tagliaferri, B; Villani, L; Zorzetto, M, 2011) |
"We report a case of successful treatment by interferon-α (IFN) and 5-fluorouracil (5-FU) combination therapy and transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT)." | 3.77 | [A case of successful treatment by interferon-α and 5-fluorouracil combination therapy (FAIT) and transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus]. ( Doki, Y; Eguchi, H; Kawamoto, K; Kishimoto, T; Kobayashi, S; Marubashi, S; Mori, M; Nagano, H; Tanemura, M; Umeshita, K; Wada, H, 2011) |
"To investigate the synergistic inhibitory effects of the combination of 5-fluorouracil (5-FU) with the natural flavanoid oroxylin A on human hepatocellular carcinoma cells HepG2 in vitro and on transplanted murine hepatoma 22 (H22) tumors in vivo and the preliminary mechanisms." | 3.76 | Synergistic effect of 5-fluorouracil and the flavanoid oroxylin A on HepG2 human hepatocellular carcinoma and on H22 transplanted mice. ( Chen, Z; Guo, QL; Mu, R; Qi, Q; Wang, J; Yang, L; You, QD; Zhao, L; Zhao, Q, 2010) |
"We investigated the efficacy of intra-arterial 5-fluorouracil (5-FU) and systemic interferon (IFN)-alpha (5-FU-IFN) in the treatment of hepatocellular carcinoma (HCC) with portal vein tumor thrombosis in the first branch or trunk (Vp3/4) and extrahepatic metastases." | 3.76 | Intra-arterial 5-fluorouracil/interferon combination therapy for hepatocellular carcinoma with portal vein tumor thrombosis and extrahepatic metastases. ( Aikata, H; Chayama, K; Hieda, M; Hiramatsu, A; Ishikawa, M; Kakizawa, H; Katamura, Y; Kawakami, Y; Kawaoka, T; Kimura, Y; Takahashi, S; Takaki, S; Waki, K, 2010) |
"The effects and mechanisms of action of beta-aescin and 5-fluorouracil (5-FU), alone and in combination, were studied in human hepatocellular carcinoma SMMC-7721 cells." | 3.76 | Synergistic effects of beta-aescin and 5-fluorouracil in human hepatocellular carcinoma SMMC-7721 cells. ( Cao, L; Hu, Y; Ming, ZJ; Qiu, YH; Zhang, XG, 2010) |
"Five fluorouracil (5-FU) is extensively used in the treatment of hepatocellular carcinoma (HCC)." | 3.76 | Novel biochemical pathways for 5-Fluorouracil in managing experimental hepatocellular carcinoma in rats. ( Abdel-Hamid, NM; Morsy, MA, 2010) |
" However, it has also been reported that 5-fluorouracil (5-FU) exacerbates liver damage in patients with liver cirrhosis (LC)." | 3.76 | Hepatotoxicity of intra-arterial combination chemotherapy in patients with liver cirrhosis and advanced hepatocellular carcinoma. ( Igarashi, Y; Iida, K; Ishii, K; Kanayama, M; Matsui, T; Momiyama, K; Nagai, H; Shinohara, M; Shizawa, K; Sumino, Y; Wakui, N; Watanabe, M, 2010) |
" Here, we provide genetic evidence that ATM kinase activity is required to trigger 5-FU- and neocarzinostatin-dependent cFLIP(L) and cFLIP(S) down-regulation, which in turn sensitize hepatocellular carcinoma (HCC) cell lines to TRAIL." | 3.76 | ATM kinase activity modulates cFLIP protein levels: potential interplay between DNA damage signalling and TRAIL-induced apoptosis. ( Barilà, D; Giaccari, D; Mingardi, M; Santini, S; Stagni, V, 2010) |
"We reported recently the clinical efficiency of interferon (IFN)-α/5-fluorouracil (5-FU) combination therapy in advanced hepatocellular carcinoma (HCC)." | 3.76 | MicroRNA-21 induces resistance to the anti-tumour effect of interferon-α/5-fluorouracil in hepatocellular carcinoma cells. ( Doki, Y; Eguchi, H; Kobayashi, S; Marubashi, S; Mori, M; Nagano, H; Takeda, Y; Tanemura, M; Tomimaru, Y; Tomokuni, A; Umeshita, K; Wada, H, 2010) |
"We report a case of advanced hepatocellular carcinoma (HCC) successfully treated by hepatic arterial infusion of 5-fluorouracil (5-FU) combined with systemic administration of interferon (IFN)-α and trans-arterial infusion (TAI) therapy of cisplatin (CDDP)." | 3.76 | [A long-term survival case of hepatocellular carcinoma with portal vein and inferior vena cava tumor thrombi]. ( Doki, Y; Eguchi, H; Hashimoto, Y; Kobayashi, S; Marubashi, S; Mori, M; Nagano, H; Takeda, Y; Tanemura, M; Umeshita, K; Wada, H, 2010) |
"Type I IFN receptor type 2 (IFNAR2) expression correlates significantly with clinical response to interferon (IFN)-alpha/5-fluorouracil (5-FU) combination therapy for hepatocellular carcinoma (HCC)." | 3.75 | Activation of Wnt/beta-catenin signalling pathway induces chemoresistance to interferon-alpha/5-fluorouracil combination therapy for hepatocellular carcinoma. ( Doki, Y; Dono, K; Kobayashi, S; Marubashi, S; Matsubara, K; Matsuura, N; Monden, M; Mori, M; Murakami, M; Nagano, H; Noda, T; Takeda, Y; Takemasa, I; Umeshita, K; Wada, H; Yoshioka, S, 2009) |
"We evaluated the efficacy and toxicity of combination chemotherapy with capecitabine and cisplatin (XP) in patients with metastatic hepatocellular carcinoma (HCC)." | 3.75 | Combination chemotherapy with capecitabine and cisplatin for patients with metastatic hepatocellular carcinoma. ( Bang, YJ; Im, SA; Kim, JH; Kim, TY; Lee, JO; Lee, KW; Oh, DY, 2009) |
"Resistance to 5-fluorouracil (5-FU) is a major cause of chemotherapy failure in advanced hepatocellular carcinoma (HCC)." | 3.75 | Rosiglitazone sensitizes hepatocellular carcinoma cell lines to 5-fluorouracil antitumor activity through activation of the PPARgamma signaling pathway. ( Cao, LQ; Chen, JS; Chen, XL; Fu, XH; Huang, XH; Jiao, XY; Lu, HW; Peng, HP; Wang, Q; Wang, XL; Xue, P; Zheng, Q, 2009) |
"The combination therapy of interferon (IFN)-alpha and 5-fluorouracil (5-FU) improved the prognosis of the patients with hepatocellular carcinoma (HCC)." | 3.75 | Combination of interferon-alpha and 5-fluorouracil inhibits endothelial cell growth directly and by regulation of angiogenic factors released by tumor cells. ( Doki, Y; Eguchi, H; Kobayashi, S; Marubashi, S; Mori, M; Murakami, M; Nagano, H; Noda, T; Takeda, Y; Tanemura, M; Umeshita, K; Wada, H; Yamamoto, H, 2009) |
"In this retrospective study, we assessed the efficacy of hepatic arterial infusion chemotherapy (HAIC) using high-dose 5-fluorouracil (5-FU) and cisplatin with or without interferon (IFN)-alpha for the treatment of advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis." | 3.75 | Hepatic arterial infusion chemotherapy using high-dose 5-fluorouracil and cisplatin with or without interferon-alpha for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis. ( Chang, JC; Eun, JR; Kim, JW; Kim, TN; Lee, HJ; Moon, HJ, 2009) |
"The aim was to assess the efficacy and safety of capecitabine (X) plus cisplatin (P) in patients with hepatocellular carcinoma (HCC)." | 3.75 | Efficacy of combination chemotherapy with capecitabine plus cisplatin in patients with unresectable hepatocellular carcinoma. ( Kim, CM; Lee, WJ; Nam, BH; Park, JW; Shim, JH, 2009) |
"Epigallocatechin gallate (EGCG) from green tea could reverse multidrug resistance (MDR) in human hepatocellular carcinoma (HCC) in vitro and in vivo." | 3.74 | [Impact of epigallocatechin gallate on gene expression profiles of human hepatocellular carcinoma cell lines BEL7404/ADM and BEL7402/5-FU]. ( Liang, G; Tang, HH; Zhou, M, 2008) |
"We report a case of combined hepatocellular and cholangiocarcinoma showing tumor growth and invasion to the diaphragm during interferon-alpha (IFN-alpha) and 5-fluorouracil (5-FU) combined intra-arterial chemotherapy." | 3.74 | [A case of combined hepatocellular and cholangiocarcinoma showing tumor growth and invasion to the diaphragm during interferon-alpha and 5-fluorouracil combined intra-arterial chemotherapy]. ( Doki, Y; Dono, K; Kobayashi, S; Marubashi, S; Monden, M; Mori, M; Murakami, M; Nagano, H; Nakayama, M; Noda, T; Shima, T; Takeda, Y; Tomimaru, Y; Umeshita, K; Wakasa, K, 2008) |
"Several studies have reported the efficacy of combination therapy of interferon (IFN) alpha and 5-fluorouracil (5-FU) for hepatocellular carcinoma (HCC)." | 3.74 | Role of the Fas/FasL pathway in combination therapy with interferon-alpha and fluorouracil against hepatocellular carcinoma in vitro. ( Damdinsuren, B; Dono, K; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Noda, T; Ota, H; Sakon, M; Takeda, Y; Umeshita, K; Wada, H; Yamamoto, T, 2007) |
" The aim of our current study was to examine the combined effect of ACE-I and 5-fluorouracil (5-FU), which is widely used for hepatogastrointestinal tumors, on hepatocellular carcinoma (HCC) growth and hepatocarcinogenesis." | 3.74 | Synergistic inhibition of hepatocellular carcinoma growth and hepatocarcinogenesis by combination of 5-fluorouracil and angiotensin-converting enzyme inhibitor via anti-angiogenic activities. ( Akahane, T; Asada, K; Fukui, H; Ikenaka, Y; Kaji, K; Kitade, M; Namisaki, T; Noguchi, R; Tsujimoto, T; Uemura, M; Yamazaki, M; Yanase, K; Yoshii, J; Yoshiji, H, 2007) |
"We experienced a patient who received successful treatment for multiple hepatocellular carcinoma (HCC) nodules, with tumor thrombi in the major portal branches, with intraarterial 5-fluorouracil perfusion chemotherapy combined with subcutaneous interferon-alpha administration." | 3.74 | Successful treatment of multiple hepatocellular carcinoma with tumor thrombi in the major portal branches by intraarterial 5-fluorouracil perfusion chemotherapy combined with subcutaneous interferon-alpha and hepatectomy. ( Damdinsuren, B; Dono, K; Fukuda, K; Imai, Y; Kondo, M; Matsumoto, H; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Noda, T; Ota, H; Sakon, M; Umeshita, K; Wada, H; Wakasa, K; Yamamoto, T, 2007) |
"To evaluate the effect of combined antisense oligonucleotides targeting midkine (MK-AS) and chemotherapeutic drugs [cisplatin(DDP), 5-fluorouracil (5-FU) and adriamycin (ADM)] on inhibition of HepG2 cell proliferation, and to analyze the efficacy of MK-AS used in combined ADM in in situ human hepatocellular carcinoma (HCC) model." | 3.74 | Enhanced therapeutic effects of combined chemotherapeutic drugs and midkine antisense oligonucleotides for hepatocellular carcinoma. ( Dai, LC; He, JF; Lu, YL; Ping, JL; Wang, X; Yao, X, 2007) |
"We encountered a case of peritoneal dissemination of hepatocellular carcinoma, successfully treated with a combination therapy of interferon-alpha-2b and oral tegafur/uracil." | 3.74 | Peritoneal dissemination of hepatocellular carcinoma treated with a combination therapy of interferon-alpha-2b and oral tegafur/uracil. ( Iwasaki, Y; Miyake, Y; Sakaguchi, K; Shiraha, H; Shiratori, Y, 2007) |
"We experienced 20 cases of advanced hepatocellular carcinoma with portal vein tumor thrombosis treated with low-dose cisplatin and 5-fluorouracil (5-FU) chemotherapy via implanted fusion port between August 1999 and September 2003." | 3.74 | [Clinical study of low-dose cisplatin and 5-fluorouracil chemotherapy via implanted fusion port in 20 patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis]. ( Abe, T; Arai, H; Hagiwara, S; Hamada, T; Kosone, T; Naganuma, A; Takagi, H; Toyoda, M; Yanagisawa, M, 2007) |
"We report two cases of hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) and lymph node (LN) metastases successfully treated by hepatic arterial infusion of 5-fluorouracil (5-FU) combined with systemic injection of interferon (IFN)-alpha following hepatic resection for the liver tumor." | 3.74 | Complete remission of hepatocellular carcinoma with portal vein tumor thrombus and lymph node metastases by arterial infusion of 5-fluorouracil and interferon-alpha combination therapy following hepatic resection. ( Damdinsuren, B; Dono, K; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Noda, T; Sakon, M; Takeda, Y; Umeshita, K; Wada, H; Wakasa, K, 2007) |
"We recently reported that interferon-alpha (IFN-alpha) and 5-fluorouracil (5-FU) combination therapy in advanced hepatocellular carcinoma (HCC) achieved excellent clinical results." | 3.74 | Combination therapy of interferon-alpha and 5-fluorouracil inhibits tumor angiogenesis in human hepatocellular carcinoma cells by regulating vascular endothelial growth factor and angiopoietins. ( Arai, I; Damdinsuren, B; Doki, Y; Dono, K; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Noda, T; Ota, H; Sakon, M; Takeda, Y; Umeshita, K; Wada, H; Yamamoto, H, 2007) |
"To investigate the multicellular resistance of human hepatocellular carcinoma HepG2 cells in three-dimensional culture to delisheng, 5-fluorouracil and adriamycin, and the possible molecular mechanisms of delisheng." | 3.74 | Chinese medicinal compound delisheng has satisfactory anti-tumor activity, and is associated with up-regulation of endostatin in human hepatocellular carcinoma cell line HepG2 in three-dimensional culture. ( Cui, J; Guo, YH; Nan, KJ; Tian, T; Wang, L; Zhao, N, 2007) |
"Intra-arterial 5-fluorouracil (5-FU) plus interferon (IFN) combination therapy is effective against advanced hepatocellular carcinoma (HCC) with portal vein tumour thrombosis." | 3.74 | Similar effects of recombinant interferon-alpha-2b and natural interferon-alpha when combined with intra-arterial 5-fluorouracil for the treatment of advanced hepatocellular carcinoma. ( Aikata, H; Chayama, K; Hiramatsu, A; Ito, K; Jeong, SC; Kawakami, Y; Kodama, H; Miki, D; Shirakawa, H; Takahashi, S; Takaki, S; Toyota, N; Uka, K, 2007) |
"Several studies have reported survival benefits of combination therapy with intraarterial 5-fluorouracil (5-FU) and subcutaneous interferon (IFN) alpha for advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT)." | 3.74 | Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma. ( Aikata, H; Chayama, K; Ito, K; Jeong, SC; Kawaoka, T; Miki, D; Takahashi, S; Takaki, S; Toyota, N; Uka, K, 2007) |
" Here, we examined the role p53 plays in the antitumour effect of combination treatment with pegylated interferon (PEG-IFN)-alpha and 5-fluorouracil (5-FU), which has been shown to effectively treat advanced hepatocellular carcinoma (HCC)." | 3.74 | Combination therapy with PEG-IFN-alpha and 5-FU inhibits HepG2 tumour cell growth in nude mice by apoptosis of p53. ( Fukuta, N; Hagiwara, S; Hayakawa, S; Kimura, M; Kudo, M; Munakata, H; Nagashima, M; Nakatani, T; Sakaguchi, Y, 2007) |
"To observe changes of sensitivity to 5'-deoxy-5-fluorouridine (5'-dFUrd), and 5-fluorouracil (5-FU) in SMMC-7721 hepatocellular carcinoma cells by interferon alpha (IFN-alpha), and its relationship with the expression of thymidine phosphorylase (TP)." | 3.74 | [Interferon alpha enhances the sensitivity of SMMC-7721 hepatocellular carcinoma cells to 5'-deoxy-5-fluorouridine related to up-regulation of thymidine phosphorylase]. ( Fan, J; Liu, YK; Sun, RX; Tang, ZY; Xiao, YS; Ye, SL; Zhao, Y; Zhou, J, 2007) |
"The combination of intra-arterial low-dose cisplatin and 5-fluorouracil (5-FU) is effective against advanced hepatocellular carcinoma (HCC)." | 3.74 | Systemic gemcitabine combined with intra-arterial low-dose cisplatin and 5-fluorouracil for advanced hepatocellular carcinoma: seven cases. ( Aikata, H; Chayama, K; Ito, K; Kawaoka, T; Miki, D; Saneto, H; Takahashi, S; Takaki, S; Toyota, N; Uka, K, 2008) |
"Several studies showed the effectiveness of combination therapy with IFN-alpha and 5-fluorouracil (5-FU) for advanced hepatocellular carcinoma." | 3.73 | Combination of IFN-alpha and 5-fluorouracil induces apoptosis through IFN-alpha/beta receptor in human hepatocellular carcinoma cells. ( Damdinsuren, B; Dono, K; Eguchi, H; Hiraoka, N; Kondo, M; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Ota, H; Sakon, M; Umeshita, K; Wada, H; Yamamoto, H; Yamamoto, T, 2005) |
"The effect of tacrolimus (FK506) and 5-fluorouracil (5-FU) on hepatocellular carcinoma remains elusive." | 3.73 | Effects of tacrolimus on proliferation, apoptosis, and fluorouracil sensitivity of liver cancer cell line of SMMC-7721. ( Cao, XW; Ding, GS; Fu, ZR, 2005) |
"We previously reported the beneficial effects of combination therapy of interferon (IFN)-alpha/5-fluorouracil (FU) for advanced hepatocellular carcinoma (HCC) with tumour thrombi in the major portal branches." | 3.73 | Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression. ( Damdinsuren, B; Dono, K; Eguchi, H; Kondo, M; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Ota, H; Sakon, M; Umeshita, K; Wada, H; Wakasa, K; Yamamoto, T, 2005) |
"We report a case of hepatocellular carcinoma (HCC) treated successfully by transarterial chemoembolization (TACE) followed by combination therapy of 5-fluorouracil (5-FU) and pegylated interferon-alpha (PEG-IFN-alpha)." | 3.73 | Successful treatment of advanced hepatocellular carcinoma by combined administration of 5-fluorouracil and pegylated interferon-alpha. ( Kita, K; Kuriyama, S; Kurokohchi, K; Masaki, T; Takaguchi, K, 2005) |
"We report a case of complete disappearance of multiple lung metastases and mediastinal lymphnode metastasis by intravenous administration of 5-fluorouracil/cisplatin (FP) after operation for primary hepatocellular carcinoma (HCC)." | 3.73 | [Complete disappearance of metastatic lung tumors and mediastinal lymphnode in a case of hepatocellular carcinoma treated by low-dose 5-fluorouracil/cisplatin therapy]. ( Anami, Y; Izai, J; Komiya, H; Matsuda, Y; Oguma, S; Ota, T; Sazawa, Y; Yamaki, T, 2005) |
"This study was designed to reveal whether the apoptosis induced in human hepatocellular carcinoma (HCC) cell lines by 5-fluorouracil (5-FU) could be enhanced by transfecting Bcl-2 small interfering RNA (siRNA)." | 3.73 | Enhanced sensitivity of human hepatoma cells to 5-fluorouracil by small interfering RNA targeting Bcl-2. ( Arai, M; Imazeki, F; Kanda, T; Saisho, H; Yokosuka, O, 2005) |
"We investigated the antiproliferative effects of interferon-alpha (IFN-alpha) and 5-fluorouracil (5-FU) in combination on a hepatocellular carcinoma (HCC) cell line." | 3.73 | Antiproliferative effects of 5-fluorouracil and interferon-alpha in combination on a hepatocellular carcinoma cell line in vitro and in vivo. ( Kojiro, M; Kojiro, S; Momosaki, S; Nishida, N; Ogasawara, S; Takemoto, Y; Yano, H, 2006) |
"Interferon (IFN) combined with 5-Fluorouracil (5-FU) treatment has recently been reported to show beneficial effects in patients with advanced hepatocellular carcinoma." | 3.73 | Combination of 5-FU and IFNalpha enhances IFN signaling pathway and caspase-8 activity, resulting in marked apoptosis in hepatoma cell lines. ( Iwasaki, Y; Koike, K; Sakaguchi, K; Shiraha, H; Shiratori, Y; Suzuki, M; Takaki, A; Tatsukawa, M, 2006) |
"Combination therapy with interferon (IFN)-alpha and 5-fluorouracil (5-FU) has been reported to show an improved therapeutic efficacy in patients with advanced hepatocellular carcinoma (HCC) but the mechanism behind this has not been completely elucidated." | 3.73 | The up-regulation of type I interferon receptor gene plays a key role in hepatocellular carcinoma cells in the synergistic antiproliferative effect by 5-fluorouracil and interferon-alpha. ( Hirano, K; Kojiro, M; Kuwano, M; Maruyama, Y; Oie, S; Ono, M; Terada, T; Ueno, T; Yamada, Y; Yano, H, 2006) |
" Anti-proliferative effects of single treatment with IFN-alpha subtypes or 5-fluorouracil (FU), and of combined treatment with each IFN-alpha subtype and 5-FU were examined on three hepatocellular carcinoma cell lines, HepG2, HLE and PLC/PRF/5." | 3.73 | Role of p53 in the inhibitory effects of interferon-alpha subtypes on proliferation of hepatocellular carcinoma cells. ( Arai, N; Ariyasu, H; Ariyasu, T; Fujioka, N; Fukuda, S; Ikeda, M; Ikegami, H; Kurimoto, M; Ohta, T; Tanimoto, T; Yamamoto, S, 2006) |
"The use of 5-fluorouracil, topotecan, or gemcitabine was tested for enhancement of the effects of low dose rate (LDR) irradiation in an in vitro model for hepatocellular carcinoma." | 3.73 | Assessment of supra-additive effects of cytotoxic drugs and low dose rate irradiation in an in vitro model for hepatocellular carcinoma. ( de Gelder, V; De Ridder, L; De Vos, F; Lambert, B; Slegers, G; Thierens, H; Van de Wiele, C, 2006) |
"This study was to investigate the effect of capecitabine on recurrent tumor and metastasis after curative resection of liver cancer, xenograft of a highly metastatic human hepatocellular carcinoma (HCC) tumor (LCI-D20), with special reference to the expression of platelet-derived endothelial cell growth factor (PD-ECGF)." | 3.72 | Capecitabine inhibits postoperative recurrence and metastasis after liver cancer resection in nude mice with relation to the expression of platelet-derived endothelial cell growth factor. ( Fan, J; Ji, Y; Li, XM; Liu, YK; Shi, YH; Sun, QM; Tang, ZY; Wu, ZQ; Xiao, YS; Ye, SL; Zhou, J, 2003) |
"To study the effect of wild type (wt) p53 gene transfection on drug resistant human hepatocellular carcinoma (HCC) cells induced by 5-Fluorouracil (5-FU)." | 3.72 | Wild type p53 increased chemosensitivity of drug-resistant human hepatocellular carcinoma Bel7402/5-FU cells. ( Li, YX; Lin, ZB; Tan, HR, 2004) |
"We report a case in which low-dose FP (5-fluorouracil/cisplatin, 5-FU/CDDP) therapy was remarkably effective for stage IVB advanced hepatocellular carcinoma (HCC) with lung and bone metastases." | 3.72 | [Complete response to treatment with low-dose FP therapy in a patient with stage IVB primary hepatocellular carcinoma with multiple lung and bone metastases]. ( Fujio, N; Fukuda, Y; Koyama, I; Mayumi, K; Osugi, H; Takatori, H; Terakura, M; Tsukazaki, T; Tsukazaki, Y, 2004) |
"To investigate the antitumor effect of interferon-alpha 2a (IFN-alpha2a) combined with capecitabine on hepatocellular carcinoma (HCC) in nude mice in relation to thymidine phosphorylase (TP) expression." | 3.72 | Interferon-alpha 2a up-regulated thymidine phosphorylase and enhanced antitumor effect of capecitabine on hepatocellular carcinoma in nude mice. ( Fan, J; Liu, YK; Sun, QM; Tang, ZY; Wu, ZQ; Xiao, YS; Xue, Q; Ye, SL; Zhao, Y; Zhou, J, 2004) |
"We evaluated the anti-tumor efficacy and toxicity of 5-fluorouracil (5-FU), mitoxantrone, and cisplatin (FMP) in patients with advanced hepatocellular carcinoma (HCC), and conducted an analysis of the prognostic factors for response to such therapy and patient survival." | 3.72 | Chemotherapy using 5-fluorouracil, mitoxantrone, and cisplatin for patients with advanced hepatocellular carcinoma: an analysis of 63 cases. ( Chang, HK; Chang, WC; Chen, JS; Liau, CT; Lin, YC; Yang, TS, 2004) |
"5-Fluorouracil (5-FU) as chemotherapy in cases of hepatocellular carcinoma (HCC), was found to initiate hepatotoxic injuries, ascites, leucopenia, thrombocytopenia and myelosupression that limit its use." | 3.72 | A combination therapy with copper nicotinate complex reduces the adverse effects of 5-fluorouracil on patients with hepatocellular carcinoma. ( El-Saadani, MA, 2004) |
"The authors performed a retrospective analysis of all patients with hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), or gallbladder carcinoma (GBC) who were ever treated with oral capecitabine." | 3.72 | Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. ( Aguayo, A; Brown, TD; Charnsangavej, C; Curley, SA; Ellis, LM; Hassan, MM; Lozano, RD; Nooka, AK; Patt, YZ; Schnirer, II; Vauthey, JN; Wolff, RA, 2004) |
"Previously we reported combined chemo-immunotherapy, using interferon (IFN)-alpha and 5-fluorouracil (5-FU) for patients with advanced hepatocellular carcinoma (HCC), and this regimen improved the prognosis." | 3.72 | Interstitial pneumonia induced by combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma. ( Aozasa, K; Dono, K; Hoshida, Y; Iizuka, N; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Sakon, M; Tomita, Y; Umeshita, K; Yamamoto, S, 2004) |
"Recently, combined chemotherapy with 5-fluorouracil (5-FU) and interferon (IFN)-alpha has been reported to show marked effects in patients with advanced hepatocellular carcinoma." | 3.72 | Genes associated with human hepatocellular carcinoma cell chemosensitivity to 5-fluorouracil plus interferon-alpha combination chemotherapy. ( Hoshida, Y; Kato, N; Kawabe, T; Moriyama, M; Omata, M; Otsuka, M; Yoshida, H, 2004) |
"To investigate the effect of biochemical modulation on antitumor activity shown by the combination of 5-Fluorouracil (5-FU) and interferon-alpha (IFN-alpha), experimental therapy was performed on human hepatocellular carcinoma cell (HuH7, PLC/PLF/5) xenografts inoculated into nude mice, using 5-FU and IFN-alpha, either alone or in combination." | 3.72 | [Influence on 5-fluorouracil metabolism by combination of interferon-alpha and 5-fluorouracil against human hepatocellular carcinoma xenografts]. ( Arai, I; Dono, K; Jin, CD; Kishin, R; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Sakon, M; Umeshita, K; Xing, X; Yamamoto, T, 2004) |
"We report a case of diffuse type advanced hepatocellular carcinoma (HCC), which was successfully treated by a combination therapy of interferon-alpha (IFN) and 5-fluorouracil (5-FU)." | 3.72 | [Intrahepatic arterial chemotherapy with 5-fluorouracil and intramuscular interferon-alpha for a patient with diffuse type of hepatocellular carcinoma]. ( Fujiwara, H; Hagiwara, A; Ichikawa, D; Kikuchi, S; Ochiai, T; Okamoto, K; Otsuji, E; Sakakura, C; Sonoyama, T; Ueda, Y; Yamagishi, H, 2004) |
"Our purpose was to explore the contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of IFNalpha and 5-fluorouracil (5-FU) combination therapy for hepatocellular carcinoma (HCC)." | 3.72 | Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of interferon-alpha/5-fluorouracil against Hepatocellular Carcinoma. ( Damdinsuren, B; Dono, K; Eguchi, H; Kondo, M; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Nakamura, M; Ota, H; Sakon, M; Umeshita, K; Wada, H; Yagita, H; Yamamoto, T, 2004) |
" In 25 patients with HCC, in vitro chemosensitivity to 5-fluorouracil (5-FU), epirubicin (EPI), and cisplatin (CDDP) was examined by CD-DST, and 5-FU, EPI, and paclitaxel (PTX) were examined in 38 patients with breast cancer." | 3.72 | [In vitro chemosensitivity test for hepatocellular carcinoma using collagen-gel droplet embedded cultures]. ( Abumiya, K; Kamachi, H; Kamiyama, N; Kamiyama, T; Khor, LW; Kobayashi, H; Kurauchi, N; Matsushita, M; Nakagawa, T; Nakajima, H; Nakanishi, K; Taguchi, K; Takahashi, H; Takahashi, M; Todo, S; Tsukahara, M; Watanabe, K, 2004) |
"This study was designed to evaluate the efficacy of hepatic arterial infusion of 5-fluorouracil (5-FU) and cisplatin (CDDP) for unresectable or recurrent hepatocellular carcinoma (HCC) with tumor thrombus of the trunk or first branches of the portal vein (PVTT)." | 3.71 | Hepatic arterial infusion of 5-fluorouracil and cisplatin for unresectable or recurrent hepatocellular carcinoma with tumor thrombus of the portal vein. ( Asahara, T; Haruta, N; Itamoto, T; Ito, K; Naito, A; Nakahara, H; Tashiro, H, 2002) |
"We report a case of recurrent hepatocellular carcinoma (HCC) successfully treated with a combination therapy of interferon-alpha (IFN-alpha) and 5-fluorouracil (5-FU), which was administered intravenously." | 3.71 | [A case of recurrent hepatocellular carcinoma successfully treated with a combination therapy of interferon-alpha and intravenous continuous infusion of 5-fluorouracil]. ( Furuhata, T; Hata, F; Hirata, K; Katsuramaki, T; Kimura, Y; Mukaiya, M; Ohmura, T; Yamaguchi, K, 2002) |
"To investigate the resistance mechanism of 5-fluorouracil (5-FU) in Bel(7402)/5-FU cells which was established in our lab by in vitro continuous stepwise exposure of human hepatocellular carcinoma (HCC) cell line Bel(7402) to 5-FU." | 3.71 | Mechanism of 5-fluorouracil required resistance in human hepatocellular carcinoma cell line Bel(7402). ( Huang, M; Jin, J; Liu, GT; Wei, HL, 2002) |
"A 67-year-old male diagnosed as having inoperable advanced hepatocellular carcinoma with portal invasion was able to undergo resection after continuous intra-arterial chemotherapy with 5-fluorouracil (5-FU) and cisplatin (CDDP)." | 3.71 | [A case of advanced hepatocellular carcinoma with portal invasion resected after treatment by continuous intra-arterial chemotherapy with cisplatin and 5-fluorouracil]. ( Furutani, S; Hara, F; Ikeda, E; Kashiyama, Y; Matsumoto, H; Mitunaga, S; Moriyama, S; Naitoh, M; Nawa, S; Ohtuka, K; Tuji, T, 2001) |
"The objective of the current study was to identify patient and disease related factors that influence response and survival for patients with unresectable hepatocellular carcinoma (HCC) who received a systemic combination chemotherapy consisting of cisplatin, alpha-interferon, doxorubicin, and 5-fluorouracil (PIAF)." | 3.71 | Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy. ( Johnson, PJ; Lai, PB; Lau, WY; Leung, TW; Tang, AM; Yu, SC; Zee, B, 2002) |
"A 69-year-old female with unresectable hepatocellular carcinoma was treated with continuous arterial infusion of low-dose cisplatin (10 mg/body/day) and 5-fluorouracil (250 mg/body/day)." | 3.71 | [A case of hepatocellular carcinoma with portal tumor thrombus effectively treated by arterial infusion chemotherapy with low-dose cisplatin and 5-fluorouracil]. ( Hasebe, Y; Hirano, K; Kobayashi, K; Kurihara, A; Nakazaki, H; Saito, N; Seo, A; Shirasaka, K; Takada, M; Takita, W; Tokura, N; Watanabe, M, 2002) |
"Between 1990 and 1997, 227 patients with hepatocellular carcinoma were treated by intrahepatic arterial injection of a Lipiodol-Epirubicin-Mitomycin C emulsion followed by intermittent hepatic artery infusion of Epirubicin, Mitomycin C and 5-FU, employing an implantable subcutaneous infusion port." | 3.70 | [Transcatheter oily chemoembolization and intermittent hepatic artery infusion chemotherapy in the management of advanced hepatocellular carcinoma]. ( An, M; Hamada, E; Ikawa, M; Matsumoto, Y; Miura, T; Murata, M; Nakasato, S; Takagi, S; Terakado, H; Watanabe, K, 1998) |
"The case described here illustrates the antitumor activity of a four-drug systemic combination chemobiotherapy with platinol, recombinant interferon alpha 2b, doxorubicin (Adriamycin), and 5-fluorouracil (5-FU) (PIAF) in a patient with diffuse hepatocellular carcinoma involving the liver and lungs." | 3.70 | Durable clinical and pathologic response of hepatocellular carcinoma to systemic and hepatic arterial administration of platinol, recombinant interferon alpha 2B, doxorubicin, and 5-fluorouracil: a communication. ( Carrasco, CH; Charnsangavej, C; Cleary, K; Ellis, L; Hoque, A; Lozano, R; Patt, YZ; Roh, M, 1999) |
"In order to assess the efficacy of repeated hepatic arterial infusion (HAI) therapy for advanced hepatocellular carcinoma, we administered HAI therapy using 5-fluorouracil, epirubicin and mitomycin C, with an implanted drug delivery system." | 3.70 | Efficacy of an implanted drug delivery system for advanced hepatocellular carcinoma using 5-fluorouracil, epirubicin and mitomycin C. ( Chiba, T; Ito, K; Kojima, K; Nakajima, N; Seno, H, 1999) |
"Seven patients with postoperative recurrence of hepatocellular carcinoma (HCC) and four patients who underwent absolute non curative resection for HCC were treated with continuous arterial infusion of low-dose cisplatin (CDDP) (10 mg/body/day) and 5-fluorouracil (5-FU) (250 mg/body/day)." | 3.70 | [Study of continuous arterial infusion chemotherapy with low-dose cisplatin and 5-fluorouracil for patients with hepatocellular carcinoma]. ( Maeda, Y; Mori, N; Nisida, M; Oka, M; Takao, T; Tamesa, T; Tangoku, A, 1999) |
"Several clinical trials have demonstrated the effectiveness of combination therapy with 5-fluorouracil (5-FU) and IFN-alpha in colon cancer, hepatocellular carcinoma (HCC), and other malignancies." | 3.70 | Augmentation of antitumor activity of 5-fluorouracil by interferon alpha is associated with up-regulation of p27Kip1 in human hepatocellular carcinoma cells. ( Dono, K; Eguchi, H; Kondo, M; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Sakon, M; Umeshita, K; Yamamoto, H, 2000) |
"Continuous systemic infusion of low-dose cisplatin (CDDP) (10 mg/body/day) and 5-fluorouracil (5-FU) (500 mg/body/day) was performed for advanced hepatocellular carcinoma (HCC) after hepatectomy with diffuse lung metastases and multiple intrahepatic metastases." | 3.70 | [Significance of reduction surgery for giant hepatocellular carcinoma with diffuse lung metastases and multiple intrahepatic metastases]. ( Maeda, Y; Mori, N; Nisida, M; Oka, M; Takao, T; Tamesa, T; Tangoku, A, 2000) |
"A patient with advanced unresectable fibrolamellar hepatocellular carcinoma is reported, who was treated with cisplatinum, epirubicin and 5-fluorouracil combination chemotherapy." | 3.69 | Fibrolamellar hepatocellular carcinoma responsive to platinum-based combination chemotherapy. ( Bower, M; Habib, N; Newlands, ES, 1996) |
"Arterial infusion chemotherapy of EPF (etoposide, cisplatin, and 5-fluorouracil) or EAP (etoposide, Adriamycin, and cisplatin) was carried out in 28 cases of advanced hepatocellular carcinoma (HCC) between January 1988 and December 1990, and assessment was made of the anticancer efficacy of each treatment method." | 3.68 | Arterial infusion chemotherapy for advanced hepatocellular carcinoma using EPF and EAP therapies. ( Midorikawa, H; Saito, Y; Sasaki, T; Takekawa, SD; Tarusawa, K; Yodono, H, 1992) |
" Regarding HAI, transcatheter hepatic arterial embolization (TAE) was applied in two cases (hepatocellular carcinoma: 1; metastasis: 1) and 5-fluorouracil (continuous) combined with leucovorin (one shot) therapy (LV + 5-FU) was given to one metastatic case." | 3.68 | [Bile duct necrosis and hepatic necrosis following hepatic arterial infusion chemotherapy]. ( Arai, K; Iwasaki, Y; Kitamura, M; Miyashita, K; Mori, T; Okamoto, A, 1991) |
"1-Hexylcarbamoyl-5-fluorouracil (HCFU) was administered orally to 63 patients with hepatocellular carcinoma (HCC) at a daily dose of 200 to 600 mg." | 3.67 | [Clinical evaluation of 1-hexylcarbamoyl-5-fluorouracil (HCFU) in hepatocellular carcinoma]. ( Abe, M; Hirai, K; Kubo, Y; Majima, Y; Ninomiya, F; Sakai, T; Sakemi, T; Sato, K; Shiraishi, K; Tanikawa, K, 1984) |
"1-Hexylcarbamoyl-5-fluorouracil (HCFU) was orally administered at doses of 300-600 mg daily for 7-360 days to 27 inoperable cirrhotics with hepatocellular carcinoma." | 3.67 | [Role of oral administration of 1-hexyl-carbamoyl-5-fluorouracil (HCFU) for multimodal treatment of inoperable cirrhotics with hepatocellular carcinoma]. ( Akiharu, W; Fujiwara, M; Higashi, T; Ito, T; Kobayashi, M; Nagashima, H; Nakatsukasa, H; Shiota, T; Yamamoto, H; Yamauchi, Y, 1984) |
"An investigation was carried out into the effects of lipiodol-transcatheter arterial chemoembolization (L-TACE) therapy on hepatocellular carcinoma (HCC) and metastatic liver cancer, as well as the effects of oral 5-fluorouracil administration after L-TACE." | 3.67 | Effects of transcatheter arterial chemoembolization with oral chemotherapy on hepatic neoplasms. ( Hashimoto, N; Inoue, J; Kawai, S; Makino, M; Masuzawa, M; Mikuriya, S; Oda, T; Shimamura, Y; Takahashi, A; Yumoto, Y, 1989) |
"In a prospective clinical trial, 65 patients were studied in an investigation into the effects of the oral administration of 5-fluorouracil on resectable and non-resectable hepatocellular carcinoma." | 3.67 | Studies on the chemotherapy with 5-fluorouracil in transcatheter arterial chemoembolization (TAE) treated patients with resectable or non-resectable hepatocellular carcinoma. Osaka Study Group on Hepatocellular Carcinoma. ( , 1989) |
"The metabolism of 1-hexylcarbamoyl-5-fluorouracil (HCFU), a drug prescribed for treating patients with hepatocellular carcinoma (HCC), was studied in relation to liver function, with the objective of clarifying the occurrence of any adverse side-effects on the central nervous system." | 3.67 | Low dose 1-hexylcarbamoyl-5-fluorouracil (HCFU) recommended for cirrhotic patients with hepatocellular carcinoma. ( Kanematsu, T; Shimada, M; Sugimachi, K; Takenaka, K, 1989) |
"UFT was administered preoperatively in 20 cases of primary hepatocellular carcinoma, and tegafur, 5-fluorouracil (5-FU), uracil, total thymidylate synthase (TS) and free TS in blood and liver tissue were determined." | 3.67 | [Study on the pharmacokinetics of UFT in patients with hepatocellular carcinoma associated with cirrhosis]. ( Ito, Y; Matsuoka, S; Misawa, K; Nagafuchi, E; Nakajima, Y; Ogasawara, K; Sato, N; Uchino, J; Une, Y, 1989) |
"HCFU was orally administered to 14 patients with hepatocellular-carcinoma, (including 11 patients with liver cirrhosis) and evaluated of HCFU and 5 fluorouracil (5-FU) levels." | 3.67 | [HCFU and 5-fluorouracil levels in the blood and tissue of hepatocellular carcinoma after oral administration of HCFU]. ( Hamazaki, K; Mimura, H; Mori, M; Orita, K, 1989) |
" In 22 resected patients with hepatocellular carcinoma (HCC), the concentrations of 5-fluorouracil (5-FU), tegafur and uracil were estimated in the serum, liver and cancer tissues after oral administration of UFT (tegafur, 300mg) before operation." | 3.67 | [5-Fluorouracil, tegafur, and uracil concentrations in serum and tissue of the patients with hepatocellular carcinoma after UFT administration]. ( Suenaga, M, 1987) |
"Before proceeding with a resection of a hepatocellular carcinoma (HCC) in patients, the concentrations of 5-FU and 1-Hexylcarbamoyl-5-fluorouracil (HCFU) have been measured in the serum, the liver, and in the cancer tissue after an oral administration of HCFU (300 mg)." | 3.67 | [5-FU and HCFU concentrations in serum and tissues in hepatocellular carcinoma after HCFU oral administration]. ( Suenaga, M, 1988) |
"Fifty-four patients with unresectable malignant liver tumors (14 of hepatocellular carcinoma, 40 of metastasis to the liver from gastric or colo-rectal cancer) were treated with intra-hepato-arterial (IHA) injections of cis-diamminedichloroplatinum (II) (CDDP) plus 5-fluorouracil (5-FU)." | 3.67 | [Hepatic arterial chemotherapy combined with hyperthermia or arterial embolization in unresectable liver tumor]. ( Hamazoe, R; Inoue, Y; Ishiguro, M; Koga, S; Maeda, M; Murakami, A; Sawata, T; Shimizu, N; Shimizu, T; Wakatsuki, T, 1988) |
"An analysis is done of 40 evaluable patients treated with a combination of 5-Fluorouracil, adriamycin and mitomycin-C for primary hepatocellular carcinoma in Saudi Arabia." | 3.67 | Primary hepatocellular carcinoma in the eastern province of Saudi Arabia: treatment with combination chemotherapy using 5-fluorouracil, Adriamycin and mitomycin-C. ( Abdel Satir, A; Al-Idrissi, HY; Al-Kasem, S; Al-Qurain, A; Ibrahim, EM; Satti, MB, 1985) |
"The pharmacokinetics of 1-(tetrahydro-2-furanyl)-5-fluorouracil (FT) and its conversion into 5-fluorouracil (FUra) in liver tissue were studied in ten patients with hepatocellular carcinoma (HCC)." | 3.67 | Hepatic conversion of 1-(tetrahydro-2-furanyl)-5-fluorouracil into 5-fluorouracil in patients with hepatocellular carcinoma. ( Imai, Y; Kawata, S; Minami, Y; Miyoshi, S; Noda, S; Saitoh, R; Tamura, S; Tarui, S, 1987) |
" An improvement of the chemotherapy of hepatocellular carcinoma with adriamycin or 5-fluorouracil and a reduction of side effects has been achieved by intra-arterial administration of the drugs." | 3.66 | [Approaches to a selective chemotherapy of hepatocellular carcinoma (author's transl)]. ( Gerok, W; Holstege, A; Keppler, D; Pausch, J, 1981) |
"The action of floxuridine depends greatly on its concentration for treatment of liver metastases of colorectal carcinomas and other tumors." | 3.66 | [Completely implantable infusion pump. A new therapeutic possibility for selected patients with liver tumors]. ( Balch, CM; Urist, MM, 1983) |
"Twenty elderly patients with hepatocellular carcinoma were treated with 5-fluorouracil (5-FU) at a daily dose of 200-300 mg per os, and with a combination of 0." | 3.66 | [Treatment of elderly patients with hepatocellular carcinomas with mitomycin C and 5-fluorouracil]. ( Asano, K; Ejiri, T; Fujii, M; Matsuka, Y; Murakami, N, 1982) |
"Tegafur fine granule preparation orally administered to the patients with primary hepatoma and liver cirrhosis, and the concentration of tegafur and 5-fluorouracil in the blood were determined." | 3.66 | [Sequential changes in blood concentrations of tegafur and 5-FU during oral administration of fine granules of tegafur in patients with primary liver cancer]. ( Hattori, M; Horiike, N; Kanaoka, M; Ohta, Y; Onji, M; Yamashita, Y; Yoshida, T, 1982) |
"Nine patients with extensive bilateral hepatic metastases of colorectal cancer were treated with hepatic artery ligation and continuous infusion of 5-fluorouracil (5-FU)." | 3.65 | Hepatic artery ligation and 5-fluorouracil infusion for metastatic colon carcinoma and primary hepatoma. ( Eilber, FR; Holmes, EC; Morton, DL; Ramming, KP; Sparks, FC, 1976) |
"The case of a young man with hypogonadism, who was treated for five years withmethyltestosterone and who developed hepatocellular carcinoma, is discussed." | 3.65 | Hepatocellular carcinoma in association with androgen therapy. ( Goodman, MA; Laden, AM, 1977) |
"The majority of hepatocellular carcinoma (HCC) cases are diagnosed at an advanced stage." | 3.30 | Combined FOLFOX4 with all-trans retinoic acid versus FOLFOX4 with placebo in treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a randomized, double-blind comparative study. ( Cheng, S; Guo, W; Huo, L; Jiang, D; Lau, WY; Liu, C; Mao, F; Shi, J; Sun, J; Zhang, F; Zhou, L, 2023) |
"Recently, treatments for unresectable hepatocellular carcinoma (HCC) have undergone remarkable development." | 3.01 | Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity. ( Iwamoto, H; Kawaguchi, T; Niizeki, T; Shimose, S; Shirono, T, 2023) |
" We conducted this phase Ib/II study to assess the safety and efficacy of anti-PD-1 antibody camrelizumab in combination with FOLFOX4 for treatment-naive advanced hepatocellular carcinoma (aHCC)." | 3.01 | Camrelizumab Combined with FOLFOX4 Regimen as First-Line Therapy for Advanced Hepatocellular Carcinomas: A Sub-Cohort of a Multicenter Phase Ib/II Study. ( Chen, Z; Li, H; Liu, Y; Meng, Z; Qin, S; Ren, Z; Wang, L; Xiong, J; Zhang, X; Zou, J, 2021) |
"Arginine is an important nutrient for hepatocellular carcinoma (HCC)." | 3.01 | Assessment of pegylated arginine deiminase and modified FOLFOX6 in patients with advanced hepatocellular carcinoma: Results of an international, single-arm, phase 2 study. ( Abou-Alfa, GK; Akce, M; Bomalaski, JS; Chen, YY; Cohen, SA; El Dika, I; Feng, YH; Harding, JJ; Ho, CL; Huang, WT; Johnston, A; Lee, DW; Lim, HY; Meyer, T; O'Reilly, EM; Qin, S; Ryoo, BY; Sarker, D; Tan, B; Yang, TS; Yen, CJ, 2021) |
"Among patients with hepatocellular carcinoma (HCC), 85% of patients have an advanced disease stage at diagnosis and curative therapies cannot be performed." | 2.90 | All-trans-retinoic acid (ATRA) plus oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX) versus FOLFOX alone as palliative chemotherapy in patients with advanced hepatocellular carcinoma and extrahepatic metastasis: study protocol for a randomized controll ( Chai, Z; Cheng, S; Liu, C; Shi, J; Sun, J; Wang, N; Zhang, H, 2019) |
"Treatment responses of advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) remain unacceptably low and treatment modalities are limited." | 2.87 | Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis. ( Bae, SH; Cho, SB; Choi, JH; Chung, WJ; Jung, YK; Kim, DY; Kim, SU; Kim, YS; Park, JY; Song, DS; Song, MJ; Suh, SJ; Yim, HJ, 2018) |
"This study aimed to evaluate the efficacy of arterial infusion of 5-fluorouracil (5-FU) combined with subcutaneous injection of pegylated interferon alpha-2b (PEG-IFNα-2b) on unresectable HCC with PVTT and to determine the potential survival benefits of patients from this therapy." | 2.80 | Arterial infusion of 5-fluorouracil combined with subcutaneous injection of pegylated interferon alpha-2b in treating unresectable hepatocellular carcinoma with portal vein tumor thrombus. ( Huang, WJ; Peng, BG; Wang, HY; Wang, YF; Wu, J; Zhou, Q, 2015) |
"Capecitabine was administered daily on days 1-14, while peginterferon α-2a was administered on days 1, 8, and 15." | 2.79 | A phase I/II trial of capecitabine combined with peginterferon α-2a in Patients with sorafenib-refractory advanced hepatocellular carcinoma. ( Chiba, T; Kanai, F; Kanogawa, N; Motoyama, T; Ogasawara, S; Ooka, Y; Suzuki, E; Tawada, A; Yokosuka, AO, 2014) |
"To compare the effect of radiofrequency ablation (RFA) combined with transcatheter arterial chemoembolization (TACE) with radiofrequency ablation alone for the treatment of 3 - 5 cm hepatocellular carcinoma (HCC)." | 2.78 | [Clinical outcomes of radiofrequency ablation combined with transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma: a single-center experience]. ( Bao, LW; Jiang, XF; Jin, XJ; Lin, JJ; Lu, LJ; Wu, W, 2013) |
"The prognosis of advanced hepatocellular carcinoma (HCC) remains poor, particularly among patients with portal vein tumor thrombosis (PVTT)." | 2.77 | Therapeutic efficacy of combination therapy with intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma with portal venous invasion. ( Kasai, K; Kasai, Y; Kuroda, H; Miyamoto, Y; Oikawa, K; Sawara, K; Suzuki, K; Takikawa, Y; Ushio, A, 2012) |
"Postoperative recurrence of hepatocellular carcinoma (HCC) is a major problem after surgical resection." | 2.75 | Adjuvant therapy with capecitabine postpones recurrence of hepatocellular carcinoma after curative resection: a randomized controlled trial. ( Li, J; Qiu, Y; Shen, F; Shi, L; Wang, K; Wu, M; Xi, T; Xia, Y; Yan, Z, 2010) |
"From 2002 to 2007, a total of 10 consecutive patients with Stage IVA HCC accompanied by PVTT were studied prospectively to examine the efficacy of treatment by intra-arterial infusion of a chemotherapeutic agents consisting of etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil." | 2.73 | Improved survival for hepatocellular carcinoma with portal vein tumor thrombosis treated by intra-arterial chemotherapy combining etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil: a p ( Imai, M; Ishikawa, T; Kamimura, H; Kamimura, T; Ohta, H; Seki, K; Togashi, T; Tsuchiya, A; Watanabe, K; Yoshida, T, 2007) |
"To evaluate the effect of tamoxifen (TAM) combined with a somatostatin analogue, octretide (OCT) on advanced liver cancer and whether tamoxifen combined with OCT is superior to regular chemotherapeutic agents 5-Fu and mitomycin C (MMC)." | 2.71 | Tamoxifen combined with octreotide or regular chemotherapeutic agents in treatment of primary liver cancer: a randomized controlled trial. ( Chen, JW; Huo, YC; Pan, DY; Qiao, JG; Shi, HA; Zhou, YK, 2003) |
" Pharmacokinetic parameters were studied during the first cycle of dose levels 1 and 2 (500 mg/m2." | 2.71 | A phase I safety and pharmacokinetic study of OGT 719 in patients with liver cancer. ( Brown, G; Chak, K; Chan, AT; Johnson, P; Leung, TW; Mok, TS; Moyses, C; Wong, H; Yeo, W, 2004) |
"Over 80% of hepatocellular carcinoma (HCC) patients are HBV carriers; however, the incidence of HBV reactivation during CT has not been well-reported." | 2.71 | Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. ( Chan, AT; Chan, PS; Ho, WM; Johnson, PJ; Lam, KC; Leung, TW; Ma, B; Mo, FK; Mok, TS; Wong, WL; Yeo, W; Zee, B, 2004) |
"Thirty-eight unresectable small hepatocellular carcinoma patients with diameter = 3 cm were selected, of which 27 patients have been followed up for 1 year." | 2.71 | [Prospective randomized trial of RFA and chemotherapy for unresectable small hepatocellular carcinoma]. ( Chen, Y; Gan, YH; Ge, NL; Ren, ZG; Wang, YH; Xia, JL; Yang, BW; Yie, SL; Zhang, BH, 2004) |
"The prognosis of patients with hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) is extremely poor." | 2.70 | Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. ( Ando, E; Fukumori, K; Kuromatsu, R; Okuda, K; Sata, M; Sumie, S; Tanaka, M; Yamashita, F; Yano, Y; Yutani, S, 2002) |
"Advanced hepatocellular carcinoma with portal vein thrombosis has a poor prognosis." | 2.70 | [Concurrent chemo-radiation therapy for advanced hepatocellular carcinoma with portal vein thrombosis]. ( Ahn, SH; Cheong, JY; Chon, CY; Han, KH; Kim, JS; Lee, DY; Moon, YM; Seong, JS; Youn, YH, 2002) |
"Pravastatin was administered at a daily dose of 40 mg." | 2.70 | Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. ( Imai, Y; Inada, M; Inui, Y; Ito, N; Kawata, S; Matsuda, Y; Matsuzawa, Y; Nagase, T; Noda, S; Tamura, S; Yamasaki, E, 2001) |
"Only a minority of patients with hepatocellular carcinoma (HCC) may benefit from curative treatments, whereas there is no standard therapy for the remaining patients." | 2.70 | A phase II trial of oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma. ( Bruix, J; Castells, L; El-Hariry, I; Llovet, JM; Peachey, M; Ruff, P; Tassopoulos, N, 2001) |
"The cases with esophageal cancer, stomach cancer, pancreatic cancer, hepatocellular carcinoma or colonic cancer co-existing with their inoperable lesion(s) were considered in this chemotherapy." | 2.69 | [Biochemical modulation of 5-FU--effect of low dose CDDP]. ( Denno, R; Hirata, K; Kimura, H; Mukaiya, M; Oikawa, I; Sasaki, K; Shirasaka, T; Tsuji, A; Yamamitsu, S, 1999) |
"Four cases of gigantic hepatocellular carcinoma, considered by surgeons to be inoperable, were treated with repeated transcatheter chemoembolization (TOCE) until the serum alfafetoprotein reduced to normal or less than half of the original level or until the tumor reduced to less than half of the original size documented by CT scan and angiogram." | 2.69 | Gigantic hepatocellular carcinoma, treated by transcatheter oily chemoembolization (TOCE) and wedge hepatic resection. ( Eurvilaichit, C; Kanjanapitak, A; Leopairut, J, 2000) |
"2 of the 7 (29%) patients with hepatoma responded." | 2.68 | Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours. ( Cunningham, D; Ellis, PA; Hickish, T; Hill, A; Nicolson, M; Norman, A; O'Brien, ME, 1995) |
"Unresectable hepatocellular carcinoma is related to a poor prognosis." | 2.68 | Intra-arterial chemotherapy followed by chemo-embolisation in unresectable hepatocellular carcinoma. ( Colleoni, M; Liessi, G; Manente, P; Mastrapasqua, G; Nelli, P; Pancheri, F; Sgarbossa, G; Vicario, G, 1997) |
" 4' epidoxorubicin combined with 5-fluorouracil given intra-arterially is not superior to the intravenous therapy, but it may diminish systemic toxicity." | 2.67 | Intra-arterial and intravenous use of 4' epidoxorubicin combined with 5-fluorouracil in primary hepatocellular carcinoma. A randomized comparison. ( Kajanti, M; Mäntylä, M; Pyrhönen, S; Rissanen, P, 1992) |
"Hepatocellular carcinoma is known to have a doubling time of approximately 41 days." | 2.66 | 194 hepatocellular cancers treated by radiation and chemotherapy combinations: toxicity and response: a Radiation Therapy Oncology Group Study. ( Fishman, EK; Guse, C; Klein, JL; Leibel, SA; Leichner, PK; Order, SE; Stillwagon, GB, 1989) |
"Forty-seven patients with hepatocellular cancer were treated in a randomised trial comparing adriamycin + VM 26 + 5-Fluorouracil (5-FU) to mAMSA + VM 26 + 5-FU." | 2.66 | Combination chemotherapy of hepatocellular cancer. Comparison of adriamycin + VM 26 + 5-fluorouracil with mAMSA + VM 26 + 5-fluorouracil. ( Bezwoda, WR; Derman, DP; Kew, M; Weaving, A, 1987) |
"Apatinib is a novel and highly selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2." | 2.55 | Significant efficacy and well safety of apatinib in an advanced liver cancer patient: a case report and literature review. ( Kong, L; Kou, P; Shao, W; Wang, H; Yu, J; Zhang, J; Zhang, Y; Zhu, H, 2017) |
"Primary liver cancer, mainly consisting of hepatocellular carcinoma (HCC), is one of common malignancies worldwide, and prevalent among the Chinese population." | 2.53 | Progress in systemic therapy of advanced hepatocellular carcinoma. ( Gong, XL; Qin, SK, 2016) |
"In advanced hepatocellular carcinoma, FOLFOX can induce clinically relevant responses, but needs prospective validation." | 2.50 | Oxaliplatin/5-fluorouracil in advanced hepatocellular carcinoma: case report and single-center retrospective review. ( Gillmore, R; Goldstein, R; Mayer, A; Meyer, T; O'Donoghue, P; Thirlwell, C; Yu, D, 2014) |
"The majority of primary liver cancer is hepatocellular carcinoma (HCC)." | 2.44 | Therapeutic strategy of advanced hepatocellular carcinoma by using combined intra-arterial chemotherapy. ( Nagai, H; Sumino, Y, 2008) |
"Gemcitabine is a well-tolerated anti-tumour drug with broad-spectrum activity." | 2.44 | [Gemcitabine and digestive carcinomas]. ( André, T; Blanchard, P; Huguet, F, 2007) |
"Colorectal cancers have been the first cancers to benefit from an efficient anti-angiogenic treatment, represented by bevacizumab, which has been approved for first-line metastatic treatment in combination with reference chemotherapies and which is under study in the adjuvant setting." | 2.44 | [Angiogenesis targeting in gastro-intestinal cancers]. ( Meric, JB, 2007) |
"Patients with hepatocellular carcinoma (HCC) frequently show early recurrence even after hepatic resection and local ablation therapy." | 2.42 | [Chemotherapy for hepatocellular carcinoma]. ( Ikeda, M; Okusaka, T; Ueno, H, 2004) |
"The prognosis of hepatocellular carcinoma(HCC) invading the major branches of the portal vein(Vp3 or 4) is extremely poor." | 2.41 | [Development and research of the new therapy for hepatocellular carcinoma--combined interferon and 5-fluorouracil therapy]. ( Monden, M; Nagano, H; Sakon, M, 2002) |
"Hepatocellular carcinoma is a rapidly fatal disease in most patients." | 2.37 | Medical treatment of hepatocellular carcinoma. ( Friedman, M; Nerenstone, S, 1987) |
"Fluorouracil has been used for a long time, remission rates reported range from 0% to 80%." | 2.36 | [Chemotherapy of gastrointestinal tumors (review of the literature)]. ( Mayr, AC, 1978) |
"Salvigenin is a Trimethoxylated Flavone enriched in Scutellariae Barbatae Herba and Scutellariae Radix and is demonstrated to have anti-tumor properties in colon cancer." | 1.91 | Salvigenin Suppresses Hepatocellular Carcinoma Glycolysis and Chemoresistance Through Inactivating the PI3K/AKT/GSK-3β Pathway. ( Chen, H; Chen, J; Chen, Y; Li, A; Liu, J; Ma, L; Shao, H; Tang, Y, 2023) |
"Molecular targeted therapy combined with immunotherapy significantly improves the prognosis of patients with advanced liver cancer." | 1.91 | Hepatic arterial infusion chemotherapy combined with anti-PD-1/PD-L1 immunotherapy and molecularly targeted agents for advanced hepatocellular carcinoma: a real world study. ( Gao, W; Guo, Z; Li, H; Li, M; Liu, C; Liu, D; Mu, H; Si, T; Xing, W; Yang, X; Yu, H; Zhang, K; Zhang, W; Zou, Q, 2023) |
"Primary liver hepatocellular carcinoma (HCC) is the third most deadly malignancy worldwide,in part, because it is often diagnosed at an advanced stage." | 1.91 | MESP1-knockdown inhibits the proliferation and epithelial mesenchymal transition of hepatocellular carcinoma and enhances the tumor-suppressive effect of 5-fluorouracil. ( Cai, C; He, X; Ji, S; Xu, M, 2023) |
" The primary endpoint was overall survival (OS), while the secondary endpoints were progression-free survival and adverse effects." | 1.72 | Efficacy and Safety of Arterial Infusion Chemotherapy in Patients with Advanced Hepatocellular Carcinoma and Child-Pugh Class B: A Retrospective Cohort Study. ( Hibi, T; Ishii, M; Itano, O; Itano, S; Iwamoto, H, 2022) |
"5-Fluorouracil (5-FU) has been widely applied in treating cancers." | 1.72 | CDK Inhibition Reverses Acquired 5-Fluorouracil Resistance in Hepatocellular Carcinoma Cells. ( Cheng, L; Li, Z; Pu, Y; Tu, L; Wang, X; Yan, D; Yu, J; Zheng, X, 2022) |
"Cinobufagin is a natural product isolated from the traditional chinese medicine Chansu." | 1.72 | Cinobufagin restrains the growth and triggers DNA damage of human hepatocellular carcinoma cells via proteasome-dependent degradation of thymidylate synthase. ( Chen, Q; Li, H; Sun, Y; Tao, Y; Wang, A; Wu, Q; Yang, A; Yang, J; Zhang, J, 2022) |
"Fibrolamellar carcinoma (FLC) is a rare liver cancer that predominantly affects younger patients without a history of liver disease." | 1.72 | Successful Liver Transplantation of Recurrent Fibrolamellar Carcinoma following Clinical and Pathologic Complete Response to Triple Immunochemotherapy: A Case Report. ( Akce, M; Draper, A; El-Rayes, B; Guadagno, J; Kang, S; Magliocca, J; Pectasides, M; Roccaro, G; Sellers, M; Zheng, W, 2022) |
" We analysed the pharmacokinetic profile of the less toxic photoform ("ring-closed" dithienylethene) of the compound in tumors, plasma, and healthy liver." | 1.72 | Towards in vivo photomediated delivery of anticancer peptides: Insights from pharmacokinetic and -dynamic data. ( Afonin, S; Babii, O; Borysko, P; Dovbynchuk, T; Dziubenko, N; Garmanchuk, LV; Gorbach, O; Khranovska, N; Komarov, IV; Kuznietsova, H; Schober, T; Shtanova, LY; Tolstanova, G; Ulrich, AS; Veselsky, SP; Yanchuk, PI, 2022) |
"Hazard ratios for overall survival and disease progression were 0." | 1.72 | A novel chemotherapy strategy for advanced hepatocellular carcinoma: a multicenter retrospective study. ( Cheng, S; Gu, J; Jiang, D; Lau, WY; Liu, C; Mao, F; Shen, L; Shi, J; Sun, J; Wang, N; Zhou, L, 2022) |
"Our results provide preliminary evidence that HAIC based on FOLFIRI regimen is efficient and safe in some patients progressing after previous treatment." | 1.72 | The Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Based on FOLFIRI for Advanced Intrahepatic Cholangiocarcinoma as Second-Line and Successive Treatment: A Real-World Study. ( Chen, Y; Huang, P; Huang, X; Shi, G; Sun, Q; Yang, G; Zhou, Y, 2022) |
"To evaluate the clinical efficacy of targeted therapy and immunotherapy combined with hepatic arterial infusion chemotherapy (HAIC) of FOLFOX and lipiodol embolization in the treatment of unresectable hepatocellular carcinoma." | 1.72 | Clinical efficacy of targeted therapy, immunotherapy combined with hepatic artery infusion chemotherapy (FOLFOX), and lipiodol embolization in the treatment of unresectable hepatocarcinoma. ( Chen, D; Chen, Y; Hu, XL; Huang, DB; Li, XQ; Lin, ZP; Xu, SX; Zhang, J; Zhong, H; Zou, XG, 2022) |
"Not all patients with unresectable hepatocellular carcinoma (uHCC) benefit from treatment with immune checkpoint inhibitors and molecular-targeted agents." | 1.62 | Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study. ( Chen, S; Guo, W; Huang, X; Li, T; Liu, Z; Wang, P; Wu, Y; Wu, Z; Xu, B; Yu, W, 2021) |
"5-Fluorouracil (5-FU) is a broad-spectrum anticancer drug, but its clinical application is limited due to drug resistance and toxic side effects." | 1.56 | Preparation and evaluation of phytantriol liquid crystal as a liquid embolic agent. ( Fang, X; Shen, A, 2020) |
"The extensive drug resistance of hepatocellular carcinoma (HCC) has become a major cause of chemotherapy failure." | 1.56 | Proteomic Analysis Reveals that EPHX1 Contributes to 5-Fluorouracil Resistance in a Human Hepatocellular Carcinoma Cell Line. ( Chu, H; Dong, C; Hao, D; Li, R; Liu, J; Sun, R; Wang, L; Zhang, L; Zhang, Y; Zhao, B, 2020) |
"Liver cancer is a major threat to human life and health, and chemotherapy has been the standard non-surgical treatment for liver cancer." | 1.56 | Rab27B enhances drug resistance in hepatocellular carcinoma by promoting exosome-mediated drug efflux. ( Dong, C; Jiang, K; Li, R; Lv, J; Sun, R; Wang, L; Wang, Q; Yin, Z; Zhang, J; Zhou, Y, 2020) |
"5-Fluorouracil (5-Fu) is a widely used as an anticancer drug." | 1.56 | CCND1 silencing suppresses liver cancer stem cell differentiation and overcomes 5-Fluorouracil resistance in hepatocellular carcinoma. ( Ding, H; Wang, Y; Zhang, H, 2020) |
"Efficient hepatocellular carcinoma (HCC) therapy remains a significant challenge due to the unsatisfactory targeting efficiency of nanoparticles (NPs) with either a passive targeting or a single active targeting property." | 1.56 | Facile Fabrication of Nanoparticles with Dual-Targeting Ligands for Precise Hepatocellular Carcinoma Therapy ( He, DX; Huang, C; Huang, W; Liu, Y; Long, J; Tan, XW; Tang, S; Wei, H; Xiang, Y; Yu, CY; Zhou, Y, 2020) |
"IORT using the INTRABEAM radiation system combined with portal vein infusion chemotherapy is promising for select patients with PVTT." | 1.56 | INTRABEAM intraoperative radiotherapy combined with portal vein infusion chemotherapy for treating hepatocellular carcinoma with portal vein tumor thrombus. ( Han, M; He, Y; Liang, H; Shao, Z; Song, X, 2020) |
" The purpose of this study was to evaluate the safety and efficacy of TACE combined with sorafenib (TACE-sorafenib) and TACE alone for the treatment of Barcelona clinical stage C HCC." | 1.56 | Transarterial Chemoembolization Combined with Sorafenib in Patients with BCLC Stage C Hepatocellular Carcinoma. ( Cheng, DL; Gao, ZG; Hao, YH; Ji, CS; Jia, WD; Liu, KC; Lv, WF; Shi, CS; Su, MX; Xu, SB; Zhou, CZ, 2020) |
" Since 5-FU is an irreversible inhibitor of thymidylate synthetase (TS), we investigated the interactions of let-7c with 5-FU at pharmacodynamic level." | 1.56 | Pharmacokinetic and Pharmacodynamic Factors Contribute to Synergism between Let-7c-5p and 5-Fluorouracil in Inhibiting Hepatocellular Carcinoma Cell Viability. ( Jilek, JL; Tu, MJ; Yu, AM; Zhang, C, 2020) |
"This paper discussed the synergistic anti-tumor effect of Shuangdan Capsules combined with 5-fluorouracil(5-FU) on human liver cancer cell line Huh-7 and tumor bearing mice." | 1.56 | [Study on synergistic anti-tumor effect of Shuangdan Capsules combined with 5-FU on hepatocellular carcinoma cells Huh-7 and xenograft mice]. ( Chen, XW; Ding, WB; Ning, Q; Song, J; Xia, Z; Zhou, XW, 2020) |
"However, its roles in hepatocellular carcinoma (HCC) cell stemness and chemotherapeutic sensitivity are never been revealed." | 1.51 | Six1 is negatively correlated with poor prognosis and reduces 5-fluorouracil sensitivity via attenuating the stemness of hepatocellular carcinoma cells. ( Chen, K; Chen, Z; Gao, T; Huang, J; Huang, M; Ou, M; Pan, D; Pan, J; Wei, H; Zhong, W, 2019) |
"Patients with advanced hepatocellular carcinoma (HCC) have a poor oncologic outcome." | 1.51 | Role and limitation of neoadjuvant hepatic arterial infusion chemotherapy in advanced hepatocelluar carcinoma patients with Child-Pugh class A. ( Cho, CW; Lee, BH; Lee, DS; Yun, SS, 2019) |
"SIGNIFICANCE: It was reported that many hepatocellular carcinoma patients are resistance to 5-Fu." | 1.51 | Quantitative proteomic and phosphoproteomic studies reveal novel 5-fluorouracil resistant targets in hepatocellular carcinoma. ( Fang, Z; Liu, Z; Miao, QR; Wang, Y; Yao, Y; Ye, M, 2019) |
"5-Fluorouracil (5-FU) is a widely used antitumor drug." | 1.51 | Aluminum chloride causes 5-fluorouracil resistance in hepatocellular carcinoma HepG2 cells. ( Cui, ZG; Feng, Q; Feril, LB; Inadera, H; Li, M; Sun, L; Zakki, SA, 2019) |
"We reported a patient survived more than 7years after undergoing hepatectomy accompanied by tumor thrombectomy in the main trunk of the portal vein after preoperative hepatic arterial chemotherapy for hepatocellular carcinoma combined with tumor thrombus in the main portal vein." | 1.48 | [A Case of a Long-Term Survivor Who Underwent Surgical Intervention for Hepatocellular Carcinoma Combined with Tumor Thrombus in the Main Trunkof the Portal Vein]. ( Fujisaki, S; Sakurai, K; Takashina, M; Takayama, T; Tomita, R, 2018) |
"Baicalein is a flavonoid extracted from Radix Scutellariae with anti-HCC activity." | 1.48 | Baicalein sensitizes hepatocellular carcinoma cells to 5-FU and Epirubicin by activating apoptosis and ameliorating P-glycoprotein activity. ( Bie, B; Duan, B; Guo, Y; Huang, C; Li, J; Li, Z; Sun, J; Yang, J; Yang, S; Zhou, R, 2018) |
"The prognosis of hepatocellular carcinoma (HCC) with tumor thrombus in the major portal vein (PV) is extremely poor." | 1.48 | Significance of hepatic resection and adjuvant hepatic arterial infusion chemotherapy for hepatocellular carcinoma with portal vein tumor thrombus in the first branch of portal vein and the main portal trunk: a project study for hepatic surgery of the Jap ( Hatano, E; Uemoto, S; Yamamoto, M; Yamaue, H, 2018) |
"This study investigated the anti-hepatoma activity of different extracts from A." | 1.46 | Studies on anti-hepatoma activity of Annona squamosa L. pericarp extract. ( Cao, YZ; Chen, JW; Chen, Y; Chen, YY; Li, FQ; Li, X; Lu, JH; Peng, CX; Zhu, XL, 2017) |
"Liver fibrosis is characterized by the progressive accumulation of extracellular matrix (ECM) and is a strong predictor of hepatocellular carcinoma (HCC) development and progression." | 1.46 | A novel three-dimensional culture system maintaining the physiological extracellular matrix of fibrotic model livers accelerates progression of hepatocellular carcinoma cells. ( Fukumitsu, K; Ishii, T; Katayama, H; Kawai, T; Kita, S; Kojima, H; Minami, T; Miyauchi, Y; Ogiso, S; Sasaki, N; Uemoto, S; Yamaoka, R; Yasuchika, K; Yasuda, K; Yoshitoshi-Uebayashi, EY, 2017) |
" In the CCRT group, concurrent hepatic arterial infusion chemotherapy with 5-fluorouracil was delivered at a dosage of 500 mg/d during the first and last 5 days of radiation therapy (median, 45 Gy)." | 1.46 | Transarterial Radioembolization Versus Concurrent Chemoradiation Therapy for Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. ( Ahn, SH; Han, KH; Jung, KS; Kim, BK; Kim, DY; Kim, SU; Lee, HW; Park, JY; Seong, J; Song, JE; Song, K; Won, JY, 2017) |
"Cancer stem cells (CSCs) in hepatocellular carcinoma (HCC) possess tumor-initiating, metastatic, and drug resistance properties." | 1.43 | Comparative study of the effects of PEGylated interferon-α2a versus 5-fluorouracil on cancer stem cells in a rat model of hepatocellular carcinoma. ( El-Boghdady, NA; El-Sayed, AM; Helmy, HS; Motawi, TK, 2016) |
"The treatment efficacy of unresectable hepatocellular carcinoma (HCC) is still not promising." | 1.43 | Combination Therapy of Radiofrequency Ablation and Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Retrospective Study. ( Bao, Y; Dai, Y; Dong, X; Feng, W; Shen, J; Tang, C; Zhang, J; Zheng, Y, 2016) |
"Metformin plays an anti-proliferative role in tumor cells in many types of cancer." | 1.43 | Metformin mediates resensitivity to 5-fluorouracil in hepatocellular carcinoma via the suppression of YAP. ( Gao, Z; Han, Z; Liang, R; Luo, N; Sun, D; Tang, B; Tian, Y; Wang, C; Wang, L; Zhang, R, 2016) |
"Locally advanced hepatocellular carcinoma (HCC) with portal vein thrombosis carries a 1-year survival rate <10%." | 1.43 | Living Donor Liver Transplantation for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis after Concurrent Chemoradiation Therapy. ( Choi, GH; Choi, JS; Han, DH; Han, KH; Joo, DJ; Kim, MS; Kim, SI; Park, YN; Seong, J, 2016) |
"BACKGROUND Hepatocellular carcinoma (HCC) causes many deaths worldwide every year, especially in Asia." | 1.43 | Prognostic and Therapeutic Values of Tumor Necrosis Factor-Alpha in Hepatocellular Carcinoma. ( He, B; Hu, X; Liu, J; Liu, S; Wang, H, 2016) |
"Dioscin is a natural steroid saponin that presents in various plants." | 1.43 | Dioscin suppresses hepatocellular carcinoma tumor growth by inducing apoptosis and regulation of TP53, BAX, BCL2 and cleaved CASP3. ( Du, B; Liu, J; Tan, Y; Wu, Y; Wu, Z; Zeng, X; Zhang, G; Zhang, R; Zhang, W; Zhang, X; Zhao, Y, 2016) |
"Liver cancer is one of the most drug-resistant cancer types, and cancer stem cells are related to drug resistance." | 1.42 | JNK signaling in hepatocarcinoma cells is associated with the side population upon treatment with anticancer drugs. ( Ahn, YH; Jee, HG; Kim, HR; Kim, JB; Kim, YJ; Lee, HS; Lee, JH; Lee, M; Park, SY; Yoon, JH; Yu, SJ, 2015) |
"A retrospective analysis of 20 patients treated for hepatocellular carcinoma between 1994 and 2007." | 1.42 | Hepatic arterial infusion in hepatocellular carcinoma: a single center experience. ( Dvorak, J; Ferko, A; Kamaradova, K; Krajina, A; Melichar, B, 2015) |
"The clinicopathological parameters and adverse effects were similar between the 2 groups (P > 0." | 1.42 | Transcatheter arterial chemoembolization combined with interferon-α is safe and effective for patients with hepatocellular carcinoma after curative resection. ( Burns, M; Hong, Y; Lei, X; Li, JL; Li, QL; Li, YG; Liu, C; Liu, HC; Liu, JS; Qiu, XX; Wang, XH; Wu, QF; Xia, M; Xiao, H; Xu, RC; Zhu, HZ; Zuo, CH, 2015) |
"To investigate the cooperative effect of Bifidobacteria lipoteichoic acid (BLTA) combined with 5-fluorouracil on tumor cells growth and apoptosis in mice bearing H22." | 1.42 | Cooperative effect of Bifidobacteria lipoteichoic acid combined with 5-fluorouracil on hepatoma-22 cells growth and apoptosis. ( Guo, B; Wang, Y; Xie, N, 2015) |
" The purpose of this study was to determine the treatment effect of irradiation in combination with hepatic arterial infusion chemotherapy (HAIC) for these patients." | 1.42 | Efficacy of hepatic arterial infusion chemotherapy in combination with irradiation for advanced hepatocellular carcinoma with portal vein invasion. ( Kanazawa, S; Katsui, K; Kobayashi, Y; Kuwaki, K; Miyahara, K; Miyake, Y; Morimoto, Y; Nakamura, S; Nouso, K; Onishi, H; Sakaguchi, K; Shiraha, H; Takaki, A; Takeuchi, Y; Wada, N; Yamamoto, K; Yasunaka, T, 2015) |
"Nineteen hepatic cancer cell lines, 50 cases of adjacent tissue and 149 cases of HCC samples were employed." | 1.42 | Epigenetic silencing of BCL6B inactivates p53 signaling and causes human hepatocellular carcinoma cell resist to 5-FU. ( Brock, MV; Guo, M; Herman, JG; Li, X; Liang, P; Tao, Q; Yu, J, 2015) |
"Chemotherapy is one of the most common treatments used for hepatocellular carcinoma (HCC), which effectively improves outcome and reduces tumor recurrence." | 1.42 | MicroRNA‑133a and microRNA‑326 co‑contribute to hepatocellular carcinoma 5‑fluorouracil and cisplatin sensitivity by directly targeting B‑cell lymphoma‑extra large. ( Guo, R; Lei, X; Ma, J; Pan, X; Peng, C; Tang, H; Wang, T; Xiang, Q; Yang, X; Yin, J; Yu, J; Zu, X, 2015) |
" Compared with either agent alone, a low dose of Dox combined with eAFP-VISA-BikDD induced better antitumor effect and prolonged longer survival of mice in two orthotopic liver cancer xenograft models." | 1.42 | Targeted expression of BikDD combined with metronomic doxorubicin induces synergistic antitumor effect through Bax activation in hepatocellular carcinoma. ( Chen, HY; Dai, HY; Hung, MC; Lai, WC; Li, LY, 2015) |
"Cucurbitacin B is a plant-derived tetracyclic triterpenoid, which has been used for a variety of cancers, especially human hepatoma." | 1.42 | Synergistic effect of cucurbitacin B in combination with curcumin via enhancing apoptosis induction and reversing multidrug resistance in human hepatoma cells. ( Chen, D; Hu, H; Huang, Z; Qiao, M; Sun, Y; Zhang, J; Zhao, X; Zhou, J, 2015) |
"Luteolin may inhibit tumor angiogenesis and tumor cell proliferation by down-regulation of LFA- 3 and PCNA and up-regulation of ICAM-1 in tumor tissue of tumor-bearing mice, thereby achieving its anti-tumor effect." | 1.42 | Effect of luteolin on gene expression in mouse H22 hepatoma cells. ( Bao, LD; Gan, HM; Guo, HP; Niu, JX; Ren, JJ, 2015) |
"HUVEC and human hepatoma cells (MHCC97H) were cultured, respectively, and then the MHCC97H cells were co-cultured with conditioned medium from HUVEC (EC-CM) with Transwell system." | 1.42 | [Effect of Conditioned Medium from Endothelial Cells on Cancer Stem Cell Phenotype of Hepatoma Cells]. ( Feng, C; Luo, Q; Song, G; Sun, J; Yang, X, 2015) |
"Fibrolamellar variant of hepatocellular carcinoma (FLHCC) does not have a favorable prognosis than conventional HCC, and there is no difference regarding the response to chemotherapy and the degree of surgical resectability." | 1.40 | Successful multimodal treatment for aggressive metastatic and recurrent fibrolamellar hepatocellular carcinoma in a child. ( Akdemir, ÜÖ; Akyol, G; Boyunağa, Ö; Dalgiç, A; Demiroğullari, B; Eser, EP; Karadeniz, C; Oğuz, A; Okur, A; Pinarli, FG; Yilmaz, G, 2014) |
" This study aimed to improve the bioavailability of TFU by preparing TFU-loaded lipid-based nanosuspensions (TFU-LNS) and perform a preclinical evaluation." | 1.40 | Preclinical studies of N₃-O-toluyl-fluorouracil-loaded lipid-based nanosuspensions in H₂₂-bearing mice. ( Li, M; Liu, Y; Liu, Z; Wang, L; Zhang, J; Zhang, N, 2014) |
" A c-myc antisense oligodeoxynucleotide can increase the sensitivity of liver cancer cells to 5-fluorouracil and decrease the dosage of the agent necessary for efficacy, providing an experimental basis for the clinical therapy of liver cancer." | 1.40 | Liposome-mediated induction of apoptosis of human hepatoma cells by c-myc antisense phosphorothioate oligodeoxynucleotide and 5-fluorouracil. ( Cai, H; Chen, YR; Guo, TK; He, J; Li, W; Yang, XJ; Yuan, Y, 2014) |
"Irinotecan (CPT-11) was used as a chemotherapeutic agent in 24 patients, gemcitabine (GEM) in 24 and doxorubicin in 59." | 1.40 | Chemotherapy for transarterial chemoembolization in patients with unresectable hepatocellular carcinoma. ( Guo, B; Liu, J; Song, L; Wu, J; Zhao, DY, 2014) |
"To observe the antitumor effect of Stihopus japonicus acidic mucopolysaccharide combined with fluorouracil in mice bearing neoplasia of H22 hepatoma cells, and study the mechanism." | 1.40 | [Antitumor effect of Stichopus japonicus acidic mucopolysaccharide combined with fluorouracil in mice bearing neoplasia of H22 hepatoma cells]. ( Chen, D; Dai, H; Song, Y, 2014) |
" Changes in liver function before and after the initial TACE procedure and hepatobiliary severe adverse events (SAEs) were compared." | 1.40 | Repeated transcatheter arterial chemoembolization is safe for hepatocellular carcinoma in cirrhotic patients with transjugular intrahepatic portosystemic shunt. ( Li, X; Luo, X; Tsauo, J; Wang, X; Wang, Z; Zhang, H; Zhao, H, 2014) |
"For locally unresectable hepatocellular carcinoma (HCC) patients, concurrent chemoradiotherapy (CCRT) has been applied as a loco-regional treatment." | 1.40 | Concurrent chemoradiotherapy shows long-term survival after conversion from locally advanced to resectable hepatocellular carcinoma. ( Choi, JS; Han, KH; Kim, JK; Kim, JW; Kim, KS; Lee, IJ; Park, YN; Seong, J, 2014) |
"To study the synergistic effect on hepatoma cell(SMMC-7721) and the reduction killing effect on normal liver cells(LO-2) treated with sodium cantharidinate (SCA) in combination with fluorouracil(5-FU) or cisplatin(DDP) as well as the related mechanism." | 1.40 | [Study on synergistic effect of sodium cantharidinate combined with chemotherapeutic drugs on hepatic carcinoma and its effective mechanism]. ( Chen, MJ; Xu, DQ; Zhang, X; Zhao, FM; Zhao, RL; Zhou, KF, 2014) |
"The prognosis of hepatocellular carcinoma (HCC) with macroscopic vascular invasion is extremely poor even after hepatic resection." | 1.39 | Adjuvant hepatic arterial infusion chemotherapy after hepatic resection of hepatocellular carcinoma with macroscopic vascular invasion. ( Baba, H; Beppu, T; Chikamoto, A; Hayashi, H; Imai, K; Nitta, H, 2013) |
"The incidence of advanced hepatocellular carcinoma (HCC) is increasing worldwide, and its prognosis is extremely poor." | 1.39 | Identification of the genes chemosensitizing hepatocellular carcinoma cells to interferon-α/5-fluorouracil and their clinical significance. ( Azumi, J; Gonda, K; Kanki, K; Mizuta, Y; Nagano, H; Sakabe, T; Shiota, G; Shomori, K; Tsuchiya, H; Wada, H; Yamada, D, 2013) |
"The prognosis of patients with hepatocellular carcinoma (HCC) and portal vein tumor thrombus remains poor." | 1.39 | PTK787/ZK222584 combined with interferon alpha and 5-fluorouracil synergistically inhibits VEGF signaling pathway in hepatocellular carcinoma. ( Akita, H; Doki, Y; Eguchi, H; Hama, N; Katsura, Y; Kawamoto, K; Kobayashi, S; Marubashi, S; Mori, M; Murakami, M; Nagano, H; Tanemura, M; Umeshita, K; Wada, H, 2013) |
"The growth of H22 hepatoma transplantation tumor was inhibited more obviously in the combination group and the 5-Fu group than in the control group (P <0." | 1.39 | [Research on the effect and mechanism of polypeptide extract from scorpion venom combined with 5-fluorouracil on vasculogenic mimicry of H22 hepatoma]. ( Jia, Q; Wang, ZP; Wang, ZX; Wu, LC; Zhang, WD; Zhang, YY; Zheng, AH, 2013) |
"Combination therapies may increase the antitumor effects and reduce the adverse effects for the treatment of hepatocellular carcinoma." | 1.39 | Enhanced 5-fluorouracil cytotoxicity in high COX-2 expressing hepatocellular carcinoma cells by wogonin via the PI3K/Akt pathway. ( Guo, QL; Lu, ZJ; Sha, YY; Yao, J; You, QD; Zhao, L; Zhao, Q; Zhu, BB, 2013) |
"Fifty hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT) were treated using hepatic arterial infusion chemotherapy (HAIC) via a subcutaneously implanted port." | 1.39 | Hepatic arterial infusion chemotherapy in hepatocellular carcinoma with portal vein tumor thrombosis. ( Bae, SH; Choi, JY; Chun, HJ; Kim, HY; Lee, HG; Lee, SW; Lee, YJ; Oh, JS; Song, DS; Song, MJ; Yoon, SK, 2013) |
"Here, we used the chitosan and hepatoma cell-specific binding molecule, glycyrrhetinic acid (GA), to synthesize glycyrrhetinic acid-modified chitosan (GA-CTS)." | 1.39 | Synthesis of glycyrrhetinic acid-modified chitosan 5-fluorouracil nanoparticles and its inhibition of liver cancer characteristics in vitro and in vivo. ( Chen, H; Cheng, M; Gao, X; Han, J; He, B; Li, Y; Wang, Y; Xu, H; Zhang, Z, 2013) |
"The prognosis in advanced hepatocellular carcinoma (HCC) with multiple intrahepatic metastases is extremely poor." | 1.39 | Debulking surgery followed by intraarterial 5-fluorouracil chemotherapy plus subcutaneous interferon alfa for massive hepatocellular carcinoma with multiple intrahepatic metastases: a pilot study. ( Endo, I; Kumamoto, T; Matsuo, K; Nakagawa, K; Taguri, M; Tanaka, K; Yabushita, Y, 2013) |
"Advanced hepatocellular carcinoma (HCC) with portal vein invasion or intrahepatic metastases has an unfavorable prognosis, even after curative hepatic resection." | 1.39 | Adjuvant hepatic arterial infusion chemotherapy with 5-Fluorouracil and interferon after curative resection of hepatocellular carcinoma: a preliminary report. ( Akiyama, H; Endo, I; Ichikawa, Y; Kumamoto, T; Matsuo, K; Matsuyama, R; Mori, R; Nojiri, K; Ota, M; Takeda, K; Tanaka, K; Taniguchi, K; Ueda, M, 2013) |
"A 44-year-old man with advanced hepatocellular carcinoma (HCC) was admitted to our institution." | 1.39 | [A case of hepatocellular carcinoma (Vp4)-combination therapy prolonged survival in a patient with advanced hepatocellular carcinoma with a tumor thrombus in the portal vein trunk]. ( Kanbara, Y; Tai, K; Terai, S, 2013) |
"Capecitabine was given concomitantly at a dose of 600 mg/m2 twice daily during radiotherapy." | 1.39 | Hypofractionated radiotheapy using helical tomotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. ( Jang, JW; Kay, CS; Kim, JY; Kim, KJ; Kwon, JH; Yoo, EJ, 2013) |
"The only drug that improves survival in hepatocellular carcinoma is sorafenib." | 1.38 | Feasibility of oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) in cirrhotic or liver transplant patients: experience in a cohort of advanced hepatocellular carcinoma patients. ( Brezault, C; Cacheux, W; Cessot, A; Chaussade, S; Coriat, R; Durand, JP; Goldwasser, F; Mir, O; Ropert, S, 2012) |
"The prognosis for hepatocellular carcinoma (HCC) along with portal vein tumor thrombi (PVTT) is poor, and surgery has not been considered an option." | 1.38 | Comparison of survival and quality of life of hepatectomy and thrombectomy using total hepatic vascular exclusion and chemotherapy alone in patients with hepatocellular carcinoma and tumor thrombi in the inferior vena cava and hepatic vein. ( Liu, B; Liu, J; Ou, Q; Wang, Y; Zhang, D, 2012) |
"Low-dose metronomic chemotherapy involves the frequent administration of comparatively low doses of cytotoxic agents with no extended breaks, and it may be as efficient as and less toxic than the conventional maximum tolerated dose therapy." | 1.38 | Efficacy and safety of metronomic chemotherapy for patients with advanced primary hepatocellular carcinoma with major portal vein tumor thrombosis. ( Bae, SH; Cha, JH; Choi, BG; Choi, JY; Chun, HJ; Jang, JW; Kim, HL; Woo, HY; Yoon, SK; Youn, JM, 2012) |
"To investigate the therapeutic efficacy of lipoteichoic acid of Bifidobacterium (BLTA) in combination with 5-fluorouracil (5-FU) treatment on the mice bearing inoculated hepatoma-22 (H(22)) cells and the effects of BLTA on immunological regulation of organism, and explore its mechanisms." | 1.38 | Lipoteichoic acid of Bifidobacterium in combination with 5-fluorouracil inhibit tumor growth and relieve the immunosuppression. ( Guo, B; Li, FR; Wang, Q; Wang, Y; Xie, N, 2012) |
"5-fluorouracil (5-FU) was administered continuously for 24 h from day 1 to day 5 every 2-4 wk via an injection reservoir." | 1.38 | Is hepatic arterial infusion chemotherapy effective treatment for advanced hepatocellular carcinoma resistant to transarterial chemoembolization? ( Fujita, K; Imajo, K; Kato, S; Kirikoshi, H; Kobayashi, N; Kubota, K; Maeda, S; Mawatari, H; Nakajima, A; Saito, S; Suzuki, K; Yoneda, M, 2012) |
"Patients with liver cirrhosis or hepatocellular carcinoma (HCC) have decreased serum insulin-like growth factor (IGF)-1 levels." | 1.38 | Serum insulin-like growth factor-1 levels predict outcomes of patients with advanced hepatocellular carcinoma receiving antiangiogenic therapy. ( Cheng, AL; Hsu, CH; Huang, CC; Lin, SD; Shao, YY, 2012) |
"Baicalein treatment significantly inhibited tumor growth of HCC xenografts in mice." | 1.38 | Preferential inhibition of hepatocellular carcinoma by the flavonoid Baicalein through blocking MEK-ERK signaling. ( Huang, C; Le, XF; Li, J; Li, ZF; Liang, RR; Liu, PJ; Qi, JA; Wang, ZD; Yang, J; Zhang, S, 2012) |
"Thirty-six hepatocellular carcinoma patients not indicated for surgical resection underwent super- selective transcatheter arterial chemoembolization, divided into small dose (n=15) and conventional dose (n=21) chemotherapy groups." | 1.38 | Liver fibrosis and five year survival of hepatocellular cancer cases undergoing transcatheter arterial chemo embolization using small doses. ( Hu, Y; Li, H; Li, N; Zhou, Y, 2012) |
"The primary treatment for nasopharyngeal carcinoma (NPC) is external beam radiotherapy." | 1.38 | Radiotherapy for nasopharyngeal carcinoma and combined capecitabine and nimotuzumab treatment for lung metastases in a liver transplantation recipient: a case experience of sustained complete response. ( Jiang, X; Wang, YX; Yan, D; Yan, S; Yang, J, 2012) |
"Flow cytometry and TUNEL assays in hepatic cancer cells showed that GC/5-FU was associated with higher rates of G0-G1 arrest and apoptosis than 5-FU." | 1.38 | 5-Fluorouracil nanoparticles inhibit hepatocellular carcinoma via activation of the p53 pathway in the orthotopic transplant mouse model. ( Chen, H; Cheng, M; Han, J; He, B; Li, Q; Wan, T; Wang, W; Xu, H; Yang, F; Ye, T; Zha, B; Zhu, W, 2012) |
"The relevant literature regarding treatment of liver cirrhosis complicated with HCC and synchronous colon Ca reveals poor and controversial outcomes." | 1.38 | How can we treat a patient with liver cirrhosis (hepatitis C virus), hepatocellular carcinoma, and synchronous colon cancer? ( Antoniou, E; Dimitroulis, D; Kostakis, A; Labadariou, A; Mantas, D; Nikitakis, N; Paraskeva, P; Smyrnis, A; Tsavaris, N; Vernicos, P, 2012) |
"The chemoresistance of human hepatocellular carcinoma (HCC) to cytotoxic drugs, especially intrinsic or acquired multidrug resistance (MDR), still remains a major challenge in the management of HCC." | 1.38 | Characterization and resistance mechanisms of a 5-fluorouracil- resistant hepatocellular carcinoma cell line. ( Cheng, BB; Fang, FF; Gu, W; Li, B; Ling, CQ, 2012) |
"To evaluate the therapeutic efficacy of sorafenib in combination with microwave coagulation therapy (MCT) and trans-arterial chemoembolization (TACE) in patients with recurrent liver cancer." | 1.38 | [Therapeutic effects of sorafenib combined with transcatheter arterial chemoembolization and microwave ablation on postsurgical recurrent hepatocellular carcinoma]. ( He, ZY; Hua, XD, 2012) |
"The impact of diabetes mellitus on the treatment of hepatocellular carcinoma, especially chemotherapy, is uncertain." | 1.37 | Diabetes mellitus impairs the response to intra-arterial chemotherapy in hepatocellular carcinoma. ( Fang, JL; Feng, YH; Huang, WT; Lin, CY; Tsao, CJ; Wu, CL, 2011) |
"There is no standardized treatment for hepatocellular carcinoma (HCC) with portal vein tumor thrombus." | 1.37 | Tyrosine kinase inhibitor PTK/ZK enhances the antitumor effects of interferon-α/5-fluorouracil therapy for hepatocellular carcinoma cells. ( Doki, Y; Eguchi, H; Kobayashi, S; Marubashi, S; Mori, M; Murakami, M; Nagano, H; Noda, T; Takeda, Y; Tanemura, M; Tomimaru, Y; Umeshita, K; Wada, H, 2011) |
"Treatment by quinacrine alone at concentrations of 10-20 mM for 1-2 d cannot kill hepatocellular carcinoma cells, such as HepG2, Hep3B, Huh7, which are also resistant to TRAIL." | 1.37 | Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents. ( Abdulghani, J; Allen, JE; Dicker, DT; Dolloff, NG; El-Deiry, WS; Gallant, JN; Hong, B; Katz, SI; Navaraj, A; Smith, CD; Wang, W, 2011) |
"Arsenic trioxide was added prior to a tyrosine kinase inhibitor or to a slightly modified PIAF regimen with capecitabine replacing 5-fluorouracil." | 1.37 | Arsenic trioxide plus cisplatin/interferon α-2b/doxorubicin/capecitabine combination chemotherapy for unresectable hepatocellular carcinoma. ( Acalovschi, M; Aldea, M; Fischer-Fodor, E; Irimie, A; Kacso, G; Mosteanu, O; Petrushev, B; Pop, T; Soritau, O; Susman, S; Tomuleasa, C, 2011) |
" A concentration- or dose-response relationship was shown between the concentration and dose of CH and Rho123 accumulation or the antitumor activity." | 1.37 | Using rhodamine 123 accumulation in CD8 cells as a surrogate indicator to study the P-glycoprotein modulating effect of cepharanthine hydrochloride in vivo. ( Cai-Hong, Z; Fang, M; Jin-Hua, J; Li, H; Ning, W; Qing-Duan, W; Xiao-Juan, G; Yan, Z, 2011) |
"Rosiglitazone is a peroxisome proliferators-activated receptor gamma (PPARgamma) ligand, which inhibits tumor growth by activating PPARgamma signaling pathways." | 1.36 | Rosiglitazone enhances 5-fluorouracil-induced cell growth inhibition in hepatocellular carcinoma cell line Hep3B. ( Cao, LQ; Peng, HP; Shao, ZL; Xia, T; Xiao, JB, 2010) |
"Established human hepatocellular carcinoma adriamycin (ADM) multi-drug resistant cell sub-lines models Bel-7402/ADMV, Bel-7402/ADML and Bel-7402/ADMS by three methods of in vitro concentration gradient increased induction, nude mice liver-implanted induction and subcutaneous-implanted induction respectively." | 1.36 | Comparison of the multi-drug resistant human hepatocellular carcinoma cell line Bel-7402/ADM model established by three methods. ( Gong, R; Meng, X; Xiong, M; Zhong, X, 2010) |
"5-fluorouracil was used as a positive control." | 1.36 | Cytotoxic activity of Thai medicinal plants against human cholangiocarcinoma, laryngeal and hepatocarcinoma cells in vitro. ( Chaijaroenkul, W; Itharat, A; Mahavorasirikul, W; Na-Bangchang, K; Viyanant, V, 2010) |
"To observe the effects of the anti-liver cancer pharmacodynamic action of the Rougan Jiedu formula through the experiments of inhibiting cell proliferation of the tumour cell in vitro." | 1.35 | [The study of Rougan Jiedu formula anti-liver cancer in vivtro]. ( Li, H; Wu, CJ, 2008) |
"Prognosis of advanced hepatocellular carcinoma is dismal when locoregional treatments have failed." | 1.35 | Complete pathological response of hepatocellular carcinoma with systemic combination chemotherapy. ( Codecà, C; Di Maria, G; Fazio, N; Ferrari, D; Fiore, J; Foa, P; Luciani, A; Maggioni, M; Oldani, S, 2008) |
"d-Allose is a novel anti-tumor monosaccharide that causes cell growth inhibition, specifically of the cancer cells, by inducing the tumor suppressor gene thioredoxin interacting protein (TXNIP)." | 1.35 | Rare sugar D-allose enhances anti-tumor effect of 5-fluorouracil on the human hepatocellular carcinoma cell line HuH-7. ( Dong, Y; Horii, M; Kamitori, K; Sanada, K; Sui, L; Tokuda, M; Yamaguchi, F, 2008) |
"Tree 1-7 on human hepatoma cell line HepG2 cultured in vitro." | 1.35 | [Cytotoxicity of the secondary metabolites of Marine Mangrove Fungus Paecilomyces sp. tree 1-7 on human hepatoma cell line HepG2]. ( Cai, XL; Gao, JP; Li, Q; Lin, YC; She, ZG; Wen, L, 2008) |
" The life prolongation rate, toxic reactions of chemotherapy, WBC count, the body weight, tumor weight, thymus index and spleen index, and phagocytic function of intra-abdominal macrophages were investigated in the H22 tumor-bearing mice." | 1.35 | The effect-enhancing and toxicity-reducing action of the extract of herba Scutellariae barbatae for chemotherapy in hepatoma H22 tumor-bearing mice. ( Dai, Z; Diao, Y; Ji, Z; Kang, H; Liu, L; Liu, X; Wang, X, 2008) |
"There were upper gastrointestinal hemorrhage in 3 cases, hepatic failure in 4, pulmonary embolism in 1, cholecystitis in 4, hepatic encephalopathy in 2, gastric perforation in 1, and intrahepatic biloma in 2 cases." | 1.35 | [Analysis of severe complications after transcatheter arterial chemoembolization for primary hepatocellular carcinoma]. ( Feng, B; Liang, SN; Liu, LL; Su, HY; Xu, K; Zhao, GS, 2008) |
" Transcatheter arterial chemoembolization is a standard treatment option for patients with unresectable HCC, especially when combined with other therapies." | 1.35 | A patient with huge hepatocellular carcinoma who had a complete clinical response to p53 gene combined with chemotherapy and transcatheter arterial chemoembolization. ( Liu, J; Sui, J; Tian, G, 2009) |
"Hepatocellular carcinoma was the second most frequent malignancy to be observed--23 patients (18." | 1.35 | [Advanced hepatic resection for malignancy]. ( Kotel'nikov, AG; Patiutko, IuI; Pylev, AL; Sagaĭdak, IV, 2009) |
"To determine the influence of HBx gene RNA interference combined with chemotherapy on stable hepatocellular carcinoma cells growth and its apoptosis mechanism." | 1.35 | [Effect of HBx gene RNA interference combined with chemotherapy on hepatocellular carcinoma cells]. ( He, X; He, Y; Lei, J; Sun, H; Wang, W, 2009) |
": Patients with unresectable hepatocellular carcinoma (HCC) have limited treatment options." | 1.35 | Accelerated treatment using intensity-modulated radiation therapy plus concurrent capecitabine for unresectable hepatocellular carcinoma. ( Al-Osaimi, AM; Angle, JF; Argo, C; Berg, C; Caldwell, S; Hagspiel, KD; McIntosh, A; Northup, P; Rich, TA; Weiss, G, 2009) |
"To evaluate the outcomes of patients with unresectable massive primary liver cancer (PLC) receiving three-dimensional conformal radiotherapy (3-DCRT) combined with transcatheter arterial chemoembolization (TACE)." | 1.35 | [Three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for massive primary liver cancer]. ( Chen, LH; Guan, J; Li, QS; Sun, HW; Wei, CJ; Zheng, XK, 2009) |
"A 66-year-old man was diagnosed with hepatocellular carcinoma with Vp3 by abdominal enhanced CT." | 1.35 | [A case of successful multimodal treatment for combined hepatocellular and cholangiocarcinoma with portal venous tumor thrombus]. ( Doki, Y; Eguchi, H; Hatano, H; Kobayashi, S; Marubashi, S; Mori, M; Murakami, M; Nagano, H; Takeda, Y; Tanemura, M; Tomimaru, Y; Tomokuni, A; Wakasa, K, 2009) |
"However, the immunological features of liver cirrhosis (LC) patients with advanced hepatocellular carcinoma (aHCC) treated by intra-arterial chemotherapy are still unclear." | 1.35 | Th1/Th2 balance: an important indicator of efficacy for intra-arterial chemotherapy. ( Higami, K; Ikehara, T; Kanayama, M; Matsui, T; Miki, K; Miyaki, D; Momiyama, K; Nagai, H; Sumino, Y; Watanabe, M, 2008) |
"We developed a recombinant defective adenovirus with an insert of gene encoding extracellular domain of mouse Flt3L (Ad-mFlt3L) under control of cytomegalovirus promoter to investigate the biological efficacy of Flt3L in combination with chemotherapeutical drug, 5-FU, in eliciting an effective anti-cancer immunity in mouse hepatoma and colon cancer model systems." | 1.34 | Eradication of hepatoma and colon cancer in mice with Flt3L gene therapy in combination with 5-FU. ( Dai, J; Fan, X; Guo, Y; Hou, S; Kou, G; Li, B; Li, J; Lin, B; Ma, J; Qian, W; Wang, H; Wu, M; Zhang, D; Zhao, J, 2007) |
"Two different hepatoma cell lines were incubated for 48h with chemotherapeutic drugs cisplatin, paclitaxel and 5-FU to determine their ability to induce cytotoxicity and DNA fragmentation as well as to modify the expression of some cell death-related genes that could be involved in the resistance to therapy." | 1.34 | Characterization of cell death events induced by anti-neoplastic drugs cisplatin, paclitaxel and 5-fluorouracil on human hepatoma cell lines: Possible mechanisms of cell resistance. ( Arce, F; Brenes, O; Díaz, C; Gätjens-Boniche, O, 2007) |
" In this study, we evaluated the response to hepatic arterial infusion of 5-fluorouracil (5-FU) in combination with subcutaneous interferon (IFN)-alpha in patients with advanced HCC." | 1.34 | Hepatic arterial infusion of 5-fluorouracil in combination with subcutaneous interferon-alpha for advanced hepatocellular carcinoma. ( Adachi, Y; Araki, J; Furjita, N; Horiike, S; Itani, T; Iwasa, M; Kaito, M; Kobayashi, Y; Konishi, M; Kuroda, M; Mifuji, R; Tanaka, H; Urawa, N; Yamamoto, M, 2007) |
"Cell proliferation assay in human hepatoma cells (HepG 2) was performed using 5-FU and/or various IFNs-alpha (C-IFN, Intron A, OIF)." | 1.34 | [Anti-tumor effects of various interferons-alpha +5-fluorouracil via downregulation of dihydropyrimidine dehydrogenase in hepatoma cells]. ( Fan, XY; Iwaki, K; Kai, S; Kitano, S; Ohta, M; Shibata, K; Uchida, H, 2007) |
"A non-invasive orthotopic hepatocellular carcinoma (HCC) model was created with human HCC cells (HepG-Luc) constitutively expressing luciferase (Luc) in nude mice." | 1.34 | Bioluminescent imaging of hepatocellular carcinoma in live mice. ( Peng, J; Sun, Z; Wang, Y; Zhan, L, 2007) |
"Case 1 was a 71-year-old woman with a hepatocellular carcinoma (HCC), 45 mm in diameter, with liver cirrhosis." | 1.34 | [Three cases of hepatocellular carcinoma, over 3 cm in diameter, with liver cirrhosis treated with combination of radiofrequency ablation and continuous hepatic arterial infusion chemotherapy]. ( Hirashita, T; Nakashima, K; Sakai, I; Sakai, M, 2007) |
"5-fluorouracil (5-FU) is a basic agent used in chemotherapy." | 1.34 | Gene expression of 5-fluorouracil metabolic enzymes in hepatocellular carcinoma and non-tumor tissue. ( Ebara, M; Nomura, F; Saisho, H; Shimada, H; Sunaga, M; Tomonaga, T; Yoshikawa, M, 2007) |
"Capecitabine was administered twice daily for 14 days at a total daily dose of 2000 mg/m2." | 1.34 | Capecitabine for treatment of advanced hepatocellular carcinoma. ( Eckel, F; Lersch, C; Mayr, M; Schmid, RM; Schulte-Frohlinde, E; Stock, K; von Delius, S, 2007) |
"The prognosis of patients with advanced hepatocellular carcinoma (HCC) is poor." | 1.33 | Prognostic factors in patients with advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy. ( Aoyama, K; Ishikawa, T; Kawaguchi, K; Kimura, T; Kurokawa, F; Okita, K; Omori, K; Sakaida, I; Tajima, K; Takami, T; Terai, S; Tsuchiya, M; Yamasaki, T; Yokoyama, Y, 2005) |
"Prognosis of advanced hepatocellular carcinoma (HCC) treated by conventional therapies has been considered to be poor." | 1.33 | [Efficacy of hepatic arterial infusion therapy for advanced hepatocellular carcinoma using 5-fluorouracil, epirubicin and mitomycin-C]. ( Ahn, SH; Cho, KB; Choi, JS; Chung, WJ; Hwang, JS; Hwang, JY; Jang, BK; Kim, GC; Kim, YH; Kwon, JH; Kwon, KM; Park, KS, 2005) |
"A 72-year-old man who had multiple hepatocellular carcinoma underwent eight times intrahepatic arterial chemotherapies of SMANCS and two times percutaneous ethanol injection (PEIT) therapies over three years, but new diffuse lesions appeared in the liver." | 1.33 | [A case of hepatocellular carcinoma with multiple lung metastases responding to intermittent intrahepatic arterial chemotherapy of CDDP+5-FU]. ( Arima, T; Horino, K; Inoue, M; Kimura, M; Kuhara, H; Nishimura, T; Uemura, K; Yamada, K, 2005) |
"Treatment for advanced stages of hepatocellular carcinoma (HCC) remains unsatisfactory." | 1.33 | The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells. ( Alajati, A; Ganslmayer, M; Hahn, EG; Herold, C; Lüders, M; Neureiter, D; Ocker, M; Schuppan, D; Zopf, S, 2005) |
"An in situ human hepatocellular carcinoma model was established in mice livers orthotopically." | 1.33 | Inhibition of tumor growth and metastasis with antisense oligonucleotides (Cantide) targeting hTERT in an in situ human hepatocellular carcinoma model. ( Lin, RX; Lü, QJ; Tuo, CW; Wang, SQ; Zhang, W, 2005) |
"Thirty-nine patients with hepatocellular carcinoma were treated with oral 5'-DFUR for more than 4 d before operation." | 1.33 | 5-Fluorouracil concentration in blood, liver and tumor tissues and apoptosis of tumor cells after preoperative oral 5'-deoxy-5-fluorouridine in patients with hepatocellular carcinoma. ( Wang, HD; Zheng, JF, 2005) |
"The prognosis of hepatocellular carcinoma (HCC) with tumor thrombosis of the main trunk or major branches of the portal vein (mPVTT) is extremely poor, even if it is curatively resected." | 1.33 | Adjuvant arterial infusion chemotherapy after resection of hepatocellular carcinoma with portal thrombosis: a pilot study. ( Mimura, T; Niguma, T; Tutui, N, 2005) |
"While 5-Fu causes mainly apoptosis in hepatoma cells, the anticancer mechanism of paclitaxel is predominantly through induction of necrosis." | 1.33 | [Effects of paclitaxel and 5-fluorouracil on growth inhibition and apoptosis of hepatoma cells: a comparative study]. ( He, JB; Ji, MF; Li, XL; Yu, YL, 2005) |
"Hepatocellular carcinoma (HCC) and pancreatic cancer are at the forefront of chemotherapy-resistant tumors with poor prognosis." | 1.33 | 5-aza-2'-deoxycytidine sensitizes hepatoma and pancreatic cancer cell lines. ( Imazeki, F; Kanda, T; Nagao, K; Saisho, H; Tada, M; Yokosuka, O, 2005) |
"Diffused hepatoma was involved in the posterior lobe, and tumor thrombus extended into the main portal vein (Vp4)." | 1.33 | [A case report of hepatocellular carcinoma (Vp4)--an attempt to reduce residual tumor thrombus using combination therapy (hepatic arterial infusion, hepatic arterial embolization and radiation)]. ( Ebisui, C; Fujimoto, T; Fujiwara, S; Fukuchi, N; Hasuike, Y; Hayashi, N; Izumiyama, K; Kida, H; Koshino, T; Sakita, I; Tsujie, M; Yoshida, T, 2005) |
"For 15 patients with advanced hepatocellular carcinoma using a same protocol, the response rate of this therapy was 33." | 1.33 | [Successful treatment of combined intraarterial (5-fluorouracil and adriamycin and cisplatin) infusion chemotherapy for advanced hepatocellular carcinoma with multiple intrahepatic metastases and/or portal vein thrombosis--two case reports]. ( Bazarragchaa, D; Dono, K; Kato, H; Marubashi, S; Miyamoto, A; Monden, M; Murakami, T; Nagano, H; Nakamura, H; Nakamura, M; Noda, T; Ota, H; Takeda, Y; Umeshita, K; Wada, H; Yoshioka, S, 2005) |
"Advanced hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT) has a poor prognosis." | 1.33 | [Effect of low dose 5-fluorouracil and cisplatin intra-arterial infusion chemotherapy in advanced hepatocellular carcinoma with decompensated cirrhosis]. ( Cheong, JY; Cho, SW; Choi, JW; Choi, SJ; Hahm, KB; Kim, JH; Kim, JK; Kim, JS; Kwon, HC; Lee, KJ; Lee, KM; Lim, TY; Sim, SJ; Won, JH; Yoo, BM, 2006) |
" 3DCRT was given with the field covering the tumor with a generous margin." | 1.33 | [Three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for hepatocellular carcinoma]. ( Chen, Z; Cheng, WW; Jiang, GL; Lin, JH; Liu, LM; Meng, ZQ; Zhang, XJ; Zhou, ZH, 2006) |
"The prognosis for patients with hepatocellular carcinoma (HCC) with progressive liver cirrhosis or extrahepatic metastases remains dismal." | 1.33 | [A case of advanced hepatocellular carcinoma with lung metastases and cirrhosis that responded to combination chemotherapy with interferon-alpha and 5-fluorouracil]. ( Ishii, E; Kondo, M; Kudo, T; Mitobe, S; Munakata, M; Muto, O; Okada, R; Sakata, Y; Shitara, K; Yabu, K, 2006) |
"Recently, we reported the beneficial effects of intra arterial 5-FU infusion chemotherapy combined with interferon-alpha (IFN-alpha/5-FU combined chemotherapy) for advanced hepatocellular carcinoma (HCC)." | 1.33 | [Intra arterial infusion chemotherapy combined with interferon-alpha following palliative hepatic resection against advanced hepatoma with portal venous tumor thrombus in the major trunk and multiple nodules--a preliminary study]. ( Damdinsuren, B; Dono, K; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamura, M; Noda, T; Ota, H; Takeda, Y; Umeshita, K; Wada, H, 2006) |
"We report a case of advanced hepatocellular carcinoma (HCC)." | 1.33 | [Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma providing a good QOL]. ( Amano, M; Fujita, M; Hayashida, H; Higaki, N; Nakagawa, S; Niinobu, T; Nishikawa, Y; Sakon, M; Yamashita, S, 2006) |
"A syngeneic rat model of hepatocellular carcinoma was used." | 1.32 | [Influence of combined cyclosporine A and tacrolimus with 5-fluorouracil on hepatocellular carcinoma rats]. ( Jiang, GP; Li, MW; Xie, HY; Yang, FC; Zeng, QL; Zheng, SS, 2003) |
"The prognosis of advanced hepatocellular carcinoma remains poor." | 1.32 | Interventional radiology for advanced hepatocellular carcinoma: comparison of hepatic artery infusion chemotherapy and transcatheter arterial lipiodol chemoembolization. ( Ando, E; Fukumori, K; Sata, M; Sumie, S; Tanaka, M; Yamashita, F; Yano, Y, 2003) |
"Human hepatoma HepG2 cells were treated with 5-Fu at the concentrations of 1X10(-1), 1X10(-2), 1X10(-3), 1X10(-4), 1X10(-5) mol/L and for 1, 2, 4, 8, 16, 24 hours, respectively." | 1.32 | Caspase-8 in apoptosis of hepatoma cell induced by 5-fluorouracil. ( Yang, LY; Yi, TB, 2003) |
"Nineteen patients with far advanced hepatocellular carcinoma received transarterial hepatic chemotherapy." | 1.32 | [Long-term outcome of advanced hepatocellular carcinoma that received transarterial hepatic chemotherapy]. ( Furukawa, H; Imamura, H; Inoue, Y; Ishida, H; Kitamura, S; Masuda, F; Masutani, S; Obana, T; Ohnishi, H; Saeki, N; Shimizu, J; Takamura, M; Tatsuta, M; Tomotsu, K; Yura, M, 2003) |
"The prognosis of advanced hepatocellular carcinoma (HCC) is extremely poor." | 1.32 | [A report of two cases--two patients of the extremely advanced hepatocellular carcinoma have responded completely for a long time after a combination therapy consisting of arterial chemotherapy and injection of interferon-alpha]. ( Danno, M; Dono, K; Hatanaka, T; Hayashi, T; Iijima, S; Kato, T; Kikkawa, N; Kurokawa, E; Monden, M; Nagano, H; Nakamori, S; Naoi, Y; Ohshima, S; Sakon, M; Tsujie, M; Umeshita, K; Yamamoto, H, 2003) |
"Five human hepatoma cell lines (Hep3B, HepG2, HuH7, PLC/PRF/5 and Chang) were used." | 1.32 | The efficacy of the combination therapy of 5-fluorouracil, cisplatin and leucovorin for hepatocellular carcinoma and its predictable factors. ( Iwasaki, T; Kogure, T; Shimosegawa, T; Ueno, Y, 2004) |
"5-fluorouracil (5-FU) that has no carbonyl group was used as control." | 1.32 | [Screening of the drug resistance-associated gene in HepG2 cell line transfected with aldose reductase like gene-1 (ARL-1)]. ( Cao, DL; Tang, DN; Wang, J; Yang, XD, 2003) |
"To study the anti-tumor effect of resveratrol and in combination with 5-FU on murine liver cancer." | 1.32 | Effect of resveratrol and in combination with 5-FU on murine liver cancer. ( Meng, KW; Pan, CE; Qin, XL; Sun, ZJ; Wu, SL; Yu, L, 2004) |
"The prognosis of hepatocellular carcinoma (HCC) is very poor, particularly in patients with tumors that have invaded the major branches of the portal vein." | 1.32 | Molecular prediction of response to 5-fluorouracil and interferon-alpha combination chemotherapy in advanced hepatocellular carcinoma. ( Dono, K; Ishii, S; Kato, K; Kurokawa, Y; Matoba, R; Monden, M; Nagano, H; Nakamori, S; Sakon, M; Takemasa, I; Ueno, N; Umeshita, K, 2004) |
"To explore the change of T cell subsets in patients suffered from hepatocellular carcinoma (HCC) before and after hepatectomy, and study the value of Roferon-A (interferon alpha-2a) combined with hepatic artery chemoembolization (HACE) and portal vein chemotherapy (PVC) after radical resection of HCC for preventing recurrence." | 1.32 | [The value of Roferon-A combined with hepatic artery chemoembolization and portal vein chemotherapy after radical resection in hepatocellular carcinoma for preventing recurrence]. ( Chen, JS; Duan, ZH; Li, HH; Wang, J; Zhang, HW, 2004) |
" The sensitivity of H22 cells to 5-FU can be markedly enhanced: The IC(50) dosage of 5-Fu can be decreased from 0." | 1.31 | The effect of calmodulin antagonist berbaminederivative-EBB on hepatoma in vitro and in vivo. ( Li, Z; Liu, J; Qi, S; Wang, T; Zhang, J; Zhu, H, 2002) |
"Advanced unresectable hepatocellular carcinoma (HCC) was treated with modified pharmacokinetic modulation chemotherapy (PMC)." | 1.31 | [Modified pharmacokinetic modulation chemotherapy (PMC) with medication of UFT and intraarterial infusion of 5-FU for advanced unresectable HCC]. ( Ito, T; Kamachi, H; Kamiyama, T; Kondo, M; Kurauchi, N; Matsushita, M; Nakagawa, T; Nishikawa, M; Ogata, T; Todo, S, 2002) |
"The prognosis of patients with advanced hepatoma is grim." | 1.31 | Identification of genes associated with sensitivity to 5-fluorouracil and cisplatin in hepatoma cells. ( Goto, T; Hoshida, Y; Kato, N; Moriyama, M; Omata, M; Otsuka, M; Seki, N; Shiratori, Y; Taniguchi, H, 2002) |
"A case of hepatocellular carcinoma (HCC) complicated by tumor thrombosis of the main trunk is presented." | 1.31 | Chemotherapy for hepatocellular carcinoma with portal hypertension due to tumor thrombus. ( Ando, E; Fukumori, K; Sata, M; Sumie, S; Tanaka, M; Yamashita, F; Yano, Y, 2000) |
"Capecitabine may inhibit the growth and metastasis of HCC." | 1.31 | [The expression of platelet-derived endothelial cell growth factor in liver cancer]. ( Fan, J; Tang, Z; Zhou, J, 2000) |
"We reported a case of hepatocellular carcinoma (HCC) with multiple lymph node metastases." | 1.31 | [Lymph node excision with laparotomy and chemo-radiation therapy for a hepatocellular carcinoma patient with multiple lymph node metastases]. ( Beppu, T; Fujiyama, S; Hirota, M; Ishiko, T; Ishiodori, H; Matsuda, T; Ogawa, M; Omuraya, M; Yamashita, Y, 2001) |
"Patients with advanced hepatocellular carcinoma (HCC) have a poor prognosis, and the development of new therapeutic strategies is necessary." | 1.31 | Combination chemotherapy for advanced hepatocellular carcinoma complicated by major portal vein thrombosis. ( Kaneko, S; Kobayashi, K; Urabe, T, 2002) |
"If hepatic reserve is satisfactory, an aggressive surgical approach combined with chemotherapy seems to be of benefit for patients having HCC with tumor thrombus in the MPV, IVC, or EBD." | 1.31 | Surgical resection combined with chemotherapy for advanced hepatocellular carcinoma with tumor thrombus: report of 19 cases. ( Aoyagi, S; Eriguchi, N; Fukuda, S; Imamura, I; Imamura, M; Okuda, K, 2002) |
"The prognosis of hepatocellular carcinoma (HCC) invading into the major branches of the portal vein (Vp3) is extremely poor." | 1.31 | Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. ( Dono, K; Iijima, S; Imai, Y; Kawata, S; Monden, M; Nagano, H; Nakamori, S; Sakon, M; Umeshita, K; Yamada, A, 2002) |
"For 6 patients with advanced hepatocellular carcinoma (HCC) in whom TAE was inefficacious, we tried hepatic arterial infusion chemotherapy." | 1.30 | [Hepatic arterial infusion chemotherapy (HAI) for advanced hepatocellular carcinoma inefficacious with transcatheter arterial embolization (TAE)]. ( Aoyama, H; Asano, T; Fukunaga, T; Isono, K; Iwasaki, K; Kenmochi, T; Kobayashi, S; Kouno, T; Matsuzaki, H; Nakagouri, S; Okazumi, S; Shinotou, K; Shutou, K; Takayama, W; Takeda, A, 1998) |
"Five different human hepatoma cell lines, Hep G2, Hep G2." | 1.30 | Apoptosis in human hepatoma cell lines by chemotherapeutic drugs via Fas-dependent and Fas-independent pathways. ( Jiang, S; Kim, SJ; Lee, MO; Park, JH; Shin, EC; Song, MJ, 1999) |
"The innate drug resistance of human hepatocellular carcinoma (HCC) Bel7402 cell line was studied in vitro." | 1.30 | The study of innate drug resistance of human hepatocellular carcinoma Bel7402 cell line. ( Huang, M; Liu, G, 1999) |
"AFP gene expression in human hepatoma cells was determined by avidin-biotin-peroxidase complex (ABC) immunocytochemical method." | 1.30 | Combined effect of alpha-fetoprotein antisense oligodeoxy-nucleotides and 5-fluorouracil on human hepatoma cell growth. ( Wang, X; Xie, H; Zhang, R, 1999) |
"Primary hepatocellular carcinoma is a very rare disease, especially in association with a pregnancy." | 1.29 | [Hepatocellular carcinoma in pregnancy]. ( Brucker, C; Debus-Thiede, G; Genz, T; Maassen, V; Schweiberer, L; Weiss, M, 1994) |
"A-68-year-old man had hepatocellular carcinoma (HCC) in the area of S6 segment which was resected surgically." | 1.29 | [A case of recurrent multiple HCC after surgical resection showing regression by two TAEs using 5-FU and zinostatin stimalamer]. ( Fukuzawa, Y; Ikeda, H; Kato, K; Murata, K; Sawada, T; Tagaya, T; Takahashi, K; Takiya, S, 1996) |
"In seven patients with advanced primary hepatocellular carcinoma the same therapeutic regime was used." | 1.28 | Hepatic chemoinfusion of 5-FU in metastasis of gastrointestinal cancer and advanced primary hepatocellular carcinoma. ( Cuan-Orozco, F; Kalk, JF; Koussouris, P; Mercado, MA; Paquet, KJ; Siemens, F, 1992) |
" After right lobectomy of the liver which contained the tumors of S6 2 cm and S8 3 cm in diameter 7 months before, the patient was treated with hepatic arterial embolization (TAE) combined with infusion of anti-cancer drug (ADM, CDDP) four times since June 1990." | 1.28 | [A case report of postoperative recurrent hepatocellular carcinoma effectively treated with HCFU administration combined with TAE]. ( Imai, Y; Ito, J; Kobayashi, K; Okamoto, M; Tagawa, K; Taniguchi, M; Tanzawa, Y; Toda, N; Unuma, T; Uta, Y, 1992) |
"Hepatectomy has been performed as a treatment for hepatocellular carcinoma (HCC) and metastatic liver carcinoma." | 1.28 | [Intermittent intra-arterial chemotherapy using subcutaneously implanted reservoir for hepatocellular carcinoma and liver metastasis of colorectal carcinoma]. ( Hanawa, S; Hasebe, Y; Kuramoto, S; Maeda, T; Nakazaki, H; Suzuki, Y; Watanabe, M; Yanagita, K; Yoshio, T, 1992) |
"Four cases of advanced hepatocellular carcinoma patients were treated by intra-portal infusion of 5-FU immediately after surgery." | 1.28 | [Intraportal vein infusion chemotherapy after hepatectomy for hepatocellular carcinoma--preliminary report]. ( Gotoda, A; Kamiyama, T; Nagabuchi, E; Nakajima, Y; Ogasawara, K; Saito, M; Sato, N; Uchino, J; Une, Y, 1991) |
"Chemosensitivity of hepatocellular carcinoma tissues from 72 patients to 6 antitumor agents was assayed using the succinate dehydrogenase inhibition test." | 1.28 | Human hepatocellular carcinoma sensitivity to antitumor drugs assayed using the succinate dehydrogenase inhibition test. ( Akazawa, K; Kanematsu, T; Maehara, Y; Matsumata, T; Shirabe, K; Sugimachi, K, 1991) |
"Fifteen patients with advanced hepatocellular carcinoma were treated by hepatic arterial infusion (HAI)." | 1.28 | [Hepatocellular carcinoma treated by continuous hepatic arterial infusion of etoposide, CDDP and 5-FU]. ( Akimura, R; Fujii, N; Ikami, I; Kanehira, J; Kimura, T; Midorikawa, H; Nakamura, Y; Sasaki, T; Tarusawa, K; Yodono, H, 1990) |
" Thus, both intraarterial and intraportal chemotherapy combined with decollateralization by silicone rubber sheeting seems to be effective for advanced cholangiocarcinoma and metastatic carcinoma." | 1.28 | [Intraarterial and intraportal chemotherapy combined with decollateralization for cholangiocellular carcinoma and metastatic liver cancer]. ( Fukuda, I; Furukawa, H; Imaoka, S; Ishikawa, O; Masutani, S; Nagano, H; Ohashi, I; Oohigashi, H; Sasaki, Y; Yasuda, T, 1990) |
"Two patients had primary hepatocellular cancer (HCC)." | 1.28 | Repeated dearterialization of hepatic tumors with an implantable occluder. ( Bengmark, S; Ekberg, H; Jeppsson, B; Lundstedt, C; Persson, BG; Tranberg, KG, 1990) |
"Human hepatoma and melanoma tumor cells and normal melanocytes, keratinocytes, and fibroblasts were incubated for 2, 24, and 48 h with graded concentrations of cis-platinum (0." | 1.28 | Rapid chemosensitivity assay with human normal and tumor cells in vitro. ( Babich, H; Borenfreund, E; Martin-Alguacil, N, 1990) |
"Six cases of unresectable hepatic cancer in infant were treated with intra-arterial infusion therapy." | 1.28 | [Clinical study of intrahepatic arterial infusion of unresectable hepatoblastoma and hepatocarcinoma in children]. ( Abe, T; Hamada, H; Hata, Y; Saito, H; Sasaki, F; Sato, N; Sawada, H; Tamura, M; Uchino, J; Une, Y, 1989) |
"In the case of gall bladder cancer cell line (NOZ), combination of adriamycin and hyperthermia showed more effective inhibition for cell proliferation than MMC + hyperthermia and 5-FU + hyperthermia." | 1.28 | [Combination therapy of hyperthermia and other methods in liver and bile tract cancers--evaluation of these methods using cancer cell lines in vitro]. ( Fujise, K; Hasumura, S; Homma, S; Kameda, H; Matsuura, T; Nagamori, S; Niiya, M; Shimizu, K; Sujino, H, 1989) |
"Lipiodol-ADM was injected for hepatocellular carcinoma every 2 months and MMC-5-FU was injected for liver metastasis of colorectal carcinoma every one or two weeks." | 1.28 | [Usefulness of subcutaneously implanted reservoir for postoperative therapy in hepatocellular carcinoma and liver metastases of colorectal carcinoma]. ( Adachi, W; Hanasaki, K; Horigome, N; Iida, F; Kajikawa, S; Kinosita, T; Kuroda, T; Sodeyama, H, 1989) |
"In 24 cases of unresectable hepatocellular carcinoma, we performed hepatic arterial catheterization and intra-arterial infusion chemotherapy." | 1.28 | [Hepatic arterial infusion chemotherapy of hepatocellular carcinoma]. ( Amioka, K; Hara, H; Iga, C; Ishibashi, T; Isozaki, H; Morita, S; Nakata, E; Nishimura, J; Okajima, K; Tanimura, M, 1989) |
"Of the 8 patients having hepatoma with increased AFP, all the patients showed a decrease of AFP following the therapy with an average ratio of 65% decrease." | 1.28 | [Hepatic arterial infusion chemotherapy and hyperthermia with degradable starch microspheres in primary and metastatic liver malignancies]. ( Haida, K; Miura, T, 1989) |
"Nineteen patients with primary hepatocellular carcinoma (7 were at Stage III and 11 were at Stage IV) and 14 patients with metastatic liver tumors (4 were at H2 and 9 were at H3 stages) received this newly developed anticancer methodology." | 1.28 | [The clinical studies of intermittent hepatic artery occlusion with infusion chemotherapy--19 cases of unresectable hepatocellular carcinoma and 14 cases of metastatic liver cancer]. ( Naito, A; Nakase, A; Tamura, K; Tarumi, T; Yamamoto, T; Yano, S, 1989) |
"A 24-year-old man with hepatocellular carcinoma presented with recurrent obstructive jaundice caused by bile duct invasion and distal migration of necrotic tumor fragments." | 1.27 | Recurrent obstructive jaundice caused by fibrolamellar hepatocellular carcinoma. ( Albaugh, JS; Keeffe, EB; Krippaehne, WW, 1984) |
"Six patients with hepatocellular carcinoma (HCC) and 9 patients with metastatic liver carcinoma (MLC) (4 with stomach cancer, 4 with pancreas cancer and 1 with colon cancer) were treated with rapid hepatic artery infusion of adriamycin." | 1.27 | [Intraarterial Adriamycin for patients with hepatocellular carcinoma and metastatic liver carcinoma]. ( Hino, I; Kimura, I; Kuroda, S; Numoto, A; Ohnoshi, T; Takahashi, M; Tsuji, M; Ueoka, H, 1984) |
"Although both patients with hepatocellular cancer and the patient with a soft tissue sarcoma responded to the regimen, only 1 of 38 patients with adenocarcinoma had a favourable response." | 1.27 | Adriamycin, CCNU, and 5-fluorouracil in patients with advanced gastrointestinal cancer. ( Cedermark, BJ; Gunven, P; Hammarberg, C, 1983) |
"A 9-year-old boy with non-resectable hepatocellular carcinoma was treated with irradiation and intra-hepatic arterial infusion of antitumor agents." | 1.27 | [HBs antigen-positive adult type liver cancer in a child with sustained remission induced by infusion of antineoplastic agents into the hepatic artery]. ( Hamawaki, M; Ito, Y; Iwata, K; Kikkawa, K; Kubonishi, S; Kuroiwa, Y; Matsuoka, K; Ohmura, T; Okano, K, 1983) |
"Fourty eight patients with cancer of head of pancreas have been treated by the intra-arterial infusion of 5-FU and Mitomycin C alone or in combination with regional hyperthermia, employing microwave machine operating at a frequency of 2450 MHz." | 1.27 | [Hyperthermia: microwave hyperthermia in combination with intra-arterial infusion chemotherapy of cancer of the pancreas]. ( Endo, Y; Funatomi, H; Hatta, Y; Hirose, N; Miura, T; Sassa, T; Taguchi, S; Yoshikawa, N, 1985) |
"Thirty-two patients with inoperable hepatic cancer underwent intra-arterial hepatic infusion using mitomycin C (MMC) and 5-fluorouracil (5-FU) or intra-arterial hepatic chemoembolization using heated albumin microspheres containing MMC with an average diameter 45 +/- 8 micron." | 1.27 | Biodegradable mitomycin C microspheres given intra-arterially for inoperable hepatic cancer. With particular reference to a comparison with continuous infusion of mitomycin C and 5-fluorouracil. ( Endoh, F; Fujimoto, S; Miyazaki, M; Morimoto, Y; Okui, K; Takahashi, O, 1985) |
"Twenty patients with malignant hepatoma were treated with sequential intraarterial doxorubicin (72-hour continuous infusion) followed by systemic 5-fluorouracil (5-FU) and semustine (methyl CCNU)." | 1.27 | Chemotherapy of malignant hepatomas with sequential intraarterial doxorubicin and systemic 5-fluorouracil and semustine. ( Hahn, RG; Moertel, CG; O'Connell, MJ; Rubin, J, 1988) |
"5-fluorouracil was effective only in patients without cirrhosis, with an overall response rate of 22%." | 1.27 | Intrahepatic chemotherapy for unresectable hepatocellular carcinoma. ( Audisio, R; Bignami, P; Bonfanti, G; Bozzetti, F; Colombo, M; Doci, R; Gennari, L, 1988) |
"Of the 8 patients with hepatoma with increased AFP, all the patients showed a decrease of AFP following therapy with an average decrease ratio of 64%." | 1.27 | [Hepatic arterial infusion chemotherapy and hyperthermia with degradable starch microspheres in primary and metastatic liver malignancies]. ( Haida, K; Miura, T, 1988) |
"A total of 850 patients with hepatocellular carcinoma seen during the last 8 years were analyzed retrospectively for survival in relation to treatment and disease stage." | 1.27 | Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. ( Hasegawa, H; Nakajima, Y; Obata, H; Ohnishi, K; Ohtsuki, T; Okazaki, N; Okuda, K; Tomimatsu, M, 1985) |
"All of the gallbladders had significant arteritis, with narrowing or occlusion of lumina or necrosis of vessel walls." | 1.27 | Chemical cholecystitis associated with hepatic arterial chemotherapy delivered by a permanently implanted pump. ( Dakhil, SR; Housholder, DF; Marymont, JV; Travers, H, 1985) |
"407 cases of unresectable hepatocellular carcinoma (HCC) occurring from 1970 to March 1985, including 107 cases receiving conservative therapy, 176 cases receiving one-shot therapy and 124 cases receiving transcatheter arterial embolization (TAE) therapy, were studied and the efficacy of chemotherapy was compared with that of TAE therapy." | 1.27 | [One-shot therapy and transcatheter arterial embolization (TAE) therapy of unresectable hepatocellular carcinoma]. ( Abe, M; Hirai, K; Kawazoe, Y; Kumagai, M; Tanikawa, K; Yamashita, K, 1985) |
"Four hepatocellular cancer patients and 11 metastatic liver cancer patients were treated with intra-hepato-arterial infusions of cis-diamminedichloroplatinum (II) plus 5-fluorouracil." | 1.27 | Intra-hepato-arterial infusions of cis-diamminedichloroplatinum (II) and 5-fluorouracil clinically effective for malignant liver tumors. ( Koga, S; Maeta, M; Murakami, A; Wakatsuki, T; Yoshioka, H, 1985) |
"5-Fluorouracil was injected by a fine needle under ultrasound guidance." | 1.27 | Percutaneous interstitial chemotherapy of a small hepatocellular carcinoma under ultrasound guidance. ( Livraghi, T; Ravetto, C; Solbiati, L; Suter, F, 1986) |
"A 69-year-old man with a large hepatoma of the right lobe extending in part to the medial segment of the left lobe was treated by ligation of the right hepatic artery combined with continuous infusion of a total dose of 5500 mg og 5-fluorouracil (5-FU) into the left hepatic artery." | 1.26 | A non-resectable hepatoma after hepatic artery ligation combined with infusion chemotherapy--an eight-year survival. ( Hiraoka, T; Konno, T; Nakakuma, K; Tashiro, S; Yokoyama, I, 1981) |
"5-Fluorouracil (5-FU) is an effective anti-tumor drug, which has been used both as a single agent and in combination with other chemotherapeutic agents for the treatment of tumors such as breast and colorectal carcinoma." | 1.26 | Metabolic and distribution studies with radiolabeled 5-fluorouracil. ( Ghanbarpour, A; Shani, J; Siemsen, JK; Vine, E; Wolf, W; Young, D, 1982) |
"One patient with hepatocellular carcinoma had compete disappearance of all disease with chemotherapy alone." | 1.26 | Preoperative chemotherapy for unresectable primary hepatic malignancies in children. ( Siegel, MM; Siegel, SE; Stanley, P; Weinblatt, ME; Weitzman, JJ, 1982) |
"N1-S1/FdUrd Novikoff hepatoma cells, which lack thymidine kinase activity, are resistant to 5-fluorouracil (FUra) as well as 5-fluorodeoxyuridine (FdUrd), suggesting that the pathway, FUra leads to FdUrd leads to FdUMP, is utilized for the conversion of FUra to FdUMP." | 1.26 | Metabolism of 5-fluorouracil in sensitive and resistant Novikoff hepatoma cells. ( Crumley, J; Wilkinson, DS, 1977) |
" Maintenance therapy was carried out by the administration of these drugs at induction dosage alternated each week as a single 24 hourly intravenous infusion." | 1.26 | Intrahepatic arterial infusion of combination of mitomycin-C and 5-fluorouracil in treatment of primary and metastatic liver carcinoma. ( Das, B; Jaiswal, MS; Misra, NC; Singh, RV, 1977) |
"Oral fluorouracil was administered weekly to 12 consecutive patients with unresectable hepatoma." | 1.26 | Oral fluorouracil therapy of hepatoma. ( Kennedy, PS; Lane, M; Lehane, DE; Smith, FE, 1977) |
"The podophyllotoxin derivative VP 16-213 was used as monotherapy in 6 patients and combined with 5-fluorouracil in another 6." | 1.26 | [Therapeutic results using VP 16-213 alone or in combination with 5-fluorouracil in liver cancer (hepatoma)]. ( Brunner, KW; Cavalli, F; Gerber, A; Ryssel, HJ; Sonntag, RW; Tschopp, L, 1977) |
" Comparison of the effects of single vs fractionated dosage was made on 2 types of experimental solid tumour with different growth, cell kinetic, histological and metastasizing properties." | 1.26 | Solid tumour models for the assessment of different treatment modalities: VII: single vs fractionated doses of 5-fluorouracil on two solid tumours and their hosts. ( Hopkins, HA; Looney, WB; Macleod, MS, 1978) |
"A case of hepatocellular carcinoma in a young female is presented in which the apparent etiology was the use of oral contraceptives for 5 1/2 years." | 1.26 | Hepatocellular carcinoma in a young woman with prolonged exposure to oral contraceptives. ( Gattanell, PN; Holland, JF; Perloff, M, 1978) |
"A 45-year-old man with hepatocellular carcinoma who developed intravascular coagulation following complete tumor regression by chemotherapy is described." | 1.26 | Complete necrotization of hepatocellular carcinoma by chemotherapy and subsequent intravascular coagulation: a case report. ( Harada, T; Makisaka, Y; Nishimura, H; Okuda, K, 1978) |
"A case of hepatocellular carcinoma associated with erythrocytosis is described." | 1.26 | Hepatocellular carcinoma associated with erythrocytosis. A nine year survival after successful chemotherapy and left lateral hepatectomy. ( Arima, M; Hattori, N; Kimura, K; Okazaki, N; Ozaki, H, 1979) |
"Pretreatment with tocopheryl nicotinate and indomethacin increased the K values in the control subjects, but was without effect on the K values in patients with primary hepatoma." | 1.26 | Decreased disappearance rate of 1-(2-tetrahydrofuryl)-5-fluorouracil (FT-207) from the blood and its unresponsiveness to tocophreyl nicotinate and indomethacin in patients with primary hepatocellular carcinoma. ( Hobara, N; Watanabe, A, 1979) |
"Although advanced gastrointestinal cancer is the most commonplace problem encountered by the medical oncologist, this group of diseases has proved exceedingly resistant to past chemotherapy efforts." | 1.25 | Clinical management of advanced gastrointestinal cancer. ( Moertel, CG, 1975) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 211 (19.38) | 18.7374 |
1990's | 115 (10.56) | 18.2507 |
2000's | 294 (27.00) | 29.6817 |
2010's | 369 (33.88) | 24.3611 |
2020's | 100 (9.18) | 2.80 |
Authors | Studies |
---|---|
El-Far, M | 1 |
Elmegeed, GA | 1 |
Eskander, EF | 1 |
Rady, HM | 1 |
Tantawy, MA | 1 |
Tuncbilek, M | 1 |
Guven, EB | 1 |
Onder, T | 1 |
Cetin Atalay, R | 1 |
Yu, HY | 1 |
Zhang, XQ | 1 |
Li, X | 16 |
Zeng, FB | 1 |
Ruan, HL | 1 |
Fu, J | 1 |
Liu, L | 10 |
Huang, Z | 2 |
Lai, Y | 1 |
Ji, H | 1 |
Peng, S | 1 |
Tian, J | 2 |
Zhang, Y | 20 |
Dai, M | 2 |
Yuan, X | 2 |
Kang, J | 1 |
Zhu, ZJ | 2 |
Yue, RC | 1 |
Yuan, H | 1 |
Chen, BY | 1 |
Zhang, WD | 3 |
Liu, RH | 2 |
Sun, QY | 2 |
Zhang, H | 13 |
Zhu, P | 1 |
Liu, J | 15 |
Yang, X | 11 |
Xu, S | 1 |
Yao, H | 1 |
Jiang, J | 2 |
Ye, W | 2 |
Wu, X | 9 |
Xu, J | 3 |
Shaaban, S | 2 |
Negm, A | 2 |
Ashmawy, AM | 2 |
Ahmed, DM | 1 |
Wessjohann, LA | 2 |
Bai, ZT | 1 |
Wu, ZR | 1 |
Xi, LL | 1 |
Chen, P | 2 |
Wang, FQ | 1 |
Meng, WB | 1 |
Zhou, WC | 1 |
Wu, XA | 1 |
Yao, XJ | 1 |
Zhang, M | 5 |
Tian, JL | 1 |
Yao, GD | 1 |
Wang, YX | 2 |
Gao, PY | 1 |
Wang, D | 2 |
Li, LZ | 1 |
Lin, B | 2 |
Huang, XX | 1 |
Song, SJ | 1 |
Hawash, MM | 1 |
Kahraman, DC | 1 |
Eren, F | 1 |
Cetin Atalay, R | 1 |
Baytas, SN | 1 |
Zhang, B | 4 |
Wang, N | 4 |
Zhang, C | 5 |
Gao, C | 1 |
Zhang, W | 8 |
Chen, K | 5 |
Wu, W | 4 |
Chen, Y | 12 |
Tan, C | 1 |
Liu, F | 4 |
Jiang, Y | 2 |
Zhang, L | 8 |
Zheng, C | 1 |
Wang, Y | 22 |
Nie, X | 1 |
Shi, D | 1 |
Wei, G | 1 |
Wang, J | 19 |
Chen, YY | 2 |
Cao, YZ | 1 |
Li, FQ | 1 |
Zhu, XL | 1 |
Peng, CX | 1 |
Lu, JH | 1 |
Chen, JW | 2 |
Ling, Y | 1 |
Gao, WJ | 1 |
Ling, C | 1 |
Meng, C | 1 |
Qian, J | 1 |
Liu, S | 8 |
Gan, H | 1 |
Wu, H | 1 |
Tao, J | 1 |
Dai, H | 2 |
Ding, Y | 2 |
Li, S | 9 |
Ge, W | 1 |
Liu, Z | 11 |
Zhang, X | 12 |
Wang, M | 2 |
Chen, T | 1 |
Zhang, Q | 4 |
Qiu, J | 2 |
Zhou, Q | 4 |
Guan, M | 1 |
Zou, Y | 3 |
Huang, X | 4 |
Zhao, Y | 6 |
Chen, W | 4 |
Gu, X | 1 |
Tawfik, HO | 1 |
Petreni, A | 1 |
Supuran, CT | 1 |
El-Hamamsy, MH | 1 |
Yue, K | 1 |
Hou, X | 2 |
Jia, G | 1 |
Zhang, J | 22 |
Tan, L | 1 |
Wang, X | 14 |
Zhang, Z | 8 |
Li, P | 1 |
Xu, W | 2 |
Suzuki, H | 2 |
Niizeki, T | 6 |
Shirono, T | 3 |
Koteda, Y | 1 |
Kinjyo, Y | 1 |
Mizukami, N | 2 |
Koda, M | 1 |
Ota, S | 1 |
Nakano, M | 4 |
Okamura, S | 3 |
Iwamoto, H | 8 |
Shimose, S | 4 |
Noda, Y | 2 |
Kamachi, N | 2 |
Kajiwara, A | 1 |
Suda, K | 1 |
Akiba, J | 1 |
Yano, H | 5 |
Kuromatsu, R | 5 |
Koga, H | 4 |
Torimura, T | 6 |
Pan, Y | 4 |
Mei, J | 4 |
Chen, J | 6 |
Zhang, D | 5 |
Yi, M | 1 |
Zhou, Z | 4 |
Chen, M | 8 |
Guo, R | 7 |
Xu, L | 10 |
Chen, S | 5 |
Xu, B | 1 |
Wu, Z | 4 |
Wang, P | 3 |
Yu, W | 2 |
Wu, Y | 4 |
Li, T | 3 |
Guo, W | 3 |
Zhu, J | 3 |
Sidaway, P | 2 |
Lyu, N | 5 |
Li, JB | 3 |
Lai, JF | 1 |
Chen, QF | 1 |
Li, SL | 2 |
Deng, HJ | 1 |
He, M | 7 |
Mu, LW | 1 |
Zhao, M | 6 |
Yu, H | 2 |
Qin, L | 2 |
Jia, Z | 1 |
Ni, C | 1 |
Feng, GY | 1 |
Cheng, Y | 4 |
Shi, ZR | 1 |
Hou, Z | 2 |
Jin, Z | 1 |
Qiu, G | 1 |
Xie, Q | 3 |
Mi, S | 1 |
Huang, J | 5 |
Ishii, M | 1 |
Itano, O | 1 |
Hibi, T | 1 |
Itano, S | 4 |
Pu, Y | 2 |
Yan, D | 4 |
Tu, L | 2 |
Cheng, L | 4 |
Yu, J | 11 |
Li, Z | 11 |
Zheng, X | 3 |
Sütcüoğlu, O | 1 |
Ulaş Kahya, B | 1 |
Özdemir, N | 1 |
Yazıcı, O | 1 |
Liu, N | 1 |
Wang, Q | 8 |
Hu, J | 1 |
Yang, A | 1 |
Wu, Q | 2 |
Chen, Q | 2 |
Yang, J | 8 |
Li, H | 10 |
Tao, Y | 2 |
Wang, A | 1 |
Sun, Y | 6 |
Ouyang, H | 1 |
He, D | 1 |
Liu, D | 4 |
Chen, H | 9 |
Pan, W | 1 |
Li, Q | 16 |
Xie, W | 1 |
Yu, C | 2 |
Kang, S | 1 |
Magliocca, J | 1 |
Sellers, M | 1 |
Roccaro, G | 1 |
Zheng, W | 1 |
Pectasides, M | 1 |
Draper, A | 1 |
Guadagno, J | 1 |
El-Rayes, B | 1 |
Akce, M | 2 |
Guo, J | 3 |
Huang, L | 2 |
Komarov, IV | 1 |
Tolstanova, G | 1 |
Kuznietsova, H | 1 |
Dziubenko, N | 1 |
Yanchuk, PI | 1 |
Shtanova, LY | 1 |
Veselsky, SP | 1 |
Garmanchuk, LV | 1 |
Khranovska, N | 1 |
Gorbach, O | 1 |
Dovbynchuk, T | 1 |
Borysko, P | 1 |
Babii, O | 1 |
Schober, T | 1 |
Ulrich, AS | 1 |
Afonin, S | 1 |
Yu, S | 4 |
Sathiyaseelan, A | 1 |
Saravanakumar, K | 1 |
Wang, MH | 1 |
Tiu, YC | 1 |
Gong, L | 1 |
Luo, J | 1 |
Yang, Y | 6 |
Tang, Y | 2 |
Lee, WM | 1 |
Guan, XY | 2 |
Narita, H | 1 |
Kawaratani, H | 1 |
Shibamoto, A | 1 |
Takeda, S | 1 |
Ozutsumi, T | 1 |
Tsuji, Y | 1 |
Fujinaga, Y | 1 |
Kitagawa, K | 1 |
Nishimura, N | 1 |
Hokuto, D | 1 |
Sho, M | 1 |
Yoshiji, H | 2 |
Lai, Z | 3 |
Bu, X | 3 |
Xu, Y | 1 |
Huang, Y | 4 |
Wen, D | 3 |
Wei, W | 5 |
Kan, A | 3 |
Shi, M | 10 |
Liu, X | 2 |
Liu, Q | 3 |
Bao, X | 1 |
Oranratnachai, S | 1 |
Rattanasiri, S | 1 |
Sirachainan, E | 1 |
Tansawet, A | 1 |
Raunroadroong, N | 1 |
McKay, GJ | 1 |
Attia, J | 1 |
Thakkinstian, A | 1 |
Sun, J | 7 |
Liu, C | 12 |
Shi, J | 3 |
Jiang, D | 2 |
Mao, F | 2 |
Gu, J | 3 |
Zhou, L | 2 |
Shen, L | 2 |
Lau, WY | 5 |
Cheng, S | 3 |
Huang, P | 1 |
Zhou, Y | 8 |
Yang, G | 1 |
Sun, Q | 1 |
Shi, G | 1 |
Liu, Y | 16 |
Qiao, Y | 1 |
Zhou, M | 4 |
Lin, Y | 4 |
Li, W | 4 |
An, C | 1 |
Li, C | 4 |
Xue, L | 1 |
He, J | 2 |
Ren, C | 1 |
Fu, X | 1 |
Lin, X | 3 |
Li, SH | 2 |
Wang, QX | 2 |
Fang, CK | 2 |
Lei, QC | 2 |
Huang, HK | 2 |
Cao, MR | 2 |
Luo, R | 2 |
Deng, JD | 2 |
Jiang, YC | 2 |
Zhao, RC | 2 |
Lu, LH | 2 |
Zou, JW | 2 |
Deng, M | 3 |
Lin, WP | 2 |
Guan, RG | 2 |
Wen, YH | 2 |
Zheng, L | 4 |
Guo, ZX | 2 |
Ling, YH | 2 |
Chen, HW | 2 |
Zhong, C | 2 |
Guo, RP | 2 |
Kawaguchi, T | 1 |
MasodKhooy, MJ | 1 |
Farasat, M | 1 |
Salehi Salmi, M | 1 |
Mirzaei, H | 1 |
Abdel-Hamid, NM | 2 |
ElNakeeb, NA | 1 |
El-Senduny, FF | 1 |
Fu, Y | 1 |
Peng, W | 1 |
Yang, Z | 5 |
Hu, Z | 3 |
Pang, Y | 1 |
Hu, D | 1 |
Du, Z | 1 |
Shen, J | 4 |
Yang, F | 4 |
Min, Y | 1 |
Shi, L | 5 |
Liu, M | 3 |
Wang, K | 5 |
Ke, S | 1 |
Gong, Y | 1 |
Lin, ZP | 1 |
Hu, XL | 1 |
Chen, D | 5 |
Zou, XG | 1 |
Zhong, H | 1 |
Xu, SX | 1 |
Li, XQ | 1 |
Huang, DB | 1 |
Shao, H | 1 |
Li, A | 1 |
Ma, L | 2 |
Zhang, K | 1 |
Gao, W | 1 |
Si, T | 1 |
Zou, Q | 1 |
Guo, Z | 1 |
Li, M | 5 |
Mu, H | 1 |
Xing, W | 1 |
Ji, S | 1 |
Xu, M | 2 |
Cai, C | 1 |
He, X | 3 |
Shi, Y | 5 |
Ma, J | 5 |
Chen, KE | 1 |
Chen, B | 2 |
Liang, H | 5 |
Lu, Y | 2 |
Yang, C | 2 |
Hamaya, S | 1 |
Oura, K | 1 |
Morishita, A | 1 |
Masaki, T | 3 |
Zhang, F | 1 |
Huo, L | 1 |
Brañes, A | 1 |
Karanicolas, P | 1 |
Asahina, Y | 2 |
Takatori, H | 3 |
Nio, K | 3 |
Okada, H | 4 |
Hayashi, T | 6 |
Hashiba, T | 2 |
Suda, T | 2 |
Nishitani, M | 1 |
Sugimoto, S | 1 |
Honda, M | 5 |
Kaneko, S | 7 |
Yamashita, T | 10 |
Wang, S | 1 |
Qiu, Z | 1 |
Zhu, C | 3 |
Zhao, S | 2 |
Qiu, W | 1 |
Lv, J | 2 |
Qi, W | 1 |
Wei, H | 3 |
Pan, J | 2 |
Chen, Z | 7 |
Pan, D | 1 |
Gao, T | 1 |
Huang, M | 3 |
Ou, M | 1 |
Zhong, W | 1 |
Lee, BH | 1 |
Lee, DS | 1 |
Cho, CW | 1 |
Yun, SS | 1 |
Yao, Y | 1 |
Fang, Z | 2 |
Miao, QR | 3 |
Ye, M | 2 |
Jin, X | 2 |
Li, B | 6 |
Wang, C | 6 |
Liao, M | 2 |
Hu, X | 5 |
Yang, M | 4 |
Varshosaz, J | 2 |
Fard, MM | 1 |
Mirian, M | 1 |
Hassanzadeh, F | 2 |
Li, F | 1 |
Wu, N | 1 |
Wei, N | 1 |
Wen, X | 1 |
Ling, S | 2 |
Shan, Q | 1 |
Liu, P | 2 |
Wei, X | 3 |
Ding, W | 1 |
Teng, X | 1 |
Xu, X | 4 |
Palmieri, LJ | 1 |
Dermine, S | 1 |
Coriat, R | 2 |
Kumar, P | 1 |
Agarwal, A | 1 |
Singh, AK | 1 |
Gautam, AK | 1 |
Chakraborti, S | 1 |
Kumar, U | 1 |
Kumar, D | 1 |
Bhattacharya, B | 1 |
Panda, P | 1 |
Saha, B | 1 |
Qidwai, T | 1 |
Maity, B | 1 |
Saha, S | 1 |
Wang, Z | 9 |
Gu, C | 1 |
Lang, Y | 1 |
Zhu, X | 2 |
Yang, H | 1 |
Ma, X | 3 |
Qiu, Y | 2 |
Zhu, L | 2 |
Ma, D | 1 |
Qin, Z | 1 |
Sun, C | 1 |
Shen, X | 1 |
Han, L | 1 |
Fang, X | 1 |
Shen, A | 1 |
Sun, R | 2 |
Dong, C | 4 |
Li, R | 4 |
Chu, H | 1 |
Hao, D | 1 |
Zhao, B | 2 |
Wang, L | 16 |
Alanazi, SA | 2 |
Harisa, GI | 3 |
Badran, MM | 3 |
Haq, N | 1 |
Radwan, AA | 1 |
Kumar, A | 2 |
Shakeel, F | 1 |
Alanazi, FK | 3 |
Hori, A | 1 |
Ohira, R | 1 |
Nakamura, T | 3 |
Kimura, Y | 3 |
Ueda, S | 3 |
Torii, M | 1 |
Kennoki, N | 1 |
Hori, S | 2 |
Terashima, T | 3 |
Toyama, T | 1 |
Shimakami, T | 1 |
Shimizu, R | 1 |
Arai, K | 3 |
Kawaguchi, K | 2 |
Kitamura, K | 1 |
Sakai, Y | 1 |
Mizukoshi, E | 2 |
Mao, J | 1 |
Ding, J | 1 |
Wang, G | 3 |
Xiang, DC | 1 |
Yang, JY | 1 |
Xu, YJ | 1 |
Zhang, S | 5 |
Zhang, CL | 1 |
Cao, W | 3 |
Noordam, L | 1 |
Verstegen, MMA | 1 |
Ma, B | 3 |
Wang, W | 7 |
Bolkestein, M | 1 |
Doukas, M | 1 |
Ma, Z | 1 |
Bruno, M | 1 |
Sprengers, D | 1 |
Kwekkeboom, J | 1 |
van der Laan, LJW | 1 |
Smits, R | 1 |
Peppelenbosch, MP | 1 |
Pan, Q | 2 |
Jiang, K | 1 |
Yin, Z | 1 |
Ding, H | 3 |
Shigesawa, T | 1 |
Maehara, O | 2 |
Suda, G | 2 |
Natsuizaka, M | 2 |
Kimura, M | 4 |
Shimazaki, T | 1 |
Yamamoto, K | 7 |
Yamada, R | 2 |
Kitagataya, T | 1 |
Nakamura, A | 1 |
Suzuki, K | 8 |
Ohara, M | 1 |
Kawagishi, N | 1 |
Umemura, M | 1 |
Nakai, M | 3 |
Sho, T | 2 |
Morikawa, K | 1 |
Ogawa, K | 3 |
Ohnishi, S | 2 |
Sugiyama, M | 1 |
Mizokami, M | 1 |
Takeda, H | 3 |
Sakamoto, N | 2 |
Owen, D | 1 |
Lukovic, J | 1 |
Hosni, A | 1 |
Crane, CH | 1 |
Hong, TS | 1 |
Dawson, LA | 1 |
Velec, M | 1 |
Lawrence, TS | 2 |
Jia, Y | 2 |
Peng, L | 1 |
Xiang, Y | 1 |
Huang, W | 3 |
Huang, C | 10 |
Long, J | 1 |
Tang, S | 2 |
He, DX | 3 |
Tan, XW | 2 |
Yu, CY | 3 |
Basu, A | 1 |
Dydowiczová, A | 1 |
Trosko, JE | 1 |
Bláha, L | 1 |
Babica, P | 1 |
Goto, Y | 1 |
Hisaka, T | 2 |
Sakai, H | 1 |
Takagi, K | 1 |
Fukutomi, S | 1 |
Akagi, Y | 1 |
Okuda, K | 10 |
Song, X | 1 |
He, Y | 5 |
Han, M | 1 |
Shao, Z | 1 |
Kobayashi, K | 6 |
Higai, K | 1 |
Mukozu, T | 3 |
Matsui, D | 3 |
Amanuma, M | 1 |
Yoshimine, N | 1 |
Ogino, Y | 1 |
Matsui, T | 5 |
Wakui, N | 4 |
Shinohara, M | 3 |
Momiyama, K | 7 |
Daido, Y | 1 |
Nagai, H | 11 |
Igarashi, Y | 5 |
Liu, KC | 1 |
Hao, YH | 1 |
Lv, WF | 1 |
Jia, WD | 1 |
Ji, CS | 1 |
Zhou, CZ | 1 |
Cheng, DL | 1 |
Xu, SB | 1 |
Gao, ZG | 1 |
Su, MX | 1 |
Shi, CS | 1 |
Jilek, JL | 1 |
Tu, MJ | 1 |
Yu, AM | 1 |
Xu, D | 2 |
Wu, J | 4 |
Xie, M | 1 |
Tang, R | 1 |
Cheng, C | 1 |
Chen, L | 4 |
Lin, S | 1 |
Luo, X | 5 |
Zheng, J | 2 |
Changou, CA | 1 |
Shiah, HS | 1 |
Chen, LT | 1 |
Luh, F | 1 |
Liu, SH | 2 |
Cheng, YC | 2 |
Yen, Y | 2 |
Yu, Z | 1 |
Sun, D | 5 |
Bhat, SS | 1 |
Mukherjee, D | 1 |
Sukharamwala, P | 1 |
Dehuri, R | 1 |
Murali, A | 1 |
Teja, BV | 1 |
Mei, N | 1 |
Zhao, N | 2 |
Tian, T | 2 |
Jiao, M | 1 |
Ding, WB | 1 |
Ning, Q | 3 |
Xia, Z | 1 |
Song, J | 3 |
Zhou, XW | 1 |
Chen, XW | 1 |
Zhu, Y | 1 |
Ke, KB | 1 |
Xia, ZK | 1 |
Li, HJ | 1 |
Su, R | 3 |
Zhou, FM | 1 |
Chen, R | 2 |
Wu, SG | 1 |
Zhao, H | 2 |
Gu, P | 1 |
Leung, KS | 1 |
Wong, MH | 1 |
Lu, G | 1 |
Zhang, JY | 1 |
Jiang, BH | 1 |
Qiu, JG | 1 |
Shi, XN | 1 |
Lin, MC | 1 |
Hu, B | 1 |
Sun, YF | 1 |
Huang, XW | 2 |
Cheng, JW | 1 |
Huang, A | 1 |
Zeng, HY | 1 |
Qiu, SJ | 1 |
Cao, Y | 1 |
Fan, J | 9 |
Zhou, J | 9 |
Yang, XR | 1 |
Hsu, SJ | 1 |
Chen, MP | 1 |
Zhao, ZY | 1 |
Yin, X | 2 |
Ge, NL | 4 |
Wang, YH | 3 |
Luo, JF | 1 |
Ren, ZG | 4 |
Chen, RX | 2 |
Elzayat, E | 1 |
Alomrani, AH | 1 |
Al Meanazel, OT | 1 |
Al Meanazel, AT | 1 |
Gottlieb, S | 1 |
O'Grady, C | 1 |
Gliksberg, A | 1 |
Kent, P | 1 |
Zhu, Q | 1 |
Hu, H | 2 |
Zhu, H | 4 |
Yang, B | 3 |
He, Q | 1 |
Yu, L | 4 |
Zeng, S | 2 |
Han, S | 1 |
Choi, HJ | 2 |
Beom, SH | 1 |
Kim, HR | 3 |
Lee, H | 1 |
Lee, JS | 1 |
Lee, HW | 3 |
Park, JY | 13 |
Kim, SU | 6 |
Kim, DY | 10 |
Ahn, SH | 11 |
Han, KH | 16 |
Seong, J | 10 |
Won, JY | 2 |
Kim, BK | 5 |
Qin, S | 5 |
Ren, Z | 4 |
Xiong, J | 1 |
Meng, Z | 1 |
Zou, J | 1 |
Cao, J | 2 |
Gui, S | 1 |
Chu, X | 1 |
Han, X | 1 |
Li, J | 16 |
Lai, J | 1 |
Deng, H | 4 |
Wang, H | 10 |
Hu, Y | 3 |
Zhao, Z | 2 |
Xie, Y | 3 |
Liu, H | 1 |
Jin, M | 1 |
Kong, L | 2 |
Han, Y | 1 |
Shiohira, H | 1 |
Fukunaga, K | 2 |
Tayag, JCS | 1 |
Tamashiro, Y | 1 |
Mushiroda, T | 1 |
Nakamura, K | 5 |
Harding, JJ | 2 |
Yang, TS | 5 |
Feng, YH | 2 |
Yen, CJ | 1 |
Ho, CL | 1 |
Huang, WT | 2 |
El Dika, I | 1 |
Tan, B | 1 |
Cohen, SA | 1 |
Meyer, T | 3 |
Sarker, D | 1 |
Lee, DW | 1 |
Ryoo, BY | 1 |
Lim, HY | 3 |
Johnston, A | 2 |
Bomalaski, JS | 1 |
O'Reilly, EM | 2 |
Abou-Alfa, GK | 2 |
Nagamatsu, H | 4 |
Ogo, E | 1 |
Ikeda, M | 7 |
Okusaka, T | 5 |
Sato, Y | 5 |
Furuse, J | 2 |
Mitsunaga, S | 1 |
Ueno, H | 5 |
Morizane, C | 4 |
Inaba, Y | 1 |
Kobayashi, T | 4 |
Arai, Y | 2 |
Nanda, A | 1 |
Suyila, Q | 1 |
Xian, L | 1 |
Xiulan, S | 1 |
Grbčić, P | 1 |
Tomljanović, I | 1 |
Klobučar, M | 1 |
Kraljević Pavelić, S | 1 |
Lučin, K | 1 |
Sedić, M | 1 |
Luo, N | 2 |
Tian, Y | 3 |
Yin, H | 2 |
Xiao, C | 1 |
Sheng, J | 1 |
Li, Y | 15 |
Tang, B | 4 |
Babaei, M | 1 |
Abnous, K | 1 |
Taghdisi, SM | 1 |
Amel Farzad, S | 1 |
Peivandi, MT | 1 |
Ramezani, M | 1 |
Alibolandi, M | 1 |
Yang, S | 4 |
Wang, XQ | 1 |
Thongkum, A | 1 |
Wu, C | 1 |
Li, YY | 1 |
Wangpaichitr, M | 1 |
Navasumrit, P | 1 |
Parnlob, V | 1 |
Sricharunrat, T | 1 |
Bhudhisawasdi, V | 2 |
Ruchirawat, M | 1 |
Savaraj, N | 1 |
Kong, Y | 4 |
Mu, L | 3 |
Pan, T | 2 |
Lin, A | 1 |
Wu, P | 4 |
Yuan, XF | 1 |
Li, ZZ | 1 |
Bao, SQ | 1 |
Zhang, XL | 2 |
Yang, YY | 1 |
Fan, DM | 1 |
Zhang, YZ | 1 |
Wu, CX | 1 |
Guo, HX | 1 |
Zhang, YJ | 1 |
Ye, Z | 1 |
Xiong, DS | 1 |
Oishi, N | 1 |
Sunagozaka, H | 2 |
Hara, Y | 2 |
Yoshida, M | 1 |
Shirasaki, T | 1 |
Miyanouchi, K | 1 |
Lian, Y | 1 |
Gu, L | 1 |
Gao, Z | 6 |
Lee, EJ | 1 |
Yang, SH | 1 |
Kim, KJ | 2 |
Cha, H | 1 |
Lee, SJ | 3 |
Kim, JH | 5 |
Chun, KH | 1 |
Hsiao, JH | 1 |
Tsai, CC | 1 |
Liang, TJ | 1 |
Chiang, CL | 1 |
Liang, HL | 3 |
Chen, IS | 1 |
Chen, YC | 3 |
Chang, PM | 1 |
Chou, NH | 1 |
Wang, BW | 1 |
Miyauchi, Y | 1 |
Yasuchika, K | 2 |
Fukumitsu, K | 2 |
Ishii, T | 2 |
Ogiso, S | 2 |
Minami, T | 1 |
Kojima, H | 1 |
Yamaoka, R | 1 |
Katayama, H | 2 |
Kawai, T | 2 |
Yoshitoshi-Uebayashi, EY | 1 |
Kita, S | 2 |
Yasuda, K | 2 |
Sasaki, N | 1 |
Uemoto, S | 3 |
Song, JE | 1 |
Jung, KS | 1 |
Song, K | 1 |
He, C | 1 |
Jing, Z | 1 |
Xie, J | 1 |
Ma, W | 1 |
Guo, XL | 3 |
Hu, F | 3 |
Fang, JM | 1 |
Zhu, ZΖ | 1 |
Wei, LΧ | 1 |
Xu, Q | 1 |
Kuramoto, K | 1 |
Beppu, T | 5 |
Nitta, H | 2 |
Imai, K | 3 |
Masuda, T | 2 |
Miyata, T | 2 |
Koga, Y | 1 |
Kitano, Y | 1 |
Kaida, T | 1 |
Nakagawa, S | 2 |
Okabe, H | 2 |
Hayashi, H | 5 |
Hashimoto, D | 1 |
Yamashita, YI | 2 |
Chikamoto, A | 3 |
Kikuchi, K | 1 |
Baba, H | 6 |
Kodama, K | 1 |
Kawaoka, T | 9 |
Aikata, H | 10 |
Uchikawa, S | 1 |
Nishida, Y | 1 |
Inagaki, Y | 2 |
Hatooka, M | 4 |
Morio, K | 4 |
Nakahara, T | 3 |
Murakami, E | 3 |
Tsuge, M | 2 |
Hiramatsu, A | 8 |
Imamura, M | 6 |
Kawakami, Y | 7 |
Masaki, K | 2 |
Honda, Y | 3 |
Mori, N | 6 |
Takaki, S | 8 |
Tsuji, K | 5 |
Kohno, H | 10 |
Moriya, T | 4 |
Nonaka, M | 2 |
Hyogo, H | 3 |
Aisaka, Y | 2 |
Kimura, T | 5 |
Nagata, Y | 1 |
Chayama, K | 10 |
Cai, X | 1 |
Fujisaki, S | 1 |
Takashina, M | 1 |
Tomita, R | 1 |
Sakurai, K | 3 |
Takayama, T | 3 |
Dong, L | 3 |
Bai, C | 1 |
Long, H | 1 |
Lin, Z | 1 |
Duan, B | 1 |
Guo, Y | 5 |
Zhou, R | 1 |
Bie, B | 1 |
Ettrich, TJ | 1 |
Ebert, M | 1 |
Lorenzen, S | 1 |
Moehler, M | 2 |
Vogel, A | 1 |
Witkowski, L | 1 |
Seufferlein, T | 1 |
Reinacher-Schick, A | 1 |
Liu, T | 1 |
Lu, W | 1 |
Zheng, F | 2 |
Long, Q | 1 |
Qiu, H | 1 |
Ge, Q | 1 |
Yu, X | 1 |
Luo, M | 2 |
Deng, W | 2 |
Li, L | 1 |
Ji, DG | 1 |
Guan, LY | 1 |
Ma, F | 1 |
Liu, HY | 1 |
Jia, QA | 1 |
Kadel, D | 1 |
Zhang, XF | 1 |
Zhang, QB | 1 |
Li, JW | 1 |
Huang, CZ | 1 |
Li, JH | 2 |
Yuan, JH | 1 |
Chen, QH | 1 |
Zhang, WF | 1 |
Xu, ZS | 1 |
Liu, YP | 1 |
Zhan, MX | 1 |
Lu, LG | 1 |
Ke, M | 1 |
Dong, J | 1 |
Lv, Y | 1 |
Wu, R | 1 |
Kobayashi, S | 15 |
Shiba, S | 1 |
Yoshida, Y | 4 |
Yamada, I | 1 |
Iwadou, S | 1 |
Horiguchi, S | 2 |
Takahashi, H | 4 |
Suzuki, E | 2 |
Moriguchi, M | 1 |
Otsuka, T | 1 |
Asagi, A | 1 |
Kojima, Y | 2 |
Takada, R | 1 |
Mizuno, N | 1 |
Ueno, M | 1 |
Awai, K | 2 |
Waki, K | 6 |
Nagaoki, Y | 2 |
Tamura, T | 1 |
Amano, H | 1 |
Katamura, Y | 3 |
Do, RK | 1 |
Dika, IE | 1 |
Hollywood, E | 1 |
Uhlitskykh, K | 1 |
Valentino, E | 1 |
Wan, P | 1 |
Hamilton, C | 1 |
Feng, X | 1 |
Bomalaski, J | 1 |
Li, CF | 1 |
Choi, JH | 1 |
Chung, WJ | 5 |
Bae, SH | 11 |
Song, DS | 3 |
Song, MJ | 6 |
Kim, YS | 5 |
Yim, HJ | 6 |
Jung, YK | 1 |
Suh, SJ | 2 |
Cho, SB | 3 |
Hatano, E | 2 |
Yamaue, H | 1 |
Yamamoto, M | 3 |
Wu, L | 4 |
Pan, C | 2 |
R Ebrahim, A | 1 |
El-Mesery, M | 1 |
El-Karef, A | 1 |
Eissa, LA | 1 |
Cheng, J | 1 |
Qian, D | 1 |
Ding, X | 2 |
Song, T | 1 |
Cai, M | 1 |
Zhao, J | 5 |
Pang, Q | 1 |
Hao, X | 2 |
Yuan, Z | 1 |
Cui, X | 1 |
Zhao, C | 3 |
Yao, X | 4 |
Qian, B | 1 |
Su, C | 4 |
Ren, Y | 1 |
Yao, Z | 2 |
Gao, X | 3 |
Ni, W | 1 |
Ji, Y | 2 |
Sun, S | 1 |
Jian, X | 1 |
Xiao, X | 1 |
Cui, R | 1 |
Miao, R | 1 |
Dong, Y | 3 |
Fan, H | 1 |
Ren, L | 1 |
Niu, W | 1 |
Qu, K | 2 |
Liu, YF | 1 |
Ye, PJ | 2 |
Gao, P | 2 |
Li, ZP | 2 |
Tang, SY | 1 |
Tang, SS | 2 |
Xiao, D | 1 |
Zhan, P | 1 |
AlQahtani, SA | 1 |
AlGhamdi, KM | 1 |
Salem-Bekhit, MM | 1 |
Ahmad, SF | 1 |
Byun, HK | 1 |
Kim, HJ | 1 |
Im, YR | 1 |
Imamura, YU | 1 |
Fukubayashi, K | 1 |
Ishiko, T | 3 |
Yao, J | 2 |
Pan, Z | 1 |
Cui, ZG | 1 |
Zakki, SA | 1 |
Feng, Q | 1 |
Sun, L | 1 |
Feril, LB | 1 |
Inadera, H | 1 |
Liu, XY | 2 |
Liu, ZH | 1 |
Chai, Z | 1 |
Asano, A | 1 |
Nakagawa, K | 3 |
Kobayashi, M | 11 |
Zou, R | 1 |
Fang, W | 1 |
Tan, G | 1 |
Le, Y | 1 |
Goyal, L | 1 |
Qadan, M | 1 |
Zhu, AX | 2 |
Burki, TK | 1 |
Sung, PS | 1 |
Yang, K | 2 |
Oh, JS | 2 |
Chun, HJ | 6 |
Nam, HC | 1 |
Jang, JW | 5 |
Choi, JY | 9 |
Yoon, SK | 9 |
Dou, C | 1 |
Roberts, L | 1 |
Xiao, Z | 1 |
Ko, HL | 1 |
Goh, EH | 1 |
Wang, B | 3 |
Ren, EC | 1 |
Sakabe, T | 1 |
Tsuchiya, H | 1 |
Kanki, K | 1 |
Azumi, J | 1 |
Gonda, K | 1 |
Mizuta, Y | 1 |
Yamada, D | 2 |
Wada, H | 27 |
Shomori, K | 1 |
Nagano, H | 45 |
Shiota, G | 1 |
Katsura, Y | 1 |
Murakami, M | 8 |
Akita, H | 3 |
Hama, N | 2 |
Kawamoto, K | 4 |
Marubashi, S | 25 |
Eguchi, H | 19 |
Tanemura, M | 10 |
Umeshita, K | 35 |
Doki, Y | 16 |
Mori, M | 17 |
Shan, L | 1 |
Tan, Y | 2 |
Qian, X | 1 |
Xia, J | 2 |
Wang, R | 2 |
Chen, C | 2 |
Yang, Q | 2 |
Miele, L | 1 |
Ran, L | 1 |
Fushiya, N | 1 |
Takagi, I | 1 |
Nishino, H | 1 |
Akizuki, S | 1 |
Ohnishi, A | 1 |
Lin, JJ | 1 |
Jiang, XF | 1 |
Jin, XJ | 1 |
Lu, LJ | 1 |
Bao, LW | 1 |
Kanekawa, T | 3 |
Kanayama, M | 7 |
Ishii, K | 4 |
Sumino, Y | 10 |
El Bouzidi, L | 1 |
Mahiou-Leddet, V | 1 |
Bun, SS | 1 |
Larhsini, M | 1 |
Abbad, A | 1 |
Markouk, M | 1 |
Fathi, M | 1 |
Boudon, M | 1 |
Ollivier, E | 1 |
Bekkouche, K | 1 |
Miao, L | 1 |
Lv, C | 1 |
Sun, H | 2 |
Wei, S | 1 |
Jiao, B | 1 |
Wu, K | 1 |
Yan, W | 1 |
Hu, L | 1 |
Yuan, J | 2 |
Jing, K | 1 |
Guo, M | 2 |
Walter, H | 1 |
Thomas, AL | 1 |
Kaseb, AO | 1 |
Shindoh, J | 1 |
Patt, YZ | 7 |
Roses, RE | 1 |
Zimmitti, G | 1 |
Lozano, RD | 3 |
Hassan, MM | 3 |
Hassabo, HM | 1 |
Curley, SA | 4 |
Aloia, TA | 1 |
Abbruzzese, JL | 1 |
Vauthey, JN | 4 |
Abdel-Rahman, O | 1 |
Abdel-Wahab, M | 1 |
Shaker, M | 1 |
Abdel-Wahab, S | 1 |
Elbassiony, M | 1 |
Ellithy, M | 1 |
Ahn, JS | 1 |
Jeon, JR | 1 |
Yoo, HS | 1 |
Park, TK | 1 |
Park, CK | 1 |
Sinn, DH | 1 |
Paik, SW | 1 |
Zheng, AH | 1 |
Wang, ZP | 3 |
Wang, ZX | 1 |
Wu, LC | 1 |
Jia, Q | 3 |
Zhang, YY | 1 |
Zhao, L | 6 |
Sha, YY | 1 |
Zhao, Q | 2 |
Zhu, BB | 1 |
Lu, ZJ | 1 |
You, QD | 2 |
Guo, QL | 2 |
Deng, L | 1 |
Shen, H | 2 |
He, SL | 1 |
Sun, XJ | 1 |
Zhu, XJ | 1 |
Liu, LM | 2 |
Dong, JC | 1 |
Lee, SW | 1 |
Kim, HY | 2 |
Lee, YJ | 2 |
Lee, HG | 1 |
Sinn, M | 1 |
Nicolaou, A | 1 |
Ricke, J | 1 |
Podrabsky, P | 1 |
Seehofer, D | 1 |
Gebauer, B | 1 |
Pech, M | 1 |
Neuhaus, P | 1 |
Dörken, B | 1 |
Riess, H | 1 |
Hildebrandt, B | 1 |
Yeh, CT | 4 |
Liang, KH | 3 |
Lin, CC | 3 |
Chang, ML | 3 |
Hsu, CL | 1 |
Hung, CF | 1 |
Bai, Y | 2 |
Thongprasert, S | 1 |
Chao, Y | 4 |
Kang, WK | 2 |
Lee, JH | 4 |
Jiang, H | 2 |
Dong, Q | 1 |
Shi, B | 2 |
Gao, H | 1 |
Kong, J | 1 |
Nouso, K | 3 |
Miyahara, K | 2 |
Uchida, D | 2 |
Kuwaki, K | 5 |
Izumi, N | 1 |
Omata, M | 5 |
Ichida, T | 2 |
Kudo, M | 4 |
Ku, Y | 3 |
Kokudo, N | 1 |
Sakamoto, M | 2 |
Nakashima, O | 1 |
Matsui, O | 2 |
Matsuyama, Y | 1 |
Ma, T | 1 |
Lv, X | 1 |
Xu, T | 1 |
Hu, T | 2 |
Li, KC | 1 |
Zeng, XY | 1 |
Kuang, CX | 1 |
Jiang, YB | 1 |
Dai, ZY | 1 |
Tan-Shalaby, J | 1 |
Yoon, EL | 1 |
Yeon, JE | 1 |
Lee, HJ | 3 |
Kang, SH | 1 |
Kang, K | 1 |
Yoo, YJ | 1 |
Byun, KS | 1 |
Cheng, M | 3 |
He, B | 5 |
Xu, H | 6 |
Han, J | 6 |
Witort, E | 1 |
Lulli, M | 1 |
Carloni, V | 1 |
Capaccioli, S | 1 |
Fan, F | 1 |
Geng, L | 1 |
Zhu, M | 1 |
Tsao, SW | 2 |
Man, K | 1 |
Feng, Y | 2 |
Oh, MJ | 1 |
Lee, SH | 2 |
Gu, W | 3 |
Fang, FF | 2 |
Huang, F | 1 |
Cheng, BB | 3 |
Tanaka, K | 5 |
Yabushita, Y | 1 |
Kumamoto, T | 2 |
Matsuo, K | 2 |
Taguri, M | 1 |
Endo, I | 2 |
Pascal, J | 1 |
Ashley, CE | 1 |
Brocato, TA | 1 |
Butner, JD | 1 |
Carnes, EC | 1 |
Koay, EJ | 1 |
Brinker, CJ | 1 |
Cristini, V | 1 |
Nakadai, E | 1 |
Tonouchi, A | 1 |
Fujita, Y | 1 |
Nakamura, J | 1 |
Miyazaki, M | 2 |
Brandi, G | 1 |
de Rosa, F | 1 |
Agostini, V | 1 |
di Girolamo, S | 1 |
Andreone, P | 1 |
Bolondi, L | 1 |
Serra, C | 1 |
Sama, C | 1 |
Golfieri, R | 1 |
Gramenzi, A | 1 |
Cucchetti, A | 1 |
Pinna, AD | 1 |
Trevisani, F | 1 |
Biasco, G | 1 |
Takeda, K | 2 |
Nojiri, K | 1 |
Mori, R | 2 |
Taniguchi, K | 1 |
Matsuyama, R | 1 |
Ueda, M | 3 |
Akiyama, H | 1 |
Ichikawa, Y | 1 |
Ota, M | 1 |
Tanaka, S | 2 |
Matsumura, S | 1 |
Murakata, A | 1 |
Ban, D | 1 |
Ochiai, T | 2 |
Irie, T | 2 |
Kudo, A | 1 |
Nakamura, N | 1 |
Tanabe, M | 1 |
Arii, S | 4 |
Tsuda, Y | 1 |
Tomimaru, Y | 8 |
Terai, S | 3 |
Tai, K | 1 |
Kanbara, Y | 1 |
Qin, Y | 1 |
Bao, H | 1 |
Yin, M | 1 |
Wu, S | 3 |
Yan, C | 1 |
Fan, D | 1 |
Xiong, D | 1 |
Cheng, Z | 1 |
Jin, Y | 2 |
Liang, X | 1 |
Dai, Z | 2 |
Lee, JE | 1 |
You, YK | 1 |
Lee, MA | 1 |
Zhang, SS | 2 |
Zhao, QD | 2 |
Zong, C | 1 |
Ye, F | 2 |
Guo, SW | 1 |
Zhang, JW | 1 |
Wu, MC | 2 |
Wei, LX | 2 |
Zha, Y | 1 |
Gan, P | 1 |
Yao, Q | 1 |
Ran, FM | 1 |
Tan, J | 1 |
Calderaro, J | 1 |
Azoulay, D | 1 |
Zafrani, ES | 1 |
Okur, A | 1 |
Eser, EP | 1 |
Yilmaz, G | 1 |
Dalgiç, A | 1 |
Akdemir, ÜÖ | 1 |
Oğuz, A | 1 |
Karadeniz, C | 1 |
Akyol, G | 1 |
Demiroğullari, B | 1 |
Boyunağa, Ö | 1 |
Pinarli, FG | 1 |
Sui, W | 1 |
Wang, PP | 1 |
Xu, DJ | 2 |
Wang, WP | 1 |
Xu, WK | 1 |
Dangi, R | 1 |
Hurkat, P | 1 |
Jain, A | 2 |
Shilpi, S | 1 |
Gulbake, A | 1 |
Jain, SK | 1 |
Tang, J | 1 |
Tao, ZH | 1 |
Wan, JL | 1 |
Liu, DL | 1 |
Cui, JF | 1 |
Sun, HC | 2 |
Wu, WZ | 2 |
Ogasawara, S | 2 |
Chiba, T | 2 |
Ooka, Y | 1 |
Kanogawa, N | 1 |
Motoyama, T | 1 |
Tawada, A | 1 |
Kanai, F | 2 |
Yokosuka, AO | 1 |
Tang, H | 4 |
Zhang, P | 2 |
Xiang, Q | 5 |
Yin, J | 5 |
Lei, X | 7 |
Wang, F | 4 |
Dai, W | 3 |
Shen, M | 1 |
Cheng, P | 1 |
Zheng, Y | 4 |
Lu, J | 3 |
Zhu, R | 1 |
Guo, C | 3 |
Tsai, WL | 1 |
Lai, KH | 2 |
Hsu, PI | 2 |
Chan, HH | 1 |
Chen, WC | 1 |
Yu, HC | 2 |
Tsay, FW | 1 |
Wang, HM | 1 |
Tsai, HC | 1 |
Cheng, JS | 2 |
Cui, W | 1 |
Jiang, JX | 1 |
Gao, S | 2 |
Pan, YZ | 1 |
Sun, CY | 1 |
Wang, SS | 1 |
Xie, X | 2 |
Wong, CS | 1 |
Choi, Y | 1 |
Fung, MC | 1 |
Zhang, N | 1 |
Ren, M | 1 |
Ye, L | 1 |
Ren, S | 1 |
Xu, K | 2 |
Jang, JY | 1 |
Park, SY | 3 |
Yang, JM | 1 |
Wang, JX | 1 |
Zhang, LY | 1 |
Wang, DM | 1 |
Yuan, Y | 2 |
Cai, H | 1 |
Yang, XJ | 1 |
Guo, TK | 1 |
Chen, YR | 1 |
Song, L | 1 |
Zhao, DY | 1 |
Guo, B | 3 |
Song, Y | 3 |
Goldstein, R | 1 |
Yu, D | 1 |
Gillmore, R | 1 |
Thirlwell, C | 1 |
O'Donoghue, P | 1 |
Mayer, A | 1 |
Liang, J | 2 |
Liang, L | 1 |
Wu, G | 2 |
Rau, KM | 1 |
Jian, Z | 1 |
Magata, H | 1 |
Kondo, K | 1 |
Otani, K | 1 |
Yano, K | 1 |
Yonei, A | 1 |
Akasu, I | 1 |
Marutsuka, H | 1 |
Fukushima, G | 1 |
Kataoka, H | 1 |
Hua, HW | 1 |
Jiang, F | 1 |
Huang, Q | 1 |
Liao, ZJ | 1 |
Ding, G | 1 |
Lin, CL | 1 |
Chien, RN | 1 |
Yeh, C | 1 |
Hsu, CW | 2 |
Tsauo, J | 1 |
Jia, K | 1 |
Feng, T | 1 |
Xu, F | 1 |
Lee, IJ | 2 |
Kim, JW | 4 |
Kim, JK | 5 |
Kim, KS | 2 |
Choi, JS | 4 |
Park, YN | 2 |
Wang, T | 3 |
Pan, X | 3 |
Kim, JB | 2 |
Ahn, YH | 1 |
Jee, HG | 1 |
Yu, SJ | 1 |
Lee, HS | 2 |
Lee, M | 2 |
Yoon, JH | 2 |
Kim, YJ | 2 |
Hu, XY | 1 |
Liang, JY | 1 |
Guo, XJ | 1 |
Guo, YB | 1 |
Hirata, H | 1 |
Sugimachi, K | 7 |
Takahashi, Y | 1 |
Sakimura, S | 1 |
Uchi, R | 1 |
Kurashige, J | 1 |
Takano, Y | 1 |
Nanbara, S | 1 |
Komatsu, H | 1 |
Saito, T | 1 |
Shinden, Y | 1 |
Iguchi, T | 1 |
Atsumi, K | 1 |
Sakamoto, K | 2 |
Doi, T | 1 |
Hirakawa, M | 1 |
Honda, H | 2 |
Mimori, K | 2 |
Melichar, B | 1 |
Dvorak, J | 1 |
Ferko, A | 1 |
Kamaradova, K | 1 |
Krajina, A | 1 |
Liu, W | 2 |
Song, W | 1 |
Zuo, CH | 1 |
Xia, M | 1 |
Liu, JS | 1 |
Qiu, XX | 1 |
Xu, RC | 1 |
Liu, HC | 1 |
Li, JL | 1 |
Li, YG | 1 |
Li, QL | 1 |
Xiao, H | 1 |
Hong, Y | 1 |
Wang, XH | 1 |
Zhu, HZ | 2 |
Wu, QF | 1 |
Burns, M | 1 |
Yan, Z | 3 |
Qu, P | 1 |
Yuan, P | 2 |
Xing, J | 1 |
Zhao, XL | 1 |
Shang, SQ | 1 |
Shen, HQ | 1 |
Chen, X | 6 |
Um, SH | 3 |
Hwang, JS | 5 |
Eun, JR | 2 |
Huang, WJ | 1 |
Wang, HY | 1 |
Wang, YF | 1 |
Peng, BG | 2 |
Yan, Y | 1 |
Hou, N | 1 |
So, S | 2 |
Kido, M | 1 |
Fukumoto, T | 2 |
Takebe, A | 1 |
Tanaka, M | 11 |
Kinoshita, H | 4 |
Kuramitsu, K | 1 |
Tsugawa, D | 1 |
Fukushima, K | 1 |
Urade, T | 1 |
Yoshida, T | 8 |
Asari, S | 1 |
Okazaki, T | 1 |
Shinzeki, M | 1 |
Matsumoto, I | 1 |
Ajiki, T | 1 |
Xie, N | 2 |
Onishi, H | 2 |
Nakamura, S | 3 |
Katsui, K | 1 |
Wada, N | 2 |
Morimoto, Y | 3 |
Takeuchi, Y | 3 |
Yasunaka, T | 1 |
Miyake, Y | 2 |
Shiraha, H | 5 |
Takaki, A | 4 |
Kobayashi, Y | 2 |
Sakaguchi, K | 3 |
Kanazawa, S | 1 |
Yoshitoshi, EY | 1 |
Mizumoto, M | 1 |
Xie, XY | 1 |
Le, F | 1 |
Li, LX | 2 |
Gan, YH | 3 |
Zhang, JB | 2 |
Xue, TC | 1 |
Xia, JL | 3 |
Zhang, BH | 2 |
Ye, SL | 5 |
Ogino, YU | 1 |
Yu, F | 1 |
Brock, MV | 1 |
Tao, Q | 1 |
Herman, JG | 1 |
Liang, P | 1 |
Saeki, I | 1 |
Yamasaki, T | 3 |
Tanabe, N | 1 |
Iwamoto, T | 1 |
Matsumoto, T | 1 |
Urata, Y | 1 |
Hidaka, I | 1 |
Ishikawa, T | 3 |
Takami, T | 2 |
Yamamoto, N | 2 |
Uchida, K | 1 |
Sakaida, I | 2 |
Zhao, RL | 1 |
Chen, MJ | 1 |
Zhao, FM | 1 |
Xu, DQ | 1 |
Zhou, KF | 1 |
Liao, B | 1 |
Morio, R | 1 |
Fukuhara, T | 1 |
Naeshiro, N | 2 |
Miyaki, D | 3 |
Takahashi, S | 9 |
Shakado, S | 3 |
Iwata, K | 3 |
Tsuchiya, N | 1 |
Kunimoto, H | 2 |
Yotsumoto, K | 2 |
Fukunaga, A | 2 |
Kuno, S | 1 |
Tanaka, T | 4 |
Iwashita, H | 2 |
Hirano, G | 2 |
Yokoyama, K | 2 |
Morihara, D | 2 |
Nishizawa, S | 1 |
Takeyama, Y | 2 |
Irie, M | 2 |
Sohda, T | 2 |
Kora, S | 1 |
Yoshimitsu, K | 1 |
Sakisaka, S | 2 |
Mukouzu, T | 1 |
Seo, JH | 1 |
He, LQ | 1 |
Wu, YX | 1 |
Wang, XS | 2 |
Zu, X | 2 |
Peng, C | 1 |
Dai, HY | 1 |
Chen, HY | 1 |
Lai, WC | 1 |
Hung, MC | 1 |
Li, LY | 1 |
Zhang, YF | 1 |
Yang, HY | 1 |
Xu, HF | 2 |
Lu, X | 2 |
Sang, XT | 1 |
Zhong, SX | 1 |
Mao, YL | 1 |
Motawi, TK | 1 |
El-Boghdady, NA | 1 |
El-Sayed, AM | 1 |
Helmy, HS | 1 |
Fujita, N | 1 |
Nishie, A | 1 |
Asayama, Y | 1 |
Ishigami, K | 1 |
Ushijima, Y | 1 |
Takayama, Y | 1 |
Okamoto, D | 1 |
Morita, K | 1 |
Shirabe, K | 2 |
Koto, K | 1 |
Kubo, Y | 2 |
Oda, Y | 1 |
Gu, YJ | 1 |
Li, HD | 1 |
He, WB | 1 |
Rui, L | 1 |
Zheng, HC | 1 |
Su, RJ | 1 |
Zhang, PJ | 1 |
Guo, JH | 1 |
Yang, RJ | 1 |
Qiao, M | 1 |
Zhao, X | 2 |
Cai, D | 1 |
He, K | 1 |
Chang, S | 1 |
Tong, D | 1 |
Lee, S | 1 |
Park, KW | 1 |
Seo, CJ | 1 |
Yun, DY | 1 |
Kim, MK | 1 |
Kim, BS | 2 |
Han, YS | 1 |
Oh, HK | 1 |
Lee, CH | 1 |
Yuan, S | 1 |
He, S | 2 |
Niu, JX | 1 |
Guo, HP | 1 |
Gan, HM | 1 |
Bao, LD | 1 |
Ren, JJ | 1 |
Gao, Q | 2 |
Shen, G | 2 |
Sun, ZP | 1 |
Shi, LH | 1 |
Zhang, XR | 1 |
Duan, Y | 1 |
Xu, WF | 1 |
Dai, G | 1 |
Wang, XJ | 1 |
Bi, T | 1 |
Qian, L | 1 |
Sumie, S | 8 |
Tajiri, N | 1 |
Aino, H | 2 |
Satani, M | 1 |
Matsugaki, S | 1 |
Kurogi, J | 3 |
Kajiwara, M | 2 |
Maeno, H | 1 |
Kawamoto, S | 1 |
Munechika, T | 1 |
Yonemitsu, K | 1 |
Nomi, M | 1 |
Okamoto, T | 1 |
Nagao, S | 1 |
Yanagisawa, J | 1 |
Long, F | 1 |
Liang, R | 3 |
Shao, S | 1 |
Kim, BH | 2 |
Kim, HK | 1 |
Shin, JK | 1 |
Hong, HJ | 1 |
Park, H | 1 |
Hwang, SG | 1 |
Rim, KS | 1 |
Qi, H | 1 |
Sun, MZ | 1 |
Feng, C | 1 |
Luo, Q | 1 |
Song, G | 1 |
Farmer, RW | 1 |
Martin, RC | 1 |
Kataoka, J | 1 |
Sawahara, H | 1 |
Nagahara, T | 1 |
Iwamuro, M | 1 |
Morimoto, H | 1 |
Yagi, T | 1 |
Teryukova, NP | 1 |
Pogodina, ON | 1 |
Ivanov, VA | 1 |
Lv, G | 1 |
Li, E | 1 |
Yamashita, M | 1 |
Ogawa, H | 1 |
Noda, T | 13 |
Asaoka, T | 1 |
Gotoh, K | 1 |
Fan, L | 1 |
Qi, F | 1 |
Ou, S | 1 |
Yi, X | 1 |
Ni, B | 1 |
Zheng, Z | 1 |
Ma, Y | 1 |
Zou, X | 1 |
Lei, L | 1 |
Wu, D | 2 |
Tang, C | 1 |
Feng, W | 1 |
Bao, Y | 1 |
Dong, X | 1 |
Dai, Y | 1 |
Wu, WR | 1 |
Zhang, R | 5 |
Shi, XD | 1 |
Yi, C | 1 |
Xu, LB | 2 |
Lin, JW | 1 |
Huang, YH | 1 |
Han, Z | 1 |
Yuan, F | 1 |
Qiao, T | 1 |
Shen, Q | 1 |
Peng, F | 1 |
Han, DH | 1 |
Joo, DJ | 1 |
Kim, MS | 2 |
Choi, GH | 1 |
Kim, SI | 1 |
Deng, G | 1 |
Qu, Y | 1 |
Qi, J | 1 |
Gou, Y | 1 |
Lee, P | 1 |
Du, B | 2 |
Yang, XY | 1 |
Yang, W | 1 |
Pan, F | 1 |
Wen, F | 1 |
Wen, S | 1 |
Feng, D | 1 |
Zang, Q | 1 |
Li, G | 1 |
Guo, X | 3 |
Gong, XL | 1 |
Qin, SK | 1 |
van Doorn, L | 1 |
Veelenturf, S | 1 |
Binkhorst, L | 1 |
Bins, S | 1 |
Mathijssen, R | 1 |
Zhang, G | 1 |
Zeng, X | 1 |
Zang, J | 1 |
Gan, R | 1 |
Kato, S | 2 |
Ohnishi, H | 2 |
Mehdizadeh, A | 1 |
Somi, MH | 1 |
Darabi, M | 1 |
Farajnia, S | 1 |
Akbarzadeh, A | 1 |
Montazersaheb, S | 1 |
Yousefi, M | 1 |
Bonyadi, M | 1 |
Yang, L | 6 |
Zheng, H | 1 |
Sun, G | 1 |
Yang, T | 2 |
Kou, P | 1 |
Shao, W | 1 |
Lan, X | 1 |
Lu, S | 1 |
Fan, X | 2 |
Wu, F | 2 |
Tu, J | 1 |
Ji, J | 1 |
Li, NM | 1 |
Xiang, L | 1 |
Su, Y | 2 |
Xia, Q | 2 |
Lacouture, ME | 1 |
Reilly, LM | 1 |
Gerami, P | 1 |
Guitart, J | 1 |
Sieben, M | 1 |
Herzer, K | 1 |
Zeidler, M | 1 |
Heinrichs, V | 1 |
Leuchs, B | 1 |
Schuler, M | 1 |
Cornelis, JJ | 1 |
Galle, PR | 2 |
Rommelaere, J | 1 |
Akiyama, M | 1 |
Miyaaki, H | 1 |
Miuma, S | 1 |
Shibata, H | 1 |
Fujimoto, M | 1 |
Takeshita, S | 1 |
Ozawa, E | 1 |
Ichikawa, T | 1 |
Nakao, K | 1 |
Eguchi, K | 1 |
Wu, CJ | 1 |
Ferrari, D | 1 |
Di Maria, G | 1 |
Fazio, N | 1 |
Codecà, C | 1 |
Fiore, J | 1 |
Luciani, A | 1 |
Oldani, S | 1 |
Maggioni, M | 1 |
Foa, P | 1 |
Iwasa, S | 1 |
Hagihara, A | 1 |
Sagawa, T | 1 |
Yamada, Y | 4 |
Takahashi, M | 4 |
Kobune, M | 1 |
Takimoto, R | 1 |
Fukaura, J | 1 |
Iyama, S | 1 |
Sato, T | 3 |
Miyanishi, K | 1 |
Matsunaga, T | 1 |
Kato, J | 1 |
Sasaki, K | 2 |
Hamada, H | 2 |
Niitsu, Y | 1 |
Ishida, K | 1 |
Hirooka, M | 2 |
Hiraoka, A | 1 |
Kumagi, T | 1 |
Uehara, T | 1 |
Hiasa, Y | 2 |
Horiike, N | 2 |
Onji, M | 4 |
Huang, S | 1 |
Yin, Y | 1 |
Saletti, P | 1 |
Sessa, C | 1 |
Cavalli, F | 2 |
Doh, KO | 1 |
Tang, HH | 1 |
Liang, G | 1 |
Yamaguchi, F | 1 |
Kamitori, K | 1 |
Sanada, K | 1 |
Horii, M | 1 |
Sui, L | 1 |
Tokuda, M | 1 |
Nagano, Y | 1 |
Numata, K | 1 |
Kunisaki, C | 1 |
Shimada, H | 2 |
Cai, XL | 1 |
Gao, JP | 1 |
Wen, L | 1 |
She, ZG | 1 |
Lin, YC | 2 |
Ji, Z | 1 |
Kang, H | 1 |
Diao, Y | 1 |
Luo, K | 1 |
Takeda, Y | 18 |
Dono, K | 23 |
Nakayama, M | 1 |
Shima, T | 1 |
Wakasa, K | 7 |
Monden, M | 31 |
Liang, SN | 1 |
Liu, LL | 1 |
Su, HY | 1 |
Feng, B | 1 |
Zhao, GS | 1 |
Xiao, YP | 1 |
Xiao, EH | 1 |
Luo, JG | 1 |
Bian, DJ | 1 |
Li, MQ | 1 |
He, Z | 1 |
Shang, QL | 1 |
Liang, B | 1 |
Xu, Z | 1 |
Yao, M | 1 |
Yata, Y | 2 |
Nakayama, Y | 1 |
Hirano, K | 4 |
Tokimitsu, Y | 1 |
Kudo, H | 1 |
Kawai, K | 1 |
Kajiura, S | 1 |
Yasumura, S | 1 |
Minemura, M | 1 |
Takahara, T | 1 |
Sugiyama, T | 1 |
Tian, G | 3 |
Zhou, JS | 1 |
Yan, F | 1 |
Wang, XM | 1 |
Sui, J | 1 |
Azakami, T | 1 |
Kenjo, M | 1 |
Toyota, N | 4 |
Ito, K | 6 |
Cafferata, EG | 1 |
Macció, DR | 1 |
Lopez, MV | 1 |
Viale, DL | 1 |
Carbone, C | 1 |
Mazzolini, G | 1 |
Podhajcer, OL | 1 |
Chen, GG | 4 |
Chan, UP | 1 |
Bai, LC | 1 |
Fung, KY | 1 |
Tessier, A | 1 |
To, AK | 1 |
Merchant, JL | 1 |
Lai, PB | 6 |
Patiutko, IuI | 1 |
Pylev, AL | 1 |
Sagaĭdak, IV | 1 |
Kotel'nikov, AG | 1 |
Finn, RS | 1 |
Takemasa, I | 2 |
Yoshioka, S | 2 |
Matsuura, N | 1 |
Matsubara, K | 1 |
Lei, J | 1 |
Mao, CY | 1 |
Hua, HJ | 1 |
Yu, DC | 1 |
Teng, LS | 1 |
Lee, JO | 2 |
Lee, KW | 1 |
Oh, DY | 2 |
Im, SA | 2 |
Kim, TY | 2 |
Bang, YJ | 2 |
Mohan, P | 1 |
Sukumar, R | 1 |
Surendran, R | 1 |
Sathyabhama, C | 1 |
Jayanthi, V | 1 |
Qi, Q | 1 |
Mu, R | 1 |
Kanda, D | 1 |
Takeuchi, S | 1 |
Hatanaka, T | 2 |
Iesaki, K | 1 |
Yoshinaga, T | 1 |
Kubota, J | 1 |
Higuchi, T | 1 |
Yoo, BK | 1 |
Gredler, R | 2 |
Vozhilla, N | 1 |
Su, ZZ | 1 |
Forcier, T | 1 |
Shah, K | 2 |
Saxena, U | 1 |
Hansen, U | 1 |
Fisher, PB | 2 |
Sarkar, D | 2 |
Xiong, YQ | 1 |
Zhu, XD | 1 |
Zhuang, PY | 1 |
Qin, LX | 1 |
Tang, ZY | 6 |
McIntosh, A | 1 |
Hagspiel, KD | 1 |
Al-Osaimi, AM | 1 |
Northup, P | 1 |
Caldwell, S | 1 |
Berg, C | 1 |
Angle, JF | 1 |
Argo, C | 1 |
Weiss, G | 1 |
Rich, TA | 1 |
Cao, LQ | 2 |
Wang, XL | 1 |
Xue, P | 1 |
Jiao, XY | 1 |
Peng, HP | 2 |
Lu, HW | 2 |
Zheng, Q | 1 |
Chen, XL | 1 |
Huang, XH | 1 |
Fu, XH | 1 |
Chen, JS | 3 |
Sun, HW | 1 |
Chen, LH | 1 |
Wei, CJ | 1 |
Zheng, XK | 1 |
Li, QS | 1 |
Guan, J | 1 |
Zhong, JL | 1 |
Xue, X | 1 |
Yue, P | 1 |
Qu, X | 2 |
Woo, HY | 3 |
Choi, BG | 3 |
Im, HU | 1 |
Cheong, JY | 3 |
Cho, SW | 2 |
Jang, BK | 4 |
Kim, SG | 2 |
Seo, YS | 2 |
Doi, Y | 1 |
Shimmura, T | 1 |
Kuribayashi, H | 1 |
Tanaka, Y | 2 |
Kanazawa, Y | 1 |
Yamamoto, H | 7 |
Sun, B | 1 |
Lu, Z | 2 |
Meng, Y | 1 |
Wu, M | 7 |
Rose, M | 1 |
Saif, MW | 3 |
Chu, E | 1 |
Foo, A | 1 |
Jiang, Z | 1 |
Su, T | 1 |
Sharma, A | 2 |
Upadhyay, AK | 1 |
Bhat, MK | 2 |
Wu, FY | 2 |
Huang, GS | 2 |
Jiang, JW | 2 |
Xu, XD | 2 |
Peng, DY | 2 |
Sun, HQ | 1 |
He, XE | 1 |
Wang, WL | 1 |
Lei, JH | 1 |
Moon, HJ | 1 |
Kim, TN | 1 |
Chang, JC | 1 |
Koehler, BC | 1 |
Urbanik, T | 1 |
Vick, B | 1 |
Boger, RJ | 1 |
Heeger, S | 1 |
Schuchmann, M | 1 |
Schulze-Bergkamen, H | 2 |
Hatano, H | 2 |
Tomokuni, A | 2 |
Ishikawa, M | 2 |
Hieda, M | 1 |
Kakizawa, H | 2 |
Koizumi, Y | 1 |
Kisaka, Y | 1 |
Abe, M | 4 |
Murakami, H | 1 |
Matsuura, B | 1 |
Yamagami, T | 1 |
Yoshimatsu, R | 1 |
Miura, H | 1 |
Tanaka, O | 1 |
Nishimura, T | 3 |
Ming, ZJ | 1 |
Qiu, YH | 1 |
Cao, L | 1 |
Zhang, XG | 1 |
Hsu, CH | 2 |
Hsu, C | 1 |
Toh, HC | 2 |
Epstein, RJ | 1 |
Hsiao, LT | 1 |
Chen, PJ | 1 |
Lin, ZZ | 1 |
Chao, TY | 1 |
Cheng, AL | 2 |
Morsy, MA | 1 |
Shizawa, K | 1 |
Watanabe, M | 5 |
Iida, K | 1 |
Han, SW | 1 |
Ma, SH | 2 |
Yip, J | 1 |
Nakamoto, Y | 2 |
Takamura, H | 1 |
Tani, T | 2 |
Zen, Y | 1 |
Hiraki, M | 1 |
Yoshida, H | 5 |
Sata, M | 11 |
Troisi, RI | 1 |
Van Huysse, J | 1 |
Berrevoet, F | 1 |
Vandenbossche, B | 1 |
Sainz-Barriga, M | 1 |
Vinci, A | 1 |
Ricciardi, S | 1 |
Bocchetti, T | 1 |
Rogiers, X | 1 |
de Hemptinne, B | 1 |
Lee, DY | 5 |
Lee, KH | 3 |
Xia, Y | 1 |
Xi, T | 1 |
Shen, F | 1 |
Ueshima, K | 1 |
Takita, M | 1 |
Nagai, T | 1 |
Tatsumi, C | 1 |
Ueda, T | 2 |
Kitai, S | 1 |
Ishikawa, E | 1 |
Yada, N | 1 |
Inoue, T | 1 |
Hagiwara, S | 3 |
Minami, Y | 2 |
Chung, H | 1 |
Shao, ZL | 1 |
Xiao, JB | 1 |
Xia, T | 1 |
Haraguchi, N | 1 |
Ishii, H | 1 |
Tanaka, F | 1 |
Ohkuma, M | 1 |
Kim, HM | 1 |
Takiuchi, D | 1 |
Barnard, GF | 1 |
Zhong, X | 1 |
Xiong, M | 1 |
Meng, X | 1 |
Gong, R | 1 |
Lin, CY | 1 |
Wu, CL | 1 |
Fang, JL | 1 |
Tsao, CJ | 1 |
Mir, O | 1 |
Cessot, A | 1 |
Brezault, C | 1 |
Ropert, S | 1 |
Durand, JP | 1 |
Cacheux, W | 1 |
Chaussade, S | 1 |
Goldwasser, F | 1 |
Song, XR | 1 |
He, G | 1 |
Luo, YF | 1 |
He, ZY | 2 |
Li, SZ | 1 |
Li, JM | 1 |
Hou, SX | 1 |
Wei, YQ | 1 |
Stagni, V | 1 |
Mingardi, M | 1 |
Santini, S | 1 |
Giaccari, D | 1 |
Barilà, D | 1 |
Mahavorasirikul, W | 2 |
Viyanant, V | 2 |
Chaijaroenkul, W | 2 |
Itharat, A | 1 |
Na-Bangchang, K | 2 |
Chon, YE | 1 |
Cha, J | 1 |
Chon, CY | 4 |
Shin, SK | 1 |
Ye, C | 1 |
Leung, BC | 1 |
Ho, RL | 2 |
Yuan, YF | 1 |
Chan, TH | 1 |
Zheng, BJ | 1 |
Ozaki, I | 1 |
Hamajima, H | 1 |
Iwane, S | 1 |
Kawaguchi, Y | 2 |
Eguchi, Y | 1 |
Mizuta, T | 1 |
Kasai, K | 2 |
Ushio, A | 2 |
Kasai, Y | 2 |
Sawara, K | 2 |
Miyamoto, Y | 2 |
Oikawa, K | 2 |
Kuroda, H | 2 |
Takikawa, Y | 2 |
Hashimoto, Y | 1 |
Sun, W | 1 |
Sohal, D | 1 |
Haller, DG | 1 |
Mykulowycz, K | 1 |
Rosen, M | 1 |
Soulen, MC | 1 |
Caparro, M | 1 |
Teitelbaum, UR | 1 |
Giantonio, B | 1 |
O'Dwyer, PJ | 1 |
Shaked, A | 3 |
Reddy, R | 1 |
Olthoff, K | 1 |
Mete, E | 1 |
Gul, HI | 1 |
Cetin-Atalay, R | 1 |
Das, U | 1 |
Sahin, E | 1 |
Gul, M | 1 |
Kazaz, C | 1 |
Dimmock, JR | 1 |
de Lima Lopes, G | 1 |
Dicksey, JS | 1 |
Peters, WP | 1 |
Palalay, M | 1 |
Chang, AY | 1 |
Ang, SF | 1 |
Tan, SH | 1 |
Poon, DY | 1 |
Ong, SY | 1 |
Foo, KF | 1 |
Choo, SP | 1 |
Hashimoto, O | 1 |
Inoue, K | 2 |
Kuwahara, R | 1 |
Kerbel, RS | 1 |
Ueno, T | 2 |
Kim, JD | 1 |
Zhong, Y | 1 |
Luo, CL | 1 |
An-Jun, Z | 1 |
Kang, SS | 1 |
Cho, HA | 1 |
Kim, JS | 4 |
Kang, WJ | 1 |
Lee, JD | 1 |
Xie, F | 1 |
Deng, B | 1 |
Mao, H | 1 |
Chuma, M | 1 |
Taguchi, H | 1 |
Yamamoto, Y | 1 |
Shimizu, S | 1 |
Nakanishi, M | 1 |
Horimoto, H | 1 |
Terashita, K | 1 |
Sakuhara, Y | 1 |
Abo, D | 1 |
Tsukuda, Y | 1 |
Tsunematsu, S | 1 |
Hige, S | 1 |
Kato, M | 1 |
Shirato, H | 1 |
Asaka, M | 1 |
Long, S | 1 |
GuangZhi, Y | 1 |
BaoJie, G | 1 |
YanYong, H | 1 |
YingLi, W | 1 |
LiHua, L | 1 |
Seki, A | 1 |
Yun, M | 1 |
Yoon, HI | 1 |
Cho, HJ | 1 |
Huang, HY | 1 |
Niu, JL | 1 |
Zhao, LM | 1 |
Lu, YH | 1 |
Liao, WJ | 1 |
Mei, MH | 1 |
Qin, LL | 1 |
Yuan, SG | 1 |
Osuga, K | 2 |
Lee, J | 2 |
Park, SH | 2 |
Park, JO | 1 |
Park, YS | 1 |
Yim, DS | 1 |
Fang, F | 1 |
Qin, W | 1 |
Gallant, JN | 1 |
Katz, SI | 1 |
Dolloff, NG | 1 |
Smith, CD | 1 |
Abdulghani, J | 1 |
Allen, JE | 1 |
Dicker, DT | 1 |
Hong, B | 1 |
Navaraj, A | 1 |
El-Deiry, WS | 1 |
Tomuleasa, C | 3 |
Soritau, O | 3 |
Fischer-Fodor, E | 1 |
Pop, T | 2 |
Susman, S | 3 |
Mosteanu, O | 2 |
Petrushev, B | 3 |
Aldea, M | 3 |
Acalovschi, M | 1 |
Irimie, A | 3 |
Kacso, G | 3 |
Park, YM | 3 |
Kim, NY | 1 |
Yun, HK | 1 |
Lee, KJ | 2 |
Park, SJ | 1 |
Yeon, JW | 1 |
Jung, G | 2 |
Ning, W | 1 |
Xiao-Juan, G | 1 |
Cai-Hong, Z | 1 |
Jin-Hua, J | 1 |
Fang, M | 1 |
Qing-Duan, W | 1 |
Zang, Y | 1 |
Zou, W | 1 |
Shen, ZY | 1 |
Liao, D | 1 |
Zhu, B | 1 |
Chien, SY | 1 |
Kuo, SJ | 1 |
Chen, YL | 1 |
Chen, DR | 1 |
Cheng, CY | 1 |
Su, CC | 1 |
Petrini, I | 1 |
Lencioni, M | 1 |
Ricasoli, M | 1 |
Iannopollo, M | 1 |
Orlandini, C | 1 |
Oliveri, F | 1 |
Bartolozzi, C | 1 |
Ricci, S | 1 |
Tani, S | 1 |
Murata, S | 1 |
Tamura, M | 2 |
Morita, M | 1 |
Hirata, Y | 1 |
Iida, H | 1 |
Kakuno, A | 1 |
Nishigami, T | 1 |
Yamanaka, N | 1 |
Choi, SB | 1 |
Park, MS | 2 |
Liu, B | 1 |
Ou, Q | 1 |
Tian, L | 1 |
Sheng, XF | 1 |
Cao, JG | 1 |
Poggi, G | 1 |
Montagna, B | 1 |
Melchiorre, F | 1 |
Quaretti, P | 1 |
Delmonte, A | 1 |
Riccardi, A | 1 |
Tagliaferri, B | 1 |
Sottotetti, F | 1 |
Di Cesare, P | 1 |
Stella, MG | 1 |
Villani, L | 1 |
Zorzetto, M | 1 |
Greco, G | 1 |
Cornalba, G | 1 |
Bernardo, G | 1 |
Ma, K | 1 |
Fei, Q | 1 |
Niu, D | 1 |
Sakai, A | 1 |
Koganemaru, M | 1 |
Abe, T | 3 |
Iwamoto, R | 1 |
Nonoshita, M | 1 |
Yoshida, S | 1 |
Uchiyama, D | 1 |
Hayabuchi, N | 1 |
Uchibori, K | 1 |
Kasamatsu, A | 1 |
Sunaga, M | 2 |
Yokota, S | 1 |
Sakurada, T | 1 |
Kobayashi, E | 1 |
Yoshikawa, M | 2 |
Uzawa, K | 1 |
Tanzawa, H | 1 |
Sato, N | 5 |
Tong, SW | 1 |
Yang, YX | 1 |
Hu, HD | 1 |
An, X | 1 |
Hu, P | 1 |
Ren, H | 2 |
Zhang, DZ | 1 |
Kishimoto, T | 1 |
Jiao, J | 1 |
Hong, S | 1 |
Shen, B | 1 |
Sahara, S | 1 |
Kawai, N | 1 |
Sato, M | 4 |
Ikoma, A | 2 |
Nakata, K | 2 |
Sanda, H | 1 |
Minamiguchi, H | 1 |
Shirai, S | 1 |
Sonomura, T | 1 |
Kawaguchi, A | 1 |
Kakuma, T | 1 |
Sadeghi, H | 1 |
Khadem, M | 1 |
Li, D | 1 |
Song, JR | 1 |
Deng, WJ | 1 |
Sun, K | 1 |
Xie, XQ | 1 |
Song, YJ | 1 |
Uchino, K | 1 |
Obi, S | 2 |
Tateishi, R | 2 |
Sato, S | 4 |
Kanda, M | 2 |
Arano, T | 1 |
Enooku, K | 1 |
Goto, E | 1 |
Masuzaki, R | 1 |
Nakagawa, H | 2 |
Asaoka, Y | 1 |
Kondo, Y | 1 |
Yamashiki, N | 1 |
Goto, T | 2 |
Shiina, S | 2 |
Koike, K | 2 |
Berindan, I | 1 |
Cristea, V | 2 |
Youn, JM | 1 |
Cha, JH | 1 |
Kim, HL | 1 |
Li, FR | 1 |
Ge, N | 1 |
Gan, Y | 1 |
Ye, S | 1 |
Kirikoshi, H | 1 |
Yoneda, M | 1 |
Mawatari, H | 1 |
Fujita, K | 1 |
Imajo, K | 2 |
Kobayashi, N | 1 |
Kubota, K | 1 |
Maeda, S | 2 |
Nakajima, A | 2 |
Saito, S | 1 |
Shao, YY | 1 |
Huang, CC | 1 |
Lin, SD | 1 |
Chen, XZ | 1 |
Cao, ZY | 1 |
Chen, TS | 1 |
Zhang, YQ | 1 |
Liu, ZZ | 1 |
Su, YT | 1 |
Liao, LM | 1 |
Du, J | 1 |
Yadunandam, AK | 1 |
Yoon, JS | 1 |
Seong, YA | 1 |
Oh, CW | 1 |
Kim, GD | 1 |
Liang, RR | 1 |
Qi, JA | 1 |
Wang, ZD | 1 |
Liu, PJ | 1 |
Le, XF | 1 |
Li, ZF | 1 |
Srivastava, J | 1 |
Siddiq, A | 1 |
Emdad, L | 1 |
Santhekadur, PK | 1 |
Shen, XN | 1 |
Robertson, CL | 1 |
Dumur, CI | 1 |
Hylemon, PB | 1 |
Mukhopadhyay, ND | 1 |
Bhere, D | 1 |
Ahmad, R | 1 |
Giashuddin, S | 1 |
Stafflinger, J | 1 |
Subler, MA | 1 |
Windle, JJ | 1 |
Orza, A | 1 |
Dudea, M | 1 |
Florea, A | 1 |
Pall, E | 1 |
Berindan-Neagoe, I | 1 |
Li, N | 1 |
Yan, S | 1 |
Jiang, X | 1 |
Fang, P | 1 |
Gao, Y | 1 |
Ding, CR | 1 |
Cui, F | 1 |
Jiao, SC | 1 |
Seki, H | 1 |
Ozaki, T | 1 |
Ooi, H | 1 |
Wan, T | 3 |
Zha, B | 2 |
Ye, T | 3 |
Rangwala, F | 1 |
Williams, KP | 1 |
Smith, GR | 1 |
Thomas, Z | 1 |
Allensworth, JL | 1 |
Lyerly, HK | 1 |
Diehl, AM | 1 |
Morse, MA | 1 |
Devi, GR | 1 |
Nishiofuku, H | 1 |
Anai, H | 1 |
Sueyoshi, S | 1 |
Masada, T | 1 |
Kichikawa, K | 1 |
Zhu, W | 1 |
Zhou, H | 1 |
Jia, L | 1 |
Lu, F | 1 |
Hou, YQ | 1 |
Yuan, ZJ | 1 |
Rong, C | 1 |
Antoniou, E | 1 |
Mantas, D | 1 |
Paraskeva, P | 1 |
Dimitroulis, D | 1 |
Smyrnis, A | 1 |
Nikitakis, N | 1 |
Labadariou, A | 1 |
Tsavaris, N | 1 |
Vernicos, P | 1 |
Kostakis, A | 1 |
Cheng, MR | 1 |
Chen, HX | 1 |
Yang, FX | 1 |
Xu, HZ | 1 |
Zha, BB | 1 |
Kong, WD | 1 |
Cao, JM | 1 |
Xu, TT | 1 |
Lu, GM | 1 |
Huang, XE | 1 |
Ling, CQ | 2 |
Yue, XJ | 1 |
Yu, XH | 1 |
Brito, AF | 1 |
Abrantes, AM | 1 |
Pinto-Costa, C | 1 |
Gomes, AR | 1 |
Mamede, AC | 1 |
Casalta-Lopes, J | 1 |
Gonçalves, AC | 1 |
Sarmento-Ribeiro, AB | 1 |
Tralhão, JG | 1 |
Botelho, MF | 1 |
Hua, XD | 1 |
Zhou, S | 1 |
Duan, X | 1 |
Kim, JY | 1 |
Yoo, EJ | 1 |
Kwon, JH | 3 |
Kay, CS | 1 |
Itamoto, T | 2 |
Nakahara, H | 2 |
Tashiro, H | 1 |
Haruta, N | 2 |
Asahara, T | 2 |
Naito, A | 2 |
Qi, S | 1 |
Ando, E | 8 |
Yamashita, F | 6 |
Yutani, S | 1 |
Fukumori, K | 6 |
Yano, Y | 6 |
Boucher, E | 1 |
Corbinais, S | 1 |
Brissot, P | 1 |
Boudjema, K | 1 |
Raoul, JL | 3 |
Katsuramaki, T | 1 |
Furuhata, T | 1 |
Yamaguchi, K | 1 |
Ohmura, T | 2 |
Hata, F | 1 |
Mukaiya, M | 2 |
Hirata, K | 2 |
Akçali, Z | 1 |
Akin, E | 1 |
Ozyilkan, O | 1 |
Jin, J | 3 |
Wei, HL | 1 |
Liu, GT | 1 |
Sakon, M | 25 |
Seong, JS | 1 |
Youn, YH | 1 |
Moon, YM | 2 |
Kamiyama, T | 5 |
Matsushita, M | 3 |
Kurauchi, N | 3 |
Nakagawa, T | 3 |
Kamachi, H | 3 |
Kondo, M | 10 |
Ito, T | 2 |
Ogata, T | 2 |
Nishikawa, M | 1 |
Todo, S | 3 |
Yi, J | 2 |
Liao, X | 2 |
Brown, TD | 3 |
Ellis, LM | 2 |
Hoshida, Y | 3 |
Moriyama, M | 2 |
Otsuka, M | 2 |
Kato, N | 2 |
Taniguchi, H | 4 |
Shiratori, Y | 3 |
Seki, N | 1 |
Shao, ZX | 1 |
Cheng, ZG | 1 |
Pulatov, DA | 1 |
Kamiyama, H | 1 |
Toyama, N | 1 |
Mori, Y | 1 |
Miyazaki, K | 2 |
Nagano, M | 1 |
Yamada, S | 1 |
Suminaga, Y | 1 |
Konishi, F | 1 |
Katzenstein, HM | 2 |
Krailo, MD | 2 |
Malogolowkin, MH | 2 |
Ortega, JA | 2 |
Qu, W | 1 |
Douglass, EC | 5 |
Feusner, JH | 2 |
Reynolds, M | 4 |
Quinn, JJ | 2 |
Newman, K | 2 |
Finegold, MJ | 2 |
Haas, JE | 2 |
Sensel, MG | 2 |
Castleberry, RP | 2 |
Bowman, LC | 2 |
Komorizono, Y | 1 |
Kohara, K | 1 |
Oketani, M | 1 |
Maeda, M | 2 |
Shibathou, T | 1 |
Shigenobu, S | 1 |
Hiramine, Y | 1 |
Yamasaki, N | 1 |
Arima, T | 3 |
Kazuaki, I | 1 |
Yang, LY | 2 |
Yi, TB | 2 |
Yang, JQ | 1 |
Uygur-Bayramiçli, O | 1 |
Gemici, C | 1 |
Yang, FC | 1 |
Zheng, SS | 1 |
Li, MW | 1 |
Zeng, QL | 1 |
Jiang, GP | 1 |
Xie, HY | 1 |
Zhou, T | 1 |
Zhai, L | 1 |
Xing, L | 1 |
Nanashima, A | 1 |
Yamaguchi, H | 1 |
Shibasaki, S | 1 |
Morino, S | 1 |
Yoshinaga, M | 1 |
Sawai, T | 1 |
Nakagoe, T | 1 |
Ayabe, H | 1 |
Teramoto, K | 1 |
Kawamura, T | 1 |
Mori, A | 1 |
BOOTH, BA | 1 |
SARTORELLI, AC | 1 |
MCBRIDE, TJ | 1 |
NOBLE, LC | 1 |
CARR, MA | 1 |
HULL, K | 1 |
OLESON, JJ | 1 |
MORSE, PA | 1 |
POTTER, VR | 1 |
Stippel, DL | 1 |
Töx, U | 1 |
Gossmann, A | 1 |
Beckurts, KT | 1 |
Hölscher, AH | 1 |
Pan, DY | 1 |
Qiao, JG | 1 |
Huo, YC | 1 |
Zhou, YK | 1 |
Shi, HA | 1 |
Masutani, S | 2 |
Shimizu, J | 3 |
Tatsuta, M | 1 |
Masuda, F | 1 |
Imamura, H | 1 |
Ishida, H | 2 |
Furukawa, H | 3 |
Tomotsu, K | 1 |
Yura, M | 1 |
Obana, T | 1 |
Kitamura, S | 1 |
Saeki, N | 1 |
Inoue, Y | 2 |
Takamura, M | 1 |
Nakanishi, K | 2 |
Ota, H | 11 |
Yamamoto, T | 10 |
Nakamura, M | 12 |
Miyamoto, A | 15 |
Nakamori, S | 16 |
Murakami, T | 3 |
Nakamura, H | 5 |
Iijima, S | 2 |
Kikkawa, N | 1 |
Kurokawa, E | 1 |
Kato, T | 1 |
Tsujie, M | 2 |
Ohshima, S | 1 |
Naoi, Y | 2 |
Danno, M | 1 |
Tamesa, T | 4 |
Okada, T | 1 |
Takemoto, N | 1 |
Tangoku, A | 4 |
Oka, M | 5 |
Lai, YC | 1 |
Shih, CY | 1 |
Jeng, CM | 1 |
Yang, SS | 1 |
Hu, JT | 1 |
Sung, YC | 1 |
Liu, HT | 1 |
Hou, SM | 1 |
Wu, CH | 1 |
Chen, TK | 1 |
Wu, ZQ | 2 |
Xiao, YS | 3 |
Shi, YH | 1 |
Li, XM | 1 |
Sun, QM | 2 |
Liu, YK | 3 |
Kogure, T | 1 |
Ueno, Y | 1 |
Iwasaki, T | 2 |
Shimosegawa, T | 1 |
Yang, XD | 1 |
Tang, DN | 1 |
Cao, DL | 1 |
Li, YX | 1 |
Lin, ZB | 1 |
Tan, HR | 1 |
Li, JT | 1 |
Ou, QJ | 1 |
Wu, YC | 1 |
Kawashima, R | 1 |
Haisa, M | 1 |
Takaoka, M | 1 |
Shirakawa, Y | 1 |
Uetsuka, H | 1 |
Gunduz, M | 1 |
Nagai, N | 1 |
Tanaka, N | 1 |
Naomoto, Y | 1 |
Zhang, ZL | 1 |
Zou, WG | 1 |
Luo, CX | 1 |
Li, BH | 1 |
Wang, JH | 1 |
Sun, LY | 1 |
Qian, QJ | 1 |
Fukuda, Y | 1 |
Fujio, N | 1 |
Tsukazaki, T | 1 |
Terakura, M | 1 |
Mayumi, K | 1 |
Koyama, I | 1 |
Tsukazaki, Y | 1 |
Osugi, H | 1 |
Qiu, F | 1 |
Lambert, B | 2 |
De Ridder, L | 2 |
Slegers, G | 2 |
De Gelder, V | 2 |
Dierckx, RA | 1 |
Thierens, H | 2 |
Xue, Q | 1 |
Ganten, TM | 1 |
Haas, TL | 1 |
Sykora, J | 1 |
Stahl, H | 1 |
Sprick, MR | 1 |
Fas, SC | 1 |
Krueger, A | 1 |
Weigand, MA | 1 |
Grosse-Wilde, A | 1 |
Stremmel, W | 1 |
Krammer, PH | 2 |
Walczak, H | 1 |
Mazzanti, R | 1 |
Giallombardo, AL | 1 |
Mini, E | 1 |
Nobili, S | 1 |
Neri, B | 1 |
Arena, U | 1 |
Pantaleo, P | 1 |
Fabbroni, V | 1 |
Ghilardi, M | 1 |
Gattai, R | 1 |
Bandettini, L | 1 |
Zhao, JG | 1 |
Feng, GS | 1 |
Kong, XQ | 1 |
Li, MH | 1 |
Cheng, YS | 1 |
Chang, HK | 1 |
Liau, CT | 1 |
Chang, WC | 1 |
Chang, UI | 2 |
Nam, SW | 2 |
Mok, TS | 5 |
Leung, TW | 6 |
Brown, G | 1 |
Moyses, C | 1 |
Chan, AT | 5 |
Yeo, W | 5 |
Wong, H | 1 |
Chak, K | 1 |
Johnson, P | 1 |
El-Saadani, MA | 1 |
Aguayo, A | 2 |
Nooka, AK | 1 |
Schnirer, II | 1 |
Wolff, RA | 1 |
Charnsangavej, C | 3 |
Hamada, A | 1 |
Yamakado, K | 1 |
Nakatsuka, A | 1 |
Takaki, H | 1 |
Akeboshi, M | 1 |
Yamamoto, S | 3 |
Tomita, Y | 1 |
Iizuka, N | 1 |
Aozasa, K | 1 |
Wu, SL | 1 |
Sun, ZJ | 1 |
Meng, KW | 1 |
Qin, XL | 1 |
Pan, CE | 1 |
Kurokawa, Y | 1 |
Matoba, R | 1 |
Ueno, N | 1 |
Ishii, S | 1 |
Kato, K | 2 |
Kawabe, T | 1 |
Noguchi, T | 3 |
Tanimoto, K | 1 |
Shimokuni, T | 1 |
Ukon, K | 1 |
Tsujimoto, H | 1 |
Fukushima, M | 1 |
Kawahara, K | 2 |
Hiyama, K | 1 |
Nishiyama, M | 1 |
Jin, CD | 1 |
Arai, I | 2 |
Kishin, R | 1 |
Xing, X | 1 |
Lam, KC | 3 |
Zee, B | 3 |
Chan, PS | 1 |
Mo, FK | 3 |
Ho, WM | 3 |
Wong, WL | 1 |
Johnson, PJ | 5 |
Matsumoto, G | 1 |
Tsuruta, K | 1 |
Okamoto, A | 2 |
Endo, M | 1 |
Sonoyama, T | 1 |
Kikuchi, S | 2 |
Ichikawa, D | 1 |
Fujiwara, H | 1 |
Okamoto, K | 1 |
Sakakura, C | 1 |
Ueda, Y | 1 |
Otsuji, E | 1 |
Hagiwara, A | 1 |
Yamagishi, H | 1 |
Damdinsuren, B | 9 |
Li, HH | 1 |
Duan, ZH | 1 |
Zhang, HW | 1 |
Yie, SL | 1 |
Yang, BW | 1 |
Yagita, H | 1 |
Kwon, KM | 2 |
Park, KS | 2 |
Cho, KB | 2 |
Kim, GC | 2 |
Kim, YH | 2 |
Nakata, S | 1 |
Tomoda, K | 3 |
Watanabe, K | 3 |
Taguchi, K | 1 |
Tsukahara, M | 1 |
Nakajima, H | 1 |
Kamiyama, N | 1 |
Khor, LW | 1 |
Abumiya, K | 1 |
Kobayashi, H | 1 |
Takezako, Y | 1 |
Wang, HE | 1 |
Wu, HC | 1 |
Kao, SJ | 1 |
Tseng, FW | 1 |
Wang, YS | 1 |
Yu, HM | 1 |
Chou, SL | 1 |
Yen, SH | 2 |
Chi, KH | 1 |
Kurokawa, F | 1 |
Aoyama, K | 1 |
Tajima, K | 1 |
Yokoyama, Y | 2 |
Omori, K | 1 |
Tsuchiya, M | 1 |
Okita, K | 1 |
Dou, J | 1 |
Iwashita, Y | 1 |
Sasaki, A | 2 |
Kai, S | 2 |
Hirano, S | 1 |
Ohta, M | 2 |
Kitano, S | 3 |
Hiraoka, N | 1 |
Hwang, JY | 1 |
Horino, K | 1 |
Inoue, M | 1 |
Kuhara, H | 1 |
Uemura, K | 1 |
Yamada, K | 1 |
Ocker, M | 1 |
Alajati, A | 1 |
Ganslmayer, M | 1 |
Zopf, S | 1 |
Lüders, M | 1 |
Neureiter, D | 1 |
Hahn, EG | 1 |
Schuppan, D | 1 |
Herold, C | 1 |
Sheng, Z | 1 |
Ruan, YB | 1 |
Guang, Y | 1 |
Yang, ML | 1 |
Zhang, ZH | 1 |
Ma, LW | 1 |
Song, SB | 1 |
Xiu, DR | 1 |
Wang, JJ | 1 |
Yang, XX | 1 |
Jia, YM | 1 |
Li, CP | 2 |
Lin, CP | 1 |
Lo, GH | 1 |
Lin, CK | 1 |
Chen, HH | 1 |
Lo, CC | 1 |
Tseng, HH | 1 |
Yin, XY | 3 |
Lü, MD | 2 |
Liang, LJ | 2 |
Lai, JM | 1 |
Li, DM | 2 |
Kuang, M | 1 |
Sugimoto, K | 1 |
Shiraki, K | 1 |
Yamanaka, Y | 1 |
Murata, K | 2 |
Nakano, T | 1 |
Rong, LF | 1 |
Li, YH | 1 |
Guo, L | 1 |
Xu, SY | 1 |
Kountouras, J | 1 |
Zavos, C | 1 |
Chatzopoulos, D | 1 |
Cao, XW | 1 |
Fu, ZR | 1 |
Ding, GS | 1 |
Cheng, SC | 2 |
Lin, RX | 1 |
Tuo, CW | 1 |
Lü, QJ | 1 |
Wang, SQ | 1 |
Haruno, M | 1 |
Shimamura, R | 1 |
Ogawa, Y | 2 |
Tanaka, H | 2 |
Sakai, K | 3 |
Araki, K | 1 |
Hillemann, A | 1 |
Brandenburg, B | 1 |
Schmidt, U | 1 |
Roos, M | 1 |
Smirnow, I | 1 |
Lemken, ML | 1 |
Lauer, UM | 1 |
Hildt, E | 1 |
Zheng, JF | 1 |
Wang, HD | 1 |
Niguma, T | 1 |
Mimura, T | 1 |
Tutui, N | 1 |
Yu, YL | 1 |
Ji, MF | 1 |
He, JB | 1 |
Li, XL | 1 |
Lin, ZY | 1 |
Shen, YF | 1 |
Yu, ZJ | 1 |
Yu, JW | 1 |
Cai, W | 1 |
Yuan, HX | 1 |
Li, XY | 1 |
Chen, JP | 1 |
Wu, XY | 1 |
Yao, DF | 1 |
Kanda, T | 2 |
Tada, M | 1 |
Imazeki, F | 2 |
Yokosuka, O | 2 |
Nagao, K | 1 |
Saisho, H | 3 |
Kurokohchi, K | 2 |
Takaguchi, K | 1 |
Kita, K | 1 |
Kuriyama, S | 2 |
Dai, J | 3 |
Koh, J | 2 |
Yu, SC | 3 |
Hui, P | 2 |
Wong, HT | 1 |
Tang, A | 1 |
Enjoji, M | 1 |
Morizono, S | 1 |
Kotoh, K | 1 |
Kohjima, M | 1 |
Miyagi, Y | 1 |
Yoshimoto, T | 1 |
Nakamuta, M | 1 |
Anami, Y | 1 |
Oguma, S | 2 |
Matsuda, Y | 2 |
Yamaki, T | 1 |
Sazawa, Y | 1 |
Komiya, H | 1 |
Izai, J | 1 |
Ota, T | 1 |
Ciccolini, J | 1 |
Mercier, C | 1 |
Dahan, L | 2 |
Evrard, A | 1 |
Boyer, JC | 1 |
Richard, K | 1 |
Dales, JP | 1 |
Durand, A | 1 |
Milano, G | 1 |
Seitz, JF | 2 |
Lacarelle, B | 1 |
Kida, H | 1 |
Hasuike, Y | 2 |
Fukuchi, N | 1 |
Fujiwara, S | 1 |
Hayashi, N | 1 |
Ebisui, C | 1 |
Sakita, I | 1 |
Fujimoto, T | 1 |
Koshino, T | 1 |
Izumiyama, K | 1 |
Uchida, S | 1 |
Nokita, H | 1 |
Horiuchi, H | 1 |
Ishikawa, H | 1 |
Kawashima, Y | 1 |
Fujishita, M | 1 |
Aoyagi, S | 4 |
Shirouzu, K | 1 |
Kato, H | 1 |
Bazarragchaa, D | 1 |
Poh, SB | 1 |
Bai, LY | 1 |
Chen, PM | 1 |
Arai, M | 1 |
Gao, WB | 1 |
Han, JD | 1 |
Du, M | 1 |
Lee, Y | 1 |
Han, SH | 1 |
Kwon, SY | 1 |
Kwon, OS | 1 |
Kim, SS | 1 |
Park, YH | 1 |
Lee, JN | 1 |
Bang, SM | 1 |
Cho, EK | 1 |
Shin, DB | 1 |
Wang, MQ | 1 |
Shao, RH | 1 |
Ye, HY | 1 |
Wang, ZQ | 1 |
Liu, FY | 1 |
Quek, R | 1 |
Lim, ST | 1 |
Ong, S | 1 |
Diasio, R | 1 |
Lim, TY | 1 |
Sim, SJ | 1 |
Choi, SJ | 1 |
Choi, JW | 1 |
Kwon, HC | 1 |
Lee, KM | 1 |
Won, JH | 1 |
Yoo, BM | 1 |
Hahm, KB | 1 |
Toune, R | 1 |
Unuma, T | 2 |
Teratani, T | 1 |
Oh, HJ | 1 |
Lee, SY | 1 |
Kim, CW | 1 |
Cha, SB | 1 |
Byun, JY | 1 |
Zhang, YN | 1 |
Kojiro, S | 1 |
Momosaki, S | 1 |
Takemoto, Y | 1 |
Nishida, N | 1 |
Kojiro, M | 3 |
Berretta, M | 1 |
Lleshi, A | 1 |
Di Benedetto, F | 1 |
Bearz, A | 1 |
Spina, M | 1 |
Tirelli, U | 1 |
Ni, H | 1 |
Terakawa, N | 1 |
Satoi, S | 1 |
Takai, S | 1 |
Yanagimoto, H | 1 |
Takahashi, K | 2 |
Komiyama, Y | 1 |
A-Hon, K | 1 |
Kamiyama, Y | 1 |
Zorzi, D | 1 |
Abdalla, EK | 1 |
Pawlik, TM | 1 |
Zhou, ZH | 1 |
Cheng, WW | 1 |
Meng, ZQ | 1 |
Lin, JH | 1 |
Zhang, XJ | 1 |
Jiang, GL | 1 |
Chau, GY | 1 |
Lui, WY | 1 |
Tsay, SH | 1 |
King, KL | 1 |
Wu, CW | 1 |
Cui, YL | 1 |
Juzi, JT | 1 |
Qian, BY | 1 |
Hao, XS | 1 |
Ohsuga, K | 1 |
Kim, T | 1 |
Tatsukawa, M | 1 |
Suzuki, M | 1 |
Iwasaki, Y | 3 |
Lei, XY | 1 |
Zhong, M | 1 |
Feng, LF | 1 |
Zhu, BY | 1 |
Liao, DF | 1 |
Oie, S | 2 |
Ono, M | 2 |
Maruyama, Y | 2 |
Terada, T | 2 |
Kuwano, M | 2 |
Fujioka, N | 1 |
Ariyasu, T | 1 |
Arai, N | 1 |
Ariyasu, H | 1 |
Tanimoto, T | 1 |
Ikegami, H | 1 |
Ohta, T | 1 |
Fukuda, S | 5 |
Kurimoto, M | 1 |
Dai, LC | 2 |
Lu, YL | 2 |
Ping, JL | 2 |
He, JF | 2 |
Zhou, JJ | 1 |
Chen, RF | 1 |
Tang, QB | 1 |
Zhou, QB | 1 |
Shitara, K | 1 |
Munakata, M | 1 |
Kudo, T | 1 |
Muto, O | 1 |
Okada, R | 1 |
Mitobe, S | 1 |
Sakata, Y | 2 |
Ishii, E | 1 |
Yabu, K | 1 |
Yanase, K | 1 |
Ikenaka, Y | 1 |
Noguchi, R | 1 |
Kitade, M | 1 |
Kaji, K | 1 |
Yoshii, J | 1 |
Namisaki, T | 1 |
Yamazaki, M | 1 |
Asada, K | 1 |
Tsujimoto, T | 1 |
Akahane, T | 1 |
Uemura, M | 1 |
Fukui, H | 1 |
Yabuuchi, S | 1 |
Katayose, Y | 1 |
Rikiyama, T | 1 |
Oikawa, M | 1 |
Onogawa, T | 1 |
Muto, M | 1 |
Unno, M | 1 |
Yamashita, S | 1 |
Niinobu, T | 1 |
Amano, M | 1 |
Nishikawa, Y | 1 |
Hayashida, H | 1 |
Higaki, N | 1 |
Fujita, M | 1 |
Mizumoto, T | 1 |
Okabe, K | 1 |
Baba, Y | 1 |
Takamori, H | 1 |
Kanemitsu, K | 1 |
Hiroto, M | 1 |
De Vos, F | 1 |
Van de Wiele, C | 1 |
Higami, K | 2 |
Okano, N | 1 |
Matsumaru, K | 1 |
Miki, K | 2 |
Enoki, T | 1 |
Kitada, K | 1 |
Harada, E | 1 |
Noshima, S | 1 |
Hamano, K | 1 |
Hou, S | 1 |
Kou, G | 1 |
Qian, W | 1 |
Brenes, O | 1 |
Arce, F | 1 |
Gätjens-Boniche, O | 1 |
Díaz, C | 1 |
Imai, Y | 5 |
Fukuda, K | 1 |
Matsumoto, H | 2 |
Zhao, QZ | 1 |
Dou, KF | 1 |
Naganuma, A | 1 |
Toyoda, M | 1 |
Hamada, T | 1 |
Yanagisawa, M | 1 |
Kosone, T | 1 |
Arai, H | 1 |
Takagi, H | 2 |
Miao, J | 1 |
Yun, JP | 1 |
Chun, SY | 1 |
Zheng, ZZ | 1 |
Chak, EC | 1 |
Xia, NS | 1 |
Yoon, YJ | 1 |
Kuroda, M | 1 |
Urawa, N | 1 |
Mifuji, R | 1 |
Araki, J | 1 |
Horiike, S | 1 |
Itani, T | 1 |
Furjita, N | 1 |
Konishi, M | 1 |
Iwasa, M | 1 |
Kaito, M | 1 |
Adachi, Y | 1 |
Chan, SL | 1 |
Leung, NW | 2 |
Lam, WY | 1 |
Tang, JW | 1 |
Chan, PK | 1 |
Fan, XY | 1 |
Uchida, H | 1 |
Iwaki, K | 1 |
Shibata, K | 1 |
Sun, Z | 1 |
Peng, J | 1 |
Zhan, L | 1 |
Hirashita, T | 1 |
Nakashima, K | 5 |
Sakai, M | 1 |
Sakai, I | 1 |
Fukushima, H | 1 |
Hosoi, F | 1 |
Deguchi, A | 1 |
Himoto, T | 1 |
Yoneyama, H | 1 |
Maeta, T | 1 |
Kiuchi, T | 1 |
Kohi, F | 1 |
Miyoshi, H | 1 |
Taminato, T | 1 |
Chung, C | 1 |
Park, SG | 1 |
Joh, JW | 1 |
Blanchard, P | 1 |
Huguet, F | 1 |
André, T | 1 |
Boige, V | 1 |
Pignon, JP | 1 |
Bouché, O | 1 |
Blanc, JF | 1 |
Jouve, JL | 1 |
Dupouy, N | 1 |
Ducreux, M | 1 |
Cui, J | 1 |
Nan, KJ | 1 |
Guo, YH | 1 |
Imai, M | 1 |
Kamimura, H | 1 |
Tsuchiya, A | 1 |
Togashi, T | 1 |
Seki, K | 1 |
Ohta, H | 2 |
Kamimura, T | 1 |
Uka, K | 3 |
Miki, D | 3 |
Jeong, SC | 2 |
Kodama, H | 1 |
Shirakawa, H | 1 |
Song, TY | 1 |
Lin, HC | 1 |
Yang, NC | 1 |
Hu, ML | 1 |
Meric, JB | 1 |
Nakatani, T | 2 |
Sakaguchi, Y | 1 |
Nagashima, M | 1 |
Fukuta, N | 1 |
Hayakawa, S | 1 |
Munakata, H | 1 |
Tejani, MA | 1 |
Sun, RX | 1 |
Jia, F | 2 |
Wei, L | 2 |
Takahashi, T | 7 |
Mamada, Y | 1 |
Taniai, N | 1 |
Mizuguchi, Y | 1 |
Shimizu, T | 2 |
Kakinuma, D | 1 |
Ishikawa, Y | 1 |
Akimaru, K | 1 |
Sugisaki, Y | 1 |
Tajiri, T | 1 |
Jiang, JM | 1 |
Liu, JY | 1 |
Zhu, JR | 1 |
Le, C | 1 |
Di Lorenzo, G | 1 |
Rea, A | 1 |
Carlomagno, C | 1 |
Pepe, S | 1 |
Palmieri, G | 1 |
Labianca, R | 1 |
Chirianni, A | 1 |
De Stefano, A | 1 |
Esposito, V | 1 |
De Placido, S | 1 |
Montesarchio, V | 1 |
Shao, ZY | 1 |
Zhai, BJ | 1 |
Zhao, CL | 1 |
Hu, K | 1 |
Shen, DM | 1 |
Hu, WJ | 1 |
Tomonaga, T | 1 |
Ebara, M | 1 |
Nomura, F | 1 |
Ikehara, T | 1 |
von Delius, S | 1 |
Lersch, C | 1 |
Mayr, M | 1 |
Stock, K | 1 |
Schulte-Frohlinde, E | 1 |
Schmid, RM | 1 |
Eckel, F | 1 |
August, DA | 1 |
Han, CJ | 1 |
Shim, JH | 1 |
Park, JW | 1 |
Nam, BH | 1 |
Lee, WJ | 1 |
Kim, CM | 1 |
Saneto, H | 1 |
Chunhu, Z | 1 |
Suiyu, H | 1 |
Meiqun, C | 1 |
Guilin, X | 1 |
Yunhui, L | 1 |
Ma, H | 1 |
Zheng, D | 1 |
Yuan, JN | 1 |
Lee, WP | 1 |
Lee, RC | 1 |
Chang, FY | 1 |
Lee, SD | 1 |
Whang-Peng, J | 1 |
Albaugh, JS | 1 |
Keeffe, EB | 1 |
Krippaehne, WW | 1 |
Falkson, G | 6 |
MacIntyre, JM | 2 |
Moertel, CG | 6 |
Johnson, LA | 1 |
Scherman, RC | 1 |
Balch, CM | 2 |
Urist, MM | 2 |
Shiraishi, K | 1 |
Majima, Y | 1 |
Sato, K | 1 |
Sakemi, T | 1 |
Sakai, T | 2 |
Hirai, K | 3 |
Ninomiya, F | 1 |
Tanikawa, K | 5 |
Akiharu, W | 1 |
Higashi, T | 1 |
Nakatsukasa, H | 1 |
Fujiwara, M | 1 |
Shiota, T | 1 |
Yamauchi, Y | 1 |
Nagashima, H | 2 |
Ueoka, H | 1 |
Kuroda, S | 1 |
Ohnoshi, T | 1 |
Kimura, I | 1 |
Numoto, A | 1 |
Hino, I | 1 |
Tsuji, M | 1 |
Heinrich, UE | 1 |
Bolkenius, M | 1 |
Daum, R | 1 |
Oppermann, HC | 1 |
Mehls, O | 1 |
Brandeis, WE | 1 |
Ohya, T | 1 |
Sheen, MC | 1 |
Huang, TJ | 1 |
Sheen, PC | 1 |
Ho, YH | 1 |
Sheu, HM | 1 |
Ou, SC | 1 |
Chen, CY | 1 |
Wu, CC | 1 |
Moser, K | 1 |
Dittrich, C | 1 |
Pirich, P | 1 |
Schneeweiss, B | 1 |
Choi, TK | 1 |
Lee, NW | 1 |
Wong, J | 1 |
Schlager, SI | 1 |
Ohanian, SH | 4 |
Oon, CJ | 1 |
Chua, EJ | 1 |
Foong, WC | 1 |
Tan, LK | 1 |
Yo, SL | 1 |
Chang, CH | 1 |
Ho, ST | 1 |
Seah, CS | 1 |
Friedman, MA | 2 |
Volberding, PA | 1 |
Cassidy, MJ | 1 |
Resser, KJ | 1 |
Wasserman, TH | 1 |
Phillips, TL | 2 |
Pausch, J | 2 |
Holstege, A | 1 |
Keppler, D | 2 |
Gerok, W | 2 |
Nakakuma, K | 1 |
Tashiro, S | 1 |
Hiraoka, T | 1 |
Konno, T | 1 |
Yokoyama, I | 1 |
Czerwiński, W | 2 |
Young, D | 1 |
Vine, E | 1 |
Ghanbarpour, A | 1 |
Shani, J | 2 |
Siemsen, JK | 1 |
Wolf, W | 2 |
Evans, AE | 1 |
Land, VJ | 1 |
Newton, WA | 1 |
Randolph, JG | 1 |
Sather, HN | 1 |
Tefft, M | 1 |
Weinblatt, ME | 1 |
Siegel, SE | 1 |
Siegel, MM | 1 |
Stanley, P | 1 |
Weitzman, JJ | 1 |
Joishy, SK | 1 |
Bennett, JM | 1 |
Balasegaram, M | 1 |
Moertel, C | 2 |
Carbone, PP | 2 |
Penalba, C | 1 |
Larouze, B | 1 |
Mechali, D | 1 |
Saimot, G | 1 |
Coulaud, JP | 1 |
Cedermark, BJ | 1 |
Gunven, P | 1 |
Hammarberg, C | 1 |
Anttila, MI | 1 |
Sotaniemi, EA | 1 |
Kairaluoma, MI | 1 |
Mokka, RE | 1 |
Sundquist, HT | 1 |
Niederhuber, JE | 1 |
Ensminger, WD | 1 |
Ramming, KP | 2 |
Kuroiwa, Y | 1 |
Kikkawa, K | 1 |
Kubonishi, S | 1 |
Hamawaki, M | 1 |
Okano, K | 1 |
Ito, Y | 3 |
Matsuoka, K | 1 |
Fujii, M | 2 |
Murakami, N | 2 |
Matsuka, Y | 2 |
Ejiri, T | 2 |
Asano, K | 2 |
Yamashita, Y | 3 |
Kanaoka, M | 1 |
Ohta, Y | 4 |
Hattori, M | 2 |
Munehisa, T | 1 |
Tajima, H | 1 |
Goto, M | 1 |
Muro, T | 1 |
Kohno, K | 1 |
Sato, A | 1 |
Furukawa, R | 1 |
Ogino, T | 1 |
Washtien, WL | 1 |
Steele, G | 1 |
Osteen, RT | 1 |
Wilson, RE | 1 |
Brooks, DC | 1 |
Mayer, RJ | 1 |
Zamcheck, N | 1 |
Ravikumar, TS | 2 |
Ellis, PA | 1 |
Norman, A | 1 |
Hill, A | 1 |
O'Brien, ME | 1 |
Nicolson, M | 1 |
Hickish, T | 1 |
Cunningham, D | 1 |
Brucker, C | 1 |
Weiss, M | 1 |
Schweiberer, L | 1 |
Genz, T | 1 |
Maassen, V | 1 |
Debus-Thiede, G | 1 |
Guyader, D | 1 |
Bretagne, JF | 1 |
Duvauferrier, R | 1 |
Bourguet, P | 1 |
Bekhechi, D | 1 |
Deugnier, YM | 1 |
Gosselin, M | 1 |
Lygidakis, NJ | 1 |
Kosmidis, P | 1 |
Ziras, N | 1 |
Parissis, J | 1 |
Kyparidou, E | 1 |
Tetef, M | 1 |
Doroshow, J | 1 |
Akman, S | 1 |
Coluzzi, P | 1 |
Leong, L | 1 |
Margolin, K | 1 |
Morgan, RJ | 1 |
Raschko, J | 1 |
Shibata, S | 1 |
Somlo, G | 1 |
Aramaki, M | 3 |
Kawano, K | 2 |
Kim, YI | 5 |
Yanagi, I | 3 |
Koga, A | 4 |
Aso, K | 3 |
Nishio, T | 2 |
Shirotani, T | 2 |
Kodama, T | 1 |
So, H | 2 |
Shibata, J | 4 |
Nagashima, J | 2 |
Nakao, A | 2 |
Nabeyama, A | 1 |
Okada, Y | 1 |
Sakagami, K | 1 |
Salminen, E | 1 |
Nikkanen, V | 1 |
Kelm, C | 1 |
Henneking, K | 1 |
Zimmermann, T | 1 |
Vollerthun, M | 1 |
Padberg, W | 1 |
Yoffe, B | 1 |
Pazdur, R | 1 |
Fischer, H | 1 |
Cleary, K | 2 |
Roh, M | 2 |
Smith, R | 1 |
Noonan, CA | 1 |
Levin, B | 1 |
Takenaka, K | 4 |
Yoshida, K | 1 |
Nishizaki, T | 1 |
Korenaga, D | 1 |
Hiroshige, K | 1 |
Ikeda, T | 1 |
Su, J | 1 |
Zhen, YC | 1 |
Qi, CQ | 1 |
Hu, JL | 1 |
Vaughn, D | 1 |
Treat, J | 1 |
Olthoff, KM | 2 |
Rosove, MH | 2 |
Shackleton, CR | 2 |
Imagawa, DK | 2 |
Farmer, DG | 2 |
Northcross, P | 2 |
Pakrasi, AL | 2 |
Martin, P | 2 |
Goldstein, LI | 2 |
Colleoni, M | 2 |
Gaion, F | 1 |
Liessi, G | 2 |
Mastropasqua, G | 1 |
Nelli, P | 2 |
Manente, P | 2 |
Iwama, T | 1 |
Mishima, Y | 1 |
Komesu, I | 1 |
Ohgami, N | 1 |
Sou, H | 1 |
Kumabe, T | 1 |
Motohara, T | 1 |
Ozawa, Z | 1 |
Morita, S | 2 |
Pizzorno, G | 1 |
Bodden, W | 1 |
Marsh, J | 1 |
Strair, R | 1 |
Pollack, J | 1 |
Hendler, R | 1 |
Hanna, J | 1 |
D'Andrea, E | 1 |
Maruhashi, Y | 1 |
Hirose, S | 1 |
Satomura, Y | 1 |
Hayakawa, Y | 1 |
Demachi, H | 1 |
Miwa, A | 1 |
Nakanuma, Y | 1 |
Iwamiya, T | 2 |
Sawada, S | 2 |
Yasui, M | 1 |
Nonami, T | 1 |
Kurokawa, T | 1 |
Harada, A | 1 |
Hashimoto, S | 1 |
Kajikawa, M | 1 |
Hiraoka, E | 1 |
Suto, T | 1 |
Moriya, N | 1 |
Watanabe, Y | 2 |
Sasaki, D | 1 |
Yodono, H | 4 |
Takekawa, SD | 2 |
Tarusawa, K | 4 |
Ikami, I | 2 |
Kanehira, J | 3 |
Saito, Y | 3 |
Sasaki, T | 4 |
Nishi, N | 2 |
Yakushiji, H | 1 |
Kitahara, K | 1 |
Sasatomi, E | 1 |
Tsutsumi, N | 1 |
Hirohashi, Y | 1 |
Iwanaga, A | 1 |
Iyama, A | 1 |
Fukagawa, H | 1 |
Wen, YJ | 1 |
Xu, HB | 1 |
Yan, XQ | 1 |
Finegold, M | 2 |
Cantor, AB | 1 |
Glicksman, A | 2 |
Sitzmann, JV | 1 |
Abrams, R | 1 |
Bismuth, H | 1 |
Chiche, L | 1 |
Adam, R | 1 |
Castaing, D | 1 |
Itsubo, M | 1 |
Lai, RQ | 1 |
Uchino, J | 5 |
Une, Y | 5 |
Gondo, H | 1 |
Nakajima, Y | 5 |
Toyoda, H | 2 |
Nakano, S | 2 |
Takeda, I | 2 |
Kumada, T | 2 |
Sugiyama, K | 2 |
Osada, T | 2 |
Kiriyama, S | 2 |
Suga, T | 2 |
Oki, H | 1 |
Ijuin, H | 1 |
Ban, S | 1 |
Sakata, K | 1 |
Ono, N | 1 |
Noguchi, H | 1 |
Itobayashi, E | 1 |
Shimauchi, A | 1 |
Lynes, AC | 1 |
Stuart, K | 1 |
Tessitore, J | 1 |
Huberman, M | 1 |
Mughal, TI | 1 |
Koriech, OM | 1 |
Sugahara, K | 1 |
Tobe, T | 1 |
Takiya, S | 1 |
Sawada, T | 2 |
Tagaya, T | 1 |
Fukuzawa, Y | 1 |
Ikeda, H | 1 |
Link, KH | 1 |
Pillasch, J | 1 |
Weindel, M | 1 |
Leder, G | 1 |
Beger, HG | 1 |
Matuo, H | 1 |
Nakayama, T | 3 |
Nakano, H | 1 |
Sasaki, Y | 3 |
Imaoka, S | 3 |
Ishikawa, O | 3 |
Kabuto, T | 2 |
Kameyama, M | 1 |
Hiratsuka, M | 1 |
Ohigashi, H | 2 |
Yasuda, T | 2 |
Iwanaga, T | 1 |
Blesing, CH | 1 |
Kerr, DJ | 1 |
Busuttil, RW | 1 |
Bower, M | 1 |
Newlands, ES | 1 |
Habib, N | 1 |
Ishimura, H | 1 |
Mastrapasqua, G | 1 |
Vicario, G | 1 |
Sgarbossa, G | 1 |
Pancheri, F | 1 |
Ono, T | 3 |
Nagasue, N | 3 |
Uchida, M | 1 |
Yukaya, H | 1 |
Yamanoi, A | 2 |
Takao, T | 4 |
Nishida, M | 2 |
Maeda, Y | 5 |
Takao, K | 1 |
Sawamura, A | 1 |
Kim, R | 1 |
Takashima, I | 1 |
Miyahara, E | 1 |
Aogi, K | 1 |
Yamaguchi, Y | 1 |
Noma, K | 1 |
Hihara, J | 1 |
Toge, T | 1 |
Jibiki, M | 1 |
Taniguchi, Y | 1 |
Matsuo, T | 1 |
Ikari, H | 1 |
Ishibashi, T | 2 |
Sugamura, Y | 1 |
Kunizaki, T | 1 |
Hirao, K | 1 |
Takayama, W | 1 |
Asano, T | 1 |
Nakagouri, S | 1 |
Kenmochi, T | 1 |
Okazumi, S | 1 |
Takeda, A | 1 |
Fukunaga, T | 1 |
Iwasaki, K | 1 |
Shutou, K | 1 |
Matsuzaki, H | 1 |
Aoyama, H | 1 |
Shinotou, K | 1 |
Kouno, T | 1 |
Isono, K | 1 |
Kato, O | 1 |
Fukuda, H | 1 |
Kusaba, T | 1 |
Mathurin, P | 1 |
Rixe, O | 1 |
Carbonell, N | 1 |
Bernard, B | 1 |
Cluzel, P | 1 |
Bellin, MF | 1 |
Khayat, D | 1 |
Opolon, P | 1 |
Poynard, T | 1 |
Miura, T | 5 |
An, M | 1 |
Matsumoto, Y | 3 |
Terakado, H | 1 |
Murata, M | 2 |
Takagi, S | 1 |
Ikawa, M | 1 |
Hamada, E | 1 |
Nakasato, S | 1 |
Jiang, W | 1 |
Diasio, RB | 1 |
Jiang, S | 1 |
Shin, EC | 1 |
Lee, MO | 1 |
Kim, SJ | 1 |
Park, JH | 1 |
Murakami, K | 1 |
Matsuura, T | 2 |
Sano, M | 1 |
Hashimoto, A | 1 |
Yonekura, K | 1 |
Sakukawa, R | 1 |
Saiki, I | 1 |
Liu, G | 1 |
Yamamitsu, S | 1 |
Tsuji, A | 1 |
Shirasaka, T | 1 |
Oikawa, I | 1 |
Kimura, H | 3 |
Denno, R | 1 |
Hoque, A | 1 |
Ellis, L | 1 |
Lozano, R | 1 |
Carrasco, CH | 1 |
Imamoto, E | 1 |
Naito, Y | 1 |
Minami, M | 1 |
Boku, Y | 1 |
Inuma, S | 1 |
Masuyama, M | 1 |
Yoshikawa, T | 1 |
Ho, SK | 1 |
Liew, CT | 1 |
Tang, AM | 2 |
Seno, H | 1 |
Kojima, K | 1 |
Nakajima, N | 1 |
Kohashi, T | 1 |
Katayama, S | 1 |
Fukuda, T | 1 |
Yano, M | 1 |
Katayama, K | 1 |
Dohi, K | 1 |
Nisida, M | 2 |
Kishimoto, S | 1 |
Eurvilaichit, C | 1 |
Kanjanapitak, A | 1 |
Leopairut, J | 1 |
Eichhorst, ST | 1 |
Müller, M | 1 |
Li-Weber, M | 1 |
Angel, P | 1 |
Takayasu, Y | 1 |
Ikeda, J | 1 |
Tominaga, M | 1 |
Takamatsu, M | 1 |
Tsuchida, S | 1 |
Sendou, H | 1 |
Suzuki, Y | 2 |
Kuroda, Y | 1 |
Shirasawa, H | 1 |
Luo, D | 1 |
Habib, NA | 1 |
Sarraf, CE | 1 |
Mitry, RR | 1 |
Havlík, R | 1 |
Nicholls, J | 1 |
Kelly, M | 1 |
Vernon, CC | 1 |
Gueret-Wardle, D | 1 |
El-Masry, R | 1 |
Salama, H | 1 |
Ahmed, R | 1 |
Michail, N | 1 |
Edward, E | 1 |
Jensen, SL | 1 |
Tang, Z | 1 |
Naitoh, M | 1 |
Hara, F | 1 |
Mitunaga, S | 1 |
Ikeda, E | 1 |
Moriyama, S | 1 |
Tuji, T | 1 |
Furutani, S | 1 |
Nawa, S | 1 |
Ohtuka, K | 1 |
Kashiyama, Y | 1 |
Guo, WJ | 1 |
Yu, EX | 1 |
Kawata, S | 3 |
Yamasaki, E | 1 |
Nagase, T | 1 |
Inui, Y | 1 |
Ito, N | 1 |
Inada, M | 1 |
Tamura, S | 2 |
Noda, S | 2 |
Matsuzawa, Y | 1 |
Guseinov, E | 1 |
Horák, D | 1 |
Titova, M | 1 |
Adamyan, A | 1 |
Kokov, L | 1 |
Kubishkin, V | 1 |
Vishnevskii, V | 1 |
Skuba, N | 1 |
Trostenyuk, N | 1 |
Nazmy El Assal, O | 1 |
Llovet, JM | 1 |
Ruff, P | 1 |
Tassopoulos, N | 1 |
Castells, L | 1 |
Bruix, J | 1 |
El-Hariry, I | 1 |
Peachey, M | 1 |
Onishi, Y | 1 |
Yajima, Y | 1 |
Hayashi, C | 1 |
Aoki, C | 1 |
Takahashi, N | 1 |
Miyazaki, A | 1 |
Eda, Y | 1 |
Ohira, S | 1 |
Oikawa, H | 1 |
Xie, H | 1 |
Omuraya, M | 1 |
Matsuda, T | 1 |
Ishiodori, H | 1 |
Hirota, M | 1 |
Fujiyama, S | 1 |
Ogawa, M | 2 |
Tsujinaka, T | 1 |
Furukawa, S | 1 |
Ito, S | 1 |
Hatakeyama, K | 1 |
Maruyama, T | 1 |
Nozue, M | 1 |
Aoyagi, H | 1 |
Sakamoto, T | 1 |
Fukue, M | 1 |
Matsui, S | 1 |
Kodaira, Y | 1 |
Monma, E | 1 |
Takada, Y | 1 |
Shidara, S | 1 |
Ikezawa, K | 1 |
Shimakura, S | 1 |
Okada, S | 2 |
Kuriyama, H | 1 |
Urabe, T | 1 |
Imamura, I | 1 |
Eriguchi, N | 1 |
Yamada, A | 1 |
Nakazaki, H | 2 |
Takita, W | 1 |
Hasebe, Y | 2 |
Tokura, N | 1 |
Seo, A | 1 |
Kurihara, A | 1 |
Takada, M | 1 |
Saito, N | 1 |
Shirasaka, K | 1 |
Benson, AB | 1 |
Mitchell, E | 1 |
Abramson, N | 1 |
Klencke, B | 1 |
Ritch, P | 1 |
Burnhan, JP | 1 |
McGuirt, C | 1 |
Bonny, T | 1 |
Levin, J | 1 |
Hohneker, J | 1 |
Liu-Mares, W | 1 |
Qin, C | 1 |
Zhang, A | 1 |
Cheb, S | 1 |
Tang, W | 1 |
Zuo, G | 1 |
Shen, W | 1 |
Gopalakrishnan, TV | 1 |
Thompson, EB | 1 |
Segerling, M | 3 |
Borsos, T | 3 |
Abe, I | 1 |
Suzuki, T | 2 |
Ono, H | 2 |
Nakase, A | 5 |
Honjo, I | 2 |
Inokuchi, K | 1 |
Iwaki, A | 1 |
Kono, K | 1 |
Yamaguchi, T | 1 |
Mayr, AC | 1 |
Holton, CP | 1 |
Burrington, JD | 1 |
Hatch, EI | 1 |
Oberfield, RA | 3 |
Shiu, MH | 1 |
Fortner, JG | 1 |
Brookhart, W | 1 |
Allen, R | 1 |
Looney, W | 1 |
Hopkins, H | 1 |
Kovacs, C | 1 |
Morris, H | 1 |
Kovacs, CJ | 6 |
Hopkins, HA | 9 |
Simon, RM | 1 |
Looney, WB | 8 |
Murad, F | 1 |
Wilkinson, DS | 4 |
Tlsty, TD | 1 |
Hanas, RJ | 1 |
Fujii, S | 1 |
Okuda, H | 1 |
Akazawa, A | 1 |
Yasuda, Y | 1 |
Terui, S | 1 |
Keczkes, K | 1 |
Barker, DJ | 1 |
Bast, RC | 1 |
Greene, SL | 1 |
Zbar, B | 1 |
Rapp, HJ | 1 |
Kirsch, WM | 2 |
Van Buskirk, JJ | 2 |
Schulz, DW | 1 |
Tabuchi, K | 1 |
Sparks, FC | 1 |
Eilber, FR | 1 |
Holmes, EC | 1 |
Morton, DL | 1 |
McBride, CM | 2 |
Schaffner, JG | 2 |
Trefil, JS | 2 |
Wakefield, JA | 2 |
Crumley, J | 2 |
Goodman, MA | 1 |
Laden, AM | 1 |
Misra, NC | 1 |
Jaiswal, MS | 1 |
Singh, RV | 1 |
Das, B | 1 |
Kennedy, PS | 1 |
Lehane, DE | 1 |
Smith, FE | 1 |
Lane, M | 1 |
Link, JS | 1 |
Bateman, JR | 1 |
Paroly, WS | 1 |
Durkin, WJ | 1 |
Peters, RL | 1 |
Kurihara, M | 1 |
Shirakabe, H | 1 |
Izumi, T | 1 |
Miyasaka, K | 1 |
Ariyama, J | 1 |
Ritenour, R | 1 |
Greenberg, N | 1 |
Schumm, DE | 1 |
Webb, TE | 1 |
Fegiz, G | 1 |
Rosati, D | 1 |
Tonelli, F | 1 |
Donfrancesco, A | 1 |
Cochrane, AM | 1 |
Murray-Lyon, IM | 1 |
Brinkley, DM | 1 |
Williams, R | 2 |
Tret'iakov, AV | 1 |
Riazanov, EM | 1 |
Filov, VA | 1 |
Cory, JG | 1 |
Grady, ED | 1 |
Nolan, TR | 1 |
Crumbley, AJ | 1 |
Rosen, AR | 1 |
Ryan, R | 1 |
Metman, EH | 1 |
Oberfield, R | 1 |
Glouse, M | 1 |
Baker, LH | 1 |
Saiki, JH | 1 |
Jones, SE | 1 |
Hewlett, JS | 1 |
Brownlee, RW | 1 |
Stephens, RL | 1 |
Vaitkevicius, VK | 2 |
Tschopp, L | 1 |
Gerber, A | 1 |
Sonntag, RW | 1 |
Ryssel, HJ | 1 |
Brunner, KW | 1 |
Habs, M | 1 |
Habs, G | 1 |
Schmähl, D | 1 |
Macleod, MS | 1 |
Schlesinger, T | 1 |
Atkins, HL | 1 |
Bradley-Moore, PR | 1 |
Casella, V | 1 |
Fowler, JS | 1 |
Greenberg, D | 1 |
Ido, T | 1 |
Lambrecht, RM | 1 |
MacGregor, R | 1 |
Mantescu, C | 1 |
Neirinckx, R | 1 |
Som, P | 1 |
Wolf, AP | 1 |
Wodinsky, I | 1 |
Meaney, K | 1 |
Gattanell, PN | 1 |
Perloff, M | 1 |
Holland, JF | 1 |
Harada, T | 1 |
Makisaka, Y | 1 |
Nishimura, H | 1 |
Senzer, NN | 1 |
Terrell, W | 1 |
Pratt, CB | 2 |
Lavin, P | 1 |
Pretorius, FJ | 1 |
Watanabe, A | 2 |
Hobara, N | 2 |
Wellwood, JM | 1 |
Cady, B | 1 |
Okazaki, N | 4 |
Ozaki, H | 1 |
Arima, M | 1 |
Hattori, N | 2 |
Kimura, K | 1 |
Schilling, A | 1 |
Gewiese, B | 1 |
Berger, G | 1 |
Boese-Landgraf, J | 1 |
Fobbe, F | 1 |
Stiller, D | 1 |
Gallkowski, U | 1 |
Wolf, KJ | 1 |
Kajanti, M | 1 |
Pyrhönen, S | 1 |
Mäntylä, M | 1 |
Rissanen, P | 1 |
Smith, FW | 1 |
Heys, SD | 1 |
Evans, NT | 1 |
Roeda, D | 1 |
Gvozdanovic, D | 1 |
Eremin, O | 1 |
Mallard, JR | 1 |
Paquet, KJ | 1 |
Kalk, JF | 1 |
Cuan-Orozco, F | 1 |
Siemens, F | 1 |
Koussouris, P | 1 |
Mercado, MA | 1 |
Ito, J | 1 |
Tanzawa, Y | 1 |
Toda, N | 1 |
Okamoto, M | 1 |
Taniguchi, M | 1 |
Uta, Y | 1 |
Tagawa, K | 1 |
van Eeden, H | 1 |
Burger, W | 1 |
Ansell, SM | 1 |
Giovannini, M | 1 |
Kanai, T | 2 |
Gotoh, M | 2 |
Tarui, T | 1 |
Monden, T | 1 |
Mori, T | 3 |
Abe, K | 2 |
Sugata, F | 2 |
Takizawa, K | 2 |
Yoshiba, M | 2 |
Takagi, T | 2 |
Kuniyasu, Y | 2 |
Okada, K | 3 |
Iwao, Y | 2 |
Aikawa, H | 1 |
Kuramoto, S | 1 |
Maeda, T | 1 |
Hanawa, S | 1 |
Yanagita, K | 1 |
Yoshio, T | 1 |
Cantor, A | 1 |
Morioka, N | 1 |
Tanigawa, N | 1 |
Okuda, Y | 1 |
Hashimoto, M | 1 |
Kawasaki, H | 1 |
Midorikawa, H | 2 |
Otani, Y | 1 |
Tsukui, M | 1 |
Goto, K | 1 |
Makuuchi, H | 1 |
Tajima, T | 1 |
Mitomi, T | 1 |
Nose, H | 1 |
Yoshimori, M | 1 |
Aoki, K | 1 |
Dhir, V | 1 |
Swaroop, VS | 1 |
Mohandas, KM | 1 |
Dinshaw, KA | 1 |
Desai, DC | 1 |
Nagral, A | 1 |
Sharma, V | 1 |
Jagannath, P | 1 |
Desouza, LJ | 1 |
Nagabuchi, E | 2 |
Ogasawara, K | 2 |
Saito, M | 2 |
Gotoda, A | 2 |
Takeda, M | 1 |
Mizuguchi, N | 1 |
Ohyama, Y | 1 |
Suzuki, S | 1 |
Itoh, M | 2 |
Mukojima, T | 1 |
Kumagai, T | 1 |
Iwasaki, H | 1 |
Tada, I | 3 |
Mori, K | 2 |
Takeyama, M | 1 |
Matsuoka, S | 2 |
Kitamura, M | 1 |
Miyashita, K | 1 |
Higashi, S | 1 |
Yokomori, K | 1 |
Hori, T | 1 |
Asoh, S | 1 |
Tuji, A | 1 |
Takemura, T | 1 |
Kajanti, MJ | 1 |
Pyrhönen, SO | 1 |
Staines, A | 1 |
Cullen, S | 1 |
Guiney, EJ | 1 |
Fitzgerald, RJ | 1 |
Breatnach, F | 1 |
Kanematsu, T | 5 |
Maehara, Y | 2 |
Matsumata, T | 3 |
Akazawa, K | 1 |
Stillwagon, GB | 2 |
Order, SE | 3 |
Guse, C | 2 |
Leibel, SA | 3 |
Asbell, SO | 1 |
Klein, JL | 3 |
Leichner, PK | 3 |
Order, S | 1 |
Pajak, T | 1 |
Leibel, S | 1 |
Asbell, S | 1 |
Leichner, P | 1 |
Ettinger, D | 1 |
Stillwagon, G | 1 |
Herpst, J | 1 |
Haulk, T | 1 |
Kopher, K | 2 |
Fujii, N | 1 |
Akimura, R | 1 |
Nakamura, Y | 2 |
Watanabe, T | 4 |
Izumi, R | 3 |
Shimizu, K | 3 |
Miyazaki, I | 1 |
Tomida, A | 1 |
Krakamp, B | 1 |
Schmitz, R | 1 |
Knöpfle, G | 1 |
Leidig, P | 1 |
Ohashi, I | 1 |
Oohigashi, H | 1 |
Fukuda, I | 2 |
Persson, BG | 1 |
Jeppsson, B | 1 |
Ekberg, H | 1 |
Tranberg, KG | 1 |
Lundstedt, C | 1 |
Bengmark, S | 1 |
Ng, TB | 1 |
Yeung, HW | 1 |
Borenfreund, E | 1 |
Babich, H | 1 |
Martin-Alguacil, N | 1 |
Hatta, Y | 1 |
Endo, Y | 2 |
Sassa, T | 1 |
Yoshikawa, N | 1 |
Hirose, N | 1 |
Funatomi, H | 1 |
Taguchi, S | 1 |
Fujimoto, S | 1 |
Endoh, F | 1 |
Takahashi, O | 1 |
Okui, K | 1 |
O'Connell, MJ | 2 |
Hahn, RG | 1 |
Rubin, J | 2 |
Fuchimoto, S | 1 |
Yasui, Y | 1 |
Gouchi, A | 1 |
Hamada, F | 1 |
Sanada, E | 1 |
Urakubo, M | 1 |
Okura, M | 1 |
Akamatsu, Y | 1 |
Orita, K | 2 |
Hashimoto, N | 1 |
Kawai, S | 1 |
Mikuriya, S | 1 |
Oda, T | 2 |
Inoue, J | 1 |
Shimamura, Y | 1 |
Takahashi, A | 1 |
Masuzawa, M | 1 |
Yumoto, Y | 1 |
Makino, M | 1 |
Muraoka, A | 1 |
Tokiwa, T | 1 |
Sato, J | 1 |
Strohmeyer, G | 1 |
Porschen, R | 1 |
Sasaki, F | 1 |
Hata, Y | 1 |
Sawada, H | 1 |
Saito, H | 1 |
Kanda, Y | 2 |
Akazawa, S | 1 |
Futatsugi, K | 1 |
Fujiki, T | 1 |
Saifuku, K | 1 |
Suzuki, F | 1 |
Nakajima, T | 1 |
Muraoka, M | 1 |
Hasumura, S | 1 |
Nagamori, S | 1 |
Fujise, K | 1 |
Homma, S | 1 |
Sujino, H | 1 |
Niiya, M | 1 |
Kameda, H | 1 |
Yano, S | 2 |
Tarumi, T | 3 |
Tamura, K | 2 |
Shimada, M | 1 |
Ling, HY | 1 |
Wang, NZ | 1 |
Shiga, T | 1 |
Nishimaki, K | 1 |
Kajikawa, S | 1 |
Horigome, N | 1 |
Hanasaki, K | 1 |
Adachi, W | 1 |
Kinosita, T | 1 |
Sodeyama, H | 1 |
Kuroda, T | 1 |
Iida, F | 1 |
Okajima, K | 1 |
Isozaki, H | 1 |
Nakata, E | 1 |
Nishimura, J | 1 |
Iga, C | 1 |
Amioka, K | 1 |
Tanimura, M | 1 |
Hara, H | 1 |
Haida, K | 2 |
Mitarai, Y | 1 |
Shibata, T | 1 |
Hurukawa, H | 1 |
Yabushita, K | 2 |
Horichi, H | 1 |
Kitabayashi, K | 1 |
Urade, M | 2 |
Iyobe, T | 1 |
Segawa, M | 1 |
Nagafuchi, E | 1 |
Misawa, K | 1 |
Takekawa, S | 1 |
Ye, WJ | 1 |
Bedenne, L | 1 |
Chauffert, B | 1 |
Lorcerie, B | 1 |
Faivre, J | 1 |
Hillon, P | 1 |
Klepping, C | 1 |
Martin, F | 1 |
Hamazaki, K | 1 |
Mimura, H | 1 |
Fishman, EK | 1 |
Soga, K | 1 |
Turuya, T | 1 |
Toshima, M | 1 |
Shibasaki, K | 1 |
Matugi, H | 1 |
Kawai, C | 1 |
Asakura, H | 1 |
Recchia, F | 1 |
Passalacqua, G | 1 |
Rodorigo, C | 1 |
Belli, L | 1 |
Morgante, A | 1 |
Rabitti, G | 1 |
Higashi, H | 2 |
Ogita, S | 3 |
Tokiwa, K | 3 |
Suenaga, M | 2 |
Lin, DY | 1 |
Liaw, YF | 1 |
Lee, TY | 1 |
Lai, CM | 1 |
Nerenstone, S | 1 |
Friedman, M | 1 |
Hannigan, JF | 1 |
Carter, SK | 1 |
Zaniboni, A | 1 |
Simoncini, E | 1 |
Marpicati, P | 1 |
Marini, G | 1 |
Doci, R | 1 |
Bignami, P | 1 |
Bozzetti, F | 1 |
Bonfanti, G | 1 |
Audisio, R | 1 |
Colombo, M | 1 |
Gennari, L | 1 |
Herlin, T | 1 |
Norup, K | 1 |
Storm, K | 1 |
Fujimura, T | 1 |
Ohhori, I | 1 |
Yonemura, Y | 1 |
Tsuda, M | 1 |
Nishioka, S | 1 |
Yataka, I | 1 |
Onoyama, Y | 1 |
Kanno, T | 1 |
Nakatsuka, H | 1 |
Hamazoe, R | 1 |
Koga, S | 2 |
Shimizu, N | 1 |
Sawata, T | 1 |
Ishiguro, M | 1 |
Wakatsuki, T | 2 |
Murakami, A | 2 |
Kusumoto, T | 1 |
Al-Idrissi, HY | 1 |
Ibrahim, EM | 1 |
Abdel Satir, A | 1 |
Satti, MB | 1 |
Al-Kasem, S | 1 |
Al-Qurain, A | 1 |
Green, AA | 1 |
Wrenn, E | 1 |
Champion, J | 1 |
Shipp, M | 1 |
Ohtsuki, T | 1 |
Obata, H | 1 |
Tomimatsu, M | 1 |
Hasegawa, H | 1 |
Ohnishi, K | 1 |
Rao, A | 1 |
O'Connell, TX | 1 |
Kagan, AR | 1 |
Steckel, RJ | 1 |
Marymont, JV | 1 |
Dakhil, SR | 1 |
Travers, H | 1 |
Housholder, DF | 1 |
Kido, C | 1 |
Kawazoe, Y | 1 |
Yamashita, K | 1 |
Kumagai, M | 1 |
Maeta, M | 1 |
Yoshioka, H | 1 |
Wang, CE | 1 |
Cao, XH | 1 |
Zhen, YY | 1 |
Kondo, H | 1 |
Fuse, M | 1 |
Naitoh, A | 1 |
Schutt, AJ | 1 |
Wieand, HS | 1 |
Glimelius, B | 1 |
Ettinger, DS | 1 |
Finney, K | 1 |
Surdyke, M | 1 |
Yamazaki, H | 1 |
Horikoshi, N | 1 |
Ueno, K | 1 |
Mukaiyama, T | 1 |
Miyaoka, K | 1 |
Iwamura, F | 1 |
Kimura, S | 1 |
Livraghi, T | 1 |
Ravetto, C | 1 |
Solbiati, L | 1 |
Suter, F | 1 |
Andersson, M | 1 |
Billström, A | 1 |
Domellöf, L | 1 |
Gustavsson, B | 1 |
Sato, R | 1 |
Ouchi, K | 1 |
Owada, Y | 1 |
Saitoh, R | 1 |
Miyoshi, S | 1 |
Tarui, S | 1 |
Imashuku, S | 1 |
Bezwoda, WR | 1 |
Weaving, A | 1 |
Kew, M | 1 |
Derman, DP | 1 |
Massey, WH | 2 |
Fletcher, WS | 2 |
Judkins, MP | 1 |
Dennis, DL | 2 |
Kanamoto, Y | 1 |
McIntire, KR | 1 |
Vogel, CL | 1 |
Princler, GL | 1 |
Patel, IR | 1 |
Weiss, JW | 1 |
Pitot, HC | 2 |
Fain, WR | 1 |
Conn, JH | 1 |
Chavez, CM | 1 |
Provan, JL | 1 |
Stokes, JF | 1 |
Edwards, D | 1 |
Kissel, P | 1 |
Bessot, M | 4 |
Duprez, A | 3 |
Geddes, EW | 1 |
Gorgun, B | 1 |
Watne, AL | 1 |
Champeau, M | 1 |
Arsac, M | 1 |
Pineau, P | 1 |
Thevenin, F | 1 |
Fays, J | 1 |
Grilliat, JP | 1 |
Anderson, JM | 1 |
Alberto, P | 1 |
Matsui, K | 1 |
Tomoe, T | 1 |
Terajima, S | 1 |
Yamasato, M | 1 |
Kondo, J | 1 |
Katsuta, K | 1 |
Hozumi, M | 1 |
Pashintseva, LP | 1 |
Krusanova, NI | 1 |
Assekritova, IV | 1 |
Ramirez, G | 1 |
Ansfield, FJ | 1 |
Curreri, AR | 1 |
Thompson, RP | 1 |
Nicholson, DC | 1 |
Farnan, T | 1 |
Whitmore, DN | 1 |
Wolberg, WH | 1 |
Sanderson, TA | 1 |
Wood, DC | 1 |
Mauuary, G | 1 |
Winsback, AM | 1 |
White, WD | 1 |
Juniper, K | 1 |
Daido, R | 1 |
Koike, A | 1 |
Nomiyama, Y | 1 |
Francis, TI | 1 |
Sugimura, M | 1 |
Ishida, M | 1 |
Iwamura, K | 1 |
Harrison, NW | 1 |
Dhru, D | 1 |
Primack, A | 1 |
Bhana, D | 1 |
Kyalwazi, SK | 1 |
al-Sarraf, M | 1 |
Go, TS | 1 |
Kithier, K | 1 |
Scott, D | 1 |
Theologides, A | 1 |
Stehlin, JS | 1 |
Hafström, L | 1 |
Greeff, PJ | 1 |
Plagemann, PG | 1 |
Erbe, J | 1 |
Schulz, D | 1 |
Young, HE | 1 |
Linder, GT | 1 |
Crook, JN | 1 |
Cohn, I | 1 |
Russell, DH | 1 |
Marton, LJ | 1 |
LeGendre, SM | 1 |
Morris, HP | 2 |
Lea, MA | 1 |
Khalil, FL | 1 |
Bullock, J | 1 |
Douglass, HO | 1 |
Mittelman, A | 1 |
Koyama, S | 1 |
Majima, S | 1 |
Matsushige, H | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Phase II Trial of Hepatic Arterial inFusion Chemotherapy Sequential transaRterial Embolization cOmbined With leNvatinib and Tislelizumab in Unresectable Hepatocellular Carcinoma (FRONT Trial)[NCT05532319] | Phase 2 | 65 participants (Anticipated) | Interventional | 2022-02-01 | Recruiting | ||
Immune Checkpoint Inhibitor Monotherapy or Combined With Molecular Targeted Drugs / Locoregional Therapy in the Treatment of Hepatocellular Carcinoma[NCT05609695] | 100 participants (Anticipated) | Observational | 2023-03-01 | Not yet recruiting | |||
A Study of the Application of Hepatic Arterial Infusion in Advanced Hepatocellular Carcinoma Previously Treated With Immune Checkpoint Inhibitors and Antiangiogenic Agents[NCT05718492] | 100 participants (Anticipated) | Interventional | 2022-10-18 | Recruiting | |||
Observation Study of Sequential Regorafenib Combined With Immunocheckpoint Inhibitors After Hepatic Artery Infusion Chemotherapy for Advanced Hepatocellular Carcinoma[NCT05573282] | 50 participants (Anticipated) | Observational | 2022-10-16 | Recruiting | |||
A Phase III Randomized Trial of Comparison of Survival Benefit of Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil/Leucovorin With Sorafenib for Patients With Barcelona-Clinic Liver Cancer (BCLC)-C Stage Hepatocellular Carcinoma[NCT03164382] | Phase 3 | 262 participants (Actual) | Interventional | 2017-03-01 | Completed | ||
A Randomized Controlled Study of the Efficacy of Hepatic Arterial Perfusion Chemotherapy Concurrently Compared to Sequentially Combined With Targeted and Immunotherapy in Potentially Resectable Intermediate and Advanced HCC[NCT06041477] | Phase 3 | 540 participants (Anticipated) | Interventional | 2023-09-30 | Recruiting | ||
Observational Study of Factors Predicting Therapeutic Effects and Clinical Prognosis After Hepatic Artery Infusion Chemotherapy (HAIC) for Locally Advanced Hepatocellular Carcinoma (HCC)[NCT05002452] | 150 participants (Anticipated) | Observational | 2021-12-20 | Recruiting | |||
An Open Label Pilot Study to Evaluate Efficacy and Safety of Durvalumab(MEDI 4736) With Hepatic Artery Infusion Chemotherapy (HAIC) in the Chinese Advanced HCC Patients With Severe Portal Vein Tumor Thrombosis (PVTT)(Vp3 or Vp4) DurHope[NCT04945720] | Phase 2 | 30 participants (Anticipated) | Interventional | 2022-04-11 | Recruiting | ||
A Prospective, Multicenter, Phase III Clinical Study Comparing Continuous Hepatic Arterial Infusion of Raltetrexed With Oxaliplatin(SALOX) Versus FOLFOX in Advanced Hepatocellular Carcinoma[NCT05231382] | Phase 3 | 426 participants (Anticipated) | Interventional | 2022-03-28 | Recruiting | ||
Hepatic Arterial Infusion Chemotherapy Combined With PD-1 Inhibitor in Treating Potentially Resectable Locally Advanced Hepatocellular Carcinoma: A Prospective, Phase II Clinical Study[NCT03869034] | Phase 2 | 40 participants (Actual) | Interventional | 2019-03-25 | Active, not recruiting | ||
Lenvatinib Combined With Hepatic Arterial Infusion of Modified FOLFOX Regimen Versus Lenvatinib Combined With Hepatic Arterial Infusion of ROX Regimen in the Treatment of Advanced Hepatocellular Carcinoma[NCT05007587] | Early Phase 1 | 60 participants (Anticipated) | Interventional | 2021-07-01 | Enrolling by invitation | ||
A Randomized Controlled, Open-label, Multicenter Phase III Clinical Trial to Evaluate the Effectiveness and Safety of Hepatic Arterial Infusion Chemotherapy (HAIC) of Oxaliplatin, 5-fluorouracil and Leucovorin (mFOLFOX7) Combined With Apatinib and Camreli[NCT05313282] | Phase 3 | 140 participants (Anticipated) | Interventional | 2022-06-15 | Recruiting | ||
A Prospective, Single-arm, Phase II Trial to Evaluate the Effectiveness and Safety of Hepatic Arterial Infusion Chemotherapy (HAIC) of Oxaliplatin, 5-fluorouracil and Leucovorin (mFOLFOX7) Combined With Apatinib-Mesylate Tablets and Camrelizumab for Injec[NCT04191889] | Phase 2 | 47 participants (Anticipated) | Interventional | 2020-04-13 | Recruiting | ||
An Exploratory Study of Sorafenib Plus Toripalimab for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus[NCT04069949] | Phase 1/Phase 2 | 39 participants (Anticipated) | Interventional | 2019-12-01 | Not yet recruiting | ||
Neoadjuvant Radiotherapy for Patients With Hepatocellular Carcinoma Involving Type I Portal Vein Tumor Thrombus[NCT04025437] | Phase 2/Phase 3 | 214 participants (Anticipated) | Interventional | 2019-03-01 | Active, not recruiting | ||
Sorafenib Alone Versus Sorafenib Combined With Hepatic Arterial Chemoinfusion for Advanced HCC With Portal Vein Tumor Thrombosis: a Multicentre Randomised Controlled Trial[NCT02774187] | Phase 3 | 247 participants (Actual) | Interventional | 2016-05-31 | Completed | ||
A Prospective, Single-armed, Multicentric, Explorative Phase II Clinical Research of Conversional Therapy With Combination of Hepatic Arterial Infusion Chemotherapy and Donafenib and Toripalimab for Unresectable Hepatocellular Carcinoma[NCT05493332] | Phase 2 | 93 participants (Anticipated) | Interventional | 2022-09-30 | Not yet recruiting | ||
Hepatic Arterial Infusion Chemotherapy as Adjuvant Treatment in the Prevention of Recurrence of Hepatocellular Carcinoma(HCC): A Prospective Randomized Controlled Clinical Trial[NCT02767375] | Phase 2/Phase 3 | 192 participants (Anticipated) | Interventional | 2015-02-28 | Recruiting | ||
The Clinical Randomized Trial of Adjuvant Chemotherapy With FOLFOX in HCC Patients at High Risk After Resection[NCT02738697] | Phase 3 | 290 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | ||
Systemic Chemotherapy VersusTranscatheter Arterial Chemoembolization As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma(HCC)[NCT02585479] | Phase 2/Phase 3 | 0 participants (Actual) | Interventional | 2015-10-31 | Withdrawn (stopped due to It doesn't meet the requirements of randomized trials) | ||
A Randomized Controlled Trial of Radical Hepatectomy With Adjuvant Transcatheter Arterial Chemoembolization Versus Adjuvant Systemic Chemotherapy for Hepatocellular Carcinoma[NCT02584556] | Phase 2/Phase 3 | 0 participants (Actual) | Interventional | 2015-10-31 | Withdrawn | ||
Gemcitabine Plus Oxaliplatin (GEMOX) Versus Oxaliplatin Plus Fluorouracil/Leucovorin(FOLFOX4) As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma(HCC)[NCT02534337] | Phase 2/Phase 3 | 0 participants (Actual) | Interventional | 2015-09-30 | Withdrawn (stopped due to It doesn't meet the requirements of randomized trials) | ||
Liposomal Doxorubicin(LD) Plus Gemcitabine Versus Oxaliplatin Plus Fluorouracil/Leucovorin(FOLFOX4) As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma(HCC)[NCT02527772] | Phase 2/Phase 3 | 0 participants (Actual) | Interventional | 2015-09-30 | Withdrawn (stopped due to It doesn't meet the requirements of randomized trials) | ||
Hepatic Resection Combined With or Without Oxaliplatin+5-Fluorouracil/ Leucovorin(5-FU/LV)(FOLFOX4) for Resectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus[NCT02452853] | Phase 2 | 51 participants (Anticipated) | Interventional | 2015-05-31 | Active, not recruiting | ||
RFA Combined With Oxaliplatin + 5-FluoroUracil/LeucoVorin (5-FU/LV) (FOLFOX4) for Recurrent HCC:an Open Lable, Single-arm, Prospective Study[NCT02426450] | Phase 2 | 28 participants (Anticipated) | Interventional | 2015-04-30 | Active, not recruiting | ||
Oxaliplatin(Eloxatin®) + 5-FU/LV (FOLFOX4) Compared With Single Agent Doxorubicin (Adriamycin®) as Palliative Chemotherapy in Advanced Hepatocellular Carcinoma Patients Ineligible for Curative Resection or Local Treatment[NCT00471965] | Phase 3 | 371 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
A Prospective, Observational, Single-center Post-marketing Surveillance Study of Telbivudine in Chronic Hepatitis B Adults With HBeAg Positive/Negative.[NCT00970216] | 160 participants (Actual) | Observational | 2009-02-28 | Completed | |||
A Phase II Randomized Placebo-Controlled Study Investigating The Combination Of YIV-906 And Sorafenib (Nexavar®) In HBV (+) Patients With Advanced Hepatocellular Carcinoma[NCT04000737] | Phase 2 | 125 participants (Anticipated) | Interventional | 2020-01-10 | Recruiting | ||
Phase II Study of Sorafenib (Bay 43-9006) and Infusional 5-Fluorouracil in Advanced Hepatocellular Carcinoma.[NCT00619541] | Phase 2 | 46 participants (Anticipated) | Interventional | 2007-01-31 | Completed | ||
A Phase 1 Study of PTC596 in Patients With Advanced Solid Tumors[NCT02404480] | Phase 1 | 31 participants (Actual) | Interventional | 2016-01-31 | Completed | ||
Human Liver Explants for HIF-1 Alpha- Analysis/Comparison[NCT00866957] | 180 participants (Actual) | Observational | 2006-02-28 | Completed | |||
Randomized Phase 2 Study of Capecitabine vs Gemcistabine Plus Cisplatin in Patients With Resected Extrahepatic Cholangiocarcinoma With Regional Lymph Node Metastasis[NCT03079427] | Phase 2 | 101 participants (Actual) | Interventional | 2017-05-15 | Completed | ||
Randomized Open-label Trial of Dose Dense, Fixed Dose Capecitabine Compared to Standard Dose Capecitabine in Metastatic Breast Cancer and Advanced/Metastatic Gastrointestinal Cancers.[NCT02595320] | Phase 2 | 200 participants (Actual) | Interventional | 2015-10-05 | Active, not recruiting | ||
A Humanitarian Device Exemption Use Protocol of Therasphere® for Treatment of Unresectable Hepatocellular and Metastatic Liver Tumors - HDE #980006[NCT00701168] | 0 participants | Expanded Access | No longer available | ||||
Combined Modality Therapy in Hepatoblastoma: South Egypt Cancer Institute Experience[NCT02557750] | 35 participants (Anticipated) | Observational | 2016-01-31 | Recruiting | |||
Phase II Trial of Sorafenib Combined With Concurrent Hepatic Arterial Infusion (HAI) of Oxaliplatin, 5-fluorouracil and Leucovorin for Hepatocellular Carcinoma[NCT02981498] | Phase 2 | 35 participants (Anticipated) | Interventional | 2015-06-30 | Completed | ||
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma[NCT02733809] | Phase 4 | 40 participants (Anticipated) | Interventional | 2014-01-31 | Recruiting | ||
Phase II Randomized Trial Evaluating the Administration of Sorafenib or Pravastatin or Association Sorafenib-pravastatin or Best Supportive Care for the Palliative Treatment of Hepatocellular Carcinoma in Patient With CHILD B Cirrhosis[NCT01357486] | Phase 2 | 160 participants (Actual) | Interventional | 2011-11-14 | Completed | ||
Efficacy and Safety of Donafenib Combined With TACE as Adjuvant Therapy of Patients With Hepatocellular Carcinoma at a High Risk of Recurrence After Radical Resection[NCT05161143] | Phase 2 | 30 participants (Anticipated) | Interventional | 2021-12-31 | Not yet recruiting | ||
The Efficacy, Safety, and Patient Reported Outcomes of Different Regimens of Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma[NCT00493402] | Phase 3 | 365 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
A Randomized Phase II Trial of Coriolus Versicolor as Palliative Therapy Compared to Placebo in Patients With Child-Pugh C Unresectable Hepatocellular Carcinoma or Who Are Unfit for Standard Therapy[NCT01097083] | Phase 2 | 20 participants | Interventional | 2010-04-30 | Terminated | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
(NCT00970216)
Timeframe: 48 weeks
Intervention | participants (Number) |
---|---|
Chronic Hepatitis B | 79 |
52 reviews available for fluorouracil and Hepatocellular Carcinoma
Article | Year |
---|---|
Use of chemotherapy to treat hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therap | 2022 |
Formulation of two lipid-based membrane-core nanoparticles for FOLFOX combination therapy.
Topics: Animals; Carcinoma, Hepatocellular; Colorectal Neoplasms; Fluorodeoxyuridylate; Fluorouracil; Lipids | 2022 |
Efficacy of various adjuvant chemotherapy methods in preventing liver metastasis from potentially curative colorectal cancer: A systematic review network meta-analysis of randomized clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; C | 2023 |
Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2023 |
Hepatic arterial infusion chemotherapy for patients with hepatocellular carcinoma: Applicability in Western countries.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Fluorouracil; Humans; Liv | 2023 |
Cisplatin in Liver Cancer Therapy.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cisplatin; Fluorouracil; Humans; Liver Ne | 2023 |
The worthy role of hepatic arterial infusion chemotherapy in combination with anti-programmed cell death protein 1 monoclonal antibody immunotherapy in advanced hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Cell Death; Cisplatin; Fluorouracil; Humans; Immunotherapy; Liver Neoplas | 2023 |
Oxaliplatin/5-fluorouracil in advanced hepatocellular carcinoma: case report and single-center retrospective review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Child; Embolization, Ther | 2014 |
[A case of long-term survival after low-dose FP systemic chemotherapy for a tumor thrombus in the inferior caval vein and multiple lung metastases from recurrent hepatocellular carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorour | 2014 |
Progress in systemic therapy of advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Deoxycytidine; Fluorourac | 2016 |
A case of unresectable combined hepatocellular cholangiocarcinoma showing favorable response to LFP therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Carcinoma, Hepatocellular; Chol | 2016 |
Significant efficacy and well safety of apatinib in an advanced liver cancer patient: a case report and literature review.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Ch | 2017 |
Therapeutic strategy of advanced hepatocellular carcinoma by using combined intra-arterial chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Clinical Trial | 2008 |
Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2009 |
Treatment of advanced hepatocellular carcinoma: intraarterial infusion chemotherapy combined with interferon.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Clinical Trials as Topic; | 2010 |
[Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Hepatocellular; Cisplatin; Fluoro | 2012 |
[Development and research of the new therapy for hepatocellular carcinoma--combined interferon and 5-fluorouracil therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Fluorouracil; Humans; Inf | 2002 |
Fibrolamellar hepatocellular carcinoma in children and adolescents.
Topics: Adolescent; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel | 2003 |
Successful treatment of radiofrequency-induced biliary lesions by interventional endoscopic retrograde cholangiography (ERC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract; Carcinoma, Hepatocellula | 2003 |
[The chemotherapy for hepatocellular carcinoma].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cis | 2003 |
[Recent progress in chemotherapy for hepatocellular carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; C | 2004 |
[Chemotherapy for hepatocellular carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Clinical Trial | 2004 |
Apoptotic and anti-angiogenic strategies in liver and gastrointestinal malignancies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2005 |
[FAIT (FU arterial infusion and interferon therapy) for hepatocellular carcinoma].
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Drug Synergism; Drug Th | 2006 |
[The progress of hepatic arterial infusion chemotherapy for hepatocellular carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Drug Administr | 2006 |
[Gemcitabine and digestive carcinomas].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopl | 2007 |
[Angiogenesis targeting in gastro-intestinal cancers].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2007 |
Safety of capecitabine use in patients with liver dysfunction.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Drug-Relate | 2007 |
[Recent developments in systemic chemotherapy for hepatocellular carcinoma].
Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Capecitabi | 2008 |
[Hepatic tumors].
Topics: alpha-Fetoproteins; Angiography; Breast Neoplasms; Bronchial Neoplasms; Carcinoembryonic Antigen; Ca | 1983 |
Update on regional treatments for hepatobiliary malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma, Hepatocellular; | 1995 |
Cancers of the large bowel and hepatobiliary tract.
Topics: Carcinoma, Hepatocellular; Colorectal Neoplasms; Fluorouracil; Humans; Liver Neoplasms; Pancreatic N | 1994 |
Adjuvant chemotherapy improves survival after liver transplantation for hepatocellular carcinoma.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatoce | 1995 |
Medical treatment of hepatocellular carcinoma: any progress?
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 1994 |
Mitoxantrone, 5-FU + folinic acid, mitomycin C for regional chemotherapy of malignant liver tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Cancer, Reg | 1996 |
Intra-hepatic arterial drug delivery.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Col | 1996 |
Review article: Overview of medical treatments in unresectable hepatocellular carcinoma--an impossible meta-analysis?
Topics: Administration, Cutaneous; Antineoplastic Agents; Carcinoma, Hepatocellular; Doxorubicin; Ethanol; F | 1998 |
Adjuvant chemotherapy after resection of hepatocellular carcinoma causes deterioration of long-term prognosis in cirrhotic patients: metaanalysis of three randomized controlled trials.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Hepa | 2001 |
Transcriptional targeted gene therapy for hepatocellular carcinoma by adenovirus vector.
Topics: Adenoviruses, Human; alpha-Fetoproteins; Animals; Antineoplastic Protocols; Antiviral Agents; Carcin | 2001 |
Nonsurgical treatment of hepatocellular carcinoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Capecitabine; Carcinoma, Hepatocellular; Chemoemboli | 2001 |
Systemic therapy for hepatocellular carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protoco | 2001 |
[Hepatic arterial infusion chemotherapy using 'low dose FP'].
Topics: Administration, Sublingual; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellula | 2001 |
[Adverse reaction of hepatic arterial infusion chemotherapy for hepatocellular carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Catheters, Indwelling; Ci | 2001 |
[Hepatic arterial infusion chemotherapy combined with interferon-alpha for hepatocellular carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Administration Sched | 2001 |
[Chemotherapy of gastrointestinal tumors (review of the literature)].
Topics: Ancitabine; Carcinoma, Hepatocellular; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combination; Fl | 1978 |
Therapeutic approaches to hepatoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Catheterization; Drug Synergism; Drug Therapy, Com | 1975 |
The biologic basis of malignant brain tumor therapy.
Topics: Animals; BCG Vaccine; Brain Neoplasms; Carcinoma, Hepatocellular; Culture Techniques; DNA, Neoplasm; | 1976 |
[Selective chemotherapy of hepatocellular carcinomas].
Topics: Animals; Carcinoma, Hepatocellular; Doxorubicin; Fluorouracil; Humans; Liver Neoplasms; Liver Neopla | 1978 |
[Interdisciplinary therapy concepts in primary and secondary neoplasms of the liver].
Topics: Carcinoma, Hepatocellular; Combined Modality Therapy; Floxuridine; Fluorouracil; Follow-Up Studies; | 1989 |
[Hepatocellular carcinoma (HCC): the long-term response to tamoxifen. A clinical case report and review of the literature].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Drug Evaluatio | 1989 |
Medical treatment of hepatocellular carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Co | 1987 |
Systemic cytostatic drug therapy in liver cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Clinical Trials as Topic; | 1986 |
128 trials available for fluorouracil and Hepatocellular Carcinoma
Article | Year |
---|---|
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China; | 2022 |
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China; | 2022 |
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China; | 2022 |
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China; | 2022 |
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China; | 2022 |
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China; | 2022 |
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China; | 2022 |
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China; | 2022 |
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China; | 2022 |
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China; | 2022 |
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China; | 2022 |
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China; | 2022 |
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China; | 2022 |
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China; | 2022 |
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China; | 2022 |
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China; | 2022 |
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China; | 2022 |
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China; | 2022 |
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China; | 2022 |
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China; | 2022 |
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China; | 2022 |
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China; | 2022 |
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China; | 2022 |
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China; | 2022 |
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; China; | 2022 |
Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: A biomolecular exploratory, phase II trial.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotr | 2022 |
Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With FOLFOX in Hepatocellular Carcinoma With Microvascular Invasion: A Multicenter, Phase III, Randomized Study.
Topics: Adjuvants, Immunologic; Carcinoma, Hepatocellular; Fluorouracil; Humans; Infusions, Intra-Arterial; | 2023 |
Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With FOLFOX in Hepatocellular Carcinoma With Microvascular Invasion: A Multicenter, Phase III, Randomized Study.
Topics: Adjuvants, Immunologic; Carcinoma, Hepatocellular; Fluorouracil; Humans; Infusions, Intra-Arterial; | 2023 |
Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With FOLFOX in Hepatocellular Carcinoma With Microvascular Invasion: A Multicenter, Phase III, Randomized Study.
Topics: Adjuvants, Immunologic; Carcinoma, Hepatocellular; Fluorouracil; Humans; Infusions, Intra-Arterial; | 2023 |
Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With FOLFOX in Hepatocellular Carcinoma With Microvascular Invasion: A Multicenter, Phase III, Randomized Study.
Topics: Adjuvants, Immunologic; Carcinoma, Hepatocellular; Fluorouracil; Humans; Infusions, Intra-Arterial; | 2023 |
Combined FOLFOX4 with all-trans retinoic acid versus FOLFOX4 with placebo in treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a randomized, double-blind comparative study.
Topics: Carcinoma, Hepatocellular; Fluorouracil; Humans; Liver Neoplasms; Treatment Outcome; Tretinoin | 2023 |
A Phase II Clinical Trial on the Combination Therapy of PHY906 Plus Capecitabine in Hepatocellular Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular; Drugs, Chin | 2021 |
Camrelizumab Combined with FOLFOX4 Regimen as First-Line Therapy for Advanced Hepatocellular Carcinomas: A Sub-Cohort of a Multicenter Phase Ib/II Study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carc | 2021 |
Assessment of pegylated arginine deiminase and modified FOLFOX6 in patients with advanced hepatocellular carcinoma: Results of an international, single-arm, phase 2 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel | 2021 |
A Phase I/II trial of continuous hepatic intra-arterial infusion of 5-fluorouracil, mitoxantrone and cisplatin for advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Catheters; C | 2017 |
Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): an open label, non-comparative, phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel | 2018 |
A phase 1 study of ADI-PEG 20 and modified FOLFOX6 in patients with advanced hepatocellular carcinoma and other gastrointestinal malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocel | 2018 |
Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cat | 2018 |
All-trans-retinoic acid (ATRA) plus oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX) versus FOLFOX alone as palliative chemotherapy in patients with advanced hepatocellular carcinoma and extrahepatic metastasis: study protocol for a randomized controll
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; China; Disease Progressio | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2019 |
[Clinical outcomes of radiofrequency ablation combined with transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma: a single-center experience].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Catheter Ablation; | 2013 |
Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Carcinoma, Hepato | 2013 |
Interventionally implanted port catheter systems for hepatic arterial infusion of chemotherapy in patients with primary liver cancer: a phase II-study (NCT00356161).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrah | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2013 |
Metronomic capecitabine in advanced hepatocellular carcinoma patients: a phase II study.
Topics: Administration, Metronomic; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecit | 2013 |
A phase I/II trial of capecitabine combined with peginterferon α-2a in Patients with sorafenib-refractory advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcin | 2014 |
Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Hepatocellular; Doxo | 2014 |
Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Hepatocellular; Doxo | 2014 |
Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Hepatocellular; Doxo | 2014 |
Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Hepatocellular; Doxo | 2014 |
Significant renoprotective effect of telbivudine during preemptive antiviral therapy in advanced liver cancer patients receiving cisplatin-based chemotherapy: a case-control study.
Topics: Acute Kidney Injury; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoc | 2014 |
A randomized study of cisplatin and 5-FU hepatic arterial infusion chemotherapy with or without adriamycin for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2015 |
Arterial infusion of 5-fluorouracil combined with subcutaneous injection of pegylated interferon alpha-2b in treating unresectable hepatocellular carcinoma with portal vein tumor thrombus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Fluo | 2015 |
Pilot Study of Hepatic Arterial Infusion Chemotherapy with Interferon-beta and 5-fluorouracil: A New Chemotherapy for Patients with Advanced Hepatocellular Carcinoma.
Topics: Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma, Hep | 2014 |
Chemoembolization alone vs combined chemoembolization and hepatic arterial infusion chemotherapy in inoperable hepatocellular carcinoma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, | 2015 |
Hepatic arterial infusion chemoembolization therapy for advanced hepatocellular carcinoma: multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cispl | 2016 |
Raltitrexed plus oxaliplatin-based transarterial chemoembolization in patients with unresectable hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoemboliz | 2016 |
Influence of the etiology of liver cirrhosis on the response to combined intra-arterial chemotherapy in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel | 2009 |
Multiple hepatic arterial injections of recombinant adenovirus p53 and 5-fluorouracil after transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a pilot phase II trial.
Topics: Adenoviruses, Human; Adult; Aged; Antimetabolites, Antineoplastic; Body Fluids; Carcinoma, Hepatocel | 2009 |
Intra-arterial 5-fluorouracil/interferon combination therapy for advanced hepatocellular carcinoma with or without three-dimensional conformal radiotherapy for portal vein tumor thrombosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Mod | 2009 |
A randomized comparative study of high-dose and low-dose hepatic arterial infusion chemotherapy for intractable, advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; D | 2010 |
Clinical studies of laser ablation in treatment of primary liver carcinoma-associated portal vein tumor thrombus.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Mod | 2010 |
Phase I/II study of PHY906/capecitabine in advanced hepatocellular carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular; Deoxy | 2009 |
Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2010 |
Adjuvant therapy with capecitabine postpones recurrence of hepatocellular carcinoma after curative resection: a randomized controlled trial.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; C | 2010 |
Hepatic arterial infusion chemotherapy using low-dose 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; F | 2010 |
Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2011 |
Final results of a prematurely discontinued Phase 1/2 study of eniluracil with escalating doses of 5-fluorouracil administered orally in patients with advanced hepatocellular carcinoma.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Hepat | 2011 |
A comparative study of high-dose hepatic arterial infusion chemotherapy and transarterial chemoembolization using doxorubicin for intractable, advanced hepatocellular carcinoma.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellul | 2010 |
Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonate | 2012 |
Combination adjuvant chemotherapy with oxaliplatin, 5-fluorouracil and leucovorin after liver transplantation for hepatocellular carcinoma: a preliminary open-label study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adju | 2011 |
Phase II trial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; C | 2012 |
Adjuvant hepatic arterial infusional chemotherapy with 5-fluorouracil and cisplatin after curative resection of hepatocellular carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adju | 2011 |
Therapeutic efficacy of combination therapy with intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma with portal venous invasion.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel | 2012 |
Randomized, phase II study comparing interferon combined with hepatic arterial infusion of fluorouracil plus cisplatin and fluorouracil alone in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel | 2011 |
Prospective evaluation of transcatheter arterial chemoembolization (TACE) with multiple anti-cancer drugs (epirubicin, cisplatin, mitomycin c, 5-fluorouracil) compared with TACE with epirubicin for treatment of hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Angiography; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hep | 2012 |
Serum vascular endothelial growth factor as a predictor of response and survival in patients with advanced hepatocellular carcinoma undergoing hepatic arterial infusion chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2012 |
Combination treatment of localized concurrent chemoradiation therapy and transarterial chemoembolization in locally advanced hepatocellular carcinoma with intrahepatic metastasis.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chemoradiotherapy; Combined | 2013 |
Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Female; | 2002 |
Treatment of hepatocellular carcinoma (HCC) with systemic chemotherapy combining epirubicin, cisplatinum and infusional 5-fluorouracil (ECF regimen).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Cohort S | 2002 |
[Concurrent chemo-radiation therapy for advanced hepatocellular carcinoma with portal vein thrombosis].
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cisplatin; Combined Modality Therapy; Female; Fluo | 2002 |
Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2003 |
[Clinical study on treatment of middle-advanced stage liver cancer by combined treatment of hepatic artery chemoembolization with gan'ai no. I and no. II].
Topics: Administration, Cutaneous; Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Ch | 2001 |
[Dynamics of clinical and biochemical indices in patients with primary liver cancer during endovascular chemotherapy].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2002 |
Fibrolamellar hepatocellular carcinoma in children and adolescents.
Topics: Adolescent; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel | 2003 |
Study of local three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for patients with stage III hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoemboliz | 2003 |
Tamoxifen combined with octreotide or regular chemotherapeutic agents in treatment of primary liver cancer: a randomized controlled trial.
Topics: Adult; Aged; alpha-Fetoproteins; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antin | 2003 |
Hepatic arterial infusion chemotherapy for hepatocellular carcinoma with portal vein tumor thrombosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Female; Fluoro | 2003 |
Treatment of locally advanced hepatocellular carcinoma by hepatic intra-artery chemotherapy: a pilot study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2004 |
A phase I safety and pharmacokinetic study of OGT 719 in patients with liver cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Evaluation; Female; Fluorouracil; Human | 2004 |
[Clinical observation on the treatment of middle-late stage liver carcinoma by combined therapy of hepato-arterial chemo-embolising and Chinese drugs for strengthening pi and regulating qi].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therap | 2004 |
Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy.
Topics: Adult; Aged; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepato | 2004 |
[Prospective randomized trial of RFA and chemotherapy for unresectable small hepatocellular carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Catheter Ablation; Cispla | 2004 |
A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepat | 2005 |
Systemic chemo-immunotherapy for advanced-stage hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; D | 2005 |
Evaluation of HCPTd1,d14-double passaged intervening chemotherapy protocol for hepatocellular carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogen | 2005 |
A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 2005 |
Re-evaluation of antitumor effects of combination chemotherapy with interferon-alpha and 5-fluorouracil for advanced hepatocellular carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Fe | 2005 |
Pegylated liposomal doxorubicin-based combination chemotherapy as salvage treatment in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; alpha-Fetoproteins; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2005 |
Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular; Cisp | 2006 |
Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Fluorouraci | 2006 |
A combination therapy with transarterial chemo-lipiodolization and systemic chemo-infusion for large extensive hepatocellular carcinoma invading portal vein in comparison with conservative management.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; An | 2007 |
Clinical monitoring of innate cellular immunity of monocytes/macrophages by tumor necrosis factor alpha productivity in whole blood stimulated by lipopolysaccharide in patients with pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Deoxycytidine; Fem | 2006 |
Postresectional adjuvant intraportal chemotherapy in patients with hepatocellular carcinoma: a case-control study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Case-Control Studies; Che | 2006 |
Postoperative transhepatic arterial chemoembolization and portal vein chemotherapy for patients with hepatocellular carcinoma: a randomized study with 131 cases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therap | 2006 |
Twenty-four hour intra-arterial infusion of 5-fluorouracil, cisplatin, and leucovorin is more effective than 6-hour infusion for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cispla | 2007 |
Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisp | 2007 |
Hepatitis B viral load predicts survival of HCC patients undergoing systemic chemotherapy.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined C | 2007 |
Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcin | 2007 |
Improved survival for hepatocellular carcinoma with portal vein tumor thrombosis treated by intra-arterial chemotherapy combining etoposide, carboplatin, epirubicin and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil: a p
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carc | 2007 |
Interferon-alpha and 5-fluorouracil combination therapy after palliative hepatic resection in patients with advanced hepatocellular carcinoma, portal venous tumor thrombus in the major trunk, and multiple nodules.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Mod | 2007 |
Activity and safety of pegylated liposomal doxorubicin, 5-fluorouracil and folinic acid in inoperable hepatocellular carcinoma: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel | 2007 |
Chemotherapy with etoposide, doxorubicin, cisplatin, 5-fluorouracil, and leucovorin for patients with advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2008 |
Primary liver cancer. An Eastern Cooperative Oncology Group Trial.
Topics: Adenoma, Bile Duct; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Body W | 1984 |
Chemotherapy for advanced hepatocellular carcinoma. Adriamycin versus quadruple chemotherapy.
Topics: Adult; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular | 1984 |
Combination chemotherapy (vincristine, adriamycin, cyclophosphamide, and 5-fluorouracil) in the treatment of children with malignant hepatoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Child; Clinical Trials as Topic; Cyclophosphamide; | 1982 |
Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma, Hep | 1995 |
Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial iodine-131-iodized oil versus medical support.
Topics: Adrenal Cortex Hormones; Aged; Anti-Inflammatory Agents, Non-Steroidal; Carcinoma, Hepatocellular; F | 1994 |
Combined transarterial targeting locoregional immunotherapy-chemotherapy for patients with unresectable hepatocellular carcinoma: a new alternative for an old problem.
Topics: Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, He | 1995 |
5-Fluorouracil and high-dose calcium leucovorin for hepatocellular carcinoma: a phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel | 1995 |
[Postoperative adjuvant arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adjuv | 1995 |
[The study of continuous arterial infusion chemotherapy with CDDP and 5-FU in patients with hepatocellular carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Drug Adm | 1995 |
Low serum alpha-fetoprotein level in patients with hepatocellular carcinoma as a predictor of response to 5-FU and interferon-alpha-2b.
Topics: Adolescent; Adult; Aged; alpha-Fetoproteins; Biomarkers; Carcinoma, Hepatocellular; Chemotherapy, Ad | 1993 |
Adjuvant chemotherapy improves survival after liver transplantation for hepatocellular carcinoma.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatoce | 1995 |
[The study of continuous arterial infusion chemotherapy with 5-FU and CDDP in patients with hepatocellular carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Drug Adm | 1994 |
[Intra-arterial chemotherapy for the treatment of advanced hepatocellular carcinoma through implantable port (reservoir)].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel | 1994 |
Percutaneous hepatic vein isolation and high-dose hepatic arterial infusion chemotherapy for unresectable liver tumors.
Topics: Adenoma, Bile Duct; Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 1994 |
Clinical study of biological response modifiers as maintenance therapy for hepatocellular carcinoma.
Topics: Aged; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Emboliza | 1994 |
Surgical treatment of hepatocellular carcinoma in cirrhosis: liver resection or transplantation?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Modality Therapy | 1993 |
Chemohormonal therapy of unresectable hepatocellular carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepato | 1993 |
A pilot study of interferon alpha and 5-fluorouracil in hepatocellular carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcin | 1996 |
Adjuvant oral chemotherapy to prevent recurrence after curative resection for hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease-Free Survival; Flu | 1996 |
Intra-arterial chemotherapy followed by chemo-embolisation in unresectable hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Hepatocellular; | 1997 |
Adjuvant chemotherapy with epirubicin and carmofur after radical resection of hepatocellular carcinoma: a prospective randomized study.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellul | 1997 |
A crossover study of oral administration of UFT in chronic liver disease: comparison of continuous and intermittent schedules.
Topics: Administration, Oral; Aged; Area Under Curve; Carcinoma, Hepatocellular; Chronic Disease; Cross-Over | 1998 |
[Biochemical modulation of 5-FU--effect of low dose CDDP].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin | 1999 |
Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 1999 |
Gigantic hepatocellular carcinoma, treated by transcatheter oily chemoembolization (TOCE) and wedge hepatic resection.
Topics: Adult; Angiography; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality The | 2000 |
[Phase I study of super high-dose chemotherapy for liver cancer with percutaneous isolated hepatic perfusion (PIHP) and peripheral blood stem cell transplantation (PBSCT)].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2000 |
E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors.
Topics: Adenoviridae; Adenovirus E1B Proteins; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplast | 2001 |
Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial.
Topics: Adult; Aged; Alanine Transaminase; alpha-Fetoproteins; Antimetabolites, Antineoplastic; Antineoplast | 2001 |
A phase II trial of oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepato | 2001 |
Phase I and pharmacokinetic study of 5-fluorouracil administered by 5-day continuous infusion in patients with hepatocellular carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Female; Fluorouracil; Human | 2002 |
Oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carci | 2002 |
Hepatocellular carcinoma in children and adolescents: results from the Pediatric Oncology Group and the Children's Cancer Group intergroup study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, | 2002 |
5-Flourouracil in hepatocellular carcinoma: report of twenty-one cases.
Topics: Administration, Oral; Adult; Aged; Carcinoma, Hepatocellular; Clinical Trials as Topic; Drug Adminis | 1977 |
Quadruple chemotherapy versus radiotherapy in treatment of primary hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Aspartate Aminotransferases; Bilirubin; Carcinoma, H | 1977 |
Chemotherapy studies in primary liver cancer: a prospective randomized clinical trial.
Topics: Adenoma, Bile Duct; Antineoplastic Agents; Bone Marrow; Carcinoma, Hepatocellular; Clinical Trials a | 1978 |
Intra-arterial and intravenous use of 4' epidoxorubicin combined with 5-fluorouracil in primary hepatocellular carcinoma. A randomized comparison.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Epirubicin; | 1992 |
Combination chemotherapy and radiation for palliation of hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy | 1992 |
Prognostic factors in unresectable hepatocellular cancer: Radiation Therapy Oncology Group Study 83-01.
Topics: Antibodies; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Moda | 1991 |
A randomized prospective trial comparing full dose chemotherapy to 131I antiferritin: an RTOG study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepa | 1991 |
194 hepatocellular cancers treated by radiation and chemotherapy combinations: toxicity and response: a Radiation Therapy Oncology Group Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Clinical Trials as Topic; | 1989 |
Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma--a randomized controlled trial.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Clinical Trials as Topic; Combined Modality Therapy; Emboliz | 1988 |
Phase III trial of irradiation plus chemotherapy for patients with hepatic metastases and hepatoma: experience of the Northern California Oncology Group.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Clinical Trials as Topic; Combined Modality Therapy; Female; | 1988 |
[The role of antineoplastic solution in transcatheter hepatic arterial embolization--in terms of survival rates affecting anticancer agents together with gelatin sponge].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Doxorubicin; Embolization | 1988 |
Systemic cytostatic drug therapy in liver cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Clinical Trials as Topic; | 1986 |
Combination chemotherapy of hepatocellular cancer. Comparison of adriamycin + VM 26 + 5-fluorouracil with mAMSA + VM 26 + 5-fluorouracil.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Clinica | 1987 |
912 other studies available for fluorouracil and Hepatocellular Carcinoma
Article | Year |
---|---|
Novel modified steroid derivatives of androstanolone as chemotherapeutic anti-cancer agents.
Topics: Animals; Antineoplastic Agents; Body Weight; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Ce | 2009 |
Synthesis of novel 6-(4-substituted piperazine-1-yl)-9-(β-D-ribofuranosyl)purine derivatives, which lead to senescence-induced cell death in liver cancer cells.
Topics: Adenosine; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Death; Cell Line, Tumor; Cellular | 2012 |
2-methoxyjuglone induces apoptosis in HepG2 human hepatocellular carcinoma cells and exhibits in vivo antitumor activity in a H22 mouse hepatocellular carcinoma model.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle Checkpo | 2013 |
Hybrid molecule from O2-(2,4-dinitrophenyl)diazeniumdiolate and oleanolic acid: a glutathione S-transferase π-activated nitric oxide prodrug with selective anti-human hepatocellular carcinoma activity and improved stability.
Topics: Animals; Antineoplastic Agents; Apoptosis; Azo Compounds; Carcinoma, Hepatocellular; Cell Line, Tumo | 2013 |
Synthesis and biological evaluation of phenyl substituted polyoxygenated xanthone derivatives as anti-hepatoma agents.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; Dose-Response Relat | 2013 |
Synthesis and antitumor activity of novel 3-oxo-23-hydroxybetulinic acid derivatives.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Proliferation; Humans; Liver Neoplas | 2014 |
Combinatorial synthesis, in silico, molecular and biochemical studies of tetrazole-derived organic selenides with increased selectivity against hepatocellular carcinoma.
Topics: Antineoplastic Agents; Antioxidants; Carcinoma, Hepatocellular; Cell Line, Tumor; Chemistry Techniqu | 2016 |
Inhibition of invasion by N-trans-feruloyloctopamine via AKT, p38MAPK and EMT related signals in hepatocellular carcinoma cells.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Coumaric Acids; Epithelial-Mesenchymal Transition; Huma | 2017 |
Cytotoxic clerodane diterpenoids from Croton crassifolius.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Croton; Diterpenes, Cler | 2017 |
Synthesis and biological evaluation of novel pyrazolic chalcone derivatives as novel hepatocellular carcinoma therapeutics.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Cycle Prot | 2017 |
Novel multi-substituted benzyl acridone derivatives as survivin inhibitors for hepatocellular carcinoma treatment.
Topics: Acridones; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; Drug Des | 2017 |
Synthesis and biological evaluation of novel podophyllotoxin-NSAIDs conjugates as multifunctional anti-MDR agents against resistant human hepatocellular carcinoma Bel-7402/5-FU cells.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Line | 2017 |
Studies on anti-hepatoma activity of Annona squamosa L. pericarp extract.
Topics: Animals; Annona; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Hepatocellular; Cell Line, | 2017 |
β-Carboline and N-hydroxycinnamamide hybrids as anticancer agents for drug-resistant hepatocellular carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Carbolines; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Prol | 2019 |
Synthesis and biochemical studies of novel organic selenides with increased selectivity for hepatocellular carcinoma and breast adenocarcinoma.
Topics: Antineoplastic Agents; Antioxidants; Biphenyl Compounds; Breast Neoplasms; Carcinoma, Hepatocellular | 2019 |
Design and synthesis of parthenolide and 5-fluorouracil conjugates as potential anticancer agents against drug resistant hepatocellular carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Nucleus; Cell Proliferation; Dose- | 2019 |
Discovery of novel quinazolinone derivatives as potential anti-HBV and anti-HCC agents.
Topics: Antineoplastic Agents; Antiviral Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Dos | 2020 |
Discovery of new carbonic anhydrase IX inhibitors as anticancer agents by toning the hydrophobic and hydrophilic rims of the active site to encounter the dual-tail approach.
Topics: Antineoplastic Agents; Carbonic Anhydrase Inhibitors; Carbonic Anhydrase IX; Carcinoma, Hepatocellul | 2022 |
Design, synthesis and biological evaluation of hybrid of ubenimex-fluorouracil for hepatocellular carcinoma therapy.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Dose-Respons | 2021 |
Robust Effect of Hepatic Arterial Infusion Chemotherapy and Radiation Therapy on Hepatocellular Carcinoma Arising from Fontan-associated Liver Disease.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorou | 2022 |
Comparison Between Portal Vein Perfusion Chemotherapy and Neoadjuvant Hepatic Arterial Infusion Chemotherapy for Resectable Intermediate to Advanced Stage Hepatocellular Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Fluorouracil; Humans; Inf | 2022 |
Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemo | 2021 |
[Curcumin combined with 5-FU promotes autophagy and down-regulates the expression of Yes-associated protein (YAP) in hepatocellular carcinoma cells].
Topics: Apoptosis; Autophagy; Carcinoma, Hepatocellular; Cell Line, Tumor; Curcumin; Fluorouracil; Humans; L | 2021 |
FOLFOX-HAIC active in large HCC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Fluorouracil; Humans; Liv | 2022 |
ASO Author Reflections: Neoadjuvant Hepatic Arterial Infusion Chemotherapy with Oxaliplatin, Fluorouracil, and Leucovorin Is an Incredible Helper in Curing Patients with Intermediate-Advanced-Stage and Technically Resectable Hepatocellular Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Fluorouracil; Humans; Inf | 2022 |
Re: "Hepatic Artery Infusion Chemotherapy Using Fluorouracil, Leucovorin, and Oxaliplatin versus Transarterial Chemoembolization as Initial Treatment for Locally Advanced Hepatocellular Carcinoma: A Propensity Score-Matching Analysis".
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therap | 2022 |
Re: "Hepatic Artery Infusion Chemotherapy Using Fluorouracil, Leucovorin, and Oxaliplatin versus Transarterial Chemoembolization as Initial Treatment for Locally Advanced Hepatocellular Carcinoma: A Propensity Score-Matching Analysis".
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therap | 2022 |
HAIC-FO improves outcomes in HCC.
Topics: Carcinoma, Hepatocellular; Fluorouracil; Humans; Liver Neoplasms; Oxaliplatin; Sorafenib | 2022 |
Correlation between Immunohistochemical Markers in Hepatocellular Carcinoma Cells and
Topics: alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Fluor | 2022 |
Efficacy and Safety of Arterial Infusion Chemotherapy in Patients with Advanced Hepatocellular Carcinoma and Child-Pugh Class B: A Retrospective Cohort Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arteries; Carcinoma, Hepatocellular; Cisplatin; Dise | 2022 |
CDK Inhibition Reverses Acquired 5-Fluorouracil Resistance in Hepatocellular Carcinoma Cells.
Topics: Carcinoma, Hepatocellular; Cell Line; Cyclin-Dependent Kinases; Drug Resistance, Neoplasm; Fluoroura | 2022 |
Can Systemic Control Be Achieved in the Treatment of Oligometastatic Hepatocellular Cancer With Hepatic Artery Infusion Fluorouracil, Leucovorin, and Oxaliplatin Treatment?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Colorectal Neoplasms; Flu | 2022 |
Inhibition of Metastatic Hepatocarcinoma by Combined Chemotherapy with Silencing VEGF/VEGFR2 Genes through a GalNAc-Modified Integrated Therapeutic System.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Fluorouracil; Galactosamine; Liver Neoplasms; | 2022 |
Cinobufagin restrains the growth and triggers DNA damage of human hepatocellular carcinoma cells via proteasome-dependent degradation of thymidylate synthase.
Topics: Amphibian Venoms; Antineoplastic Agents; Bufanolides; Carcinoma, Hepatocellular; Cell Proliferation; | 2022 |
Functionalized PAMAM-based Nanoformulation for Targeted Delivery of 5-Fluorouracil in Hepatocellular Carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Carriers; Drug Del | 2022 |
Successful Liver Transplantation of Recurrent Fibrolamellar Carcinoma following Clinical and Pathologic Complete Response to Triple Immunochemotherapy: A Case Report.
Topics: Adult; Carcinoma, Hepatocellular; Female; Fluorouracil; HSP40 Heat-Shock Proteins; Humans; Liver Neo | 2022 |
Towards in vivo photomediated delivery of anticancer peptides: Insights from pharmacokinetic and -dynamic data.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Fluorouracil; Liver Neoplasms; Peptides; | 2022 |
Uricase sensitizes hepatocellular carcinoma cells to 5-fluorouracil through uricase-uric acid-UMP synthase axis.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Fluorouracil; Humans; Liver | 2022 |
Cerium oxide decorated 5-fluorouracil loaded chitosan nanoparticles for treatment of hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cerium; Chitosan; Fibroblasts; Fluorouracil; Liver Neoplasms; Ma | 2022 |
GLIPR1 promotes proliferation, metastasis and 5-fluorouracil resistance in hepatocellular carcinoma by activating the PI3K/PDK1/ROCK1 pathway.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Epithelial-Mesenchymal Transition; | 2022 |
Long-term survival with sorafenib-based multidisciplinary treatment for Vp4 hepatocellular carcinoma: a case report.
Topics: Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; Humans; Interferons; Liver Neoplasms; Male; Port | 2022 |
Treatment outcomes of advanced hepatocellular carcinoma in real-life practice: Chemotherapy versus multikinase inhibitors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Fluorouracil; Humans; Leu | 2023 |
A novel chemotherapy strategy for advanced hepatocellular carcinoma: a multicenter retrospective study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Disease Progression; Fluo | 2022 |
The Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Based on FOLFIRI for Advanced Intrahepatic Cholangiocarcinoma as Second-Line and Successive Treatment: A Real-World Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carci | 2022 |
Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and sequential ablation in the treatment of advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2023 |
Circ_0003998 upregulates ARK5 expression to elevate 5-Fluorouracil resistance in hepatocellular carcinoma through binding to miR-513a-5p.
Topics: AMP-Activated Protein Kinases; Animals; Carcinoma, Hepatocellular; Caspase 3; Cell Proliferation; Fl | 2022 |
One day versus two days of hepatic arterial infusion with oxaliplatin and fluorouracil for patients with unresectable hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Fluorouracil; Humans; Inf | 2022 |
Combinatorial treatment with Silybum marianum essential oil enhances the therapeutic efficacy of a 5-fluorouracil base therapy for hepatocellular carcinoma.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Fluorouracil; Liver Neoplasms; Mice; NF-kappa B; Oils | 2023 |
Efficient chemosensitizing and antimetastatic combinations of a naturally occurring trans-ferulic acid with different chemotherapies on an in vitro hepatocellular carcinoma model.
Topics: alpha-Fetoproteins; Carcinoma, Hepatocellular; Cell Line, Tumor; Cisplatin; Doxorubicin; Fluorouraci | 2023 |
Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Fluorouracil; Humans; Ind | 2023 |
Novel Steroidal[17,16-
Topics: Androsterone; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation | 2023 |
Clinical efficacy of targeted therapy, immunotherapy combined with hepatic artery infusion chemotherapy (FOLFOX), and lipiodol embolization in the treatment of unresectable hepatocarcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Ethiodized Oil; Fluoroura | 2022 |
Salvigenin Suppresses Hepatocellular Carcinoma Glycolysis and Chemoresistance Through Inactivating the PI3K/AKT/GSK-3β Pathway.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance | 2023 |
Hepatic arterial infusion chemotherapy combined with anti-PD-1/PD-L1 immunotherapy and molecularly targeted agents for advanced hepatocellular carcinoma: a real world study.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Hep | 2023 |
MESP1-knockdown inhibits the proliferation and epithelial mesenchymal transition of hepatocellular carcinoma and enhances the tumor-suppressive effect of 5-fluorouracil.
Topics: Basic Helix-Loop-Helix Transcription Factors; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Move | 2023 |
Konjac glucomannan enhances 5-FU-induced cytotoxicity of hepatocellular carcinoma cells via TLR4/PERK/CHOP signaling to induce endoplasmic reticulum stress.
Topics: Animals; Carcinoma, Hepatocellular; Disease Models, Animal; Endoplasmic Reticulum Stress; Fluorourac | 2022 |
IGF2BP3-induced activation of EIF5B contributes to progression of hepatocellular carcinoma cells.
Topics: Carcinoma, Hepatocellular; Cell Line; Computational Biology; Fluorouracil; Humans; Liver Neoplasms | 2022 |
Adjuvant Hepatic Artery Infusion Chemotherapy: Still Swimming in Dark Water?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; C | 2024 |
Beta-Hydroxyisovaleryl-Shikonin Eradicates Epithelial Cell Adhesion Molecule-Positive Liver Cancer Stem Cells by Suppressing dUTP Pyrophosphatase Expression.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Epithelial Cell Adhesion Molecule; Fluorouracil; Humans | 2023 |
Six1 is negatively correlated with poor prognosis and reduces 5-fluorouracil sensitivity via attenuating the stemness of hepatocellular carcinoma cells.
Topics: Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Female; Fluorouracil; Gene Knockdown Technique | 2019 |
Role and limitation of neoadjuvant hepatic arterial infusion chemotherapy in advanced hepatocelluar carcinoma patients with Child-Pugh class A.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; C | 2019 |
Quantitative proteomic and phosphoproteomic studies reveal novel 5-fluorouracil resistant targets in hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Fluorouracil; Humans; Liver | 2019 |
Glycochenodeoxycholate induces cell survival and chemoresistance via phosphorylation of STAT3 at Ser727 site in HCC.
Topics: Carcinoma, Hepatocellular; Cell Survival; Drug Resistance, Neoplasm; Flavonoids; Fluorouracil; Gene | 2020 |
Targeted Nanoparticles for Co-delivery of 5-FU and Nitroxoline, a Cathepsin B Inhibitor, in HepG2 Cells of Hepatocellular Carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cathepsin B; Chitosan; Chondroitin; Drug | 2020 |
H1, a derivative of tetrandrine, enhances the efficacy of 5-FU in Bel7402/5-FU cells via suppressing STAT3/MCL-1 and inducing PUMA.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Benzylisoquinolines; Carcinoma, Hep | 2019 |
Ubiquitin-Specific Protease 22/Silent Information Regulator 1 Axis Plays a Pivotal Role in the Prognosis and 5-Fluorouracil Resistance in Hepatocellular Carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Fluo | 2020 |
Potential Areas of Interest in a Trial of Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin for Hepatocellular Carcinoma-In Reply.
Topics: Carcinoma, Hepatocellular; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Oxaliplatin; Portal Ve | 2019 |
Potential Areas of Interest in a Trial of Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin for Hepatocellular Carcinoma.
Topics: Carcinoma, Hepatocellular; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Oxaliplatin; Portal Ve | 2019 |
Antineoplastic properties of zafirlukast against hepatocellular carcinoma via activation of mitochondrial mediated apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Hepatocellular; | 2019 |
Caffeine enhances the anti-tumor effect of 5-fluorouracil via increasing the production of reactive oxygen species in hepatocellular carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; | 2019 |
NOD1 inhibits proliferation and enhances response to chemotherapy via suppressing SRC-MAPK pathway in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line, Tumor; | 2020 |
Preparation and evaluation of phytantriol liquid crystal as a liquid embolic agent.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Chemoemb | 2020 |
Proteomic Analysis Reveals that EPHX1 Contributes to 5-Fluorouracil Resistance in a Human Hepatocellular Carcinoma Cell Line.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Drug Re | 2020 |
Cholesterol-Conjugate as a New Strategy to Improve the Cytotoxic Effect of 5-Fluorouracil on Liver Cancer: Impact of Liposomal Composition.
Topics: Carcinoma, Hepatocellular; Cholesterol; Drug Carriers; Fluorouracil; Hep G2 Cells; Humans; Liposomes | 2020 |
Transarterial chemoembolization for pulmonary or mediastinal metastases from hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoemboliz | 2020 |
IL-28B variant as a predictor in patients with advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Female; | 2020 |
Comparative proteomic analysis of protein methylation provides insight into the resistance of hepatocellular carcinoma to 5-fluorouracil.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Fluorouracil; Humans; Liver | 2020 |
The combination of ulinastatin and 5-fluorouracil synergistically inhibits hepatocellular carcinoma growth.
Topics: Antimetabolites, Antineoplastic; Biomarkers; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proli | 2020 |
Protective effect of Andrographolide on 5-Fu induced intestinal mucositis by regulating p38 MAPK signaling pathway.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; | 2020 |
LGR5 marks targetable tumor-initiating cells in mouse liver cancer.
Topics: Ablation Techniques; Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; C | 2020 |
Rab27B enhances drug resistance in hepatocellular carcinoma by promoting exosome-mediated drug efflux.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; | 2020 |
CCND1 silencing suppresses liver cancer stem cell differentiation and overcomes 5-Fluorouracil resistance in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Culture Techniques; Cell Differentiation; Cyc | 2020 |
Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR1-3 signaling, but not FGFR4 signaling.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Female; Fibroblast Growth Factor 2; Fibroblast | 2021 |
Challenges in Reirradiation of Intrahepatic Tumors.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2020 |
Hydrazinocurcumin and 5-fluorouracil enhance apoptosis and restrain tumorigenicity of HepG2 cells via disrupting the PTEN-mediated PI3K/Akt signaling pathway.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell | 2020 |
Facile Fabrication of Nanoparticles with Dual-Targeting Ligands for Precise Hepatocellular Carcinoma Therapy
Topics: A549 Cells; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line; Cell Line, Tumor | 2020 |
Ready to go 3D? A semi-automated protocol for microwell spheroid arrays to increase scalability and throughput of 3D cell culture testing.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Culture Techniques; Cell Proliferat | 2020 |
Salvage Surgery for Initially Unresectable Locally Advanced Hepatocellular Carcinoma Downstaged by Hepatic Arterial Infusion Chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Disease- | 2020 |
INTRABEAM intraoperative radiotherapy combined with portal vein infusion chemotherapy for treating hepatocellular carcinoma with portal vein tumor thrombus.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Modality T | 2020 |
Tivantinib Decreases Hepatocyte Growth Factor-Induced BCRP Expression in Hepatocellular Carcinoma HepG2 Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Membe | 2020 |
Transarterial Chemoembolization Combined with Sorafenib in Patients with BCLC Stage C Hepatocellular Carcinoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellul | 2020 |
Pharmacokinetic and Pharmacodynamic Factors Contribute to Synergism between Let-7c-5p and 5-Fluorouracil in Inhibiting Hepatocellular Carcinoma Cell Viability.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Su | 2020 |
MTIF2 impairs 5 fluorouracil-mediated immunogenic cell death in hepatocellular carcinoma in vivo: Molecular mechanisms and therapeutic significance.
Topics: Aged; Animals; Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Inducing Factor; Carcinoma, Hep | 2021 |
Two nanoformulations induce reactive oxygen species and immunogenetic cell death for synergistic chemo-immunotherapy eradicating colorectal cancer and hepatocellular carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Hepatocellular; C | 2021 |
Thiolated polymer nanocarrier reinforced with glycyrrhetinic acid for targeted delivery of 5-fluorouracil in hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Fluorouracil; Glycyrrhetinic Acid; Liver Neoplasms; Polymers; Ra | 2021 |
Biological features, gene expression profile, and mechanisms of drug resistance of two- and three-dimensional hepatocellular carcinoma cell cultures.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Culture Techniques; Cell Line, Tum | 2021 |
[Study on synergistic anti-tumor effect of Shuangdan Capsules combined with 5-FU on hepatocellular carcinoma cells Huh-7 and xenograft mice].
Topics: Animals; Capsules; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drugs, Chinese H | 2020 |
Discovery of vanoxerine dihydrochloride as a CDK2/4/6 triple-inhibitor for the treatment of human hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin-Depe | 2021 |
Arsenic trioxide induces differentiation of cancer stem cells in hepatocellular carcinoma through inhibition of LIF/JAK1/STAT3 and NF-kB signaling pathways synergistically.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Bl | 2021 |
Hepatic Arterial Infusion Chemotherapy with Modified FOLFOX as an Alternative Treatment Option in Advanced Hepatocellular Carcinoma Patients with Failed or Unsuitability for Transarterial Chemoembolization.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Fluorouracil; Humans; Infusions, Intra-Ar | 2021 |
Crosstalk of low density lipoprotein and liposome as a paradigm for targeting of 5-fluorouracil into hepatic cells: cytotoxicity and liver deposition.
Topics: Animals; Carcinoma, Hepatocellular; Cell Survival; Drug Delivery Systems; Fluorouracil; Hep G2 Cells | 2021 |
Early Experiences with Triple Immunochemotherapy in Adolescents and Young Adults with High-Risk Fibrolamellar Carcinoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Child; | 2021 |
Upregulation of histone acetylation reverses organic anion transporter 2 repression and enhances 5-fluorouracil sensitivity in hepatocellular carcinoma.
Topics: Acetylation; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Dose-Response Relationship, | 2021 |
Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoradiotherapy; Cispla | 2021 |
Preparation, Synergism, and Biocompatibility of in situ Liquid Crystals Loaded with Sinomenine and 5-Fluorouracil for Treatment of Liver Cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Death; Drug Carriers; Drug Liberatio | 2021 |
Hepatic Artery Infusion Chemotherapy Using Fluorouracil, Leucovorin, and Oxaliplatin versus Transarterial Chemoembolization as Initial Treatment for Locally Advanced Hepatocellular Carcinoma: A Propensity Score-Matching Analysis.
Topics: Adult; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Fluorouracil; Hepatic Artery; Huma | 2021 |
Investigation of the Physical Properties and Clinical Application of Embosphere Microspheres.
Topics: Angiography; Arsenic Trioxide; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Drug Carri | 2021 |
Gut microbiota enhances the chemosensitivity of hepatocellular carcinoma to 5-fluorouracil in vivo by increasing curcumin bioavailability.
Topics: Apoptosis; Biological Availability; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; | 2021 |
Effect of 5-fluorouracil on mRNA expression of drug metabolizing enzyme and transporter genes in human hepatoma cell lines.
Topics: Carcinoma, Hepatocellular; Cell Line; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Fluoro | 2021 |
Usefulness of a novel transarterial chemoinfusion plus external-beam radiation therapy for advanced hepatocellular carcinoma with tumor thrombi in the inferior vena cava and right atrium: Case study.
Topics: Carcinoma, Hepatocellular; Fluorouracil; Heart Atria; Humans; Liver Neoplasms; Pulmonary Embolism; V | 2022 |
Hepatoprotective Mongolian prescription II enhances the antitumor effects of chemotherapeutics in hepatocellular carcinoma xenografts.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Female; Fluo | 2017 |
Dual sphingosine kinase inhibitor SKI-II enhances sensitivity to 5-fluorouracil in hepatocellular carcinoma cells via suppression of osteopontin and FAK/IGF-1R signalling.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; Dose-Response Relat | 2017 |
USP22 knockdown enhanced chemosensitivity of hepatocellular carcinoma cells to 5-Fu by up-regulation of Smad4 and suppression of Akt.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; | 2017 |
Synthesis of theranostic epithelial cell adhesion molecule targeted mesoporous silica nanoparticle with gold gatekeeper for hepatocellular carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Survival; Drug Carriers; D | 2017 |
XLF-mediated NHEJ activity in hepatocellular carcinoma therapy resistance.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Cell-Free System; Chemoemboliza | 2017 |
The Combination of Arginine Deprivation and 5-Fluorouracil Improves Therapeutic Efficacy in Argininosuccinate Synthetase Negative Hepatocellular Carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Argin | 2017 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
Surface expression of anti-CD3scfv stimulates locoregional immunotherapy against hepatocellular carcinoma depending on the E1A-engineered human umbilical cord mesenchymal stem cells.
Topics: Adenoviridae; alpha-Fetoproteins; Animals; Antibody-Dependent Cell Cytotoxicity; Antimetabolites, An | 2017 |
A Novel mTOR Inhibitor; Anthracimycin for the Treatment of Human Hepatocellular Carcinoma.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Epithelia | 2017 |
GTSE1 promotes cell migration and invasion by regulating EMT in hepatocellular carcinoma and is associated with poor prognosis.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neo | 2017 |
Inter-alpha Inhibitor H4 as a Potential Biomarker Predicting the Treatment Outcomes in Patients with Hepatocellular Carcinoma.
Topics: Adult; Aged; Biomarkers, Tumor; Blood Proteins; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Mo | 2018 |
Adjuvant hepatic arterial infusion chemotherapy is beneficial for selective patients with Hepatocellular carcinoma undergoing surgical treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel | 2017 |
A novel three-dimensional culture system maintaining the physiological extracellular matrix of fibrotic model livers accelerates progression of hepatocellular carcinoma cells.
Topics: Animals; Biopsy; Carcinoma, Hepatocellular; Cell Culture Techniques; Cell Line, Tumor; Cell Prolifer | 2017 |
Transarterial Radioembolization Versus Concurrent Chemoradiation Therapy for Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellu | 2017 |
The use of 5-fluorouracil-loaded nanobubbles combined with low-frequency ultrasound to treat hepatocellular carcinoma in nude mice.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Fluorouracil; Hep G2 Cells; Human | 2017 |
Inhibition of autophagy in hepatocarcinoma cells promotes chemotherapeutic agent-induced apoptosis during nutrient deprivation.
Topics: Adenine; Antineoplastic Agents; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Carcinoma, Hepat | 2018 |
Hepatic Resection Followed by Hepatic Arterial Infusion Chemotherapy for Hepatocellular Carcinoma with Intrahepatic Dissemination.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, He | 2018 |
Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor Thrombosis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; | 2018 |
[A Case of a Long-Term Survivor Who Underwent Surgical Intervention for Hepatocellular Carcinoma Combined with Tumor Thrombus in the Main Trunkof the Portal Vein].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
USP27-mediated Cyclin E stabilization drives cell cycle progression and hepatocellular tumorigenesis.
Topics: Animals; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Movement; Cyclin E; Fluoroura | 2018 |
Baicalein sensitizes hepatocellular carcinoma cells to 5-FU and Epirubicin by activating apoptosis and ameliorating P-glycoprotein activity.
Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Autophagy; bcl-X Protein; Carcin | 2018 |
Sorafenib and hepatic arterial infusion chemotherapy: another failed combination.
Topics: Adult; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; Humans; Liver Neoplasms; Sorafenib | 2018 |
[ASCO- and ESMO-update 2017 - highlights of the 53. meeting of the American Society of Clinical Oncology/ASCO 2017 and European Society for Medical Oncology/ESMO congress 2017].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Fluorouracil; Gastrointes | 2018 |
RBFOX3 Regulates the Chemosensitivity of Cancer Cells to 5-Fluorouracil via the PI3K/AKT, EMT and Cytochrome-C/Caspase Pathways.
Topics: Animals; Antigens, Nuclear; Apoptosis; Carcinoma, Hepatocellular; Caspases; Cell Line, Tumor; Cell M | 2018 |
Inhibition of MALAT1 sensitizes liver cancer cells to 5-flurouracil by regulating apoptosis through IKKα/NF-κB pathway.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line; Cell Line, Tumor; | 2018 |
Targeting mTORC1/2 Complexes Inhibit Tumorigenesis and Enhance Sensitivity to 5-Flourouracil (5-FU) in Hepatocellular Carcinoma: A Preclinical Study of mTORC1/2-Targeted Therapy in Hepatocellular Carcinoma (HCC).
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinogenesis; Carcinoma, Hepatoc | 2018 |
Six2 is negatively correlated with good prognosis and decreases 5-FU sensitivity via suppressing E-cadherin expression in hepatocellular carcinoma cells.
Topics: Antigens, CD; Cadherins; Carcinoma, Hepatocellular; Cell Line, Tumor; Down-Regulation; Fluorouracil; | 2018 |
MEL-pep, an analog of melittin, disrupts cell membranes and reverses 5-fluorouracil resistance in human hepatocellular carcinoma cells.
Topics: Animals; Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B; Carcinoma, | 2018 |
Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; | 2018 |
Significance of hepatic resection and adjuvant hepatic arterial infusion chemotherapy for hepatocellular carcinoma with portal vein tumor thrombus in the first branch of portal vein and the main portal trunk: a project study for hepatic surgery of the Jap
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2018 |
lncRNA KRAL reverses 5-fluorouracil resistance in hepatocellular carcinoma cells by acting as a ceRNA against miR-141.
Topics: Carcinoma, Hepatocellular; Down-Regulation; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression | 2018 |
Vitamin D potentiates anti-tumor activity of 5-fluorouracil via modulating caspase-3 and TGF-β1 expression in hepatocellular carcinoma-induced in rats.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Disease Models, Ani | 2018 |
High PGAM5 expression induces chemoresistance by enhancing Bcl-xL-mediated anti-apoptotic signaling and predicts poor prognosis in hepatocellular carcinoma patients.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Carcinoma, Hepatocellular; Cohort Stu | 2018 |
SND1 acts as an anti-apoptotic factor via regulating the expression of lncRNA UCA1 in hepatocellular carcinoma.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; Endonucleases; Fluorouracil; Gene Expressi | 2018 |
Dual-Targeting Nanoparticles: Codelivery of Curcumin and 5-Fluorouracil for Synergistic Treatment of Hepatocarcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biotin; Carcinoma, Hepatocellular; Curcumin | 2019 |
Bile salt (glycochenodeoxycholate acid) induces cell survival and chemoresistance in hepatocellular carcinoma.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; Cell Surv | 2019 |
Prognostic predictors for patients with hepatocellular carcinoma receiving adjuvant transcatheter arterial chemoembolization.
Topics: Alanine Transaminase; Alkaline Phosphatase; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy | 2019 |
Delivery of Liver-Specific miRNA-122 Using a Targeted Macromolecular Prodrug toward Synergistic Therapy for Hepatocellular Carcinoma.
Topics: ADAM17 Protein; Animals; Apoptosis; Biocompatible Materials; Carcinoma, Hepatocellular; Cell Line; C | 2019 |
Early recurrence detected in hepatocellular carcinoma patients after transcatheter arterial chemoembolization treatment with plasma cell-free DNA.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoemboliz | 2019 |
Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin in Hepatocellular Cancer with Extrahepatic Spread.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; China; Clini | 2019 |
Nano-erythrocyte membrane-chaperoned 5-fluorouracil liposomes as biomimetic delivery platforms to target hepatocellular carcinoma cell lines.
Topics: Animals; Biomimetics; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Delayed-Action Pre | 2019 |
Dose escalation by intensity modulated radiotherapy in liver-directed concurrent chemoradiotherapy for locally advanced BCLC stage C hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Chemorad | 2019 |
A 12-year Recurrence-free Survival After Multidisciplinary Treatment for a Patient With Combined Hepatocellular-Cholangiocarcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Carcinoma, Hepatocellular; Chol | 2019 |
Polyethylenimine (PEI)-Mediated E1A Increases the Sensitivity of Hepatocellular Carcinoma Cells to Chemotherapy.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Deoxycytidine; Docet | 2019 |
Aluminum chloride causes 5-fluorouracil resistance in hepatocellular carcinoma HepG2 cells.
Topics: Aluminum Chloride; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line, Tumor; C | 2019 |
Hepatitis C Virus-Induced FUT8 Causes 5-FU Drug Resistance in Human Hepatoma Huh7.5.1 Cells.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Dr | 2019 |
Metformin Regulates the Expression of CD133 Through the AMPK-CEBPβ Pathway in Hepatocellular Carcinoma Cell Lines.
Topics: AC133 Antigen; AMP-Activated Protein Kinase Kinases; Animals; Apoptosis; Carcinoma, Hepatocellular; | 2019 |
Another Treatment Option for Advanced Hepatocellular Carcinoma With Portal Vein Thrombosis in China.
Topics: Carcinoma, Hepatocellular; China; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Oxaliplatin; Po | 2019 |
Hepatic arterial chemotherapy for hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Oxaliplatin; Portal Ve | 2019 |
Reduction of Intrahepatic Tumour by Hepatic Arterial Infusion Chemotherapy Prolongs Survival in Hepatocellular Carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Female; | 2019 |
TLX3 repressed SNAI1-induced epithelial-mesenchymal transition by directly constraining STAT3 phosphorylation and functionally sensitized 5-FU chemotherapy in hepatocellular carcinoma.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Chromatin Immunoprecipitation; Epit | 2019 |
Adjuvant hepatic arterial infusion chemotherapy after hepatic resection of hepatocellular carcinoma with macroscopic vascular invasion.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellul | 2013 |
hnRNP K suppresses apoptosis independent of p53 status by maintaining high levels of endogenous caspase inhibitors.
Topics: Antineoplastic Agents; Apoptosis; BH3 Interacting Domain Death Agonist Protein; Carcinoma, Hepatocel | 2013 |
Identification of the genes chemosensitizing hepatocellular carcinoma cells to interferon-α/5-fluorouracil and their clinical significance.
Topics: Adult; Aged; AMP-Activated Protein Kinases; Animals; Antimetabolites, Antineoplastic; Apoptosis; Car | 2013 |
PTK787/ZK222584 combined with interferon alpha and 5-fluorouracil synergistically inhibits VEGF signaling pathway in hepatocellular carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Antiviral | 2013 |
Efficient total synthesis and biological activities of 6-deoxyisojacareubin.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line; Cell Line, Tumor; Fluorouracil; Humans; | 2013 |
Proteomic-based analysis for identification of proteins involved in 5-fluorouracil resistance in hepatocellular carcinoma.
Topics: Antimetabolites, Antineoplastic; Base Sequence; Blotting, Western; Carcinoma, Hepatocellular; Cell L | 2014 |
Reversing resistance of multidrug-resistant hepatic carcinoma cells with parthenolide.
Topics: Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette | 2013 |
Genetic polymorphisms of enzymes related to oral tegafur/uracil therapeutic efficacy in patients with hepatocellular carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon Hydroxylases; Asian People; C | 2013 |
Influence of etiology on host immunity in liver cirrhosis patients with advanced hepatocellular carcinoma receiving intra-arterial chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Case-Control Studie | 2013 |
Cytotoxic withanolides from the leaves of Moroccan Withania frutescens.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Carcinoma, Hepatocellular; Chromatography, High P | 2013 |
Wentilactone B induces G2/M phase arrest and apoptosis via the Ras/Raf/MAPK signaling pathway in human hepatoma SMMC-7721 cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle Proteins; Enzyme Ac | 2013 |
Epigenetic silencing of DACH1 induces loss of transforming growth factor-β1 antiproliferative response in human hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Azacitidine; Carcinoma, Hepatocellular; DNA Methylation; Eye Proteins; Fema | 2013 |
Liver resection following FOLFOXIRI plus bevacizumab: a detailed pathological review.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2013 |
Modified cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel | 2013 |
Hepatoid adenocarcinoma of the stomach: an unusual case of elevated alpha-fetoprotein with prior treatment for hepatocellular carcinoma.
Topics: Adenocarcinoma; Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Camptothec | 2013 |
[Research on the effect and mechanism of polypeptide extract from scorpion venom combined with 5-fluorouracil on vasculogenic mimicry of H22 hepatoma].
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Charybdotoxin; Fluorouracil; Hypoxia-Inducible | 2013 |
Enhanced 5-fluorouracil cytotoxicity in high COX-2 expressing hepatocellular carcinoma cells by wogonin via the PI3K/Akt pathway.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Line, Tumor | 2013 |
Schedule-dependent antitumor effects of 5-fluorouracil combined with sorafenib in hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Hepatocellular; Cell C | 2013 |
Efficacy of capecitabine and oxaliplatin regimen for extrahepatic metastasis of hepatocellular carcinoma following local treatments.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular | 2013 |
Hepatic arterial infusion chemotherapy in hepatocellular carcinoma with portal vein tumor thrombosis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chi-Square D | 2013 |
A single nucleotide polymorphism on the GALNT14 gene as an effective predictor of response to chemotherapy in advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; F | 2014 |
The monoclonal antibody CH12 augments 5-fluorouracil-induced growth suppression of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinom | 2014 |
Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatoce | 2013 |
MiR-27a modulates the MDR1/P-glycoprotein expression by inhibiting FZD7/β-catenin pathway in hepatocellular carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; beta Cate | 2013 |
[A preliminary study of the inhibitive efficacy of iodized linoleic acid and its fluorodeoxyuridine ester in hepatocellular cancer].
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Fluorouracil; Humans; Inhibitory Concentration | 2013 |
Complete radiographic remission with 5-fluorouracil and leucovorin after sorafenib failure in hepatocellular carcinoma: is there a role for chemotherapy after targeted agents?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Hepatocellular; Fatal Outcome; Fl | 2013 |
Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular | 2014 |
Synthesis of glycyrrhetinic acid-modified chitosan 5-fluorouracil nanoparticles and its inhibition of liver cancer characteristics in vitro and in vivo.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line; Cell Line, Tumor; Chitosan; Drug Carriers; Drug Deliv | 2013 |
Anticancer activity of an antisense oligonucleotide targeting TRADD combined with proteasome inhibitors in chemoresistant hepatocellular carcinoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tum | 2013 |
[Effect of plasmid transfected shMRE11 on the drug-resistance of BEL7402/5-FU hepatoma cells].
Topics: Carcinoma, Hepatocellular; DNA-Binding Proteins; Drug Resistance, Neoplasm; Fluorouracil; Humans; Li | 2013 |
MiR-23a-mediated inhibition of topoisomerase 1 expression potentiates cell response to etoposide in human hepatocellular carcinoma.
Topics: 3' Untranslated Regions; Animals; Antigens, Neoplasm; Antineoplastic Agents, Phytogenic; Base Sequen | 2013 |
Efficacy and safety of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma as first-line therapy.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Carcinoma, Hepatocellular; Cisplatin; Diarrhea; Disease- | 2013 |
Reversal effect of bufalin on multidrug resistance in human hepatocellular carcinoma BEL-7402/5-FU cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, | 2014 |
Debulking surgery followed by intraarterial 5-fluorouracil chemotherapy plus subcutaneous interferon alfa for massive hepatocellular carcinoma with multiple intrahepatic metastases: a pilot study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel | 2013 |
Mechanistic modeling identifies drug-uptake history as predictor of tumor drug resistance and nano-carrier-mediated response.
Topics: Carcinoma, Hepatocellular; Cell Death; Cell Line, Tumor; Cisplatin; Deoxycytidine; Doxorubicin; Drug | 2013 |
[A case of huge advanced hepatocellular carcinoma resected after hepatic arterial infusion therapy of 5-FU/LV/CDDP].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Combined Modal | 2013 |
Adjuvant hepatic arterial infusion chemotherapy with 5-Fluorouracil and interferon after curative resection of hepatocellular carcinoma: a preliminary report.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Combined Modality Therapy; Female; | 2013 |
EpCAM-targeted therapy for human hepatocellular carcinoma.
Topics: Animals; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2014 |
[Long-term survival of a patient with hepatocellular carcinoma with portal vein tumor thrombus treated with interferon-α and 5-fluorouracil combination therapy].
Topics: Antimetabolites, Antineoplastic; Antiviral Agents; Carcinoma, Hepatocellular; Chemoembolization, The | 2013 |
[A case of hepatocellular carcinoma (Vp4)-combination therapy prolonged survival in a patient with advanced hepatocellular carcinoma with a tumor thrombus in the portal vein trunk].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Modality | 2013 |
SUMOylation alterations are associated with multidrug resistance in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cysteine Endopeptidases; Drug Resistance, Neoplasm | 2014 |
Suppression of orthotopically implanted hepatocarcinoma in mice by umbilical cord-derived mesenchymal stem cells with sTRAIL gene expression driven by AFP promoter.
Topics: alpha-Fetoproteins; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Differentiation; | 2014 |
SM5-1-conjugated PLA nanoparticles loaded with 5-fluorouracil for targeted hepatocellular carcinoma imaging and therapy.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellu | 2014 |
Epirubicin, cisplatin, 5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepat | 2014 |
Inhibition of p53 increases chemosensitivity to 5-FU in nutrient-deprived hepatocarcinoma cells by suppressing autophagy.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Autophagy; Benzothiazoles; Carcinoma, Hepatocellular; Ce | 2014 |
Downregulation of Rap1 promotes 5-fluorouracil-induced apoptosis in hepatocellular carcinoma cell line HepG2.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Blotting, Western; Carcinoma, Hepatoce | 2014 |
Hepatocellular carcinoma and nodular regenerative hyperplasia after chemotherapy for metastatic colorectal carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Colorectal Neoplasms; Drug Therapy; Fluorouracil; | 2014 |
Successful multimodal treatment for aggressive metastatic and recurrent fibrolamellar hepatocellular carcinoma in a child.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Child; Cisplatin; Combine | 2014 |
Antitumor effect of a selective COX-2 inhibitor, celecoxib, may be attributed to angiogenesis inhibition through modulating the PTEN/PI3K/Akt/HIF-1 pathway in an H₂₂ murine hepatocarcinoma model.
Topics: Animals; Antigens, CD34; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Celecoxib; Cell | 2014 |
Astragaloside Ⅳ reduces the expression level of P-glycoprotein in multidrug-resistant human hepatic cancer cell lines.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biologic | 2014 |
Targeting liver cancer via ASGP receptor using 5-FU-loaded surface-modified PLGA nanoparticles.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Drug Delivery Systems; Fluorouracil; Hep | 2014 |
MiR-612 suppresses the stemness of liver cancer via Wnt/β-catenin signaling.
Topics: Animals; beta Catenin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cisplatin; D | 2014 |
Let-7 g microRNA sensitizes fluorouracil-resistant human hepatoma cells.
Topics: Antimetabolites, Antineoplastic; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Col | 2014 |
The synergistic in vitro and in vivo antitumor effect of combination therapy with salinomycin and 5-fluorouracil against hepatocellular carcinoma.
Topics: Analysis of Variance; Animals; Blotting, Western; Carcinoma, Hepatocellular; Cell Line; Colony-Formi | 2014 |
Hepatic arterial infusion chemotherapy for patients with huge unresectable hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2014 |
Preparation of biocompatible heat-labile enterotoxin subunit B-bovine serum albumin nanoparticles for improving tumor-targeted drug delivery via heat-labile enterotoxin subunit B mediation.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Bacterial Toxins; Carcinoma, Hepatocellular; Cell Line, | 2014 |
Overexpression of microRNA-125b sensitizes human hepatocellular carcinoma cells to 5-fluorouracil through inhibition of glycolysis by targeting hexokinase II.
Topics: 3' Untranslated Regions; Apoptosis; Base Sequence; Carcinoma, Hepatocellular; Cell Line, Tumor; Down | 2014 |
HepG2 cells recovered from apoptosis show altered drug responses and invasiveness.
Topics: Ablation Techniques; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Movement; Dos | 2014 |
Preclinical studies of N₃-O-toluyl-fluorouracil-loaded lipid-based nanosuspensions in H₂₂-bearing mice.
Topics: Animals; Carcinoma, Hepatocellular; Diffusion; Drug Evaluation, Preclinical; Female; Fluorouracil; H | 2014 |
Polysaccharides from Tricholoma matsutake and Lentinus edodes enhance 5-fluorouracil-mediated H22 cell growth inhibition.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Dow | 2014 |
A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepat | 2015 |
A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepat | 2015 |
A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepat | 2015 |
A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepat | 2015 |
The synergistic effect of organic silicone quaternary ammonium salt and 5-fluorouracil on hepatocellular carcinoma in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, He | 2014 |
Liposome-mediated induction of apoptosis of human hepatoma cells by c-myc antisense phosphorothioate oligodeoxynucleotide and 5-fluorouracil.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Prolif | 2014 |
Importance of branched-chain amino acids in patients with liver cirrhosis and advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy.
Topics: Aged; Amino Acids, Branched-Chain; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepato | 2014 |
Chemotherapy for transarterial chemoembolization in patients with unresectable hepatocellular carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Hepatocellular; Chemo | 2014 |
[Antitumor effect of Stichopus japonicus acidic mucopolysaccharide combined with fluorouracil in mice bearing neoplasia of H22 hepatoma cells].
Topics: Animals; Carcinoma, Hepatocellular; Cell Line; Cell Line, Tumor; Fluorouracil; Glycosaminoglycans; L | 2014 |
Re-sensitization of 5-FU resistance by SPARC through negative regulation of glucose metabolism in hepatocellular carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Fema | 2015 |
Repeated transcatheter arterial chemoembolization is safe for hepatocellular carcinoma in cirrhotic patients with transjugular intrahepatic portosystemic shunt.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoemboliz | 2014 |
Metformin reverses multidrug resistance in human hepatocellular carcinoma Bel‑7402/5‑fluorouracil cells.
Topics: AMP-Activated Protein Kinases; ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Hepatocellu | 2014 |
Concurrent chemoradiotherapy shows long-term survival after conversion from locally advanced to resectable hepatocellular carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Hepatocellular; Chem | 2014 |
Let-7b binding site polymorphism in the B-cell lymphoma-extra large 3'UTR is associated with fluorouracil resistance of hepatocellular carcinoma.
Topics: 3' Untranslated Regions; Antimetabolites, Antineoplastic; bcl-X Protein; Binding Sites; Carcinoma, H | 2015 |
JNK signaling in hepatocarcinoma cells is associated with the side population upon treatment with anticancer drugs.
Topics: Anthracenes; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Fluo | 2015 |
5-Fluorouracil combined with apigenin enhances anticancer activity through mitochondrial membrane potential (ΔΨm)-mediated apoptosis in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apigenin; Apoptosis; Carcinoma, Hepatocellu | 2015 |
Downregulation of PRRX1 Confers Cancer Stem Cell-Like Properties and Predicts Poor Prognosis in Hepatocellular Carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Blotting, Western; Carcinoma, H | 2015 |
Hepatic arterial infusion in hepatocellular carcinoma: a single center experience.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cisplatin; Czech Republic; Disease-Fr | 2015 |
Targeting the microRNA-21/AP1 axis by 5-fluorouracil and pirarubicin in human hepatocellular carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Hepatocellula | 2015 |
Nanoparticles inhibit cancer cell invasion and enhance antitumor efficiency by targeted drug delivery via cell surface-related GRP78.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Cell | 2015 |
Transcatheter arterial chemoembolization combined with interferon-α is safe and effective for patients with hepatocellular carcinoma after curative resection.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoemboliz | 2015 |
Transarterial chemoembolization aggravated peritumoral fibrosis via hypoxia-inducible factor-1α dependent pathway in hepatocellular carcinoma.
Topics: Adult; Aged; Animals; Carcinoma, Hepatocellular; Cell Hypoxia; Chemoembolization, Therapeutic; Disea | 2015 |
Dual Inhibition of Cdc7 and Cdk9 by PHA-767491 Suppresses Hepatocarcinoma Synergistically with 5-Fluorouracil.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Cycle Prote | 2015 |
Chlorogenic acid enhances the effects of 5-fluorouracil in human hepatocellular carcinoma cells through the inhibition of extracellular signal-regulated kinases.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; C | 2015 |
[Long-term survival in a patient receiving multidisciplinary therapy for hepatocellular carcinoma with left iliac bone metastasis].
Topics: Abdomen; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Hepatocell | 2014 |
Cooperative effect of Bifidobacteria lipoteichoic acid combined with 5-fluorouracil on hepatoma-22 cells growth and apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Bifidobacterium; Carcinoma, H | 2015 |
Efficacy of hepatic arterial infusion chemotherapy in combination with irradiation for advanced hepatocellular carcinoma with portal vein invasion.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel | 2015 |
Keratin 19, a Cancer Stem Cell Marker in Human Hepatocellular Carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line, T | 2015 |
Oxaliplatin and 5-fluorouracil hepatic infusion with lipiodolized chemoembolization in large hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel | 2015 |
VEGF in patients with advanced hepatocellular carcinoma receiving intra-arterial chemotherapy.
Topics: Aged; Carcinoma, Hepatocellular; Cisplatin; Female; Fluorouracil; Gene Expression Regulation, Neopla | 2015 |
MiR-141 Activates Nrf2-Dependent Antioxidant Pathway via Down-Regulating the Expression of Keap1 Conferring the Resistance of Hepatocellular Carcinoma Cells to 5-Fluorouracil.
Topics: 3' Untranslated Regions; Antioxidants; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Down- | 2015 |
Epigenetic silencing of BCL6B inactivates p53 signaling and causes human hepatocellular carcinoma cell resist to 5-FU.
Topics: Aged; Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Carcinoma, Hepatocellular; Cell Proli | 2015 |
A new therapeutic assessment score for advanced hepatocellular carcinoma patients receiving hepatic arterial infusion chemotherapy.
Topics: Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biomarkers, Ph | 2015 |
[Study on synergistic effect of sodium cantharidinate combined with chemotherapeutic drugs on hepatic carcinoma and its effective mechanism].
Topics: Antineoplastic Agents; Apoptosis; Cantharidin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cisplati | 2014 |
Suberoylanilide hydroxamic acid enhances chemosensitivity to 5-fluorouracil in hepatocellular carcinoma via inhibition of thymidylate synthase.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell | 2015 |
Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Vessels; Carci | 2015 |
Host Immunity Influences the Efficacy of Combined Intra-Arterial Chemotherapy for Advanced Hepatocellular Carcinoma in Liver Cirrhosis Patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Female; | 2014 |
Education and Imaging. Hepatobiliary and Pancreatic: Complete remission after hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with decompensated cirrhosis.
Topics: Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcino | 2016 |
[Novel hybrids of (phenylsulfonyl)furoxan and N-benzyl matrinol as anti-hepatocellular carcinoma agents].
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Fluorouracil; Hep G2 Cells; Humans; Liver Neoplasm | 2015 |
MicroRNA‑133a and microRNA‑326 co‑contribute to hepatocellular carcinoma 5‑fluorouracil and cisplatin sensitivity by directly targeting B‑cell lymphoma‑extra large.
Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; Carcinoma, Hepatocellular; Cell Proliferation; Cisp | 2015 |
Targeted expression of BikDD combined with metronomic doxorubicin induces synergistic antitumor effect through Bax activation in hepatocellular carcinoma.
Topics: Adaptor Proteins, Signal Transducing; alpha-Fetoproteins; Animals; Apoptosis Regulatory Proteins; bc | 2015 |
The response of Golgi protein 73 to transcatheter arterial chemoembolization in patients with hepatocellular carcinoma may relate to the influence of certain chemotherapeutics.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Chemoembolization, | 2015 |
Comparative study of the effects of PEGylated interferon-α2a versus 5-fluorouracil on cancer stem cells in a rat model of hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Hepatocellular; Disease Models, Animal | 2016 |
Significance of the Signal Intensity of Gadoxetic Acid-enhanced MR Imaging for Predicting the Efficacy of Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antimetabolites, Antineoplastic; Antineoplastic | 2016 |
GRP78 confers the resistance to 5-FU by activating the c-Src/LSF/TS axis in hepatocellular carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; CSK Tyrosine-Protein Kinase; DN | 2015 |
Synergistic effect of cucurbitacin B in combination with curcumin via enhancing apoptosis induction and reversing multidrug resistance in human hepatoma cells.
Topics: Adenosine Triphosphate; Animals; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; | 2015 |
MicroRNA-302b Enhances the Sensitivity of Hepatocellular Carcinoma Cell Lines to 5-FU via Targeting Mcl-1 and DPYD.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Combined Modality Therapy; Dihyd | 2015 |
Sorafenib inhibits cancer side population cells by targeting c‑Jun N‑terminal kinase signaling.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette | 2015 |
A case of hepatoblastoma misdiagnosed as combined hepatocellular carcinoma and cholangiocarcinoma in an adult.
Topics: Adult; Carcinoma, Hepatocellular; Cholangiocarcinoma; Cisplatin; Diagnostic Errors; Doxorubicin; Dru | 2015 |
Downregulation of δ opioid receptor by RNA interference enhances the sensitivity of BEL/FU drug‑resistant human hepatocellular carcinoma cells to 5‑FU.
Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Hepatocellular; Cell | 2016 |
Effect of luteolin on gene expression in mouse H22 hepatoma cells.
Topics: Animals; Carcinoma, Hepatocellular; CD58 Antigens; Cell Line, Tumor; Cell Proliferation; Fluorouraci | 2015 |
Quercetin induces apoptosis and enhances 5-FU therapeutic efficacy in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell | 2016 |
Aminopeptidase N inhibitor 4cc synergizes antitumor effects of 5-fluorouracil on human liver cancer cells through ROS-dependent CD13 inhibition.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; CD13 | 2015 |
Oxymatrine synergistically enhances the inhibitory effect of 5-fluorouracil on hepatocellular carcinoma in vitro and in vivo.
Topics: Alkaloids; Animals; Antimetabolites, Antineoplastic; Antiviral Agents; Apoptosis; Blotting, Western; | 2016 |
[New FP Therapy Was Effective for a Case of Massive Hepatocellular Carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Combined Modal | 2015 |
Nogo-B receptor promotes the chemoresistance of human hepatocellular carcinoma via the ubiquitination of p53 protein.
Topics: Animals; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Cycle; Cell Proliferation; Dr | 2016 |
[Fluoroscopy-induced Subacute Radiation Dermatitis in Patient with Hepatocellular Carcinoma].
Topics: Carcinoma, Hepatocellular; Embolization, Therapeutic; Fluoroscopy; Fluorouracil; Gamma Rays; Humans; | 2016 |
ANXA11 regulates the tumorigenesis, lymph node metastasis and 5-fluorouracil sensitivity of murine hepatocarcinoma Hca-P cells by targeting c-Jun.
Topics: Animals; Annexins; Antineoplastic Agents; Carcinogenesis; Carcinoma, Hepatocellular; Cell Line, Tumo | 2016 |
[Effect of Conditioned Medium from Endothelial Cells on Cancer Stem Cell Phenotype of Hepatoma Cells].
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Coculture Techniques; Culture Me | 2015 |
Epithelial cell adhesion molecule in human hepatocellular carcinoma cell lines: a target of chemoresistence.
Topics: Carcinoma, Hepatocellular; Cell Survival; Cisplatin; Doxorubicin; Drug Resistance, Neoplasm; Epithel | 2016 |
Loss of Runt-related transcription factor 3 induces resistance to 5-fluorouracil and cisplatin in hepatocellular carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Line, Tumor; Cisplatin; Core | 2016 |
[Spontaneous cytotoxicity treated with anti-tumor drugs of splenocytes of rats on a model of hepatoma cell monolayer cultures].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell | 2015 |
Enhancement of anti-tumor effects of 5-fluorouracil on hepatocellular carcinoma by low-intensity ultrasound.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Prolifer | 2016 |
A CD13 inhibitor, ubenimex, synergistically enhances the effects of anticancer drugs in hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; CD13 Antigens; | 2016 |
Allicin sensitizes hepatocellular cancer cells to anti-tumor activity of 5-fluorouracil through ROS-mediated mitochondrial pathway.
Topics: Acetylcysteine; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepat | 2016 |
Combination Therapy of Radiofrequency Ablation and Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Retrospective Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Catheter Abl | 2016 |
Notch2 is a crucial regulator of self-renewal and tumorigenicity in human hepatocellular carcinoma cells.
Topics: Animals; Biomarkers, Tumor; Carcinogenesis; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; | 2016 |
Acute exacerbation of hepatitis C in hepatocellular carcinoma patients receiving chemotherapy.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cisplatin; Drug Therapy; Female; Fluorouraci | 2017 |
Metformin mediates resensitivity to 5-fluorouracil in hepatocellular carcinoma via the suppression of YAP.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Animals; Antineoplastic Agents; Carcinoma, Hepato | 2016 |
Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy and Sorafenib in Patients with Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2016 |
The Effects and Mechanisms of Periplaneta americana Extract Reversal of Multi-Drug Resistance in BEL-7402/5-FU Cells.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Tr | 2016 |
Living Donor Liver Transplantation for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis after Concurrent Chemoradiation Therapy.
Topics: Adult; Carcinoma, Hepatocellular; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Female; Fluor | 2016 |
Nestin overexpression in hepatocellular carcinoma associates with epithelial-mesenchymal transition and chemoresistance.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Line, Tumor | 2016 |
Multidrug Delivery Systems Based on Human Serum Albumin for Combination Therapy with Three Anticancer Agents.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Deliver | 2016 |
Gold Nanoparticle-Mediated Targeted Delivery of Recombinant Human Endostatin Normalizes Tumour Vasculature and Improves Cancer Therapy.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Models, | 2016 |
FOLFOX4 or sorafenib as the first-line treatments for advanced hepatocellular carcinoma: A cost-effectiveness analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; China; Cohort Studies; Co | 2016 |
Increased NEK2 in hepatocellular carcinoma promotes cancer progression and drug resistance by promoting PP1/Akt and Wnt activation.
Topics: Carcinogenesis; Carcinoma, Hepatocellular; Cell Proliferation; Drug Resistance, Neoplasm; Fluorourac | 2016 |
The HIF-2α-MALAT1-miR-216b axis regulates multi-drug resistance of hepatocellular carcinoma cells via modulating autophagy.
Topics: Autophagy; Base Sequence; Basic Helix-Loop-Helix Transcription Factors; Carcinoma, Hepatocellular; C | 2016 |
Capecitabine and the Risk of Fingerprint Loss.
Topics: Capecitabine; Carcinoma, Hepatocellular; Colorectal Neoplasms; Dermatoglyphics; Female; Fluorouracil | 2017 |
Prognostic and Therapeutic Values of Tumor Necrosis Factor-Alpha in Hepatocellular Carcinoma.
Topics: Adult; Aged; Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Female; | 2016 |
Dioscin suppresses hepatocellular carcinoma tumor growth by inducing apoptosis and regulation of TP53, BAX, BCL2 and cleaved CASP3.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associ | 2016 |
miR-503 inhibits proliferation making human hepatocellular carcinoma cells susceptible to 5‑fluorouracil by targeting EIF4E.
Topics: Carcinoma, Hepatocellular; Cell Proliferation; Cells, Cultured; Down-Regulation; Drug Resistance, Ne | 2017 |
Liposome-mediated RNA interference delivery against Erk1 and Erk2 does not equally promote chemosensitivity in human hepatocellular carcinoma cell line HepG2.
Topics: Carcinoma, Hepatocellular; Down-Regulation; Fluorouracil; Gene Knockdown Techniques; Hep G2 Cells; H | 2017 |
Low-dose 5-fluorouracil sensitizes HepG2 cells to TRAIL through TRAIL receptor DR5 and survivin-dependent mechanisms.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell | 2017 |
Interactions between interleukin-6 and myeloid-derived suppressor cells drive the chemoresistant phenotype of hepatocellular cancer.
Topics: Animals; Antibodies, Neutralizing; Antimetabolites, Antineoplastic; Arginase; Carcinoma, Hepatocellu | 2017 |
In vitro and in vivo evaluation of macromolecular prodrug GC-FUA based nanoparticle for hepatocellular carcinoma chemotherapy.
Topics: A549 Cells; Absorption, Physiological; Animals; Antimetabolites, Antineoplastic; Carcinoma, Hepatoce | 2017 |
Astragaloside II sensitizes human hepatocellular carcinoma cells to 5-fluorouracil via suppression of autophagy.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Carcinoma, Hepatocellular; Cell Line, | 2017 |
Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib.
Topics: Administration, Topical; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinom | 2008 |
Killing of p53-deficient hepatoma cells by parvovirus H-1 and chemotherapeutics requires promyelocytic leukemia protein.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cisplatin; Combined M | 2008 |
Significance of trans-hepatic arterial chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombus.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therap | 2008 |
[The study of Rougan Jiedu formula anti-liver cancer in vivtro].
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Prolif | 2008 |
Complete pathological response of hepatocellular carcinoma with systemic combination chemotherapy.
Topics: alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemo | 2008 |
Predictive factors of outcome and tumor response to systemic chemotherapy in patients with metastatic hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy | 2008 |
Treatment of hepatocellular carcinoma by AdAFPep/rep, AdAFPep/p53, and 5-fluorouracil in mice.
Topics: Adenoviridae; alpha-Fetoproteins; Animals; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellula | 2008 |
Treatment of hepatocellular carcinoma using arterial chemoembolization with degradable starch microspheres and continuous arterial infusion of 5-fluorouracil.
Topics: Absorbable Implants; Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Carci | 2008 |
Down-regulation of Sonic hedgehog signaling pathway activity is involved in 5-fluorouracil-induced apoptosis and motility inhibition in Hep3B cells.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Down-Regulation; Fluorouracil | 2008 |
Commentary 2008: 25 or 50 years later?
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Colorectal Neopl | 2008 |
Hepatocellular carcinoma-related gene targeting using the large circular antisense library.
Topics: Antisense Elements (Genetics); Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Surviva | 2008 |
[Impact of epigallocatechin gallate on gene expression profiles of human hepatocellular carcinoma cell lines BEL7404/ADM and BEL7402/5-FU].
Topics: Anticarcinogenic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Hepatoc | 2008 |
Rare sugar D-allose enhances anti-tumor effect of 5-fluorouracil on the human hepatocellular carcinoma cell line HuH-7.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Dose-Response Rel | 2008 |
[A resected case of huge advanced hepatocellular carcinoma(BCC)treated with intra-arterial infusion chemotherapy combined with interferon-alpha].
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Fluorouracil; Hepatecto | 2008 |
[Cytotoxicity of the secondary metabolites of Marine Mangrove Fungus Paecilomyces sp. tree 1-7 on human hepatoma cell line HepG2].
Topics: Antineoplastic Agents; Benzoates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Dose-R | 2008 |
The effect-enhancing and toxicity-reducing action of the extract of herba Scutellariae barbatae for chemotherapy in hepatoma H22 tumor-bearing mice.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined | 2008 |
Changes of host immunity in relation to efficacy in liver cirrhosis patients with advanced hepatocellular carcinoma treated by intra-arterial chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Case-Control Studie | 2009 |
Andrographolide enhances 5-fluorouracil-induced apoptosis via caspase-8-dependent mitochondrial pathway involving p53 participation in hepatocellular carcinoma (SMMC-7721) cells.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Carcinoma, Hepatocellular; Caspase 8; | 2009 |
[A case of combined hepatocellular and cholangiocarcinoma showing tumor growth and invasion to the diaphragm during interferon-alpha and 5-fluorouracil combined intra-arterial chemotherapy].
Topics: alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chola | 2008 |
[Analysis of severe complications after transcatheter arterial chemoembolization for primary hepatocellular carcinoma].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinom | 2008 |
[Comparison between pathological findings and MR diffusion-weighted imaging in primary hepatocellular carcinoma after transcatheter arterial chemoembolization].
Topics: Adolescent; Adult; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cisplatin; Diffusion M | 2008 |
Epidermal growth factor receptor vIII enhances tumorigenicity and resistance to 5-fluorouracil in human hepatocellular carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement | 2009 |
[A case of hepatocellular carcinoma rapidly progressing after percutaneous radiofrequency ablation successfully treated with low-dose 5-FU and CDDP].
Topics: Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2009 |
[Expression of ERK5 in multidrug-resistant hepatocellular carcinoma cell line].
Topics: Carcinoma, Hepatocellular; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fluoro | 2009 |
A patient with huge hepatocellular carcinoma who had a complete clinical response to p53 gene combined with chemotherapy and transcatheter arterial chemoembolization.
Topics: Adenoviruses, Human; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, | 2009 |
A novel A33 promoter-based conditionally replicative adenovirus suppresses tumor growth and eradicates hepatic metastases in human colon cancer models.
Topics: Adenoviridae; Adenovirus E1A Proteins; Animals; Antimetabolites, Antineoplastic; beta-Galactosidase; | 2009 |
ZBP-89 reduces the cell death threshold in hepatocellular carcinoma cells by increasing caspase-6 and S phase cell cycle arrest.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Caspase 6; Cell Cycle; Cell Death; Cell Line, Tumo | 2009 |
[Advanced hepatic resection for malignancy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatoce | 2009 |
Activation of Wnt/beta-catenin signalling pathway induces chemoresistance to interferon-alpha/5-fluorouracil combination therapy for hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; | 2009 |
[Effect of HBx gene RNA interference combined with chemotherapy on hepatocellular carcinoma cells].
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; C | 2009 |
Combined use of chemotherapeutics and oncolytic adenovirus in treatment of AFP-expressing hepatocellular carcinoma.
Topics: Adenoviridae; alpha-Fetoproteins; Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplas | 2009 |
Combination chemotherapy with capecitabine and cisplatin for patients with metastatic hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular | 2009 |
Hepatocellular carcinoma in membranous obstruction of the inferior vena cava--a causal or a casual presentation.
Topics: Adult; Angioplasty, Balloon; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Female; Flu | 2009 |
Synergistic effect of 5-fluorouracil and the flavanoid oroxylin A on HepG2 human hepatocellular carcinoma and on H22 transplanted mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, He | 2010 |
[A case of advanced hepatocellular carcinoma effectively treated with 5-fluorouracil and high-concentration cisplatin suspended in lipiodol by short-term hepatic arterial infusion chemotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Hepatocellular; Cisplatin; | 2009 |
Identification of genes conferring resistance to 5-fluorouracil.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Adhesion Molecules; Cell L | 2009 |
Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells.
Topics: Antigens, CD; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Cadherins; Carcinoma, Hepatocellu | 2009 |
Accelerated treatment using intensity-modulated radiation therapy plus concurrent capecitabine for unresectable hepatocellular carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Combined Moda | 2009 |
Rosiglitazone sensitizes hepatocellular carcinoma cell lines to 5-fluorouracil antitumor activity through activation of the PPARgamma signaling pathway.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cyclooxygenase 2; Down-Regulation; Drug | 2009 |
[Three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for massive primary liver cancer].
Topics: Adult; Aged; Camptothecin; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modal | 2009 |
N(3)-o-toluyl-fluorouracil inhibits human hepatocellular carcinoma cell growth via sustained release of 5-FU.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Prolifer | 2010 |
Quantitative (19)F imaging of nmol-level F-nucleotides/-sides from 5-FU with T(2) mapping in mice at 9.4T.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; F | 2009 |
Combination of interferon-alpha and 5-fluorouracil inhibits endothelial cell growth directly and by regulation of angiogenic factors released by tumor cells.
Topics: Angiogenic Proteins; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Prolif | 2009 |
Inhibition of Hsp27 and Hsp40 potentiates 5-fluorouracil and carboplatin mediated cell killing in hepatoma cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Apoptosis; Carboplatin; Carcinom | 2009 |
[Survivin antisense oligodeoxynucleotides inhibits the proliferation of hepatocellular carcinoma cells and enhances the cell chemosensitivity to 5-Fu].
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Prolifer | 2009 |
Knockdown of HBx by RNAi inhibits proliferation and enhances chemotherapy-induced apoptosis in hepatocellular carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Hep | 2010 |
Hepatic arterial infusion chemotherapy using high-dose 5-fluorouracil and cisplatin with or without interferon-alpha for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Female; | 2009 |
TRAIL-induced apoptosis of hepatocellular carcinoma cells is augmented by targeted therapies.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-X Protein; Carcinoma, Hepatocellular; Cell Line, Tumo | 2009 |
[A case of successful multimodal treatment for combined hepatocellular and cholangiocarcinoma with portal venous tumor thrombus].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2009 |
[A long-term survival case of hepatocellular carcinoma with lymph node metastasis on the posterior surface of the pancreas head and portal vein tumor thrombus successfully treated with hepatopancreatoduodenectomy and adjuvant interferon-alpha and 5-fluoro
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adjuv | 2009 |
Intra-arterial 5-fluorouracil/interferon combination therapy for hepatocellular carcinoma with portal vein tumor thrombosis and extrahepatic metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progressio | 2010 |
Mass reduction by radiofrequency ablation before hepatic arterial infusion chemotherapy improved prognosis for patients with huge hepatocellular carcinoma and portal vein thrombus.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Catheter Ablation; Combin | 2010 |
Implantation of port-catheter system for hepatic arterial infusion chemotherapy with catheter tip fixation in a patient with celiac arterial obstruction.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arterial Occlusive Diseases; Carcinoma, Hepato | 2010 |
Synergistic effects of beta-aescin and 5-fluorouracil in human hepatocellular carcinoma SMMC-7721 cells.
Topics: Aesculus; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinom | 2010 |
[Survivin antisense oligodeoxynucleotides inhibits the proliferation of hepatocellular carcinoma cells and enhances 5-FU sensitivity].
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Prolifer | 2010 |
Novel biochemical pathways for 5-Fluorouracil in managing experimental hepatocellular carcinoma in rats.
Topics: alpha-Fetoproteins; Animals; Carcinoma, Hepatocellular; Fluorouracil; Glucosamine; Glycosaminoglycan | 2010 |
Hepatotoxicity of intra-arterial combination chemotherapy in patients with liver cirrhosis and advanced hepatocellular carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Carcinoma, Hepatocellular; Cisplatin; | 2010 |
Clinical outcomes of sorafenib treatment in patients with metastatic hepatocellular carcinoma who had been previously treated with fluoropyrimidine plus platinum-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonate | 2011 |
Therapeutic effect of alpha-fetoprotein promoter-mediated tBid and chemotherapeutic agents on orthotopic liver tumor in mice.
Topics: alpha-Fetoproteins; Animals; Antineoplastic Agents; BH3 Interacting Domain Death Agonist Protein; Ca | 2010 |
Insulin-like growth factor-binding protein 7 alters the sensitivity to interferon-based anticancer therapy in hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, T | 2010 |
Oncostatin m renders epithelial cell adhesion molecule-positive liver cancer stem cells sensitive to 5-Fluorouracil by inducing hepatocytic differentiation.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellul | 2010 |
Intra-arterial therapy with cisplatin suspension in lipiodol and 5-fluorouracil for hepatocellular carcinoma with portal vein tumour thrombosis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cause of Death; Cis | 2010 |
Evolution of laparoscopic left lateral sectionectomy without the Pringle maneuver: through resection of benign and malignant tumors to living liver donation.
Topics: Adenocarcinoma; Adenoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Loss, Su | 2011 |
Long-term clinical outcomes of hepatic arterial infusion chemotherapy with cisplatin with or without 5-fluorouracil in locally advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; D | 2011 |
Rosiglitazone enhances 5-fluorouracil-induced cell growth inhibition in hepatocellular carcinoma cell line Hep3B.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Prolifer | 2010 |
CD13 is a therapeutic target in human liver cancer stem cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carcinoma, Hepatocellular; CD13 Antige | 2010 |
Comparison of the multi-drug resistant human hepatocellular carcinoma cell line Bel-7402/ADM model established by three methods.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, | 2010 |
Diabetes mellitus impairs the response to intra-arterial chemotherapy in hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; D | 2011 |
Feasibility of oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) in cirrhotic or liver transplant patients: experience in a cohort of advanced hepatocellular carcinoma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adjuv | 2012 |
Tyrosine kinase inhibitor PTK/ZK enhances the antitumor effects of interferon-α/5-fluorouracil therapy for hepatocellular carcinoma cells.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Antiviral | 2011 |
Development of PLGA nanoparticles simultaneously loaded with vincristine and verapamil for treatment of hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Chemistry, Pharmaceutical; Drug | 2010 |
ATM kinase activity modulates cFLIP protein levels: potential interplay between DNA damage signalling and TRAIL-induced apoptosis.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Apoptosis; Ataxia Telangiectasia Mutat | 2010 |
Cytotoxic activity of Thai medicinal plants against human cholangiocarcinoma, laryngeal and hepatocarcinoma cells in vitro.
Topics: Antineoplastic Agents, Phytogenic; Atractylodes; Carcinoma, Hepatocellular; Cell Line, Tumor; Cholan | 2010 |
Gastroduodenal complications after concurrent chemoradiation therapy in patients with hepatocellular carcinoma: endoscopic findings and risk factors.
Topics: Adult; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Chemoradiotherapy; Duodenal Ulcer | 2011 |
Susceptibility of Hep3B cells in different phases of cell cycle to tBid.
Topics: Antimetabolites, Antineoplastic; Apoptosis; BH3 Interacting Domain Death Agonist Protein; Blotting, | 2011 |
MicroRNA-21 induces resistance to the anti-tumour effect of interferon-α/5-fluorouracil in hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Division; DNA Primers; Drug Evaluation, Precl | 2010 |
Clinical significance of CHD1L in hepatocellular carcinoma and therapeutic potentials of virus-mediated CHD1L depletion.
Topics: Adenoviridae; Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bioma | 2011 |
Vitamin K2 augments 5-fluorouracil-induced growth inhibition of human hepatocellular carcinoma cells by inhibiting NF-κB activation.
Topics: Antineoplastic Agents; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Prolifer | 2011 |
Combination therapy of intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel | 2011 |
[A long-term survival case of hepatocellular carcinoma with portal vein and inferior vena cava tumor thrombi].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2010 |
The design and cytotoxic evaluation of some 1-aryl-3-isopropylamino-1-propanone hydrochlorides towards human Huh-7 hepatoma cells.
Topics: Acetone; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Crystallography, X-Ray; | 2011 |
Activity of thalidomide and capecitabine in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular | 2012 |
Metronomic S-1 chemotherapy and vandetanib: an efficacious and nontoxic treatment for hepatocellular carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, He | 2011 |
Which treatment modality should we choose for advanced hepatocellular carcinoma?
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonate | 2010 |
[Effect of bushen jianpi decoction and its disassemble recipes on tumor growth in mice with transplanted primary hepatic carcinoma].
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Drugs, Chinese Herbal; Fluorouracil | 2011 |
Biodistribution and improved anticancer effect of NIK-siRNA in combination with 5-FU for hepatocellular carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Prolifer | 2011 |
18F-fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma.
Topics: Adult; Aged; Analysis of Variance; Carcinoma, Hepatocellular; Chemoradiotherapy; Cisplatin; Disease- | 2011 |
Combination of interferon-α and 5-fluorouracil induces apoptosis through mitochondrial pathway in hepatocellular carcinoma in vitro.
Topics: Apoptosis; bcl-X Protein; BH3 Interacting Domain Death Agonist Protein; Calcium; Carcinoma, Hepatoce | 2011 |
Efficacy of therapy for advanced hepatocellular carcinoma: intra-arterial 5-fluorouracil and subcutaneous interferon with image-guided radiation.
Topics: Carcinoma, Hepatocellular; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Humans; Imm | 2011 |
Cytotoxic activity of artemisinin derivatives against cholangiocarcinoma (CL-6) and hepatocarcinoma (Hep-G2) cell lines.
Topics: Antigens, CD; Antineoplastic Agents; Artemisinins; ATP Binding Cassette Transporter, Subfamily B; AT | 2011 |
Shikonin derivatives protect immune organs from damage and promote immune responses in vivo in tumour-bearing mice.
Topics: Adjuvants, Immunologic; Animals; Antigens, CD19; Antineoplastic Agents, Phytogenic; Boraginaceae; Ca | 2012 |
Switching the loaded agent from epirubicin to cisplatin: salvage transcatheter arterial chemoembolization with drug-eluting microspheres for unresectable hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, | 2012 |
Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose in predicting treatment response in unresectable hepatocellular carcinoma patients treated with external beam radiotherapy.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chemoradiotherapy; Female; F | 2012 |
Reversal effect of 2',4'-dihydroxy-6'-methoxy-3',5'-dimethylchalcone on multi-drug resistance in resistant human hepatocellular carcinoma cell line BEL-7402/5-FU.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Line, Tumor; Chalcones; Chromatogra | 2011 |
GALNT14 SNP as a potential predictor of response to combination chemotherapy using 5-FU, mitoxantrone and cisplatin in advanced HCC.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Carcinoma, | 2011 |
[The inhibitory effect of RNA interference on STAT3 expression in liver cancer cell line SMMC7721].
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Fluorouracil; Gene Knockdown Techni | 2011 |
Long-term outcome of combined interferon-α and 5-fluorouracil treatment for advanced hepatocellular carcinoma with major portal vein thrombosis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Fluorouraci | 2011 |
FBI-1 promotes cell proliferation and enhances resistance to chemotherapy of hepatocellular carcinoma in vitro and in vivo.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; DNA-Binding | 2012 |
Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Camptothecin; Carcinoma, Hepatocellular; Cell Dea | 2011 |
Arsenic trioxide plus cisplatin/interferon α-2b/doxorubicin/capecitabine combination chemotherapy for unresectable hepatocellular carcinoma.
Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Capecit | 2011 |
Combination treatment with intrahepatic arterial infusion and intratumoral injection chemotherapy in patients with far-advanced hepatocellular carcinoma and arterioportal or arteriovenous shunts: preliminary results.
Topics: Aged; Angiography; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cispla | 2011 |
Using rhodamine 123 accumulation in CD8 cells as a surrogate indicator to study the P-glycoprotein modulating effect of cepharanthine hydrochloride in vivo.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzylisoquinolines; Carcinoma, He | 2011 |
miRNA-195 sensitizes human hepatocellular carcinoma cells to 5-FU by targeting BCL-w.
Topics: Antineoplastic Agents; Apoptosis Regulatory Proteins; Blotting, Western; Carcinoma, Hepatocellular; | 2012 |
Enhancement of carboplatin- and quercetin-induced cell death by roscovitine is Akt dependent and p53 independent in hepatoma cells.
Topics: Antineoplastic Agents; Antioxidants; Apoptosis; Carboplatin; Carcinoma, Hepatocellular; Caspase 3; C | 2011 |
Tanshinone IIA inhibits human hepatocellular carcinoma J5 cell growth by increasing Bax and caspase 3 and decreasing CD31 expression in vivo.
Topics: Abietanes; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; bcl-2-Associ | 2012 |
[Effectiveness of systemic chemotherapy of GEM+CBDCA+5-FU/LV and hepatic arterial infusion of CDDP in a case of advanced, combined hepatocellular-cholangiocarcinoma with multiple lung metastases].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2011 |
Comparison of survival and quality of life of hepatectomy and thrombectomy using total hepatic vascular exclusion and chemotherapy alone in patients with hepatocellular carcinoma and tumor thrombi in the inferior vena cava and hepatic vein.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cost-Benefit Analy | 2012 |
Casticin-induced apoptosis involves death receptor 5 upregulation in hepatocellular carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Caspas | 2011 |
Hepatic intra-arterial cetuximab in combination with 5-fluorouracil and cisplatin as salvage treatment for sorafenib-refractory hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2011 |
DNA methylation-regulated miR-193a-3p dictates resistance of hepatocellular carcinoma to 5-fluorouracil via repression of SRSF2 expression.
Topics: Animals; Base Sequence; Carcinoma, Hepatocellular; Cell Line, Tumor; DNA Methylation; Drug Resistanc | 2012 |
Hepatic arterial infusion chemotherapy with a coaxial reservoir system using a non-braided spiral tip microcatheter.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Catheter | 2012 |
Establishment and characterization of two 5-fluorouracil-resistant hepatocellular carcinoma cell lines.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Growth Processes; Cell Line, Tumor; | 2012 |
Proteomic investigation of 5-fluorouracil resistance in a human hepatocellular carcinoma cell line.
Topics: Adult; Aged; Annexin A3; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Re | 2012 |
[A case of successful treatment by interferon-α and 5-fluorouracil combination therapy (FAIT) and transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Modality T | 2011 |
Opsin3 sensitizes hepatocellular carcinoma cells to 5-fluorouracil treatment by regulating the apoptotic pathway.
Topics: Antimetabolites, Antineoplastic; Apoptosis; bcl-2-Associated X Protein; Carcinoma, Hepatocellular; C | 2012 |
Galactosylated nanostructured lipid carriers for delivery of 5-FU to hepatocellular carcinoma.
Topics: Acetone; Amines; Antineoplastic Agents; Asialoglycoprotein Receptor; Carcinoma, Hepatocellular; Dela | 2012 |
Systemic chemotherapy using carboplatin and 5-fluorouracil for extrahepatic metastasis of hepatocellular carcinoma.
Topics: Adrenal Gland Neoplasms; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carbo | 2012 |
Targeting autophagy potentiates chemotherapy-induced apoptosis and proliferation inhibition in hepatocarcinoma cells.
Topics: Adenine; Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin | 2012 |
Systemic combination therapy of intravenous continuous 5-fluorouracil and subcutaneous pegylated interferon alfa-2a for advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2012 |
Metformin plus PIAF combination chemotherapy for hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Carcinoma, Hepatocellular; Cel | 2012 |
Efficacy and safety of metronomic chemotherapy for patients with advanced primary hepatocellular carcinoma with major portal vein tumor thrombosis.
Topics: Administration, Metronomic; Adult; Aged; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepat | 2012 |
Lipoteichoic acid of Bifidobacterium in combination with 5-fluorouracil inhibit tumor growth and relieve the immunosuppression.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bifidobacterium; Carcinoma, Hepatocellular; | 2012 |
Prognostic significance of alpha-fetoprotein status in the outcome of hepatocellular carcinoma after treatment of transarterial chemoembolization.
Topics: Adult; Aged; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization | 2012 |
Is hepatic arterial infusion chemotherapy effective treatment for advanced hepatocellular carcinoma resistant to transarterial chemoembolization?
Topics: Aged; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Fluorouracil; Hepatic Arter | 2012 |
Serum insulin-like growth factor-1 levels predict outcomes of patients with advanced hepatocellular carcinoma receiving antiangiogenic therapy.
Topics: Administration, Metronomic; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Mon | 2012 |
Water extract of Hedyotis Diffusa Willd suppresses proliferation of human HepG2 cells and potentiates the anticancer efficacy of low-dose 5-fluorouracil by inhibiting the CDK2-E2F1 pathway.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Growth Proc | 2012 |
Prospective impact of 5-FU in the induction of endoplasmic reticulum stress, modulation of GRP78 expression and autophagy in Sk-Hep1 cells.
Topics: Apoptosis; Autophagy; Calcium; Carcinoma, Hepatocellular; Caspase 12; Cell Line, Tumor; Endoplasmic | 2012 |
Preferential inhibition of hepatocellular carcinoma by the flavonoid Baicalein through blocking MEK-ERK signaling.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Caspase 9; Cell Line, Tumor; Enzyme Inhibi | 2012 |
Astrocyte elevated gene-1 promotes hepatocarcinogenesis: novel insights from a mouse model.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Adhesion Molecules; Cell Transformat | 2012 |
Gold nanoparticles conjugated with cisplatin/doxorubicin/capecitabine lower the chemoresistance of hepatocellular carcinoma-derived cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Capecitabine; Carcinoma, Hepatocellular; Cell Death; Cell Prolifer | 2012 |
Liver fibrosis and five year survival of hepatocellular cancer cases undergoing transcatheter arterial chemo embolization using small doses.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therap | 2012 |
Radiotherapy for nasopharyngeal carcinoma and combined capecitabine and nimotuzumab treatment for lung metastases in a liver transplantation recipient: a case experience of sustained complete response.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Car | 2012 |
MiR-195 regulates cell apoptosis of human hepatocellular carcinoma cells by targeting LATS2.
Topics: 3' Untranslated Regions; Antimetabolites; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; C | 2012 |
Reversal effect of melanoma differentiation associated gene-7/interleukin-24 on multidrug resistance in human hepatocellular carcinoma cells.
Topics: Carcinoma, Hepatocellular; Cell Differentiation; Cell Line, Tumor; Doxorubicin; Drug Resistance, Mul | 2012 |
Dual-phase CT angiography through the port-catheter system for hepatic arterial infusion chemotherapy using multislice CT: assessment of system dysfunction and impact on predicting clinical problems.
Topics: Aged; Aged, 80 and over; Angiography, Digital Subtraction; Antineoplastic Agents; Carcinoma, Hepatoc | 2012 |
Preliminary pharmacology of galactosylated chitosan/5-fluorouracil nanoparticles and its inhibition of hepatocellular carcinoma in mice.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Lin | 2012 |
Differential effects of arsenic trioxide on chemosensitization in human hepatic tumor and stellate cell lines.
Topics: Adult; AMP-Activated Protein Kinases; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blotting, | 2012 |
Hepatic arterial thrombosis: a critical complication during combination therapy of arterial chemoinfusion and sorafenib.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carc | 2012 |
Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma according to Child-Pugh classification.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel | 2012 |
5-Fluorouracil nanoparticles inhibit hepatocellular carcinoma via activation of the p53 pathway in the orthotopic transplant mouse model.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; bcl-2-Associated X Protein; Carcinoma, Hepatoce | 2012 |
Glycogenes mediate the invasive properties and chemosensitivity of human hepatocarcinoma cells.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement | 2013 |
TFPI-2 downregulates multidrug resistance protein in 5-FU-resistant human hepatocellular carcinoma BEL-7402/5-FU cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; | 2013 |
Reversal of P-glycoprotein-mediated multidrug resistance of human hepatic cancer cells by Astragaloside II.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Astragalus Plant; ATP Binding Ca | 2012 |
How can we treat a patient with liver cirrhosis (hepatitis C virus), hepatocellular carcinoma, and synchronous colon cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Hepatocellular; Chemotherapy, Adj | 2012 |
Galactosylated chitosan/5-fluorouracil nanoparticles inhibit mouse hepatic cancer growth and its side effects.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Hepat | 2012 |
Impact of low versus conventional doses of chemotherapy during transcatheter arterial chemo-embolization on serum fibrosis indicators and survival of liver cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoemboliz | 2012 |
Characterization and resistance mechanisms of a 5-fluorouracil- resistant hepatocellular carcinoma cell line.
Topics: Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; bcl-2-Asso | 2012 |
Bmi1 gene silencing inhibits the proliferation and invasiveness of human hepatocellular carcinoma cells and increases their sensitivity to 5-fluorouracil.
Topics: Antigens, CD; Antimetabolites, Antineoplastic; Apoptosis; Cadherins; Carcinoma, Hepatocellular; Cell | 2013 |
Hepatocellular carcinoma and chemotherapy: the role of p53.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Carcinoma, Hepatocellular; Cell Line, | 2012 |
[Therapeutic effects of sorafenib combined with transcatheter arterial chemoembolization and microwave ablation on postsurgical recurrent hepatocellular carcinoma].
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Hepatocellular; Catheter Ablation; Chemo | 2012 |
RNAi-mediated EZH2 depletion decreases MDR1 expression and sensitizes multidrug-resistant hepatocellular carcinoma cells to chemotherapy.
Topics: Antimetabolites, Antineoplastic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Bindi | 2013 |
The noncytotoxic dose of sorafenib sensitizes Bel-7402/5-FU cells to 5-FU by down-regulating 5-FU-induced Nrf2 expression.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Carcin | 2013 |
Hypofractionated radiotheapy using helical tomotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Chemoradiothe | 2013 |
Hepatic arterial infusion of 5-fluorouracil and cisplatin for unresectable or recurrent hepatocellular carcinoma with tumor thrombus of the portal vein.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Drug Adm | 2002 |
The effect of calmodulin antagonist berbaminederivative-EBB on hepatoma in vitro and in vivo.
Topics: Alkaloids; Animals; Antimetabolites, Antineoplastic; Benzylisoquinolines; Calmodulin; Carcinoma, Hep | 2002 |
[A case of recurrent hepatocellular carcinoma successfully treated with a combination therapy of interferon-alpha and intravenous continuous infusion of 5-fluorouracil].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Administration Sched | 2002 |
Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Doxorubicin; F | 2002 |
Mechanism of 5-fluorouracil required resistance in human hepatocellular carcinoma cell line Bel(7402).
Topics: Buthionine Sulfoximine; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Fluorescein; Fluoroura | 2002 |
[Modified pharmacokinetic modulation chemotherapy (PMC) with medication of UFT and intraarterial infusion of 5-FU for advanced unresectable HCC].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Combina | 2002 |
Study on the changes in microvessel density in hepatocellular carcinoma following transcatheter arterial chemoembolization.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, | 2001 |
Identification of genes associated with sensitivity to 5-fluorouracil and cisplatin in hepatoma cells.
Topics: Carcinoma, Hepatocellular; Cisplatin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; F | 2002 |
Resection of hepatocellular carcinoma with tumor thrombus of the portal vein after neoadjuvant regional chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; C | 2002 |
[A case of advanced hepatocelluar carcinoma achieving a complete response following the hepatic arterial infusion chemotherapy and subsequent lipiodolization].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therap | 2003 |
Systemic combined chemotherapy with low dose of 5-fluorouracil, cisplatin, and interferon-alpha for advanced hepatocellular carcinoma: a pilot study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Dose-Res | 2003 |
[Role of caspase-8 and caspase-3 in hepatoma cells apoptosis induced by 5-fluorouracil].
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Caspase 8; Caspase | 2003 |
Is liver disease an octreotide side effect?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Hepatocellular; Drug | 2003 |
[Influence of combined cyclosporine A and tacrolimus with 5-fluorouracil on hepatocellular carcinoma rats].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cyclo | 2003 |
Fibrosis and inflammatory activity in noncancerous tissue and mitotic index of cancer tissue in patients with hepatocellular carcinoma: relationship to clinicopathological factors and prognosis after hepatic resection.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; F | 2003 |
Dihydropyrimidine dehydrogenase and thymidylate synthase activities in hepatocellular carcinomas and in diseased livers.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biopsy; Carcinoma, Hepatocellular; | 2003 |
GROWTH INHIBITION OF A SPECTRUM OF TRANSPLANTED MOUSE TUMORS BY COMBINATIONS OF INHIBITORS OF NUCLEIC ACID BIOSYNTHESIS AND ALKYLATING AGENTS.
Topics: Alkylating Agents; Animals; Antineoplastic Agents; Azaguanine; Azaserine; Carcinoma, Ehrlich Tumor; | 1963 |
CHEMOTHERAPEUTIC STUDIES WITH OSTEOGENIC SARCOMA HE10734.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma 256, Walker; Carcinoma, Hepatocellular; Fl | 1964 |
PYRIMIDINE METABOLISM IN TISSUE CULTURE CELLS DERIVED FROM RAT HEPATOMAS. I. SUSPENSION CELL CULTURES DERIVED FROM THE NOVIKOFF HEPATOMA.
Topics: Animals; Carcinoma, Hepatocellular; Cell Culture Techniques; Floxuridine; Fluorouracil; Glycine; Liv | 1965 |
Expression of angiogenic factors in hepatocellular carcinoma after transcatheter arterial chemoembolization.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Catheterization, Pe | 2003 |
Interventional radiology for advanced hepatocellular carcinoma: comparison of hepatic artery infusion chemotherapy and transcatheter arterial lipiodol chemoembolization.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel | 2003 |
Caspase-8 in apoptosis of hepatoma cell induced by 5-fluorouracil.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Hepatocellular; Caspase 8; Caspase 9; Caspase | 2003 |
[Long-term outcome of advanced hepatocellular carcinoma that received transarterial hepatic chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Female; | 2003 |
[Postoperative adjuvant intraarterial chemotherapy of combined cisplatin and 5-FU for advanced hepatocellular carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; C | 2003 |
[A case of successful treatment of advanced hepatocellular carcinoma with tumor thrombi in the major portal branches and inferior vena cava with combined intraarterial 5-fluorouracil, adriamycin and cisplatin therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Doxorubi | 2003 |
[A report of two cases--two patients of the extremely advanced hepatocellular carcinoma have responded completely for a long time after a combination therapy consisting of arterial chemotherapy and injection of interferon-alpha].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy | 2003 |
[A case of Vp4 hepatocellular carcinoma treated with surgical resection and continuous intrahepatic artery infusion chemotherapy of low-dose cisplatin and 5-fluorouracil].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Drug Administr | 2003 |
Capecitabine inhibits postoperative recurrence and metastasis after liver cancer resection in nude mice with relation to the expression of platelet-derived endothelial cell growth factor.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Fl | 2003 |
The efficacy of the combination therapy of 5-fluorouracil, cisplatin and leucovorin for hepatocellular carcinoma and its predictable factors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Survival; Cisplatin; | 2004 |
[Screening of the drug resistance-associated gene in HepG2 cell line transfected with aldose reductase like gene-1 (ARL-1)].
Topics: Aldehyde Reductase; Aldo-Keto Reductases; Antineoplastic Agents; ATP Binding Cassette Transporter, S | 2003 |
Wild type p53 increased chemosensitivity of drug-resistant human hepatocellular carcinoma Bel7402/5-FU cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Drug Resistance, Multiple; Drug Resista | 2004 |
[Application of arsenic trioxide in comprehensive therapy of liver carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Carcinoma | 2003 |
Cyclin A correlates with the sensitivity of human cancer cells to cytotoxic effects of 5-FU.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Line, Tumor; Collagen; Colonic Neop | 2004 |
An armed oncolytic adenovirus system, ZD55-gene, demonstrating potent antitumoral efficacy.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cells, Cu | 2003 |
[Complete response to treatment with low-dose FP therapy in a patient with stage IVB primary hepatocellular carcinoma with multiple lung and bone metastases].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, | 2004 |
An antisense plasmid targeting survivin expression induces apoptosis and sensitizes hepatocarcinoma cells to chemotherapy.
Topics: Antigens, Neoplasm; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Hepatocellular; Cell Line | 2003 |
Screening for supra-additive effects of cytotoxic drugs and gamma irradiation in an in vitro model for hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cisplatin; Deoxycytidine; Dose-R | 2004 |
Interferon-alpha 2a up-regulated thymidine phosphorylase and enhanced antitumor effect of capecitabine on hepatocellular carcinoma in nude mice.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; En | 2004 |
Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs.
Topics: Adaptor Proteins, Signal Transducing; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Apop | 2004 |
Changes of tumor microcirculation after transcatheter arterial chemoembolization: first pass perfusion MR imaging and Chinese ink casting in a rabbit model.
Topics: Animals; Carbon; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Contrast Media; Diagnost | 2004 |
Chemotherapy using 5-fluorouracil, mitoxantrone, and cisplatin for patients with advanced hepatocellular carcinoma: an analysis of 63 cases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; F | 2004 |
Therapeutic efficacy of multimodal combination therapy using transcatheter arterial infusion of epirubicin and cisplatin, systemic infusion of 5-fluorouracil, and additional percutaneous ethanol injection for unresectable hepatocellular carcinoma.
Topics: Administration, Cutaneous; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular | 2004 |
A combination therapy with copper nicotinate complex reduces the adverse effects of 5-fluorouracil on patients with hepatocellular carcinoma.
Topics: Alkaline Phosphatase; Antimetabolites, Antineoplastic; Bilirubin; Carcinoma, Hepatocellular; Cerulop | 2004 |
Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma.
Topics: Administration, Oral; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Carcinoma, Hepato | 2004 |
Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma.
Topics: Administration, Oral; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Carcinoma, Hepato | 2004 |
Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma.
Topics: Administration, Oral; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Carcinoma, Hepato | 2004 |
Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma.
Topics: Administration, Oral; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Carcinoma, Hepato | 2004 |
Hepatic arterial infusion chemotherapy with use of an implanted port system in patients with advanced hepatocellular carcinoma: prognostic factors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Catheters, I | 2004 |
Interstitial pneumonia induced by combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Fatal Outcome; Fluorourac | 2004 |
Effect of resveratrol and in combination with 5-FU on murine liver cancer.
Topics: Animals; Anticarcinogenic Agents; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell C | 2004 |
Molecular prediction of response to 5-fluorouracil and interferon-alpha combination chemotherapy in advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth | 2004 |
Genes associated with human hepatocellular carcinoma cell chemosensitivity to 5-fluorouracil plus interferon-alpha combination chemotherapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Dr | 2004 |
Aberrant methylation of DPYD promoter, DPYD expression, and cellular sensitivity to 5-fluorouracil in cancer cells.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Sq | 2004 |
[Influence on 5-fluorouracil metabolism by combination of interferon-alpha and 5-fluorouracil against human hepatocellular carcinoma xenografts].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Dihydrouracil De | 2004 |
5-fluorouracil and hydroxyurea enhance adenovirus-mediated transgene expression in colon and hepatocellular carcinoma cells.
Topics: Adenoviridae; Antimetabolites, Antineoplastic; Antineoplastic Agents; beta-Galactosidase; Carcinoma, | 2005 |
[Successful hepatic arterial infusion therapy of CDDP/5-FU/IFN-beta3 for recurrent hepatocellular carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2004 |
[Intrahepatic arterial chemotherapy with 5-fluorouracil and intramuscular interferon-alpha for a patient with diffuse type of hepatocellular carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Administration | 2004 |
[A case of long-term survivor with multiple pulmonary metastases of HCC after hepatic resection].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Drug Combinati | 2004 |
[The value of Roferon-A combined with hepatic artery chemoembolization and portal vein chemotherapy after radical resection in hepatocellular carcinoma for preventing recurrence].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combi | 2004 |
Partial contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway to antitumor effects of interferon-alpha/5-fluorouracil against Hepatocellular Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis | 2004 |
[Efficacy of hepatic arterial infusion therapy for advanced hepatocellular carcinoma using 5-fluorouracil and cisplatin].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; F | 2004 |
[Hepatic arterial infusion chemotherapy (HAIC)--hepatocellular carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Dose-Response | 2004 |
[In vitro chemosensitivity test for hepatocellular carcinoma using collagen-gel droplet embedded cultures].
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Hepatocellular; Cisplatin; Collagen; Culture Med | 2004 |
Modulation of 5-fluorouracil cytotoxicity through thymidylate synthase and NF-kappaB down-regulation and its application on the radiolabelled iododeoxyuridine therapy on human hepatoma cell.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Down-Regulation; Fluorouracil; Humans; Idoxuridine; Iod | 2005 |
Prognostic factors in patients with advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepat | 2005 |
Consensus interferon enhances the anti-proliferative effect of 5-fluorouracil on human hepatoma cells via downregulation of dihydropyrimidine dehydrogenase expression.
Topics: Antimetabolites, Antineoplastic; Antiviral Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell | 2005 |
Combination of IFN-alpha and 5-fluorouracil induces apoptosis through IFN-alpha/beta receptor in human hepatocellular carcinoma cells.
Topics: Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Blotting, Western; Carcinoma, Hepatocellular; | 2005 |
[Efficacy of hepatic arterial infusion therapy for advanced hepatocellular carcinoma using 5-fluorouracil, epirubicin and mitomycin-C].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Epirubicin; | 2005 |
[A case of hepatocellular carcinoma with multiple lung metastases responding to intermittent intrahepatic arterial chemotherapy of CDDP+5-FU].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Combined | 2005 |
The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Carcinoma, Hepatocellular; | 2005 |
CpG oligodeoxynucleotides inhibit tumor growth and reverse the immunosuppression caused by the therapy with 5-fluorouracil in murine hepatoma.
Topics: Animals; Carcinoma, Hepatocellular; Combined Modality Therapy; CpG Islands; Fluorouracil; Genetic Th | 2005 |
[Adjuvant chemotherapy after orthotopic liver transplantation for advanced hepatocellular carcinoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adju | 2005 |
Intraarterial chemotherapy: another choice for unresectable advanced hepatocellular carcinoma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therap | 2004 |
Clinical effects of intra-arterial infusion chemotherapy with cisplatin, mitomycin C, leucovorin and 5-flourouracil for unresectable advanced hepatocellular carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Drug Adm | 2004 |
Images of interest. Hepatobiliary and pancreatic: Tumor thrombi in esophageal varices.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Endoscopy; Eso | 2005 |
Anti-hepatocarcinoma effects of 5-fluorouracil encapsulated by galactosylceramide liposomes in vivo and in vitro.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Capsules; Carcinoma, Hepatocellular; Cell Line, | 2005 |
Effects of tacrolimus on proliferation, apoptosis, and fluorouracil sensitivity of liver cancer cell line of SMMC-7721.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Female; Fluo | 2005 |
P-glycoprotein expression induced by glucose depletion enhanced the chemosensitivity in human hepatocellular carcinoma cell-lines.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Hepatocel | 2005 |
Inhibition of tumor growth and metastasis with antisense oligonucleotides (Cantide) targeting hTERT in an in situ human hepatocellular carcinoma model.
Topics: alpha-Fetoproteins; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; DNA | 2005 |
[A case of hepatocellular carcinoma with tumor thrombi in the first branch of the portal vein and hepatic vein trunks treated by transcatheter hepatic arterial chemoembolization and hepatic arterial infusion chemotherapy--two years and six months follow-u
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, | 2005 |
Protein transduction with bacterial cytosine deaminase fused to the TLM intercellular transport motif induces profound chemosensitivity to 5-fluorocytosine in human hepatoma cells.
Topics: Animals; Base Sequence; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Membrane Permeability; Cyt | 2005 |
5-Fluorouracil concentration in blood, liver and tumor tissues and apoptosis of tumor cells after preoperative oral 5'-deoxy-5-fluorouridine in patients with hepatocellular carcinoma.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Hepatocellular; Female; Floxuridine; Fluorour | 2005 |
Adjuvant arterial infusion chemotherapy after resection of hepatocellular carcinoma with portal thrombosis: a pilot study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel | 2005 |
[Effects of paclitaxel and 5-fluorouracil on growth inhibition and apoptosis of hepatoma cells: a comparative study].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Hepatocell | 2005 |
Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Disease Prog | 2005 |
[Transcatheter hepatic arterial chemoembolization on recurrent hepatocellular carcinoma after resection].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2005 |
5-aza-2'-deoxycytidine sensitizes hepatoma and pancreatic cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Azacitidine; Carcinoma, Hepatocel | 2005 |
Successful treatment of advanced hepatocellular carcinoma by combined administration of 5-fluorouracil and pegylated interferon-alpha.
Topics: Aged; Antimetabolites, Antineoplastic; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Co | 2005 |
Transfection of Smac sensitizes tumor cells to etoposide-induced apoptosis and eradicates established human hepatoma in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Re | 2006 |
[Complete disappearance of metastatic lung tumors and mediastinal lymphnode in a case of hepatocellular carcinoma treated by low-dose 5-fluorouracil/cisplatin therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Dose-Response | 2005 |
Toxic death-case after capecitabine + oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine deshydrogenase deficiency.
Topics: Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Capecitabine; Carcinoma, Hepatocellul | 2006 |
[A case report of hepatocellular carcinoma (Vp4)--an attempt to reduce residual tumor thrombus using combination therapy (hepatic arterial infusion, hepatic arterial embolization and radiation)].
Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Embolization, Therapeutic; Fluorouracil; | 2005 |
[The hepatic artery injection chemotherapy and prostaglandin E1 administration for hepatocellular carcinoma invading the biliary tract with jaundice].
Topics: Aged; Alprostadil; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; | 2005 |
[Successful treatment of combined intraarterial (5-fluorouracil and adriamycin and cisplatin) infusion chemotherapy for advanced hepatocellular carcinoma with multiple intrahepatic metastases and/or portal vein thrombosis--two case reports].
Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineopl | 2005 |
Enhanced sensitivity of human hepatoma cells to 5-fluorouracil by small interfering RNA targeting Bcl-2.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, | 2005 |
[Observation on efficiency of shelian capsule as adjuvant of embolismic chemotherapy on primary hepatic carcinoma].
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protoco | 2005 |
[Investigation of bile duct injury after transcatheter arterial chemoembolization].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Ducts; Carcinom | 2005 |
Hepatocellular carcinoma--Pathological complete response to oral capecitabine, megestrol and thalidomide.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular; Deoxy | 2006 |
Is capecitabine safe in patients with gastrointestinal cancer and dihydropyrimidine dehydrogenase deficiency?
Topics: Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Contraindications; Deoxycy | 2006 |
[Effect of low dose 5-fluorouracil and cisplatin intra-arterial infusion chemotherapy in advanced hepatocellular carcinoma with decompensated cirrhosis].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; D | 2006 |
[Establishment of a multidrug-resistant cell line BEL-7402/5-FU of human hepatocellular carcinoma and its biological characteristics].
Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Do | 2006 |
Antiproliferative effects of 5-fluorouracil and interferon-alpha in combination on a hepatocellular carcinoma cell line in vitro and in vivo.
Topics: Angiogenic Proteins; Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Hepatocellular; | 2006 |
Oxaliplatin and capecitabine (Xelox) in association with highly active antiretroviral therapy in advanced hepatocarcinoma HIV/HCV-infected patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Capeci | 2006 |
TIP30 inhibits growth of HCC cell lines and inhibits HCC xenografts in mice in combination with 5-FU.
Topics: Acetyltransferases; Adenoviridae; Animals; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Wes | 2006 |
Subtotal hepatectomy following neoadjuvant chemotherapy for a previously unresectable hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal; Carcinoma, Hepa | 2006 |
[Three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for hepatocellular carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Carcinoma, Hepatocellular; Che | 2006 |
Combination of 5-FU and IFNalpha enhances IFN signaling pathway and caspase-8 activity, resulting in marked apoptosis in hepatoma cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Caspase 8; Cas | 2006 |
Bcl-XL small interfering RNA enhances sensitivity of Hepg2 hepatocellular carcinoma cells to 5-fluorouracil and hydroxycamptothecin.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; bcl-X Protein; Camptothecin; Car | 2006 |
Role of the Fas/FasL pathway in combination therapy with interferon-alpha and fluorouracil against hepatocellular carcinoma in vitro.
Topics: Antibodies; Antineoplastic Agents; Apoptosis; Base Sequence; Carcinoma, Hepatocellular; CASP8 and FA | 2007 |
The up-regulation of type I interferon receptor gene plays a key role in hepatocellular carcinoma cells in the synergistic antiproliferative effect by 5-fluorouracil and interferon-alpha.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Growth Processes; Ce | 2006 |
Role of p53 in the inhibitory effects of interferon-alpha subtypes on proliferation of hepatocellular carcinoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Ce | 2006 |
Antisense oligonucleotides targeting midkine induced apoptosis and increased chemosensitivity in hepatocellular carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Cell Line, Tumor; | 2006 |
[Preparation of 5-fluorouracil encapsulated in amphiphilic polysaccharide nano-micelles and its killing effect on hepatocarcinoma cell line HepG2].
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Prolifer | 2006 |
[A case of advanced hepatocellular carcinoma with lung metastases and cirrhosis that responded to combination chemotherapy with interferon-alpha and 5-fluorouracil].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Administration Sched | 2006 |
Synergistic inhibition of hepatocellular carcinoma growth and hepatocarcinogenesis by combination of 5-fluorouracil and angiotensin-converting enzyme inhibitor via anti-angiogenic activities.
Topics: Angiogenesis Inhibitors; Angiotensin-Converting Enzyme Inhibitors; Animals; Antineoplastic Combined | 2007 |
[A case of an elderly patient having advanced hepatocellular carcinoma with tumor thrombus in the inferior vena cava treated with chemo-radio-therapy--intraarterial infusion of weekly high dose 5-FU (WHF)].
Topics: Aged, 80 and over; Carcinoma, Hepatocellular; Combined Modality Therapy; Fluorouracil; Humans; Infus | 2006 |
[Intra arterial infusion chemotherapy combined with interferon-alpha following palliative hepatic resection against advanced hepatoma with portal venous tumor thrombus in the major trunk and multiple nodules--a preliminary study].
Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Female; Fluorouracil; Hepatectomy; Human | 2006 |
[Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma providing a good QOL].
Topics: Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2006 |
[A 42-month disease free survival case of combined hepatocellular-cholangiocarcinoma with lymph node metastases treated with multimodal therapy].
Topics: alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, | 2006 |
Assessment of supra-additive effects of cytotoxic drugs and low dose rate irradiation in an in vitro model for hepatocellular carcinoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; | 2006 |
[A case of multiple lung metastases of hepatocellular carcinoma after resection of liver and tumor thrombi in the inferior vena cava responding to chemotherapy using 5-FU, mitoxantrone and CDDP].
Topics: alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cispl | 2007 |
Eradication of hepatoma and colon cancer in mice with Flt3L gene therapy in combination with 5-FU.
Topics: Adenoviridae; Adoptive Transfer; Animals; Antimetabolites, Antineoplastic; Bone Marrow; Carcinoma, H | 2007 |
Characterization of cell death events induced by anti-neoplastic drugs cisplatin, paclitaxel and 5-fluorouracil on human hepatoma cell lines: Possible mechanisms of cell resistance.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Carcinoma, Hepatocellular; Caspase 3; | 2007 |
Successful treatment of multiple hepatocellular carcinoma with tumor thrombi in the major portal branches by intraarterial 5-fluorouracil perfusion chemotherapy combined with subcutaneous interferon-alpha and hepatectomy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Fluorouracil; Hepatectomy | 2007 |
Methylation of Ras association domain family protein 1, isoform A correlated with proliferation and drug resistance in hepatocellular carcinoma cell line SMMC-7721.
Topics: Animals; Antineoplastic Agents; Azacitidine; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor | 2007 |
Enhanced therapeutic effects of combined chemotherapeutic drugs and midkine antisense oligonucleotides for hepatocellular carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Line, Tumor | 2007 |
Peritoneal dissemination of hepatocellular carcinoma treated with a combination therapy of interferon-alpha-2b and oral tegafur/uracil.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic C | 2007 |
[Anti-tumor effect of interferon for hepatocellular carcinoma-from the clinical consideration].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Modality T | 2007 |
[Clinical study of low-dose cisplatin and 5-fluorouracil chemotherapy via implanted fusion port in 20 patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; D | 2007 |
Identification and characterization of BH3 domain protein Bim and its isoforms in human hepatocellular carcinomas.
Topics: Alternative Splicing; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Carcinoma, He | 2007 |
Hepatic arterial infusion of 5-fluorouracil in combination with subcutaneous interferon-alpha for advanced hepatocellular carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Dose-Response Relat | 2007 |
[Anti-tumor effects of various interferons-alpha +5-fluorouracil via downregulation of dihydropyrimidine dehydrogenase in hepatoma cells].
Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Division; Cell Line, Tumor; Dihydro | 2007 |
Bioluminescent imaging of hepatocellular carcinoma in live mice.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 2007 |
[Three cases of hepatocellular carcinoma, over 3 cm in diameter, with liver cirrhosis treated with combination of radiofrequency ablation and continuous hepatic arterial infusion chemotherapy].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2007 |
Complete remission of hepatocellular carcinoma with portal vein tumor thrombus and lymph node metastases by arterial infusion of 5-fluorouracil and interferon-alpha combination therapy following hepatic resection.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Combined Modality Therapy; Drug Therapy, | 2007 |
[A case of chronic hepatitis C virus-related advanced hepatocelluar carcinoma surviving more than 8 years].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Drug Administr | 2007 |
Alteration of dihydropyrimidine dehydrogenase expression by IFN-alpha affects the antiproliferative effects of 5-fluorouracil in human hepatocellular carcinoma cells.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Dihydrouracil Dehydrogenase (NADP); | 2007 |
Successful treatment of hypovascular advanced hepatocellular carcinoma with lipiodol-targetting intervention radiology.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Combined Modality Therapy; Contrast Medi | 2007 |
Interferon-gamma sensitizes hepatitis B virus-expressing hepatocarcinoma cells to 5-fluorouracil through inhibition of hepatitis B virus-mediated nuclear factor-kappaB activation.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Fluorouracil; Genes, Reporter; Hepatitis B virus; Human | 2007 |
Combination therapy of interferon-alpha and 5-fluorouracil inhibits tumor angiogenesis in human hepatocellular carcinoma cells by regulating vascular endothelial growth factor and angiopoietins.
Topics: Angiopoietins; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepato | 2007 |
Chinese medicinal compound delisheng has satisfactory anti-tumor activity, and is associated with up-regulation of endostatin in human hepatocellular carcinoma cell line HepG2 in three-dimensional culture.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Hepatocellular; Cell Line, Tumo | 2007 |
Similar effects of recombinant interferon-alpha-2b and natural interferon-alpha when combined with intra-arterial 5-fluorouracil for the treatment of advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cost-Benefit | 2007 |
Antiproliferative and antimetastatic effects of the ethanolic extract of Phellinus igniarius (Linnearus: Fries) Quelet.
Topics: Animals; Antineoplastic Agents; Basidiomycota; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Mov | 2008 |
Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cohort Studi | 2007 |
Combination therapy with PEG-IFN-alpha and 5-FU inhibits HepG2 tumour cell growth in nude mice by apoptosis of p53.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, He | 2007 |
[Interferon alpha enhances the sensitivity of SMMC-7721 hepatocellular carcinoma cells to 5'-deoxy-5-fluorouridine related to up-regulation of thymidine phosphorylase].
Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Drug Sy | 2007 |
Coupled down-regulation of mTOR and telomerase activity during fluorouracil-induced apoptosis of hepatocarcinoma cells.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Down-Regulation; Fluorouracil; Gene Expressi | 2007 |
Profiling of fluorouracil-related genes by microdissection technique in hepatocellular carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; DNA, Complementary; Female; Fluoro | 2007 |
Effects of endogenous nitric oxide induced by 5-fluorouracil and L-Arg on liver carcinoma in nude mice.
Topics: Animals; Antimetabolites; Apoptosis; Arginine; bcl-2-Associated X Protein; Carcinoma, Hepatocellular | 2007 |
Synergistic effect of mTOR inhibitor rapamycin and fluorouracil in inducing apoptosis and cell senescence in hepatocarcinoma cells.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cellular Senescence; Fluorouracil; Humans; L | 2008 |
Cytotoxic effects and in vitro reversal of multidrug resistance by therapeutic ultrasound in human hepatocarcinoma cell line (HepG2).
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cisplatin; Doxorubicin; Drug Resistance, Multiple; Drug | 2008 |
Adjuvant intraportal venous chemotherapy for patients with hepatocellular carcinoma and portal vein tumor thrombi following hepatectomy plus portal thrombectomy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adju | 2008 |
Gene expression of 5-fluorouracil metabolic enzymes in hepatocellular carcinoma and non-tumor tissue.
Topics: Carcinoma, Hepatocellular; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Gene Expression | 2007 |
Th1/Th2 balance: an important indicator of efficacy for intra-arterial chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Drug Mon | 2008 |
Capecitabine for treatment of advanced hepatocellular carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Bilirubin; Capecitabine; Carcinoma, Hepatocellular; Deoxycyti | 2007 |
A new trick for an old drug: mTOR inhibitor rapamycin augments the effect of fluorouracil on hepatocellular carcinoma by inducing cell senescence.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Division; Cellul | 2008 |
Efficacy of combination chemotherapy with capecitabine plus cisplatin in patients with unresectable hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular; Cisplatin; | 2009 |
Systemic gemcitabine combined with intra-arterial low-dose cisplatin and 5-fluorouracil for advanced hepatocellular carcinoma: seven cases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; D | 2008 |
Antiproliferative and apoptotic effects of paeonol on human hepatocellular carcinoma cells.
Topics: Acetophenones; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell P | 2008 |
AAV-mediated TRAIL gene expression driven by hTERT promoter suppressed human hepatocellular carcinoma growth in mice.
Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Carcinoma, Hep | 2008 |
Recurrent obstructive jaundice caused by fibrolamellar hepatocellular carcinoma.
Topics: Adult; Carcinoma, Hepatocellular; Cholestasis, Extrahepatic; Combined Modality Therapy; Doxorubicin; | 1984 |
[Intra-arterial chemotherapy using an implantable infusion pump in liver metastases of colorectal tumors and hepatomas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Colonic Neoplasms; Doxoru | 1984 |
[Clinical evaluation of 1-hexylcarbamoyl-5-fluorouracil (HCFU) in hepatocellular carcinoma].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Fluorou | 1984 |
[Role of oral administration of 1-hexyl-carbamoyl-5-fluorouracil (HCFU) for multimodal treatment of inoperable cirrhotics with hepatocellular carcinoma].
Topics: Administration, Oral; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; C | 1984 |
[Intraarterial Adriamycin for patients with hepatocellular carcinoma and metastatic liver carcinoma].
Topics: Adult; Aged; Alkaline Phosphatase; Carcinoma, Hepatocellular; Doxorubicin; Drug Administration Sched | 1984 |
Virilizing hepatoblastoma--significance of alpha-1-fetoprotein and human chorionic gonadotropin as tumor markers in diagnosis and follow-up.
Topics: alpha-Fetoproteins; Carcinoma, Hepatocellular; Chorionic Gonadotropin; Cyclophosphamide; Doxorubicin | 1981 |
[Clinical evaluation of chemotherapeutic agents in the treatment of primary liver cancer].
Topics: Adult; Aged; alpha-Fetoproteins; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Fluor | 1982 |
Continuous intra-arterial infusion chemotherapy of hepatoma.
Topics: Adult; Aged; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Doxorubicin; Fema | 1983 |
Tumor cell lipid composition and sensitivity to humoral immune killing. I. Modification of cellular lipid and fatty acid content by metabolic inhibitors and hormones.
Topics: Animals; Carcinoma, Hepatocellular; Cardiolipins; Cattle; Cholesterol; Cytotoxicity, Immunologic; Da | 1980 |
Adriamycin in the treatment of resectible and irresectible primary hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Doxorubicin; Drug Therapy, Combination; Fluorourac | 1980 |
Therapy of hepatocellular cancer with combined intrahepatic arterial chemotherapy and whole liver irradiation.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Doxorubicin; Drug Administration Schedule; Drug Evaluation; | 1980 |
[Approaches to a selective chemotherapy of hepatocellular carcinoma (author's transl)].
Topics: Antineoplastic Agents; Asialoglycoproteins; Azo Compounds; Carcinoma, Hepatocellular; Cell Membrane | 1981 |
A non-resectable hepatoma after hepatic artery ligation combined with infusion chemotherapy--an eight-year survival.
Topics: Aged; Carcinoma, Hepatocellular; Fluorouracil; Follow-Up Studies; Hepatic Artery; Humans; Ligation; | 1981 |
[Advanced liver neoplasms in children].
Topics: Adolescent; Carcinoma, Hepatocellular; Child; Child, Preschool; Female; Fluorouracil; Humans; Infant | 1981 |
Metabolic and distribution studies with radiolabeled 5-fluorouracil.
Topics: Adenocarcinoma; Adult; Aged; Animals; Biotransformation; Breast Neoplasms; Carcinoma, Hepatocellular | 1982 |
Preoperative chemotherapy for unresectable primary hepatic malignancies in children.
Topics: Adolescent; Antineoplastic Agents; Carcinoma, Hepatocellular; Child; Child, Preschool; Cyclophospham | 1982 |
Clinical and chemotherapeutic study of hepatocellular carcinoma in Malaysia: a comparison with African and American patients.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Female; Fluorouracil; Follow-Up Studies; Humans; Liver Neopl | 1982 |
Prolonged survival with hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Time Factors | 1982 |
Adriamycin, CCNU, and 5-fluorouracil in patients with advanced gastrointestinal cancer.
Topics: Adenocarcinoma; Adult; Carcinoma, Hepatocellular; Doxorubicin; Drug Administration Schedule; Drug Th | 1983 |
[Completely implantable infusion pump. A new therapeutic possibility for selected patients with liver tumors].
Topics: Carcinoma, Hepatocellular; Catheters, Indwelling; Colonic Neoplasms; Floxuridine; Fluorouracil; Hepa | 1983 |
Pharmacokinetics of ftorafur after intravenous and oral administration.
Topics: Administration, Oral; Adult; Aged; Carcinoma, Hepatocellular; Female; Fluorouracil; Half-Life; Human | 1983 |
Surgical considerations in the management of hepatic neoplasia.
Topics: Adenoma, Bile Duct; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheterization; Floxuridine; | 1983 |
The effectiveness of hepatic artery infusion in treatment of primary hepatobiliary tumors.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Administration Schedule; Fluorouracil; Hepati | 1983 |
[HBs antigen-positive adult type liver cancer in a child with sustained remission induced by infusion of antineoplastic agents into the hepatic artery].
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Child; Cyclophosphamide; Doxorubicin; Fluorouracil | 1983 |
[Treatment of elderly patients with hepatocellular carcinomas with mitomycin C and 5-fluorouracil].
Topics: Aged; Carcinoma, Hepatocellular; Drug Administration Schedule; Drug Therapy, Combination; Female; Fl | 1982 |
[Sequential changes in blood concentrations of tegafur and 5-FU during oral administration of fine granules of tegafur in patients with primary liver cancer].
Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Fluorouracil; Humans | 1982 |
[Chemotherapy of gastrointestinal cancer in elderly patients--evaluation of combination therapy with mitomycin C and 5-fluorouracil].
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma, Hepatocellular; Colonic Neoplasms; Drug Synergism; Dru | 1983 |
[Evaluation of chemotherapy in hepatocellular carcinoma with liver cirrhosis].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Doxorubicin; | 1983 |
Comparison of 5-fluorouracil metabolism in two human gastrointestinal tumor cell lines.
Topics: Carcinoma, Hepatocellular; Cell Cycle; Cell Line; Fluorouracil; Gastrointestinal Neoplasms; Humans; | 1984 |
Patterns of failure after surgical cure of large liver tumors. A change in the proximate cause of death and a need for effective systemic adjuvant therapy.
Topics: Adult; Aged; Carcinoembryonic Antigen; Carcinoma, Hepatocellular; Colonic Neoplasms; Combined Modali | 1984 |
[Hepatocellular carcinoma in pregnancy].
Topics: Adult; Carcinoma, Hepatocellular; Cesarean Section; Chemotherapy, Adjuvant; Combined Modality Therap | 1994 |
[Efficacy of treatment with frequent and low-dose epirubicin in two cases of pulmonary metastases after surgery of liver cancer].
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma, Hepatocellular; Drug Administration Schedule; Epirubic | 1995 |
Exceptional toxicity of 5-fluorouracil and interferon-alpha in a patient with hepatocellular carcinoma.
Topics: Aged; Carcinoma, Hepatocellular; Fluorouracil; Humans; Interferon-gamma; Liver Neoplasms; Male | 1995 |
[Palliative therapy of primary liver tumors].
Topics: Adenoma, Bile Duct; Adolescent; Adult; Aged; alpha-Fetoproteins; Angiography; Antineoplastic Combine | 1993 |
Postoperative prophylactic lipiodolization reduces the intrahepatic recurrence of hepatocellular carcinoma.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Che | 1995 |
Antibiotic C3368-A, a fungus-derived nucleoside transport inhibitor, potentiates the activity of antitumor drugs.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Benzofurans; Biological Transport; Carc | 1995 |
The significance of portal vein chemotherapy for liver micrometastases: an experimental study of a rat model.
Topics: Animals; Carcinoma, Hepatocellular; Drug Therapy, Combination; Fluorouracil; Heparin; Infusions, Int | 1994 |
[A case of poorly differentiated hepatic cell carcinoma which showed 90% decrease in size after chemotherapy with intraarterial infusion of mitomycin C and oral administration of tegafur].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellula | 1994 |
Repeated arterial infusion chemotherapy for inoperable hepatocellular carcinoma using an implantable drug delivery system.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; D | 1994 |
Effects of hepatic arterial infusion chemotherapy on unresectable or recurrent hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Doxorubicin; | 1994 |
Combination therapy consisting of arterial infusion chemotherapy (EPF, EAP) and transcatheter arterial embolization (TAE).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 1994 |
[A comparative study on the serum and tissue 5-FU concentrations in patients with hepatocellular carcinoma after preoperative oral administration of UFT and 5'-DFUR].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepato | 1994 |
[Application of crossed assay design in test of drug sensitivity in vitro in combined chemotherapy of liver cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Doxorubicin; D | 1993 |
Diagnosis and therapy for primary hepatic carcinoma: transcatheter inferior phrenic arteriography and chemoembolization.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, | 1993 |
Cisplatin, vincristine, and fluorouracil therapy for hepatoblastoma: a Pediatric Oncology Group study.
Topics: Actuarial Analysis; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel | 1993 |
Improved survival for hepatocellular cancer with combination surgery and multimodality treatment.
Topics: Actuarial Analysis; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combi | 1993 |
[The present status of chemotherapy for hepatocellular carcinoma].
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcino | 1993 |
[Pathomorphological study of resected hepatocellular carcinoma after transcatheter hepatic arterial chemo-embolization].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therap | 1993 |
[The study of continuous local arterial-infusion chemotherapy with 5-FU + CDDP for patients with severely advanced HCC--for the elongation of the life-span and the improvement of QOL].
Topics: Activities of Daily Living; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellula | 1993 |
[Complication of gastro-duodenum with intra-hepatic arterial infusion chemotherapy using implantable reservoir system for hepatic tumors].
Topics: Carcinoma, Hepatocellular; Cisplatin; Drug Administration Schedule; Duodenal Diseases; Female; Fluor | 1993 |
[Clinical study of continuous local arterial-infusion chemotherapy for severely advanced hepatocellular carcinoma (HCC) using reservoir].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Drug Administr | 1993 |
Percutaneous hepatic arterial chemotherapy and chemoembolization.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therap | 1993 |
5-Fluorouracil and alpha-interferon in hepatocellular carcinoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Ataxia; Carcinoma, Hepatocellular; Disease P | 1996 |
[A case of recurrent multiple HCC after surgical resection showing regression by two TAEs using 5-FU and zinostatin stimalamer].
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Embolization, Therapeutic; Fluorou | 1996 |
[Usefulness of continuous arterial infusion chemotherapy for post operative multiple recurrence and residual hepatocellular carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Drug Administr | 1996 |
[A case of successful management of advanced cholangiocellular carcinoma by repeated hepatic resection].
Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Hepatocel | 1996 |
Continuous infusional 5-fluorouracil chemotherapy.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 1996 |
Fibrolamellar hepatocellular carcinoma responsive to platinum-based combination chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Hepatocellular; Cisplatin; | 1996 |
[Chemosensitivity test on hepatocellular carcinoma (HCC) and drug resistance].
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Hepatocel | 1996 |
A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein.
Topics: Aged; alpha-Fetoproteins; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineop | 1997 |
A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein.
Topics: Aged; alpha-Fetoproteins; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineop | 1997 |
A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein.
Topics: Aged; alpha-Fetoproteins; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineop | 1997 |
A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein.
Topics: Aged; alpha-Fetoproteins; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineop | 1997 |
[Continuous arterial infusion of low-dose cisplatin, 5-fluorouracil as adjuvant therapy in cytoreductive surgery for advanced hepatocellular carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; C | 1997 |
[The study of continuous infusion chemotherapy with low-dose cisplatin and 5-fluorouracil for patients with primary liver cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cholangiocarcinoma; | 1997 |
[A case of advanced hepatocellular carcinoma with portal invasion effectively treated by continuous intra-arterial chemotherapy with 5-fluorouracil].
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Fluorouracil; Humans; Infusions, I | 1997 |
[A case of postoperative recurrence of hepatocellular carcinoma successfully treated with arterial infusion chemotherapy using cisplatin and 5-fluorouracil].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Drug Adm | 1997 |
[Hepatic arterial infusion chemotherapy (HAI) for advanced hepatocellular carcinoma inefficacious with transcatheter arterial embolization (TAE)].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, | 1998 |
[Transcatheter oily chemoembolization and intermittent hepatic artery infusion chemotherapy in the management of advanced hepatocellular carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therap | 1998 |
[Resection of primary liver cancer following transcatheter arterial chemoembolization: clinicopathological features and postoperative course in cases].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Catheterizat | 1997 |
Dihydropyrimidine dehydrogenase activity in hepatocellular carcinoma: implication in 5-fluorouracil-based chemotherapy.
Topics: Adult; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; China; Dihydrouracil Dehydrogenas | 1997 |
Apoptosis in human hepatoma cell lines by chemotherapeutic drugs via Fas-dependent and Fas-independent pathways.
Topics: Antibodies; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Division; Cisplatin; f | 1999 |
4-[3,5-Bis(trimethylsilyl)benzamido] benzoic acid (TAC-101) inhibits the intrahepatic spread of hepatocellular carcinoma and prolongs the life-span of tumor-bearing animals.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Benzoates; Body Weight | 1998 |
The study of innate drug resistance of human hepatocellular carcinoma Bel7402 cell line.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Casset | 1999 |
Durable clinical and pathologic response of hepatocellular carcinoma to systemic and hepatic arterial administration of platinol, recombinant interferon alpha 2B, doxorubicin, and 5-fluorouracil: a communication.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Doxorubi | 1999 |
[A case of advanced hepatocellular carcinoma treated by repeated arterial infusion chemotherapy of 5-FU, LV, CDDP with an implanted reservoir].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Drug Adm | 1999 |
Efficacy of an implanted drug delivery system for advanced hepatocellular carcinoma using 5-fluorouracil, epirubicin and mitomycin C.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellu | 1999 |
[Hepatic arterial infusion of low-dose cisplatin, 5-fluorouracil for hepatocellular carcinoma with tumor thrombi in the portal vein].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Female; | 1999 |
[Study of continuous arterial infusion chemotherapy with low-dose cisplatin and 5-fluorouracil for patients with hepatocellular carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Drug Adm | 1999 |
[A case report of hepatocellular carcinoma with hepatic and portal venous tumor thrombus and multiple intrahepatic metastasis who survived over 1 year after the operation with combined locoregional chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Combined | 1999 |
Augmentation of antitumor activity of 5-fluorouracil by interferon alpha is associated with up-regulation of p27Kip1 in human hepatocellular carcinoma cells.
Topics: Apoptosis; Carcinoma, Hepatocellular; CDC2-CDC28 Kinases; Cell Cycle; Cell Cycle Proteins; Cell Divi | 2000 |
A novel AP-1 element in the CD95 ligand promoter is required for induction of apoptosis in hepatocellular carcinoma cells upon treatment with anticancer drugs.
Topics: 5' Untranslated Regions; Antineoplastic Agents; Apoptosis; Base Sequence; Carcinoma, Hepatocellular; | 2000 |
[Hepatic arterial infusion chemotherapy using totally implantable port system].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Doxorubicin; D | 2000 |
Chemotherapy for hepatocellular carcinoma with portal hypertension due to tumor thrombus.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Female; | 2000 |
[Significance of reduction surgery for giant hepatocellular carcinoma with diffuse lung metastases and multiple intrahepatic metastases].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Combine | 2000 |
[Hepatocellular carcinoma with tumor thrombus in the portal and hepatic veins treated successfully with hepatectomy and chemotherapy--a case report].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Combine | 2000 |
Study of multi-drug resistant mechanisms in a taxol-resistant hepatocellular carcinoma QGY-TR 50 cell line.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transport | 2001 |
[The expression of platelet-derived endothelial cell growth factor in liver cancer].
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; En | 2000 |
[A case of advanced hepatocellular carcinoma with portal invasion resected after treatment by continuous intra-arterial chemotherapy with cisplatin and 5-fluorouracil].
Topics: Aged; Carcinoma, Hepatocellular; Cisplatin; Combined Modality Therapy; Fluorouracil; Hepatitis C, Ch | 2001 |
Evaluation of combined therapy with chemoembolization and irradiation for large hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoemboliz | 2000 |
Endovascular occlusion of branches of hepatic artery with poly(2-hydroxyethyl methacrylate) emboli as a single occlusive measure in hepatology.
Topics: Abdominal Neoplasms; Adolescent; Adult; Aged; Arterial Occlusive Diseases; Carcinoid Tumor; Carcinom | 2000 |
[A case of advanced hepatocellular carcinoma (Vp3) with right adrenal gland metastasis successfully treated with repeated arterial infusion chemotherapy using low dose CDDP and 5-FU through an implanted reservoir].
Topics: Adrenal Gland Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2001 |
Combined effect of alpha-fetoprotein antisense oligodeoxy-nucleotides and 5-fluorouracil on human hepatoma cell growth.
Topics: alpha-Fetoproteins; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Division; Fluor | 1999 |
[Lymph node excision with laparotomy and chemo-radiation therapy for a hepatocellular carcinoma patient with multiple lymph node metastases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorour | 2001 |
[A case of hepatocellular carcinoma responding to hepatic arterial infusion chemotherapy with low-dose cisplatin and 5-fluorouracil].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Catheters, Indwelli | 2001 |
[Examination of in vitro chemosensitivity test using methylthiazole tetrazolium bromide chemosensitivity (MTT) test with combined drugs in hepatic arterial infusion chemotherapy for carcinoma of the liver].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Color | 2001 |
Preoperative administration of 5-FU and interferon beta may prevent recurrence of hepatitis B and C virus.
Topics: Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fluorouracil | 2002 |
[A case of spindle cell type hepatocellular carcinoma responding to hepatic intra-arterial infusion chemotherapy].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Dru | 2002 |
Combination chemotherapy for advanced hepatocellular carcinoma complicated by major portal vein thrombosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; | 2002 |
Surgical resection combined with chemotherapy for advanced hepatocellular carcinoma with tumor thrombus: report of 19 cases.
Topics: Adult; Aged; Angiography; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bile Ducts, Extrah | 2002 |
Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Fluo | 2002 |
Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bilirubin; Carcinoma, Hepat | 2002 |
[A case of hepatocellular carcinoma with portal tumor thrombus effectively treated by arterial infusion chemotherapy with low-dose cisplatin and 5-fluorouracil].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Drug Adm | 2002 |
[Apoptosis effects of human liver carcinoma cells induced by 5-fluorouracil].
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Hepatocellular; Enzyme Inhibitors; Fluorourac | 2002 |
[The interaction between 5-fluorouracil and marini on QGY cell line in vitro].
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Division; Dose-Response Relationship, Drug; D | 2002 |
Effect of concanavalin A on tyrosine aminotransferase in rat hepatoma tissue culture cells. Rapid reversible inactivation of soluble enzyme.
Topics: Alanine Transaminase; Animals; Carcinoma, Hepatocellular; Cell Line; Concanavalin A; Cyclic AMP; Cyc | 1977 |
Chemotherapeutic drugs increase killing of tumor cells by antibody and complement.
Topics: Animals; Antigen-Antibody Reactions; Antineoplastic Agents; Azacitidine; Carcinoma, Hepatocellular; | 1975 |
Enhancing effect by metabolic inhibitors on the killing of tumor cells by antibody and complement.
Topics: Animals; Antibodies, Neoplasm; Antigen-Antibody Reactions; Antineoplastic Agents; Azacitidine; Carci | 1975 |
Beta-glucuronidase activity of Yoshida ascites hepatomas of different drug-sensitivity and its change after treatment of host rats with various anticancer agents.
Topics: Animals; Antineoplastic Agents; Bleomycin; Carbazilquinone; Carcinoma, Hepatocellular; Chromomycins; | 1976 |
Evaluation of hepatoma chemotherapy by alpha-fetoprotein determination.
Topics: Adult; Aged; alpha-Fetoproteins; Carcinoma, Hepatocellular; Chemotherapy, Cancer, Regional Perfusion | 1976 |
Hepatic dearterialization for nonrespectable primary and secondary tumors of the liver.
Topics: Adult; Aged; alpha-Fetoproteins; Carcinoma, Hepatocellular; Female; Fluorouracil; Hemangiosarcoma; H | 1976 |
Enhancement of the cancer chemotherapeutic effect by anticancer agents in the form of fat emulsion.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Animals; Bleomycin; Breast Neoplasms; Carcinoma, | 1977 |
A multiple chemotherapeutic approach to the management of hepatoblastoma. A preliminary report.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Child; Cyclophosphamide; Doxorubicin; Drug Therapy | 1975 |
Recent trends in chemotherapy of solid tumors.
Topics: Alkylating Agents; Antibiotics, Antineoplastic; Antineoplastic Agents; Brain Neoplasms; Breast Neopl | 1975 |
Current status of regional arterial infusion chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Hepatocellular; Carotid Arteries; Catheterization; | 1975 |
Current management of hepatic tumors.
Topics: Angiography; Biopsy, Needle; Blood Platelet Disorders; Carcinoma, Hepatocellular; Child; Child, Pres | 1975 |
Clinical management of advanced gastrointestinal cancer.
Topics: Adenoma, Islet Cell; Carcinoma, Hepatocellular; Carmustine; Colonic Neoplasms; Cytarabine; Drug Ther | 1975 |
A study of trace and minor elements in the solid tumor model 3924A hepatoma before and after treatment with t-fluorouracil.
Topics: Animals; Carcinoma, Hepatocellular; Cattle; Disease Models, Animal; Female; Fluorouracil; Liver; Liv | 1975 |
Effects of 5-fluorouracil on the cell kinetic and growth parameters of hepatoma 3924A.
Topics: Animals; Carcinoma, Hepatocellular; Cell Count; Connective Tissue; Deoxyuridine; DNA, Neoplasm; Dose | 1975 |
Increased urinary excretion of cyclic guanosine monophosphate in rats bearing Morris hepatoma 3924A.
Topics: Animals; Carcinoma, Hepatocellular; Cyclic AMP; Cyclic GMP; Female; Fluorouracil; Liver Neoplasms; N | 1975 |
The inhibition of ribosomal RNA synthesis and maturation in Novikoff hepatoma cells by 5-fluorouridine.
Topics: Animals; Carcinoma, Hepatocellular; Cells, Cultured; Floxuridine; Fluorouracil; In Vitro Techniques; | 1975 |
[Studies on the fate of 1-(2-tetrahydrofuryl)-5-fluorouracil (FT-207), a carcinostatic agent. III. Absorption, distribution, excretion and metabolism after rectal administration of FT-207 (author's transl)].
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Fluorouracil; Liver Neoplasms; Male; Neop | 1975 |
Experimental study on drug sensitivity of the rat ascites hepatoma cells in embryonated eggs.
Topics: Animals; Carcinoma, Hepatocellular; Chick Embryo; Drug Evaluation, Preclinical; Fluorouracil; Liver | 1975 |
Malignant hepatoma associated with acquired hepatic cutaneous porphyria.
Topics: Carcinoma, Hepatocellular; Chemotherapy, Cancer, Regional Perfusion; Feces; Female; Fluorouracil; Hu | 1976 |
Regression of established tumors and induction of tumor immunity by intratumor chemotherapy.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Carmustine; Dacarbazine; Dactinomycin; Do | 1976 |
Hepatic artery ligation and 5-fluorouracil infusion for metastatic colon carcinoma and primary hepatoma.
Topics: Adolescent; Adult; Aged; Carcinoma, Hepatocellular; Chemotherapy, Cancer, Regional Perfusion; Colect | 1976 |
Primary carcinoma of the liver.
Topics: Adenoma, Bile Duct; Adolescent; Adult; Aged; Carcinoma; Carcinoma, Hepatocellular; Child; Child, Pre | 1976 |
Solid tumour models for the assessment of different treatment modalities: IV. the combined effects of radiation and 5-fluorouracil.
Topics: Animals; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Dose-Response Relationship, Ra | 1976 |
Walter Hubert lecture Chemotherapy of upper gastrointestinal carcinoma.
Topics: Adenoma, Islet Cell; Antineoplastic Agents; Carcinoid Tumor; Carcinoma, Hepatocellular; Carcinoma, S | 1976 |
Utilization of 3H from deoxyuridine and thymidine for synthesis of DNA and tother macromolecules in various organs of the rat.
Topics: Animals; Bone Marrow; Carcinoma, Hepatocellular; Deoxyuridine; DNA; Fluorouracil; Intestinal Mucosa; | 1977 |
Differential recovery of intestine, bone marrow, and thymus of rats with solid tumors following 5-fluorouracil administration.
Topics: Animals; Bone Marrow; Carcinoma, Hepatocellular; Deoxyuridine; DNA; Dose-Response Relationship, Drug | 1976 |
Metabolism of 5-fluorouracil in sensitive and resistant Novikoff hepatoma cells.
Topics: Animals; Carcinoma, Hepatocellular; Cell Division; Cell Line; Deoxyuridine; DNA Replication; Drug Re | 1977 |
Hepatocellular carcinoma in association with androgen therapy.
Topics: Adult; Carcinoma, Hepatocellular; Fluorouracil; Humans; Liver Neoplasms; Male; Methyltestosterone | 1977 |
Intrahepatic arterial infusion of combination of mitomycin-C and 5-fluorouracil in treatment of primary and metastatic liver carcinoma.
Topics: Adult; Carcinoma, Hepatocellular; Drug Synergism; Drug Therapy, Combination; Female; Fluorouracil; H | 1977 |
Oral fluorouracil therapy of hepatoma.
Topics: Administration, Oral; Carcinoma, Hepatocellular; Drug Administration Schedule; Female; Fluorouracil; | 1977 |
Futraful therapy on liver cancer.
Topics: Administration, Oral; Adult; Aged; Alkaline Phosphatase; Carcinoma, Hepatocellular; Drug Administrat | 1977 |
Solid tumor models for assessment of different treatment modalities: therapeutic strategy for sequential chemotherapy with radiotherapy.
Topics: Animals; Carcinoma, Hepatocellular; Female; Fluorouracil; Liver Neoplasms; Neoplasms, Experimental; | 1977 |
Uridine kinase activities and pyrimidine nucleoside phosphorylation in fluoropyrimidine-sensitive and -resistant cell lines of the Novikoff hepatoma.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line; Drug Resistance; Female; Fluorouracil; Isoenzymes; Ki | 1977 |
A case report of hepatoblastoma treated by chemotherapy and hepatic lobectomy.
Topics: Carcinoma, Hepatocellular; Child, Preschool; Female; Fluorouracil; Hepatectomy; Hepatic Artery; Huma | 1977 |
[Effect of 5-fluorouracil and thiophosphamide on the activity and fractional content of phosphatases of Zajdela hepatoma].
Topics: Adenosine Triphosphatases; Animals; Carcinoma, Hepatocellular; Fluorouracil; Liver Neoplasms; Lysoso | 1977 |
Evidence for role of purine nucleoside phosphorylase in sensitivity of Novikoff hepatoma cells to 5-fluorouracil.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Line; DNA, Neoplasm; Fluorouracil; | 1976 |
Internal radiation therapy of liver cancer (90-Yttrium resin spheres intra-arterially) to supplement external radiation therapy, local and systemic chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Carcinoembryonic Antigen; Carcinoma, Hepatocellular; Female; Fluorourac | 1977 |
[Fluorinated pyrimidines administered by percutaneous arterial perfusion in primary or secondary cancers of the liver].
Topics: Carcinoma, Hepatocellular; Floxuridine; Fluorouracil; Humans; Infusions, Intra-Arterial; Liver Neopl | 1977 |
Adriamycin and 5-fluorouracil in the treatment of advanced hepatoma: a Southwest Oncology Group study.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Doxorubicin; Drug Evaluation; Drug Therapy, Combination; Fem | 1977 |
[Therapeutic results using VP 16-213 alone or in combination with 5-fluorouracil in liver cancer (hepatoma)].
Topics: Adult; Aged; Carcinoma, Hepatocellular; Drug Therapy, Combination; Etoposide; Female; Fluorouracil; | 1977 |
Chemotherapy studies in autochthonous rat tumors: hepatomas.
Topics: Animals; Carcinogens; Carcinoma, Hepatocellular; Cyclophosphamide; Doxorubicin; Female; Fluorouracil | 1977 |
Synchronization of host and tumor responses for sequential therapy in experimental solid tumors.
Topics: Animals; Bone Marrow Diseases; Carcinoma, Hepatocellular; Cell Cycle; DNA, Neoplasm; Drug Administra | 1978 |
Solid tumour models for the assessment of different treatment modalities: VII: single vs fractionated doses of 5-fluorouracil on two solid tumours and their hosts.
Topics: Animals; Bone Marrow; Carcinoma, Hepatocellular; DNA; Drug Administration Schedule; Fluorouracil; Li | 1978 |
Distribution of 18F-5-fluorouracil in tumor-bearing mice and rats.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Fluo | 1978 |
Hepatocellular carcinoma in a young woman with prolonged exposure to oral contraceptives.
Topics: Adult; Carcinoma, Hepatocellular; Carmustine; Contraceptives, Oral; Contraceptives, Oral, Combined; | 1978 |
Complete necrotization of hepatocellular carcinoma by chemotherapy and subsequent intravascular coagulation: a case report.
Topics: Acute Kidney Injury; Antineoplastic Agents; Carcinoma, Hepatocellular; Disseminated Intravascular Co | 1978 |
Evaluation of a chemotherapeutic regimen for primary liver cancer in children.
Topics: Adolescent; Antineoplastic Agents; Carcinoma, Hepatocellular; Carmustine; Child; Doxorubicin; Drug E | 1978 |
[Characteristic pharmacodynamic in 1-(2-tetrahydrofuryl)-5-fluorouracil metabolism and its clinical efficacy in patients with primary hepatoma (author's transl)].
Topics: Adult; Aged; Carcinoma, Hepatocellular; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Li | 1978 |
Treatment of primary liver cancer: response to regional chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemotherapy, Cancer, Reg | 1979 |
Clinical studies in Asian patients with irresectible primary hepatocellular carcinoma treated by adriamycin and prednisolone alone or in combination with 5-fluorouracil, vincristine and prednisolone.
Topics: Adolescent; Adult; Aged; Carcinoma, Hepatocellular; Child; Doxorubicin; Drug Therapy, Combination; F | 1978 |
Hepatocellular carcinoma associated with erythrocytosis. A nine year survival after successful chemotherapy and left lateral hepatectomy.
Topics: Carcinoma, Hepatocellular; Erythropoietin; Fluorouracil; Hepatectomy; Humans; Liver Neoplasms; Male; | 1979 |
Decreased disappearance rate of 1-(2-tetrahydrofuryl)-5-fluorouracil (FT-207) from the blood and its unresponsiveness to tocophreyl nicotinate and indomethacin in patients with primary hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Fluorouracil; Humans; Indomethacin; Kinetics; Liver Cirrhosis; Liver Neop | 1979 |
Liver tumors: follow-up with P-31 MR spectroscopy after local chemotherapy and chemoembolization.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Colorectal Neoplasms; Female; Fluorouraci | 1992 |
Pattern of 2-deoxy-2-[18F]-fluro-D-glucose accumulation in liver tumours: primary, metastatic and after chemotherapy.
Topics: Adenocarcinoma; Carcinoma, Hepatocellular; Colonic Neoplasms; Deoxyglucose; Fluorodeoxyglucose F18; | 1992 |
Hepatic chemoinfusion of 5-FU in metastasis of gastrointestinal cancer and advanced primary hepatocellular carcinoma.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Drug Administration Schedule; Female; Fluorouracil; Gastroin | 1992 |
[Hepatic blood flow in patients treated by continuous hepatic artery infusion chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Female; | 1992 |
[A case report of postoperative recurrent hepatocellular carcinoma effectively treated with HCFU administration combined with TAE].
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Embolization, Therapeut | 1992 |
5-Fluorouracil and leucovorin in hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Drug Therapy, Combination; Fe | 1992 |
[Treatment of hepatic malignant tumors with percutaneous echoguided injections of absolute alcohol and 5 FU- folinic acid-ultrafluid lipiodol combination. Preliminary results in 17 patients].
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Drug Therapy, Combina | 1992 |
[The efficacy of transarterial immuno-embolization therapy in patients with hepatocellular carcinoma].
Topics: Administration, Oral; Aged; Carcinoma, Hepatocellular; Embolization, Therapeutic; Fibrinogen; Fluoro | 1992 |
[Effects of intra-arterial infusion chemotherapy with radiation therapy for advanced hepatocellular carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Modality Therapy | 1992 |
[Prophylactic chemotherapy by regional arterial infusion in resected hepatoma patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Doxorubicin; F | 1992 |
[Intermittent intra-arterial chemotherapy using subcutaneously implanted reservoir for hepatocellular carcinoma and liver metastasis of colorectal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; C | 1992 |
Chemotherapy can convert unresectable hepatoblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; C | 1992 |
[Repeated arterial infusion chemotherapy for inoperable hepatocellular carcinoma using implantable drug delivery system].
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Doxorubic | 1992 |
Arterial infusion chemotherapy for advanced hepatocellular carcinoma using EPF and EAP therapies.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 1992 |
[Clinical evaluation of operative and non-operative treatment in hepatocellular carcinoma with main portal vein tumor thrombus].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; C | 1992 |
Prognostic factors in patients with hepatocellular carcinoma receiving systemic chemotherapy.
Topics: alpha-Fetoproteins; Analysis of Variance; Antineoplastic Agents; Ascites; Bilirubin; Carcinoma, Hepa | 1992 |
[The efficacy of transcatheter arterial infusion chemotherapy in patients with hepatocellular carcinoma].
Topics: Administration, Oral; Adult; Aged; alpha-Fetoproteins; Carcinoma, Hepatocellular; Doxorubicin; Femal | 1992 |
[Intraportal vein infusion chemotherapy after hepatectomy for hepatocellular carcinoma--preliminary report].
Topics: Adult; Carcinoma, Hepatocellular; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studies | 1991 |
[A case of recurrent hepatocellular carcinoma after hepatic resection surviving over five years by hepatic arterial infusion of lipiodol-anticancer drug suspension].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Doxorubicin; D | 1991 |
[Efficacy of anticancer agent-lipiodol emulsion for hepatic arterial infusion and regional hyperthermia in patients with nonresectable hepatoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Combined Modal | 1991 |
[Intra-arterial infusion chemotherapy for unresectable hepatocellular carcinoma using an implantable reservoir].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Hepatocellular; Cisplatin; D | 1991 |
[Bile duct necrosis and hepatic necrosis following hepatic arterial infusion chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Ducts, Intrahepatic; Carcinoma, Hepatocel | 1991 |
[Effects of intraarterial infusion chemotherapy on liver function in patients with hepatocellular carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cytarabine; | 1991 |
Complete disappearance of unresectable hepatoblastoma by continuous infusion therapy through hepatic artery.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Doxorubicin; F | 1991 |
Phase II intravenous study of epirubicin with 5-fluorouracil in patients with advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 1991 |
Combination chemotherapy in the treatment of hepatoblastoma.
Topics: Adenomatous Polyposis Coli; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Biom | 1990 |
Human hepatocellular carcinoma sensitivity to antitumor drugs assayed using the succinate dehydrogenase inhibition test.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Doxorubicin; Drug Screening Assays, Antitumo | 1991 |
[Hepatocellular carcinoma treated by continuous hepatic arterial infusion of etoposide, CDDP and 5-FU].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 1990 |
[Intra-hepato-arterial infusion chemotherapy using catheter inserted and placed in hepatic artery via the left radial artery on liver malignancy].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 1990 |
Cytocidal activity of a synthetic isoprenoid, N-solanesyl-N,N'-bis(3,4-dimethoxybenzyl)ethylenediamine, and its potentiation of antitumor drugs against multidrug-resistant and sensitive cells in vitro.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel | 1990 |
Application of traditional Chinese drugs in comprehensive treatment of primary liver cancer.
Topics: Carcinoma, Hepatocellular; Cobalt Radioisotopes; Combined Modality Therapy; Doxorubicin; Drugs, Chin | 1990 |
[Primary and metastatic liver tumors--evaluation of tumor regression and response with regional cytostatic drug therapy by sonography and fine needle puncture histology].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Hepatocellular; Carmustin | 1990 |
[Intraarterial and intraportal chemotherapy combined with decollateralization for cholangiocellular carcinoma and metastatic liver cancer].
Topics: Adenoma, Bile Duct; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile | 1990 |
Repeated dearterialization of hepatic tumors with an implantable occluder.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Catheterization; Catheters, Indwelling; Colonic Neoplasms; E | 1990 |
Toxicities of trichosanthin and alpha-momorcharin, abortifacient proteins from Chinese medicinal plants, on cultured tumor cell lines.
Topics: Abortifacient Agents, Nonsteroidal; Animals; Carcinoma, Hepatocellular; Carcinoma, Squamous Cell; Ce | 1990 |
Rapid chemosensitivity assay with human normal and tumor cells in vitro.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Survival; Cells, Cultured; Cisplatin; Dose-Re | 1990 |
[Hyperthermia: microwave hyperthermia in combination with intra-arterial infusion chemotherapy of cancer of the pancreas].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Hepatocellular; Combined | 1985 |
Biodegradable mitomycin C microspheres given intra-arterially for inoperable hepatic cancer. With particular reference to a comparison with continuous infusion of mitomycin C and 5-fluorouracil.
Topics: Adult; Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Biodegradation, Env | 1985 |
Chemotherapy of malignant hepatomas with sequential intraarterial doxorubicin and systemic 5-fluorouracil and semustine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Doxorubicin; | 1988 |
[Favorable response of advanced hepatocellular carcinoma to proper hepatic arterial administration of cytokines and the significance of the administration].
Topics: Animals; Carcinoma, Hepatocellular; Drug Combinations; Fluorouracil; Hepatic Artery; Humans; Injecti | 1988 |
Effects of transcatheter arterial chemoembolization with oral chemotherapy on hepatic neoplasms.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Carcinoma, Hepatocellular; | 1989 |
Effects of chemotherapeutic agents on alpha-fetoprotein secretion and growth of human hepatoma cell lines in vitro.
Topics: alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Division; Cell Line; Cisp | 1989 |
[Clinical study of intrahepatic arterial infusion of unresectable hepatoblastoma and hepatocarcinoma in children].
Topics: Adolescent; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocel | 1989 |
[A case of hepatocellular carcinoma (HCC) with lung metastasis which responded to chemotherapy with a single use of 1-hexylcarbamoyl-5-fluorouracil (HCFU)].
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Fluorouracil; Humans; Liver Neoplasms; Lung Neopla | 1989 |
Studies on the chemotherapy with 5-fluorouracil in transcatheter arterial chemoembolization (TAE) treated patients with resectable or non-resectable hepatocellular carcinoma. Osaka Study Group on Hepatocellular Carcinoma.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Catheterization, Peripheral; Doxorubicin; Embolization, Ther | 1989 |
[Combination therapy of hyperthermia and other methods in liver and bile tract cancers--evaluation of these methods using cancer cell lines in vitro].
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line; Combined Modality Therapy; Doxorubicin; | 1989 |
[Clinical studies of intermittent hepatic arterial occlusion with infusion chemotherapy for unresectable hepatocellular carcinoma associated with arterioportal or arteriovenous shunts].
Topics: Aged; Carcinoma, Hepatocellular; Combined Modality Therapy; Embolization, Therapeutic; Female; Fluor | 1989 |
Low dose 1-hexylcarbamoyl-5-fluorouracil (HCFU) recommended for cirrhotic patients with hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Fluorouracil; Humans; Liver Cirrhosis; Liv | 1989 |
[Preliminary study of traditional Chinese medicine-Western medicine treatment of patients with primary liver carcinoma].
Topics: Adjuvants, Immunologic; Adult; Camptothecin; Carcinoma, Hepatocellular; Cimetidine; Drugs, Chinese H | 1989 |
[New approach for unresectable primary liver cancer--intra-arterial combination chemotherapy during and after operation with local injection of ethanol].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Modality T | 1989 |
[Usefulness of subcutaneously implanted reservoir for postoperative therapy in hepatocellular carcinoma and liver metastases of colorectal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Colorectal Neoplasms; Com | 1989 |
[Hepatic arterial infusion chemotherapy of hepatocellular carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Doxorubicin; Drug E | 1989 |
[Hepatic arterial infusion chemotherapy and hyperthermia with degradable starch microspheres in primary and metastatic liver malignancies].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; Combin | 1989 |
[A case of recurrent hepatocellular carcinoma successfully treated by arterial chemoembolization in combination with local hyperthermia].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Modality | 1989 |
[A long-survival case of hepatocellular carcinoma treated by intra-arterial chemotherapy and immunotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Carcinoma, Hepatocellular | 1989 |
[Analysis of prognostic factors in patients with hepatocellular cancer treated by hepatic arterial infusion chemotherapy].
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellula | 1989 |
[Study on the pharmacokinetics of UFT in patients with hepatocellular carcinoma associated with cirrhosis].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Fluo | 1989 |
[A case of hepatocellular carcinoma effectively treated by intraarterial infusion of CDDP and other agents].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Emboliza | 1989 |
[Hepatic artery embolization for primary hepatic carcinoma].
Topics: Adult; Aged; Carcinoma, Hepatocellular; Doxorubicin; Embolization, Therapeutic; Female; Fluorouracil | 1989 |
[Advanced hepatocellular carcinoma: value of systemic chemotherapy combining adriamycin, amiodarone and 5-fluorouracil].
Topics: Adult; Aged; Amiodarone; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 1989 |
[HCFU and 5-fluorouracil levels in the blood and tissue of hepatocellular carcinoma after oral administration of HCFU].
Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Fluorouracil; Humans | 1989 |
[Two cases of digestive cancer demonstrated remarkable regression by hyperthermia with systemic chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Colonic N | 1989 |
[The clinical studies of intermittent hepatic artery occlusion with infusion chemotherapy--19 cases of unresectable hepatocellular carcinoma and 14 cases of metastatic liver cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Catheterizat | 1989 |
[1-Hexylcarbamoyl-5-fluorouracil (HCFU) effective in hepatocellular carcinoma metastatic to the lungs--a case report].
Topics: Administration, Oral; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Fluorouracil; | 1987 |
Intraarterial chemotherapy with lipid contrast medium for hepatic malignancies in infants.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Doxorubicin; D | 1987 |
[5-Fluorouracil, tegafur, and uracil concentrations in serum and tissue of the patients with hepatocellular carcinoma after UFT administration].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Combinations; Fluoro | 1987 |
Clinical management of recurrent hepatocellular carcinoma after primary resection.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Combined Modality Therapy; Female; Fluorouracil; Follow-Up S | 1988 |
Phase II study of 5-fluorouracil (5-FU) and high dose folinic acid (HDFA) in hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Evaluat | 1988 |
Intrahepatic chemotherapy for unresectable hepatocellular carcinoma.
Topics: Adult; Age Factors; Antineoplastic Agents; Carcinoma, Hepatocellular; Doxorubicin; Drug Evaluation; | 1988 |
[5-FU and HCFU concentrations in serum and tissues in hepatocellular carcinoma after HCFU oral administration].
Topics: Administration, Oral; Carcinoma, Hepatocellular; Fluorouracil; Humans; Liver; Liver Neoplasms | 1988 |
Treatment of unresectable hepatoblastoma with cisplatin, vincristine and 5-fluorouracil.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Child, Preschool; Cisplat | 1988 |
[Combined hepatic arterial infusion chemotherapy with transcatheter arterial embolization and hyperthermia in primary liver cancer].
Topics: Adenoma, Bile Duct; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Carcinoma, | 1988 |
[Accumulation of lipiodol in hepatocellular carcinoma after transarterial chemoembolization with 5 FU-lipiodol-emulsion].
Topics: Carcinoma, Hepatocellular; Embolization, Therapeutic; Emulsions; Fluorouracil; Hepatic Artery; Human | 1988 |
[Hepatic arterial infusion chemotherapy and hyperthermia with degradable starch microspheres in primary and metastatic liver malignancies].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; Combin | 1988 |
[Hepatic arterial chemotherapy combined with hyperthermia or arterial embolization in unresectable liver tumor].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Hepatocellular; Cispla | 1988 |
Sensitivity to six antitumor drugs differs between primary and metastatic liver cancers.
Topics: Aclarubicin; Antineoplastic Agents; Carbazilquinone; Carcinoma, Hepatocellular; Cisplatin; Doxorubic | 1988 |
Primary hepatocellular carcinoma in the eastern province of Saudi Arabia: treatment with combination chemotherapy using 5-fluorouracil, Adriamycin and mitomycin-C.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Doxorubicin; | 1985 |
Effective cisplatin (DDP) based chemotherapy in the treatment of hepatoblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Child, Preschool; Cisplat | 1985 |
Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients.
Topics: Adolescent; Adult; Aged; Carcinoma, Hepatocellular; Embolization, Therapeutic; Female; Fluorouracil; | 1985 |
Primary liver tumor in a young man: a brief review of diagnostic strategies and treatment options.
Topics: Adult; Carcinoma, Hepatocellular; Doxorubicin; Fluorouracil; Humans; Liver Neoplasms; Male; Parenter | 1985 |
Chemical cholecystitis associated with hepatic arterial chemotherapy delivered by a permanently implanted pump.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Arteritis; Carcinoma, Hepatocellular; Cholecystitis; Ch | 1985 |
[Low-dose intermittent intra-arterial infusion chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Dox | 1985 |
[One-shot therapy and transcatheter arterial embolization (TAE) therapy of unresectable hepatocellular carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Doxorubicin; Embolization | 1985 |
Intra-hepato-arterial infusions of cis-diamminedichloroplatinum (II) and 5-fluorouracil clinically effective for malignant liver tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carcinoma, Hepato | 1985 |
[Physiologic hepatic dearterialization and 5-FU intra-arterial perfusion in primary hepatic carcinoma].
Topics: Adult; Aged; Carcinoma, Hepatocellular; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Int | 1985 |
[Blood level of 5-fluorouracil (5-FU) by oral administration of 1-hexylcarbamoyl-5-fluorouracil (HCFU) and tegafur in patients with hepatocellular carcinoma].
Topics: Administration, Oral; Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Fluorouracil; | 1985 |
[Evaluation of intermittent hepatic arterial occlusion with infusion chemotherapy of unresectable hepatocellular carcinoma].
Topics: Aged; Animals; Carcinoma, Hepatocellular; Dogs; Embolization, Therapeutic; Female; Fluorouracil; Hep | 1986 |
A phase II study of combined 5-fluorouracil, doxorubicin, and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellul | 1986 |
Radiolabeled antibody in the treatment of primary and metastatic liver malignancies.
Topics: Animals; Antibodies; Biliary Tract Neoplasms; Carcinoembryonic Antigen; Carcinoma, Hepatocellular; C | 1986 |
[Combination chemotherapy of cis-diamminedichloroplatinum (CDDP) and 5-fluorouracil (5-FU) in gastrointestinal tumors].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; C | 1986 |
[A case of hepatoma effectively treated by TAE and intra-arterial and intraportal infusion chemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Modality | 1986 |
Percutaneous interstitial chemotherapy of a small hepatocellular carcinoma under ultrasound guidance.
Topics: Administration, Cutaneous; Antineoplastic Agents; Biopsy, Needle; Carcinoma, Hepatocellular; Fluorou | 1986 |
Cardio-pulmonary elimination of 5-fluorouracil after bolus injection in the hepatic artery.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Female; Fluorouracil; Hepatic Artery; Humans; Injections, In | 1987 |
[FT, 5-FU and uracil concentrations of the blood, bile and tissue of hepatoma with liver cirrhosis after oral administration of UFT].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Bile; Carcinoma, Hepatocellula | 1987 |
Hepatic conversion of 1-(tetrahydro-2-furanyl)-5-fluorouracil into 5-fluorouracil in patients with hepatocellular carcinoma.
Topics: Aged; Carcinoma, Hepatocellular; Drug Therapy, Computer-Assisted; Fluorouracil; Humans; In Vitro Tec | 1987 |
Combination chemotherapy for unresectable hepatoblastoma in children.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Modality Therapy | 1987 |
Intraarterial injection of anti-tumor drugs dispersed in lipid contrast medium: a choice for initially unresectable hepatoblastoma in infants.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Doxorubicin; F | 1987 |
Hepatic artery infusion for metastatic malignancy using percutaneously placed catheters.
Topics: Adenoma, Islet Cell; Adult; Aged; Bile Duct Neoplasms; Breast Neoplasms; Carcinoid Tumor; Carcinoma, | 1971 |
Effect of various anticancer agents on DNA polymerase.
Topics: Adenosine Triphosphate; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Bleomycin; Bone | 1971 |
Serum alpha-fetoprotein as a biochemical marker for hepatocellular carcinoma.
Topics: Adolescent; Adult; Age Factors; Alpha-Globulins; Blood Transfusion; Carcinoma, Hepatocellular; Femal | 1972 |
Inhibition of ribosomal ribonucleic acid maturation by 5-azacytidine and 8-azaguanine in Novikoff hepatoma cells.
Topics: Animals; Azacitidine; Azaguanine; Carcinoma, Hepatocellular; Cells, Cultured; Cytidine; Dactinomycin | 1974 |
Response of alpha-fetoprotein to chemotherapy in patients with hepatomas.
Topics: Adult; Aged; Alpha-Globulins; Antigens, Neoplasm; Antineoplastic Agents; Carcinoma, Hepatocellular; | 1974 |
[Intra-arterial treatment of malignant neoplasms in children (author's transl)].
Topics: Adolescent; Carcinoma, Hepatocellular; Child; Female; Fluorouracil; Humans; Injections, Intra-Arteri | 1972 |
Continuous arterial infusion chemotherapy. Experience with 44 cases.
Topics: Adenocarcinoma; Arteries; Brain Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Squamous Cell; Cath | 1967 |
Hepatic artery infusion chemotherapy in hepatoma.
Topics: Aged; Alkaline Phosphatase; Angiography; Aorta; Brachial Artery; Carcinoma, Hepatocellular; Catheter | 1968 |
[Loco-regional and sequential chemotherapy of advanced cancer].
Topics: Adult; Carcinoma; Carcinoma, Hepatocellular; Chemotherapy, Cancer, Regional Perfusion; Dysgerminoma; | 1968 |
Malignant hepatoma in the Bantu.
Topics: Adenoma, Bile Duct; Africa, Eastern; Alanine Transaminase; Antineoplastic Agents; Aspartate Aminotra | 1970 |
Infusion chemotherapy in hepatoma and metastatic liver tumors.
Topics: Adenocarcinoma; Adolescent; Aged; Carcinoma, Hepatocellular; Chemical and Drug Induced Liver Injury; | 1967 |
Infusion of liver tumours.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemotherapy, Cancer, Regional Perfusion; Floxurid | 1968 |
[Primary cancer of the liver in a child detected by angiography and treated by exeresis and antimitotics].
Topics: Adolescent; Angiography; Carcinoma, Hepatocellular; Cholangiography; Diagnosis, Differential; Echino | 1968 |
[Apropos of a hepatoma: rôle of regional chemotherapy].
Topics: Adult; Carcinoma, Hepatocellular; Fluorouracil; Hepatomegaly; Humans; Liver Neoplasms; Male; Perfusi | 1968 |
Infusion of liver tumours.
Topics: Carcinoma, Hepatocellular; Chemotherapy, Cancer, Regional Perfusion; Fluorouracil; Hepatomegaly; Hum | 1968 |
[Treatment of cancer of the liver by regional perfusion].
Topics: Adult; Aged; Angiography; Carcinoma, Hepatocellular; Catheterization; Colonic Neoplasms; Fluorouraci | 1968 |
[Comments on the treatment of solid tumors with 5-fluorouracil].
Topics: Adenocarcinoma, Scirrhous; Adult; Breast Neoplasms; Carcinoma, Hepatocellular; Female; Fluorouracil; | 1969 |
[Clinical study on continuous 5-FU infusion for the treatment of primary liver cancer].
Topics: Adult; Aged; Carcinoma, Hepatocellular; Female; Fluorouracil; Humans; Injections, Intra-Arterial; In | 1970 |
[Autopsy case of liver cancer undetected until the terminal stage].
Topics: Aged; Antineoplastic Agents; Autopsy; Carcinoma, Hepatocellular; Fluorouracil; Humans; Liver Functio | 1970 |
[Some data from a biochemical study of patients with primary cancer of the liver during chemotherapy].
Topics: Carcinoma, Hepatocellular; Fluorouracil; Humans; Liver Neoplasms | 1970 |
Hepatoma: long-term survival with disseminated tumor treated with 5-fluorouracil.
Topics: Carcinoma, Hepatocellular; Fluorouracil; Humans; Liver Neoplasms; Long-Term Care; Lung Neoplasms; Ma | 1970 |
Cutaneous porphyria due to a malignant primary hepatoma.
Topics: Aged; Carcinoma, Hepatocellular; Feces; Female; Fluorouracil; Humans; Liver Neoplasms; Photosensitiv | 1970 |
Considerations in the development of a predictive system for cancer chemotherapy.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line; DNA; Floxuridine; Fluorouracil; Liver N | 1971 |
Experience with hepatic arterial infusions.
Topics: Adult; Aged; Bile Duct Neoplasms; Carcinoma, Hepatocellular; Female; Floxuridine; Fluorouracil; Gall | 1971 |
Lactic dehydrogenase isoenzyme alterations in malignant disease of the liver.
Topics: Alkaline Phosphatase; Aspartate Aminotransferases; Bronchial Neoplasms; Carcinoma, Hepatocellular; C | 1971 |
[Study in man of recirculation and tissue uptake of 5-FU 6 H3].
Topics: Adenoma, Bile Duct; Antimetabolites; Carcinoma, Hepatocellular; Chemotherapy, Cancer, Regional Perfu | 1971 |
Primary cancer of the liver: a review of 25 cases and report of two prolonged survivals.
Topics: Adult; Aged; Body Weight; Carcinoma, Hepatocellular; Female; Fluorouracil; Hepatectomy; Humans; Live | 1972 |
[Effects of selective administration of anticancer agents in massive dosage combined with fibrolytic enzyme (urokinase) in hepatic cancer].
Topics: Carcinoma, Hepatocellular; Fibrinolytic Agents; Fluorouracil; Humans; Liver Neoplasms; Male; Middle | 1972 |
Continuous prolonged intrahepatic infusion of 5-fluorouracil in the treatment of hepatoma in Ibadan.
Topics: Adult; Carcinoma, Hepatocellular; Chemotherapy, Cancer, Regional Perfusion; Fluorouracil; Humans; Li | 1972 |
[Intra-arterial chemotherapy of primary hepatoma and changes in -fetoprotein levels].
Topics: Aged; Carcinoma, Hepatocellular; Female; Fetal Proteins; Fluorouracil; Humans; Injections, Intra-Art | 1972 |
[Clinical studies of primary hepatic carcinoma].
Topics: Adenoma, Bile Duct; Adolescent; Adult; Aged; Alkaline Phosphatase; Autopsy; Biopsy; Carcinoma, Hepat | 1971 |
Inhibition of ribosomal ribonucleic acid maturation in Novikoff hepatoma cells by 5-fluorouracil and 5-fluorouridine.
Topics: Animals; Carbon Isotopes; Carcinoma, Hepatocellular; Cell Line; Electrophoresis; Fluorine; Fluoroura | 1973 |
Clinical management of advanced gastrointestinal cancer.
Topics: Adenocarcinoma; Alkylating Agents; Biliary Tract; Carcinoid Tumor; Carcinoma, Hepatocellular; Fluoro | 1973 |
The surgical management of primary hepatocellular carcinoma in Uganda.
Topics: Adolescent; Adult; Carcinoma, Hepatocellular; Catheterization; Female; Fluorouracil; Hepatectomy; He | 1973 |
Proceedings: Primary liver cancer. A review of the clinical features, blood groups, serum enzymes, therapy, and survival of 65 cases.
Topics: ABO Blood-Group System; Adenoma, Bile Duct; Adolescent; Adult; Aged; Alanine Transaminase; Alkaline | 1974 |
Hepatoma, erythrocytosis and increased serum erythropoietin developing in long-standing hemochromatosis.
Topics: Aged; Animals; Biopsy, Needle; Carcinoma, Hepatocellular; Chronic Disease; Erythropoietin; Female; F | 1974 |
Experience with infusion and resection in cancer of the liver.
Topics: Adult; Aged; Breast Neoplasms; Carcinoma, Hepatocellular; Catheterization; Colonic Neoplasms; Female | 1974 |
The deoxyribonucleoside transport systems of cultured Novikoff rat hepatoma cells.
Topics: Animals; Biological Transport; Carcinoma, Hepatocellular; Cell Line; Cell Membrane Permeability; Cel | 1974 |
Effects of sodium warfarin and other carcinostatic agents on malignant cells: a study of drug synergy.
Topics: Animals; Carbon Radioisotopes; Carcinoma, Bronchogenic; Carcinoma, Hepatocellular; Carcinoma, Squamo | 1974 |
Primary liver carcinoma.
Topics: Adolescent; Adrenal Gland Neoplasms; Adult; Aged; Biopsy; Bone Neoplasms; Carcinoma, Hepatocellular; | 1974 |
Polyamine depletion of tumor tissue and subsequent elevation of spermidine in the sera of rats with 3924A hepatomas after 5-fluorouracil administration.
Topics: Animals; Carcinoma, Hepatocellular; Female; Fluorouracil; Liver; Liver Neoplasms; Neoplasms, Experim | 1974 |
Incorporation of precursors and inhibitors of nucleic acid synthesis into hepatomas and liver of the rat.
Topics: Amino Acids; Animals; Carbon Radioisotopes; Carcinoma, Hepatocellular; Cell Line; Fluorouracil; Inje | 1974 |
Metabolic studies of 5-fluorouracil. II. Influence of the route of administration on the dynamics of distribution in man.
Topics: Administration, Oral; Bile; Carbon Radioisotopes; Carcinoma, Hepatocellular; Chromatography, Thin La | 1974 |
[Treatment of liver cancer with oral administration of N-(2'-furanidyl)-5 fluorouracil (FT207) (author's transl)].
Topics: Adenocarcinoma; Administration, Oral; Aged; Carcinoma, Hepatocellular; Fluorouracil; Humans; Liver N | 1974 |
Studies on the mechanism and prevention of local recurrence of carcinoma at the suture line after colonic resection.
Topics: Animals; Carcinoma, Hepatocellular; Colon; Colonic Neoplasms; Fluorouracil; Intestinal Mucosa; Liver | 1971 |